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Colorectal  tumorigenesis  is  one  of  the  best  known  processes  of  cellular 
transformation in human beings.  Its characterization has moved ahead by leaps and 





regulator  of  epithelial  homeostasis.    Other  crucial  alterations  affect  key  genes 
involved in different signal transduction pathways, apoptosis, and DNA repair such 
as mismatch repair.  These events, which seem to appear at specific stages of tumor 
progre e c i n
 
ssion, eventually lead to malignant and invasiv  neoplasti  les o s. 
Colorectal  cancer  was  assumed  for  many  years  to  be  a  homogenous 
condition, but recently it turned out to include several distinct clinical, histological, 
and molecular phenotypes.  Such heterogeneity can also be recognized in the lesions 
believed  to  be  its  precursors.    Advances  in  the  fields  of  endoscopy  and  pathology 
have provided us with a more accurate classification of preinvasive  lesions, which 
better reflects their relevance in colorectal tumorigenesis.   Precancerous colorectal 
lesions  have  been  thus  reclassified  into  different  categories  based  on  their 
morphological and histological appearance.   Macroscopically,  they are divided  into 
polypoid  (pedunculated and sessile) and nonpolypoid  (slightly elevated, completely 
flat  or  depressed)  lesions.    Histologically,  they  can  present  classical  adenomatous 
features  or  a  peculiar  architecture  characterized  by  infolding  of  the  glandular 
epithelium  (also  called  serration).    Serrated  lesions  display  some  molecular 
alterations usually non detected in adenomas, and they are believed to progress into 
colorectal cancer by means of a new pathway of tumorigenesis, namely the serrated 
pathway.    The  distinction  of  precancerous  colorectal  lesions  based  on  their 
morphology,  and  the belief  that  they  represent different  entities, were  the  central 
themes  driving  the  design  of  this  study.    In  an  attempt  to  identify  genes  and 




polypoid  colorectal  precancerous  lesions.    Our  study  represents  the  first  gene 
expression  analysis  of  a  large  collection  of  the  two  types  of  precancerous  lesions.  




of  precancerous  lesions  could  be  easily  segregated  into  different  clusters  using 
several  unsupervised  and  supervised  analytical  tools.    A  prominent  prevalence  of 
expression changes in genes involved in cell cycle related networks was observed in 
the polypoid group of  lesions,  suggesting  that a profound dysregulation of  the cell 
cycle  is  crucial  for  propulsion  of  cell  proliferation  in  these  lesions.    In  contrast, 
nonpolypoid  lesions  were  characterized  by  an  overrepresentation  of  expression 
changes  in genes  involved  in growth  factor  signaling pathways,  apoptosis  and cell 
adhesion,  suggesting  that  these  lesions  might  exploit  activation  of  cell  survival 
pathways and avoidance of apoptosis for their progression.  We have identified a list 
of  genes  whose  expression  changes  are  more  specifically  associated  with  the 
polypoid or  the nonpolypoid phenotype.   These changes will be complemented by 
additional data  from other  ‐omics  studies  (a metabolomics  study  is  in progress  in 
our  laboratory)  in  order  to  investigate  the  differences  between  polypoid  and 
nonpolypoid lesions within a systems biology framework. 
The data analysis also showed that the transcriptome of nonpolypoid lesions 
was  less  dramatically  subverted  than  that  of  the  polypoid  lesions  (in  comparison 
with  normal  mucosa  samples).    In  a  large  proportion  of  changes,  the  up‐  or 
downregulation  of  transcript  levels  followed  a  normal mucosa   nonpolypoid  
polypoid sequence, although expression values in nonpolypoid lesions were always 
closer  to  that  of  the  cognate,  precancerous  group  of  samples.    Certain  biological 
processes,  such as Wnt signaling, cytoskeleton remodelling and  immune response, 
were  similarly  dysregulated  in  the  two  groups  of  lesions.    In  addition,  supervised 
analyses identified the diameter of the  lesions and degree of cytological dysplasia as 





In  conclusion,  although  nonpolypoid  lesions  appear  to  explore  different 
pathways of transformation, they also share many similarities with polypoid lesions. 
This  was  expected,  since  both  precancerous  lesions  arise  and  grow  in  the  same 
organ and are likely forced to overcome a series of similar selection pressures.   At 
this  stage  of  our  investigation,  we  could  only  suggest  that  it  is  wise  to  apply  the 
ame level of clinical surveillance to both types of precancerous lesions.  s
 
One  gene  transcript  whose  expression  changes  were  dramatic  in  all  the 
precancerous  lesions  was  TMIGD1  (transmembrane  and  immunoglobulin  domain 
containing 1).  In comparison with the transcript levels in the corresponding normal 
mucosa  samples,  TMIGD1  was  found  to  be  19  and  66  (log2  values)  times  less 
expressed  in  nonpolypoid  and  polypoid  lesions  respectively,  and  even more  ‐152 
fold  ‐  in  adenocarcinomas.    This  striking  phenomenon  and  the  originality  of  the 
finding (probes for the analysis of the expression level of this gene were not present 
in  the microarray platforms used  in previous  studies),  along with  the  fact  that  its 




tissues  and we  found  that  the  expression of  the TMIGD1 mRNA was higher  in  the 
lower  gastrointestinal  tract  and  kidney.    The  stable  expression  of  the  full  length 
TMIGD1  cDNA  in  TMIGD1‐deficient  SW480  colon  cancer  cells  showed  that  this 
protein is expressed in the cytoplasm.  An accumulation of TMIGD1 was evident in 




In  immunohistochemical  studies,  the  expression  of  TMIGD1  was  limited  to  the 
upper  portion  of  the  intestinal  epithelial  crypts  (where  differentiated  cells  are 
                                                                                                                                               Summary 
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located), while  it was  absent  in  the  proliferative  compartment.    In  the  villi  of  the 
terminal  ileum and  in  renal  tubules, TMIGD1 was markedly  localized  in  the brush 
border.    As  expected,  its  expression  decreased  dramatically  in  nonpolypoid  and 












Die  Entstehung  von  Darmkrebs  beim  Menschen  ist  einer  der  am  besten 
verstandenen Abläufe der zellulären Entartung. Das Verständnis dieses Prozesses ist 
in  den  letzten  drei  Jahrzehnten  sprunghaft  angestiegen,  nicht  zuletzt  durch  die 
Fortschritte  auf  den  Gebieten  der  Endoskopie,  der  Histologie  und  der 
Molekularbiologie.  Der  kanzerogene  Prozess  beginnt,  wenn  genetische  oder 
epigenetische Veränderungen in den Zellen der Krypten des Darmepithels auftreten 
und  sich  anhäufen.  In  den  meisten  Fällen  geht  diese  Transformation  mit  einer 
qualitativen,  quantitativen  und  räumlichen  Zerstörung  des Wnt‐Signalweges,  dem 
physiologischen  Regulator  der  zellulären  Homeostasis,  einher.  Weitere  wichtige 
Veränderungen betreffen Schlüsselgene, welche in verschiedenen Signalwegen, dem 
programmierten  Zelltod  und  DNA‐Reparaturwegen,  z.B.  der  postreplikativen 
Fehlpaarungsreparatur,  eine  wichtige  Rolle  spielen.  Diese  Ereignisse  scheinen 




einheitliches  Krankheitsbild  handele.  In  neuere  Studien  wurden  jedoch 
unterschiedliche  klinische,  histologische  und  molekulare  Krankheitsbilder 
festgestellt. Diese Unterschiede können auch schon in Vorläuferstadien der Tumore 
beobachtet  werden.  Fortschritte  in  der  Endoskopie  und  Pathologie  ermöglichen 
heutzutage  eine  bessere  Klassifizierung  der  prä‐invasiven  Läsionen wodurch  sich 
genauere Rückschlüsse auf die weitere Entartung schließen  lassen. Daher hat man 





(auch  gezahnt  genannt)  gekennzeichnet  sind.  Gezahnte  Läsionen  weisen  einige 
molekulare Veränderungen  auf,  die normalerweise nicht  in Adenomen beobachtet 
werden.  Man  geht  davon  aus,  dass  sich  diese  über  einen  neuartigen  Weg  zu 
                                                                                                                              Zusammenfassung 
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Darmkrebs  ausweiten  können,  den  so  genannten  „gezahnten“  Weg.  Die 
Unterscheidung  von  präkanzerösen  Läsionen  mittels  ihrer  Morphologie  und  die 
Annahme, dass diese verschiedene Einheiten darstellen, war das zentrale Leitmotiv 
für  die  Aufnahme  dieser  Studie.  In  dem  Versuch  Gene  und  Signalwege  zu 
identifizieren, deren Deregulation ein wichtige Rolle in der Krebsentstehung spielt, 
haben  wir  eine  umfassende  Transkriptions‐Analyse  von  nicht‐polypösen  und 
polypösen  Läsionen,  die  als  Darmkrebsvorläufer  angesehen  werden  können, 
durchgeführt.  Unsere  Studie  ist  daher  die  erste  Genexpressionsanalyse  mit  einer 
großen Anzahl dieser beiden unterschiedlichen Arten von präkanzerösen Läsionen. 
Darüber hinaus haben wir unsere Analyse mir der Affymetrix exon array Plattform 
durchgeführt,  die  es  uns  erlaubt  die  Expressionsniveaus  aller  Transkripte  des 
menschlichen Genoms in nie da gewesener Genauigkeit zu untersuchen. 
  Die  Analyse  unserer  Daten  durch  ungeordnete  und  geordnete  Methoden 
zeigte,  dass  sich  beide  Arten  der  präkanzerösen  Läsionen  leicht  in  zwei 
unterschiedliche  Gruppen  aufteilen  lassen.  In  der  Gruppe  der  polypösen  Läsionen 
zeigten  Gene,  welche  mit  dem  Zellzyklus  assoziiert  sind,  ein  verändertes 
Expressionsmuster.  Dies  legt  nahe,  dass  eine massive Deregulation  des  Zellzyklus 
für die Proliferation der Zellen bei dieser Art der Läsion von Nöten ist. Im Gegensatz 
dazu werden die nicht‐polypösen Läsionen dadurch  gekennzeichnet,  dass  sie  eine 
Überexpression  von  Genen  aufweisen,  welche  in  Signalwegen  von 
Wachstumsfaktoren,  dem programmierten Zelltod oder der Zelladhäsion  ein Rolle 
spielen. Dies lässt darauf schließen, dass eine Aktivierung von Signalwegen nötig ist, 
die  das Überleben  der  Zellen  fördern  und  den Zelltod unterdrücken. Wir  konnten 
eine  Liste  von  Genen  erstellen,  deren  veränderte  Expression  mit  dem  polypösen 
oder  nicht‐polypösen  Erscheinungsbild  der  Läsionen  assoziiert  ist.  Diese 
Änderungen  werden  durch  Daten  von  anderen  „‐omics“‐Studien    (eine 
Metabolomics‐Studie wird zurzeit  in unserem Labor durchgeführt) vervollständigt. 
Dadurch  erhoffen  wir  uns,  die  Unterschiede  zwischen  polypösen  und  nicht‐
nnen. polpöyen Läsionen in einem systembiologischen Rahmenwerk studieren zu kö
  Die  Analyse  unserer  Daten  zeigt  zudem,  dass  das  Transkriptom  der  nicht‐
polypösen  Läsionen weniger  „zerrüttet“ war  als  das  der    polypösen  Läsionen  (im 
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Vergleich  zu  den  Proben  der  normalen  Schleimhaut).  Die meisten  Veränderungen 
der Hoch‐ oder Runterregulierung der Transkripte folgten einem ähnlichen Muster: 
normale Schleimhaut  nicht polypöse Läsion  polypöse Läsion (wobei die Werte 
der  nicht‐polypösen  Läsionen  immer  näher  an  den  Werten  ihrer  verwandten 
Gruppe,  der  polypösen  Läsionen,  lagen).  Bestimmte  biologische  Prozesse, wie  der 
Wnt  ‐Signalweg,  der  Aufbau  der  Zytoskeletts  und  die  Immunantwort,  waren  in 
beiden  Gruppen  gleichermaßen  verändert.  Zusätzlich  stellten  wir  mittels 
„überwachten“  multivarianten  Analysen  fest,  dass  die  zwei  klinisch  relevanten 
Variablen  (Durchmesser  der  Läsionen  und Grad  der  zytologischen  Entartung) mit 
einem bestimmten Muster der Genexpression assoziiert  sind, wie es auch  in einer 
früheren  Studie  aus  unserem  Labor  mit  polypösen  Läsionen  der  Fall  war. 
Zusammengefasst  lässt  sich  sagen,  dass  nicht‐polypöse  und  polypöse  Läsionen 
vielen  Gemeinsamkeiten  aufweisen,  obwohl  die  nicht‐polypösen  Läsionen  einen 
anderen  Weg  der  malignen  Entartung  einschlagen.  Dies  war  in  sofern  nicht 
verwunderlich, als dass die präkanzerösen Läsionen im selben Organ entstehen und 
daher  sehr  wahrscheinlich  ist,  dass  für  ihre  maligne  Transformation  ähnliche 
Hürden  überwunden  werden  müssen.  Folglich  lässt  sich  durch  unsere  Studie 
schließen, dass es sinnvoll wäre, bei beiden Arten der präkanzerösen Läsionen die 
 gleichen klinischen Beobachtungen einzuleiten.
  Ein Transkript,  dessen Expression  sich  in  allen prä‐kanzerogenen Läsionen 
sehr drastisch verändert  ist TMIGD1(transmembrane and  immunoglobulin domain 
containing  1).  Im  Vergleich  zu  den  Transkriptionsniveaus  in  den  entsprechenden 
Proben der normalen Schleimhaut, wurde TMIGD1 in nicht‐polypösen Läsionen  und 
polypösen Läsionen 19‐fach bzw.  66‐fach  geringer  exprimiert  (log2 Werte)  und  in 
Adenokarzinomen  sogar  152‐fach. Diese  beachtliche Tatsache  und die Originalität 
unserer  Ergebnisse  (in  unserer  Analyse  wurde  die  Expression  dieses  Genes  im 
Gegensatz  zu  früheren Microarrays  durch  spezifische  Sonden  für  abgedeckt),  und 
die  Tatsache,  dass  die  biologische  Funktion  bisher  nicht  bekannt  ist,  veranlassten 







Trakt  und  in  der Niere  erhöht  ist.  Die  stabile  Expression  der  kompletten TMIGD1 
cDNA  in der TMIGD1‐defizienten Krebszelllinie SW480 zeigte, dass das Protein  im 
Zytoplasma  exprimiert wird.   Wir  stellten  sowohl  eine  perinukleäre  Ansammlung 
des  Proteins  (sehr  wahrscheinlich  handelt  es  sich  um  eine  Assoziation  mit  dem 
rauen  endoplasmatischen  Retikulum,  jedoch  sollte  ein  Lokalisation  in  den 
Mitochondrien  nicht  ausser  Acht  gelassen  werden)  als  auch  eine  Lokalisation  im 
gesamten  Zytoplasma  und  an  der  Zellmembran  fest.  Die  faserartige  Färbung  legt 
ine As ne soziation von TMIGD1 mit dem Zytoskelett  ahe. 
  Durch  immunohistochemische  Analysen  konnten  wir  zeigen,  dass  die 
Expression  von  TMIGD1  auf  dem  oberen  Abschnitt  der  intestinalen‐epithelialen 
Krypten  beschränkt  war  (hier  befinden  sich  differenzierte  Zellen),  wobei  die 
Expression  in  den  zellteilungs‐aktiven  Bereichen  fehlte.  In  den  Zotten  des 
terminalen  Ileums  und  in  den  Nierengefäßen  lokalisierte  TMIGD1  eindeutig  im 
Bürstensaum.  Wir  zu  erwarten  war,  war  die  Expression  in  nicht‐polypösen  und 
polypösen  Läsion  als  auch  in  den  Adenokarzinomen  dramatisch  reduziert. 
Interessanterweise zeigte die Färbung  für TMIGD1 eine Korrelation zwischen dem 
Grad  der  zellulären  Differenzierung,  wobei  die  Expression  in  schwach 
differenzierten gänzlich Neoplasma fehlte. Daher könnte TMIGD1 ein neuer Marker 
für die epitheliale Differenzierung im unteren Margen‐Darm‐Traks und in der Niere 









Colorectal  carcinoma  (CRC)  represents  one of  the main  causes of mortality 




in  developing  countries,  the  economic  development  and  the  adoption  of  western 
life‐styles have led to an increased of it.  Based on cancer incidence rates estimated 
in the United States, colorectal cancer is the fourth most frequent cancer in humans 
(after prostate, breast and  lung cancers).1   Wide geographic variation  in colorectal 
cancer  incidence  and mortality  rates  are  believed  to  be  due,  partially,  to  life  style 
(i.e.  obesity,  consumption  of  red meat,  inverse  relation with  physical  activity  and 
consum uption of fr its and vegetables) and environmental factors.  
Colorectal  cancer  is  actually  a  multifactorial  disease  whose  development 





most  of  the  hereditary  syndromes  predisposing  to  colorectal  cancer,  in  the  large 
majority of cases, the etiology still remains elusive. Colorectal cancer is traditionally 









A  brief  introduction  will  be  also  done  about  the  intestinal  cell  renewal 
mechanism because its (de)regulation is closely linked to cancer onset. 
Around  200  cells  per  crypt  are  generated  every  day  in  the  intestine.    This 
complicated  and  precise mechanism  needs  to  be  strictly  controlled  to  preserve  a 
correct equilibrium.  This equilibrium is called homeostasis and it is maintained by, 
at  least,  three  different  coordinated  processes:  cell  proliferation2,  cell  migration3, 
and anoikis.   The intestinal cell proliferation is not  individually driven by each cell 






















The  lower  gastrointestinal  tract  is  constituted  of  the  small  and  large 
intestine.    The  large  intestine  or  colon  extends  from  the  end  of  the  ileum  (i.e., 
terminal  part  of  the  small  intestine)  to  the  anus.  It  is divided  into:  caecum,  colon, 
rectum  and  anus.    The  large  intestine  is  long  1.2  to  1.8 meters  and  its  calibre  is 
greater  than  that of  the small  intestine.   The  first part of  the  large  intestine  is  the 












The  descending  colon  is  the  part  of  the  colon  from  the  splenic  flexure  to  the 
beginning  of  the  sigmoid  colon.    The  sigmoid  colon  is  the  last  part  of  the  large 







tract.  Four  concentric  layers  surrounding  the  inner  cavity,  the  lumen,  can  be 
distinguished: mucosa, submucosa, muscularis propria, and serosa.   The innermost 
layer  of  the  colon,  surrounding  the  lumen,  is  the mucosa.    The  normal  colorectal 
mucosa  is  constituted  by  3  main  elements:  epithelium  of  the  surface  and  crypts, 
lamina propria and muscolaris mucosae,  the  latter  separates  the mucosa  from the 




these  two  compartments.  Epithelial  cell  migration  and  differentiation  occurs 
continuously, and the process of cellular renewal takes approximately three to five 
days.  Shedding cells are removed from the crypts by a process known as anoikis, in 
which  altered  cellular  adhesion  results  in  apoptosis.    The  epithelial  layer  of  the 






the  colon:  the  colonocytes  or  absorptive  cells,  responsible  for  ions  and  water 
absorption,  the  mucus‐secreting  goblet  cells,  which  synthesize,  store  and  secrete 
mucin, peptide hormone‐secreting cells and Paneth cells, which secrete antibacterial 
protein s ns (ly ozyme and defe sins).   
The  lamina  propria  extends  between  crypts  and  reaches  the  muscularis 
mucosae;  it  contains  a  variety  of  cells,  including  fibroblasts  lymphocytes,  plasma 
cells, eosinophils, macrophages and mast cells, which are arranged among strands of 
collagen tissue.  Colonic mucosa contains also well formed gut associated lymphoid 
tissue which  is  responsible  for  local defence against harmful  agents originating  in 
the gut lumen.   
The muscularis mucosae is a thin layer of smooth muscle which separates the 
epithel a r   oium  nd lamina p opria from the submuc sa.   
The  submucosa  is  a  loose  connective  tissue  layer  containing  numerous 
arteries  as  well  as  venous  and  lymphatic  plexuses  that  support  the  mucosa,  and 
muscularis  mucosae.  It  also  joins  the  mucosa  to  the  bulk  of  underlying  smooth 
muscle.    The muscularis  propria  consists  of  a  circular  inner muscular  layer  and  a 
longitudinal outer muscular layer condensed into three bands, the teniae coli.   
The serosa is a mesothelial cell layer overlying loose connective tissue coated 




The  colon  has  different  functions:  to  lubricate  waste  products,  to  absorb 
remaining  fluids  (added  to  the  food  during  digestion),  salts  and  vitamins,  and  to 
store  waste  products  until  excretion.    It  has  no  digestive  function  (no  digestive 
enzymes  are  secreted).    By  the  time  the  chyme  has  reached  the  colon,  almost  all 
nutrients  and  90%  of  the  water  have  been  absorbed  by  the  body  in  the  small 
intestine.  At this point some electrolytes like sodium, magnesium, and chloride are 
left  as  well  as  indigestible  carbohydrates  known  as  dietary  fiber.    As  the  chyme 
moves  through  the  large  intestine, most of  the  remaining water  is  removed, while 
the chyme is mixed with mucus and bacteria known as gut flora, and becomes feces.  
The bacteria break down  some of  the  fiber  for  their  own nourishment  and  create 
acetate, propionate, and butyrate as waste products, which in turn are used by the 









Preinvasive  lesions  of  the  human  colorectum  are  small  areas  of  tissue  that 
alter the surface contour of the gut mucosa.  They are conventionally referred to as 




It  is  nowadays  accepted  that  there  are  also  others, which  are  only  slightly 
raised above the mucosal surface, or flat, or even depressed.  Standard colonoscopy 
is performed  to  identify and resect  these benign  lesions  in  the belief  that  some of 
them  will  progress  to  cancer.  Figure  1  illustrates  the  conventional  pathway  by 
which  this  progression  is  thought  to  occur.    The  first  step  is  the  development  of 
early morphologic changes in discrete clusters of epithelial crypts.  In aberrant crypt 
foci  (ACFs)  the  aberrant  crypts  are  usually  larger  than  normal  and  have  thicker 





should  be.    However,  they  often  display  signs  of  hyperplasia  and  infolding  of  the 
epithelium  into  the  crypt  lumen,  a  phenomenon  referred  to  as  serration, which  is 
discussed on greater details below.   Dysplastic  crypts  in contrast, present  signs of 
cellular  atypia  (mucin  depletion,  nuclear  enlargement,  stratification  and  loss  of 
polarity) and upward expansion of the proliferative compartment toward the mouth 
of  the  crypts.    ACFs  are  encountered  much  more  frequently  in  colons  harboring 
adenomatous polyps or adenocarcinomas  (80%‐100% of all  cases), and 20%‐50% 
of  these  show  signs  of  dyplasia15.    The  view  of  ACFs  as  probable  precursors  of 




β‐catenin,  aberrant  DNA methylation,  and  low‐level  genomic  instability  have  also 
been  reported  in  some ACFs.    The weight  that  should  be  assigned  to ACFs  ‐  their 
presence,  number  and  type  –  in  planning  surveillance  colonoscopy  is  currently 






Figure 1.  A simplified 4-stage model of the transformation of normal colorectal mucosa 
into adenocarcinoma.  
 
The figure shows the histologic features of the four stages of the adenoma-carcinoma pathway to 
colorectal cancer. In order, from top to bottom: normal mucosa; aberrant crypt focus (ACF); 
tubulo-villous adenoma with epithelial dysplasia and invasive adenocarcinoma. The dysplastic 
ACF  came from the colon of a patient with colon cancer (H&E staining, 25x magnification). The 
photomicrogram shows approximately 12 of the 50 or so aberrant crypts included in the ACF, 
which is slightly raised above (≈ 500 μm) the surface of the gut mucosa. Compared with the 
surrounding normal crypts (right, upper corner), the aberrant crypts are larger and longer with 
initial signs of branching and infolding of the epithelium. The epithelial lining presents low-grade 
dysplasia (mild mucin depletion, hyperchromatic nuclei, initial signs of nuclear enlargement, 
occasional areas of stratification). In the lower left corner, the crypt lumens are enlarged – a 
frequent finding at the borders of ACFs. The adenomatous polypoid lesion shows a prevalent 
tubular growth pattern with some villous projections. The degree of dysplasia varies from low-
grade (left half of the lesion) to high-grade (right half, superficial). In the lower left corner is 
present a portion of normal mucosa of the stalk. Adenocarcinoma: irregular branching of glands 
showing atypical epithelium. They are surrounded by stroma composed of dense fibrous tissue 
comprising spindle cells in a collagenuos and inflammatory background (desmoplastic reaction). 




Preinvasive neoplasms –  the next stage – are also a  frequent  finding.   They 
are identified in a roughly one third of all asymptomatic adults undergoing standard 
colonoscopy,  but,  some  may  regress  on  their  own,  and  only  a  fraction  will  be 
transformed in cancer.  The progression process generally involves increases in size 
and in the degree of cellular atypia.  Lesions over 1 cm in diameter with high degree 
of dysplasia  (referred  to as advance adenomas)  are  the ones  farthest  along on  the 
road  toward  malignancy.    (The  term  adenoma  is  used  hereafter  to  refer  to 
neoplasms  –  regardless  of  their macroscopic  appearance  –  that  display  epithelial 
dysplasia).  Several lines of evidence indicate that some of these preinvasive lesions 
will  indeed  give  rise  to  colorectal  cancers.    For  one  thing,  the  frequency  of  these 
benign  neoplasms  and  that  of  colorectal  cancers  both  increase  with  age,  but  the 
age/prevalence curve for the former is shifted to the left by ~10 years.  The regional 
distribution  of  cancers within  the  colon  also  parallels  that  of  large  adenomas.    In 
addition,  the  expected  incidence  of  colorectal  cancer  is  substantially  reduced  by 
colonoscopy  with  polypectomy  (even  though  10‐20%  of  all  premaligant  lesions, 
mainly  those  with  diameter  <  5  mm,  are  likely  to  be  missed  on  standard 
endoscopy16).   And  finally,  there  is  the  impressive  frequency at which preinvasive 
adenocarcinomas  are  detected  within  an  advanced  adenoma,  especially  those 
displaying villous growth patterns and particularly severe dysplasia.   About half of 
all  the  adenocarcinomas  are  elevated  above  the  surrounding  mucosa,  and  in  the 






For  decades,  all  preinvasive  colorectal  lesions  were  referred  to  as  polyps.  
Preneoplastic growth that did not protrude into the gut lumen was first detected in 




where  they  represented  10‐40%  of  all  the  preinvasive  neoplasms  encountered 
during screening colonoscopy18.  Since then, attempts have been made to reclassify 
preinva v e digessi e lesions of th tive tract.   




widely  referred  to as  “flat” although most are actually  slightly elevated  (< 2.5 mm 








had  classic  adenomatous  features,  others  presented  a  peculiar  histologic  pattern 
characterized  by  infolding  of  the  glandular  epithelium.    As  noted  earlier,  this 
phenomenon  is  referred  to  as  serration,  because  it  produces  a  saw‐toothed  (or 







Figure 2.  Polypoid and nonpolypoid preinvasive lesions of the colorectum.  
 
A and B, Types of tumor growth associated with the development of colorectal neoplasia (Paris 
classification). Polypoid (A) lesions can be pedunculated (Type Ip) or sessile (Type Is); most 
nonpolypoid (B) lesions are slightly elevated (Type IIa), but some are completely flat (Type IIb) or 
depressed (Type IIc). Mixed growth patterns can also be found. The endoscopic appearances of 
polypoid (pedunculated) and nonpolypoid (slightly elevated) lesions are shown in panel C and D, 
respectively. Histological examination shows conventional adenomatous features (tubular 
proliferation with low-grade epithelial dysplasia) in a pedunculated polyp (E; magnification, 10X) 
and the serrated pattern (irregular shape of the crypts with serration of glandular lumens) in a 
nonpolypoid lesion (F; magnification, 10X). Either of these histological patterns can be found in 




They  had  long  been  considered  innocuous  with  a  negligible  risk  for 
progression to cancer, mainly because, in spite of their architectural abnormalities, 
they  showed no  clear  signs of  epithelial  dysplasia.    The  term hyperplastic polyp  is 
gradually being abandoned  in  favour  to nondysplastic  serrated polyp  (although  in 
both  cases,  the  term  “polyp”  is  a  misnomer  since  many  of  these  lesions  are 
nonpolypoid).    It  is  also  becoming  increasingly  clear  that  this  category  includes 




agreed  that  they  are  unlikely  to  progress  to  cancer.    These  lesions  are  found 
primarily in the left colon and most are small rectal lesions.  They contain enlarged,  













the  right  colon.    They  are  characterized  by  L‐shaped  or  inverted‐T  shaped  crypts 
lined with infolded epithelium from base to mouth.  The proliferative compartment 
is sometimes expanded, but as noted, there is no real cytologic dysplasia.  Histologic 
and  molecular  findings  suggest  that  SSAs  evolve  from  MVSPs  and  that  some  do 
eventually  become  dysplastic.    But  at  this  point,  they  are  usually  referred  to  as 
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serrated  adenomas  (SAs).    The  histologic  definition  of  this  term  is  still  matter  of 
debate  among  pathologists  so  their  diagnosis  displays  substantial  interobserver 
variation.  Because cellular dysplasia is an essential feature of SAs, some are likely to 
be  classified  as  conventional  adenomas.    Mixed  lesions  containing  serrated  areas 
interspersed with areas displaying conventional adenomatous changes can also be 
found22.   
In  a  recent  study23,  65%  of  the  premalignant  lesions  resected  during 
standard  colonoscopy  were  conventional  adenomas.    The  other  35%  displayed 
serrated architecture and were generally classified as “hyperplastic polyps”.  Most of 
the latter were MVSPs or GCSPs (30%), a few were SSAs (~4%), and less than 2% 
were  dysplastic.    Similar  figures  (60%  conventional  adenomas,  ~40%  serrated 
lesions) emerged from another study based on magnifying chromoendoscopy24.  9% 
of all lesions removed in this study were SSAs, and 2.4% were dysplastic (SAs).   
Therefore  alongside  the  conventional  adenoma‐carcinoma  pathway  illustrated  in 
figure  1,  there  seems  to  be  a  second,  less  frequent  route,  the  serrated  pathway, 
which also leads to the development of colorectal adenocarcinoma (Figure 3).   
There is evidence of its existence at both ends of the transformation process.  
Serrated  crypt  morphology  has,  in  fact,  been  described  in  some  nondysplastic 
ACFs25, and ~10% of all colorectal cancers have predominantly serrated histologic 
patterns  (the  serrated  adenocarcinomas)26  or  contain  peripheral  remnants  of 







Figure 3.  The best characterized pathways to colorectal adenocarcinoma. 
 
The conventional adenomatous pathway is the most common route to adenocarcinoma. 
The cancers that arise through this pathway can be located anywhere in the colorectum, but they 
are more frequent in the left colon and rectum. Progressively severe cellular and architectural 
dysplasia (shaded region) is the hallmark of this pathway. It can already be found in the earliest-
stage lesions, such as ACFs. The putative stations in the “less traveled” serrated pathway are 
shown on the right. Architectural abnormalities are an early feature of this pathway, whereas 
cellular ysplasia appears late (details in the text). Among the lesions that develop through this 
pathway, those most likely to develop into cancer are located in the right colon. 
d
 
  In  summary,  2  out  of  3  preinvasive  colorectal  lesions  discovered  at 
endoscopy are classic adenomas with tubular and/or villous architecture and some 
degree of dysplasia.   The  third will present a  serrated histological pattern,  in  rare 





equally  represented.    Small  serrated  polyps  (<5  mm  in  diameter)  with 
microvesicular or goblet‐cell  features are  likely to be encountered in the  left colon 





ones  that  evolve  along  the  serrated  pathway,  presumably  giving  rise  to  20%  of 
adenoc uarcinomas fo nd in the colorectum.   







The  availability  of  tissue  samples  of  preinvasive  lesions  removed  during 
endoscopy or surgery fuelled attempts to identify the crucial molecular events that 




Interestingly,  molecular  alterations  considered  highly  relevant  to  the 
transformation  process  in  the  colon  are  often  found  in  some  but  not  all 
premalignant  lesions,  and  when  they  are  present,  their  prevalence  frequently 
correlates poorly with  the  size or  severity of  lesions.    Some well known examples 
are oncogene mutations (KRAS and BRAF) ad more extensive genetic or epigenetic 
alterations, such as microsatellite instability or the methylator phenotype.  The fact 
that  some  of  these  changes  appear  to  be  mutually  exclusive  suggest  that 
 25
                                                                                                                                          Introduction                                   
precancerous  cells  can  be  transformed  into  invasive  cancer  cells  by  different 
sequences of mutations.   
Nevertheless, there does seem to be a common denominator in the onset and 
progression  of  most,  if  not  all,  precancerous  lesions  of  the  colorectum:  aberrant 
activation of the Wnt signaling cascade.   
Canonical Wnt  signaling  is  a  crucial  driver  of  epithelial‐cell  division within 
the  lower  third  of  the  intestinal  crypt,  which  represents  one  of  the  simplest  self 
renewing  biological  entities  in  mammals30  (more  details  in  the  chapter  in  the 
Appendix).    Constitutive Wnt  signaling  leads  to  an  expansion  of  the  proliferative 
compartment  of  the  crypt,  destroying  the  equilibrium  between  proliferation  and 
differentiation,  and  this  loss  generally  coincides  with  the  development  of 




APC  mutation  is  therefore  a  frequent  event  in  the  initial  stages  of  colon 
tumorigenesis, but it is not the only cause of the altered stability and distribution of 
β‐catenin  that  characterizes  colorectal  tumors.    Wnt  signaling  can  also  be 




Many  human  tumors  develop  and  evolve  as  a  result  of  the  deregulation  of 
multiple  signaling  pathways,  and  this  is  undoubtedly  true  of  colorectal  tumors  as 
well, but colorectal tumorigenesis also seems to be characterized by the selection of 
repeated  alterations  (or  hits)  involving  the  Wnt  pathway.    These  observations 
suggest  that  Wnt  signaling  dysregulation  itself  may  be  modulated  during 
transformation  to  meet  the  specific  needs  of  the  tumor  at  various  points  in  its 
journey.  The quality of the dysregulated signaling also changes when one pathway 
component  instead  of  another  is  altered.    For  instance,  compared  with  tumors 
bearing β‐catenin mutations,  those with abnormal APC  function are  thought  to be 
more prone to DNA ploidy changes, because APC is also involved in mitotic spindle 




APC  mutations42,  43,  although  no  genomic  imbalances  were  found  when  a  small 
series  of  adenomas  with  biallelic  APC  mutations  were  recently  subjected  to 
compa e n analys  rativ  genomic hybridizatio is44.   
The  RAS/RAF/MEK/ERK  cascade  is  another  signaling  pathway  that  is 
frequently  dysregulated  in  colorectal  carcinogenesis,  and  it,  too,  transforms 
extracellular signals into transcriptional regulation.   
The MAPK/ERK cascade is a classical “survival” pathway, in that it promotes 
cell  proliferation  and prevents  apoptosis.    Two of  its  gene  components, KRAS and 
BRAF,  are  known  oncogenes  that  often  present  gain‐of‐function  mutations  in 
preinvasive  colorectal  lesions.    The  hyperactive  mutant  kinases  they  encode 
(KRASG12D    and  BRAFV600E  ,  for  example) maintain  a  state  of  chronically  activated 
“surviv lal signa ing” in premalignant cells.   
Loss of  this normal homeostatic  equilibrium  seems  to be associated with a 
substantial  increase  in  DNA  replication  stress.    Unlike  the  proliferating  cells  of 
normal  colorectal  crypts,  premalignant  epithelial  cells  with  oncogene‐activated 
survival  signaling  display  classic  examples  of  cellular  responses  to  DNA  damage, 
including  phosphorylation  of  checkpoint  kinase  CHK2  and  the  histone  H2AX,  or 
signs, of  telomere attrition45,  46.   These events halt  the cells at specific stage of  the 
cell cycle so that the DNA damage can be repaired.  This checkpoint repair system is 




can already be detected  in ACFs25.   The  former  is more  frequent  in serrated ACFs, 
and  the  latter  is more  common  in ACFs  that  lack  serration.    Interestingly  enough, 
this difference is maintained as transformation progresses.  In fact, BRAF mutations 
are  found  in  over  2/3  of  all  MVSPs,  SSAs,  and  dysplastic  SAs,  and  they  are  also 
present  in  ~15%  of  all  adenocarcinomas,  mainly  those  right‐colon  cancers  that 
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Figure 4.  Molecular pathways and crossroads in colorectal transformation.  
 
The conventional adenomatous pathway and the serrated pathway are currently the best 
characterized stepwise models of colorectal carcinogenesis. In both, dysregulation of Wnt signaling (β-
catenin stabilization and nuclear translocation) is an early event. It can be caused by different 
(epi)mutations. (In the conventional adenomatous pathway, the most frequent cause is APC mutation). 
Other early events have also been documented, including mutations affecting components of the 
MAPK/ERK cascades (i.e., KRAS or BRAF mutations, which are mutually exclusive) and chromosomal 
changes, like CIN (lower-level compared to that seen in advanced adenocarcinomas) or CIMP. And there 
are undoubtedly others that have yet to be discovered. They account for roughly half of all 
adenocarcinomas, i.e., those with no evidence of the early alterations listed above (far right column – light 
blue segment). Mutations involving “survival signaling” cascades (e.g., MAPK/ERK) alter the normal 
homeostatic equilibrium between proliferation, checkpoint repair of DNA damage, and apoptosis, allowing 
preinvasive lesions to survive for years. Additional mutations are necessary to allow the tumor to move on 
into the advanced stage, where malignancy is imminent. The nature of these “brake-releasing” events 
differs, depending on which pathway the tumor is moving along. Crossroad warning sign: Accelerators: 
Colon cancer predisposition syndromes - each represents high-speed transformation along one of the 
pathways shown in this figure: the adenomatous pathway in Lynch syndrome and familial adenomatous 
polyposis; the serrated pathway in hyperplastic polyposis. The information reported in this figure is based on 
rates of detection of a dozen or so genetic and epigenetic alterations in preinvasive colorectal lesions and 
their persistence in advanced adenocarcinomas. The relative frequency of a given alteration or combination 
of alterations can vary considerably from study to study owing to differences in inclusion criteria (i.e., types 
of lesion studied), in the number and type of molecular changes investigated, and in the method(s) 
employed to detect these changes. Abbreviations: CIN (chromosomal instability); CIMP (CpG island 






of either mutation.    If, as  it seems, oncogene activation of survival signaling allows 
preinvasive lesions to avoid cell death for many years, it seems reasonable to expect 
that  benign  lesions  without  KRAS  or  BRAF  mutation  would  have 






on  the  nature  of  the  preinvasive  neoplasm.    Some  lesions  are  set  in  motion  by 
mutation  of  the  tumor  suppressor  gene  TP53,  which  is  often  altered  in  advance 
colorectal  tumors;  in  others,  the  crucial  event  affects  another  survival  signaling 


















relevant  gene  promoters,  like  those  of  p16  and MLH127,  49­56.    Relatively  rare  in 
conventional  adenomas,  the  CIMP  is  found  in  70%‐80%  of  all  dysplastic  serrated 
lesions  of  the  right  colon,  and  it  is  closely  associated with BRAF  mutations.    The 
basis of this association is unknown, and it is also unclear why CIMP‐positive tumors 
prefer  the  right  colon  of  women.    The  latter  aspect  presumably  highlights  roles 
played by hormonal and environmental  factors  (including cigarette smoking57 and 
hypoxia58, 59).   











of  colon  cancer.    In  this  section,  after  a  general  overview of  familial  and  sporadic 
colon cancer, major emphasis will be put in the hyperplastic polyposis syndrome, as 
a  model  of  the  serrated  pathway  of  transformation.  (For  details  on  inherited 
syndromes  refers  to  chapters:  Cattaneo  et  al.    “Pathways  and  crossroads  to 
colorectal cancer”.  In Advances in understanding the basic pathogenesis and clinical 
management  of  pre­invasive  disease.  Edited  by  Fitzegerald  R.,  2009,  in  press  and  
Sabates‐Bellver et al., Getting familiar with familial colon cancer. Chapter in the Falk 







developing  colorectal  cancer  increases  to  10‐15%  in  individuals  with  one  first‐
degree relative affected by CRC62.   
The percentage increases considerably if more than one relative are affected 
by  CRC  or  other  cancers  often  diagnosed  in  familial  aggregations  of  CRC.    The 
cumulative  lifetime  probability  reaches  60‐100%  in  carriers  of  a  mutation  in  a 
highly penetrant allele, such as in one of the DNA mismatch repair (MMR) genes63 in 
hereditary non‐polyposis colon cancer (HNPCC, also known as Lynch syndrome) or 
in  the  adenomatous  polypoisis  coli  (APC)  gene  in  familial  adenomatous  polyposis 
(FAP)64.     MMR‐defective HNPCC represents  the most  frequent CRC predisposition 
syndrome of known aetiology, and adenocarcinomas of MMR(‐) HNPCC account for 
~3%  of  all  cancers  in  the  colon.    FAP  is  responsible  for  ~0.5%  of  all  CRC,  and 
additional  ~0.5%  arise  in  the  colorectum  of  individuals  affected  by  one  of  the 
hamartomatous  polyposis  syndromes  or  by  hyperplastic  polyposis,  whose 
underlying genetic alterations are the subject of intense research.   
A  genetic  susceptibility  underlines  an  additional  15%  of  all  CRC65,  also 
referred  to  as  familial  or  hereditary,  but  the  underlying  genetic  disorder  is 
unknown.  In this large portion of familial colon cancers the cumulative lifetime risk 
is  very variable,  ranging  from very high  in  familial  aggregations  that  are  clinically 
indistinguishable from HNPCC, but not associated with MMR defects,  to conditions 
with  only  a  slightly  higher  predisposition  to  CRC  as  compared  to  the  general 
population.  
At this latter end of the spectrum lies a blurred border between familial and 
non‐familial  (hereafter  called  sporadic)  CRC.    In  this  group  lie  many  apparently 
sporadic cases that could be familial (i.e., in small families where only one case has 
been  detected  so  far,  in  cases  of  poor  diagnosis  or  where  medical  records  are 























The  paradigm  of  “fast‐track  transformation”  along  the  serrated  pathway  is 
the  syndrome  known  as hyperplastic polyposis  (HP),  a  rare  (and  underdiagnosed) 
condition  that  is  often  associated with BRAFV600E  and  the  CIMP.    HP  is  diagnosed 
when  there  are66:i)  at  least  five  histologically  diagnosed  hyperplastic  polyps 
proximal  to  the  sigmoid  colon,  including  two with  diameter  exceeding  10 mm;  ii) 
any number of hyperplastic polyps proximal to the sigmoid colon plus first‐degree 















there  are  actually  two  different  phenotypes.    They  advocate  reserving  the  term 
“hyperplastic  polyposis”  for  cases  characterized  by  multiple,  small,  pancolonic 
hyperplastic  polyps  and  using  “serrated  adenomatous  polyposis”  when  there  are 
smaller numbers of relatively  large, proximal, hyperplastic polyps with  features of 
SSA.    Familial  aggregations  has  been  documented  in  relatively  few  cases.    When 




have  a  significantly  higher  frequency  of  methylated  alleles  in  the  normal  colon 
mucosa73,  74,  and  this  finding  is  also  consistent  with  the  possibility  of  genetically 
determ Pined CIM :   
Serrated  adenomatous  polyposis  is  likely  to  be  diagnosed  with  increasing 
frequency  thanks  to  the  introduction  of  innovative  colonoscopy  technologies  and 
greater  awareness  of  these  lesions  among  pathologists.    If  its  inherited  nature  is 














in  the  study  were  obtained  during  colonoscopy.    Polypoid  lesions  and  matched 
normal mucosa were  collected  during  a  previous  study61  at  the  Gastroenterology 
Unit of the Belcolle Hospital (Viterbo, Italy). 














to  enhance  the  characteristics  of  both  normal  and  abnormal  gastrointestinal 
mucosa.   Chromoendoscopy in the colon pursues the following aims: screening for 
polyp  and  nonpolypoid  or  depressed  neoplasia,  and  differentiating  between 
hyperplastic and adenomatous lesions. 
Nonpolypoid  lesions were  collected only  from  the proximal  segment of  the 
colon (caecum, ascending, hepatic flexure and transversum) and their macroscopic 
appearance was  classified according  to  the Paris Endoscopic Classification76.   This 





mucosal  layer whose height  is  less  than  one  third  of  its  diameter.  The  distinction 
between a sessile lesion and a slightly elevated lesion is based on the extent of the 
elevation  from  the  adjacent  mucosa  (the  cut‐off  limit  is  2.5  mm  in  the  columnar 
epithelium).  In  agreement with  this  classification,  lesions morphologically  defined 
slightly  elevated  (IIa),  completely  flat  (IIb),  depressed  (IIc)  or  mixed  (i.e  IIa‐IIc) 
were considered for the collection of nonpolypoid lesions in the study.  
Immediately after  removal,  a  small  sample of  epithelial  tissue  (30 mg) was 
cut from the surface of each lesion to reduce contamination with sub‐mucosal, non‐
epithelial  tissue  (Figure 5).   We excluded  lesions of  less  than 1 cm of diameter  to 
ensure  that  this  sampling  procedure  would  not  interfere  with  the  histological 
diagnosis.  The  approach  used  allowed  us  to  obtain  specimens  with  a  high 




the  corresponding  normal  colonic mucosa.    The  lesional  samples  and  the  normal 







Figure 5. Sampling procedure from nonpolypoid lesions for RNA extraction.  
 
Immediately after endoscopic excision, the tissue sample was immersed in RNAlater solution (1).  
A portion of the lesion was then cut by an expert pathologist (2), and the necrotic areas (from the 
endoscopic cauterization) removed (3). The tissue section was further divided into small pieces to 
allow fast penetration of the RNAlater solution (4 and 5).  A total of ~20 mg of tissue was thus 
stored at 4ºC for one night, and at -20ºC till RNA was extracted 
 
Total  RNA  was  extracted  (RNeasy  Mini  Kit,  Qiagen,  Valencia,  CA)  from 







Figure 6.  Evaluation of RNA integrity and efficiency of rRNA reduction.  
 
The degree of RNA degradation was assed by the Experion system and RNA StdSens analysis 
kit (BioRad). Ratio of the two large ribosomal RNA molecules (28S/18S rRNA) provides a 
measure of RNA degradation since the 28S rRNA is more susceptible to degradation than the 
18S rRNA fragment. Intact eukaryotic RNA samples generally have a 28S/18S ribosomal RNA 
ratio of 2.0-2.2.The Experion software automatically determines the 28S/18SrRNA ratio and 
provides a visual assessment of degradation in electropherograms or virtual gel images. In panel 
A, a gel-like image of high quality RNA extracted from nonpolypoid lesions is shown.The 18S and 
28S ribosomal RNA bands are clearly visible, with 28S/18S ratio between 1.8-2.0. the 
electropherogram in panel B shows the 28S and 18S rRNA peaks before (red) and after (blue) 
the process of ribosomal reduction. This analysis was performed to verify the efficiency of this 






Two μg of  total RNA were processed as  follows (Figure 7).   The ribosomal 
RNA  was  first  removed  with  RiboMinus  Human  Transcriptome  Isolation  kit 
(Invitrogen),  in  order  to  significantly  reduce  the  28S  and  18S  ribosomal  subunits 
population  from  the  total  RNA  sample.    This  step minimizes  the  background  and 
thereby  increases  the  array detection  sensitivity  and  specificity.   Double‐stranded 
cDNA was synthesized with random hexamers tagged with a T7 promoter sequence 
using  the Whole Transcript Sense Target Labeling kit  (Affymetrix, Santa Clara, CA, 
USA).  The  cDNA  was  subsequently  amplified  by  T7  RNA  polymerase  to  produce 








Hybridization was  performed  using  5  µg  of  biotinylated,  fragmented  cDNA 
(i.e.  target),  which  was  applied  to  the  GeneChip  Human  Exon  1.0  ST  array 
(Affymetrix).    Incubation  was  performed  at  45°C  for  16  hours.  Following 
hybridization,  the non‐specifically bound material was removed by washing  in the 
Affymetrix Fluidics Station 450 (protocol FS450_0001, and using reagents from the 
GeneChip  Hybridization,  Wash  and  Stain  kit  of  Affymetrix),  and  detection  of 






Figure 7.  The complete Exon array workflow 
 
Scheme of the standard steps of exon microarray sample preparation. Total RNA was subjected 
to ribosomal RNA reduction, then it was reverse transcribed to cDNA by random hexamers 
tagged with a T7 promoter. cDNA was amplified by a T7 RNA Polymerase in order to obtain 
many copies of cRNA. cRNA was subsequently subjected to a second cDNA synthesis to 
produce single stranded DNA in a sense orientation. The sense strand DNA was fragmented by 
UDG and APE1 and then biotin-labeled by TdT. Fragmented DNA was hybridized to the 
GeneChip Human Exon 1.0 ST array. Following hybridization, the non-specifically bound material 
as removed by washing and detection of specifically-bound targets was performed by scanning 





Cell  intensities  (.CEL  files)  were  captured  by  the  Affymetrix  GeneChip 
Operating  Software  (GCOS)  and  Affymetrix  Expression  Console  Software 







inclusive  as  possible  at  the  exon  level,  deriving  from  annotations  ranging  from 
empirically determined, highly curated mRNA sequences to ab‐initio computational 
predictions77.   The Exon array contains approximately 5.4 million probes,  grouped 
into  1.4  million  probe  sets  interrogating  over  1  million  exon  clusters  (i.e.,  usually 
corresp e x nonding to on  e o ). 
A  probe  set  is  a  set  of  synthetic  oligonucleotide  probes,  usually  four  in 
number, on Exon array that  interrogate gene expression from one exon.   The exon 






Figure 8.Human Exon 
array design 
 
The human Exon Array 
was designed to target 
all the annotated and 
predicted exons in 
humans. To this aim, 
5.4 million of probes 
were designed. Four 
probes form a unit 
called probe set which 
recognizes an exon in 
most of the cases. 1.4 
million of probe sets 
can virtually be 
resembled into over 
262.000 transcript 
clusters according to a 
range of annotation 
source. Well annotated probe sets encompass the core set of 17.800 transcript clusters. 





does  not  include  a  paired  mismatch  feature  for  each  perfect  match  feature; 
surrogate  mismatch  intensities  are  derived  from  25,000  pooled  “anti‐genomic” 
background probes with the same GC content as each perfect match feature.   Anti‐
gen pomic sequences are not  resent in the human, rat or mouse genome. 
The  Exon  array  probe  sets  are  classified  based  on  the  level  of  annotational 
con efid nce77: 
 :  d e e1. “Core” (17,800 transcript clusters) RefSeq an  full l ngth G nBank mRNAs; 
2. “Extended”  (129,000  transcript  clusters):  core  probe  sets  and  cDNA 
transcripts,  syntenic  rat  and mouse mRNA,  Ensemble, microRNA, Mitomap, 
Vegagene and VegaPseudogene annotations; 
3. “Full”  (262,000  transcript  clusters):  core  and  extended  probe  sets  and  ab‐






clusters).    The  analysis  was  therefore  not  restricted  to  the  core  set,  but  was 
extended to all the well‐annotated transcripts (303,603 probe sets) with the aim to 










adjustments and normalization  in order  to  remove biases of non‐biological origin.  
                                                                                                                      Materials and Methods 
 42
Much  of  the  variation  in  intensity  levels  can  arise  from  technical  rather  than 
biological  causes.    Non  biological  sources  of  variation  can  be  introduced  during 
sample  preparation,  array  manufacture,  hybridization  and  in  the  measurement 
process.  Therefore, it is really important to normalize data, as much as possible, in 
order  to  remove  the  technical  variation  while  still  retaining  the  informative 
biologi acal v riation.  
The  background  noise  was  detected  by  the  “Detection  above  Background” 
(DABG)  algorithm78.    The  DABG  score  can  be  calculated  for  each  probe  sets  by 
matching perfect match probes to members of the background pool with the same 
GC content and measuring the relative distance between the two.  
Only  after  background  correction  it  is  possible  to  perform  the  expression 
summary.    The  expression  summary  is  the  process  by which  the  values  for  each 
individual probe in a probe set are summarized to generate a single value for that 
probe  set.    There  are  many  different  techniques  used  to  perform  the  expression 
summa vry, e en if they all perform some kind of weighted average.  
The  normalization  was  carried  out  using  the  “quantile  normalization” 
algorithm  for  both  the  exon  and  the  gene  (transcript  clusters)  levels,  and  it  was 
performed  within  each  array  and  also  between  arrays.    The  robust  multichip 
analysis  (RMA)79  algorithm,  was  used  to  estimate  exon  signal  based  on  probe 
intensities.    Since  RMA  does  not  use  mismatch  probes,  after  normalization  (by 
default, quantile), data are fitted to a global model of expression and probe affinities.  
The  model  is  based  on  the  hypothesis  that  the  intensity  measured  for  a  perfect 
match spot depends on three things: the amount of material available to bind to the 










v2.r2.genomic.bgp,  HuEx‐1_0‐st‐v2.r2.pgf,  HuEx‐1_0‐st‐v2.r2.qcc,  HuEx‐1_0‐st‐
v2.r2.antigenomic.bgp, and HuEx‐1_0‐st‐v2.r2.unmapped‐transcripts.ps. 
Expression  data  were  subjected  to  three  multivariate  analyses80:  Principal 
Component  Analysis  (PCA),  Between  Group  Analysis  (BGA)  based  on 
Correspondence  Analysis  (CoA),  which  are  dimension  reduction  methods,  and 
hierarchical clustering, an agglomerative approach. 
Reduction  methods  simplify  the  data  set,  ideally  in  ways  that  impart 
additional  information  about  its  structure  and  they  are  considered  unsupervised 
(PCA)  meaning  that  the  reduction  is  derived  solely  from  the  data  rather  than 
reflecting any a priori knowledge or classification scheme.  Each of these approaches 
project the data into a new multidimensional space based on linear combination of 
variabl  r n r ta va nes that etai  a large amount of the o iginal da riatio . 
Much  like  PCA,  correspondence  analysis  displays  a  low‐dimensional 
projection of the data into a plane.  CoA attempts to separate dissimilar objects from 
each  other  (i.e.,  samples  dispersion),  while  similar  objects  are  clustered  together 
resulting  in  small  distances.    Furthermore,  CoA  represents  variables  in  a  high 
dimensional space as vectors and it does so for two variables simultaneously, thus 
revealing associations between them.  
Between  Group  Analysis  is  a  multiple  discriminant  approach  (supervised) 
that can be safely used with any combination of numbers of genes and samples.  It is 
often  the  case,  especially when  dealing with microarray  data,  that  the  number  of 







analysis was  performed.  There  are  various  hierarchical  clustering  algorithms  that 
differ in the manner in which distances are calculated between the growing clusters 




profiles  are  joined  to  form  groups, which  are  further  joined  until  the  process  has 
been carried to completion, forming a single hierarchical tree. 
  A  further  analysis  performed  was  the  redundancy  analysis  (RDA).  RDA 
expresses how much of the variance in one set of variables (independent variables) 
can be explained by  the others  (dependent variables). The proportion of  the  total 
variance in the dependent variables that can be explained by a linear combination of 







nonpolypoid  and  polypoid  lesions  versus  normal  mucosa.    Benjamini‐Hochberg 
multiple  testing  correction  was  applied  with  a  false  discovery  rate  of  0.001(step 
down m detho ).  
Gene  ontology  analysis  was  performed  by  using  a  GeneGo  MetaCore 
software.  The list of differentially expressed genes (p value <0.05) outcoming from 
the    pairwise  comparisons  (  nonpolypoid  lesions  vs  normal mucosa  and  polypoid 
lesions vs normal mucosa) were applied for the analysis.  The main interest was  to 
identify  differentially  affected  pathways  and  processes  between  the  two  groups.  
Thus,  Enrichment  analysis  consisted  of  matching  gene  IDs  of  possible  targets 
















the  entry  vector  clone  was  then  recombined  via  an  attL­attR  reaction  into  a 
“destination”  vector,  the  pcDNA  3.2/V5‐DEST  (Invitrogen).    To  facilitate  both 
cloning and characterization of the cloned genes in their host, the destination vector 
contains  a  CcdB  gene  in  between  the  recombination  sites.    The  bactericidal  toxin 
CcdB, encoded by the F plasmid ccd (control of cell division or death) locus, belongs 
to a recently discovered programmed cell death system and it targets the bacterial 
gyrase.   When  its  action  is  not  prevented  by  the  CcdA  antidote,  CcdB  causes  cell 
death.  In a gateway vector system, CcdB is inactivated by the insertion of a foreign 
DNA  fragment.   The  introduction of  an  insert  into  cloning  sites  located within  the 
5’end of a fused CcdB results in the sole recovery of E.Coli bearing vectors with an 
insert.  The recombination reaction was transformed into E. coli and the expression 
vector  selected  with  Neomycin  0.4mg/ml  (G‐418,  Geneticin  Sulphate,  11811‐031 
Gibco, UK). 
SW480  cells  cultured  in  Leibovit’s  L‐15  medium  (GIBCO,  Invitrogen), 
supplemented  with  10%  fetal  bovine  serum,  10,000  U/ml  penicillin  and  10,000 
µg/ml streptomycin were stably transfected for 24 hours using   the Lipofectamine 









was performed with  the Roche LightCycler  480  System using  the  LightCycler  480 
SYBR  Green  I  Master  kit  (Roche,  Basel,  Switzerland)  in  compliance  with  the 
manufacturer’s instructions. 
The RNA extracted from precancerous lesions and normal mucosa was first 
converted  to  cDNA  by  using  Transcriptor  First  Strand  cDNA  syntesis  kit  (Roche, 
Basel,  Switzerland).  0.5  µM  of  each  oligonucleotide  primer  (Microsynth,  Balgach, 
Switzerland) and 100 ng of cDNA were mixed in 20 µl of standard reaction volume.  
Primer enc     sequ es and RT‐PCR reaction conditions are available on request. 
The  Ct  is  the  cycle  that  corresponds  to  the  beginning  of  the  log‐phase 
amplification;  one  cycle  difference  in  Ct  corresponds  to  a  ~2‐fold  change  in  RNA 
concentration. A relative quantification analysis was done by comparing the  levels 
of two different target sequences in a single sample (e.g., target gene of interest and 
GAPDH),  with  the  final  result  being  the  ratio  of  these  targets.  For  comparison 
purposes  the  second  gene  is  a  reference  gene  that  is  found  in  constant  copy 
numbers  under  all  test  conditions.  This  reference  gene  provides  a  basis  for 
normalizing  sample‐to‐sample  differences.  A  relative  quantification  analysis 
compa w tres t o ra ios:  















5’‐AAGGCCTGCTGAAAATGACTG‐3’  (forward)  and  5’‐CAAAGAATGGTCCTGCACCAG‐
3’ (reverse), while the exon 15 of BRAF gene was amplified as 103 bp fragment using 




Mutations were  then  assessed  by  ABI  PRISM  SNaPshot Multiplex  Kit  (Applied 
Biosystems,  Foster  City,  CA, USA)  at  the  relevant  nucleotides,  (i.e.  c.34,  c.35    c.37, 
c.38  and  c.1799  of  KRAS  and  BRAF,  respectively)  using  single  base  extension 







for  45  min.    After  heat  inactivation  of  the  enzyme  at  the  80C  for  15  min,  the 
fluorescently labeled products were separated using a 7 min run on ABI Prism 3130 







Gene  Cod n o Nucleotide  Primer o  rientation Primer sequence (5’→3’) 
Primer 
le h ngt
KRAS  12  c.34  forward  AACTTGTGGTAGTTGGAGCT  20 
KRAS  12  c.34  reverse  ct(gac )2CACTCTTGCCTACGCCAC t 28 
KRAS  12  c.35  forward  (gact)4ACTTGTGGTAGTTGGAGCTG  36 
KRAS  12  c.35  reverse  (gact)6GCACTCTTGCCTACGCCA  42 
KRAS  13  c.37  forward  (gact)7TTGTGGTAGTTGGAGCTGGT  48 
KRAS  13  c.37  reverse  act(gac 8AAGGCACTCTTGCCTACGCt)   54 
KRAS  13  c.38  forward  t(gact)10GTGGTAGTTGGAGCTGGTG  60 
KRAS  13  c.38  reverse  act (gact)11CAAGGCACTCTTGCCTACG  66 
BRAF  600  c.1799  forward  act(gact 12GTGATTTTGGTCTAGCTACA) G  72 







Brescia.    Ten  µm  serial  sections  from  paraffin  blocks  were mounted  on  silanised 
slides, t dhen deparaffinised an  rehydrated.  
The  antigen  retrieval was  carried  out  by  heating  the  section  in  a  pressure 
cooker  at  120°C  for  2  min  in  10  mM  citrate‐buffered  solution  (pH  6.0).  DAKO 
peroxidase  blocking  reagent  and  goat  serum  were  sequentially  used  to  suppress 
non‐specific  staining  due  respectively  to  endogenous  peroxidase  activity  and 
nonspecific  binding  of  antibodies.    Incubation  with  primary  antibodies  was 
performed as follow: anti‐hMSH2: 24 hours at 4°C with Ab NA27 (Calbiochem); anti‐
hMSH6: 24 hours at 4°C (pH 9.0) with BD610919 (BD PharMingen); anti‐hMLH1: 24 
hour  at  4°C with  BD551091  (BD  PharMingen);  anti‐hPMS2:  24  hours  at  4°C with 




After  washing,  anti‐mouse  (anti‐rabbit  for  TMIGD1)  secondary  antibodies 
conjugated to peroxidase labeled polymer (DAKO EnVision+ kit) were applied for 30 
min  at  RT,  and  the  peroxidase  activity  was  developed  by  incubation  with  3,  3’ 
diaminobenzidine  (DAB)  chromogen  solution  (DAKO).  The  sections  were  then 
counterstained slightly with haematoxylin. 











and  then  incubated 24 hours with anti‐TMIGD1  (1:50; HPA021946,  Sigma).   After 
being washed  three  times with  PBS,  the  cells were  incubated with  the  secondary 
antibody  (labelled  polymer‐HRP  anti‐rabbit,  DakoCytomation  EnVision+  System‐
HRP;  K4010)  for  30 min  and  then washed  again  three  times with  PBS.    The  cells 
were  finally  incubated  for  10  min  with  DAB  (3,3‐diaminobenzidine 
tetrahydrochloride),  quickly  washed  with  PBS  and  then  mounted  in  mounting 












X‐100  for  30  min  at  RT.    Incubation  with  primary  anti‐TMIGD1  antibody  was 












buffer  (50 mM TrisCl  pH  8.0,  150 mM NaCl  ,  0.02%  Sodium  azide,  0.1%  SDS,  1% 
Triton  X‐100,  1%  Sodium  deoxycholate,  2  mM  EDTA,  1mM  PMSF,  1X  Complete 
EDTA‐free,  30  mM  DTT),  the  cells  were  collected  by  scraping,  homogeneized  by 
mixing with a 18 G needle and a 2ml syringe  and the suspension gently rocked on 
an orbital shaker at 4°C for 20‐40 min.  The completion of the cell lysis was verified 
under the microscope with  trypan blue staining.   The  lysate was centrifuged  in an 






PMSF,  1X  Complete  EDTA‐free),  the  cells  were  collected  by  scraping.    The  cells 
suspension was homogeneized by mixing with a 25G needle and a 2‐ml syringe.  Cell 
lysis was verified under the microscope with trypan blue staining.   The  lysate was 
subjected  to  a  first  step  of  centrifugation  (100  xg  ,  4°C,  for  10  min)  in  order  to 




ultracentrifuge  tube  (12ml  PA,  PKG  50,  03699,  Thermo  Scientific,USA)  and  an 
ultracentrifugation (41,000 rpm) was performed at 4°C for 45 min.  The supernatant 
was  discarded,  the  membrane  pellet  homogeneized  and  then  resuspended  in  a 
proper amount of resuspension buffer (300 mM Mannitol, 20 mM Hepes‐Tris pH 7.4, 
2  mM  EDTA,  H2O,  ,  0.1%  Triton  X‐100,  0.5%  Na‐deoxycholate,  1mM  PMSF,  1X 
Complete EDTA‐free).  The membrane suspension was collected and snap frozen in 
liquid nitrogen and stored at ‐80°C. 
Crypts  isolation  for  protein  extraction  (adapted  from  Fujimoto  K.  et  al., 
81Gastroenterology 2002;123:1941)   









of  the  suspension  of  isolated  crypts  was  assessed  by  light  microscopy.    Crypt 
architecture was well  preserved  in most  of  the  crypts.  The  crypts  containing  PBS 














of  the culture medium and then  incubated for 8 hours with  fetal bovin serum free 
medium.   After 8 hours,  the medium was  collected  and  spin down  to  remove any 
particles in regular 60 ml Falcon tubes.  Protease inhibitors were added (1mM PMSF 
and 1X Complete EDTA‐free).  
  Filters  of  Amicon  Ultra‐15  centrifugal  filter  units  columns  (Millipore, 
MA,USA)  were  first  washed  twice  with  PBS  and  then  the  Amicon  colums  were 
centrifuged for 5 min at 3000 xg    in a swinging bucket rotor.   Clarified cell culture 








Seventy  µg  of  total  proteins  from  each  sample were  loaded  on  a  12%  SDS 




incubated  with  the  following  primary  antibodies  for  2  hours  at  RT:  anti 
TMIGD1(Rabbit  polyclonal,1:300;  HPA021946,  Sigma  ),  anti‐MSH6  (Mouse 
monoclonal,1:2000; 610918, BD Transduct Laboratories) 
After being washed three times with TBS‐T, the blots were incubated with a 
horseradish  peroxidase  (HRP)‐coupled  secondary  antibody  for  1  hour  at  RT.  
Following another three wash steps, immunoreactive proteins were detected using 









The  main  goal  of  this  study  was  to  identify  biomarkers  of  colorectal 
tumorigenesis through the molecular analysis of different types of early neoplastic 
lesions  of  the  human  large  intestine.    Preneoplastic  lesions  of  the  colon  are 
heterogeneous, they display distinct clinical, histological and molecular phenotypes.  
Polypoid  lesions  with  classical  adenomatous  histology  have  been  the  subject  of 
innumerable studies, whereas nonpolypoid lesions remain still poorly investigated.  
The study was  thus  focused on the  identification of biological differences between 
the  two  groups.    To  this  aim,  we  performed  a  powerful  analysis  of  the  gene 
expression  profile  of  nonpolypoid  lesions  and  compared  it  with  that  of  polypoid 
ones,  the  ultimate  goal  being  the  identification  of  genes  and  pathways  whose 











of MMR(‐)  sporadic  colorectal  cancers,  especially  if  located  in  the  proximal  colon 
(caecum, ascending, and transversum).   Twenty five nonpolypoid  lesions (type  IIa, 
IIb,  IIc  or  mixed),  each  with  matched  normal  mucosa,  were  thus  prospectively 
collected from the proximal colon of 21 patients.  Seventeen polypoid lesions (type 
Ip)  from  17  patients,  each  with  matched  normal  mucosa,  were  also  collected 

































AM(1) *  75  F  T  70  IIa­IIb  3S­3L  VA  HGD  7 
AM(2) *      T  20  IIa  3S­3L  VA  HGD   
BG(1) *  72  F  C  30  IIa  4  TA  LGD  9 
BG(2) *      T  20  IIa  3S­3L  TA  LGD   
GG  75  F  T  40  IIa­IIc  3S­3L  TA  HGD  1 
CE  73  F  A  40  IIa­IIc  2­3L  SA (mixed) ≠  HGD  1 
BE  44  M  HF  35  IIa  3S­3L  TA  LGD  2 
BR  79  F  A  20  IIa  4  TA  LGD  1 
GM  67  F  A  20  IIa  3L  TA  LGD  1 
MGF  48  M  HF  15  IIa  3L  TA  LGD  1 
ML  69  F  A  40  IIa  3L  TVA  LGD  1 
SG  83  M  A  25  IIa  3L  TA  LGD  4 
ZP  66  M  C  25  IIa  3L  TA  HGD  2 
AR  79  M  A  35  IIa­IIc  5N  TVA  HGD  2 
OO(1) *  54  F  C  45  IIa  3L  TVA  LGD  16 
OO(2) *      A  12  IIa  3L  TA  LGD   
BGP  74  F  C  50  IIa  3L  TVA  LGD  1 
SG  62  F  A  15  IIa  3S­3L  SA (mixed)  LGD  1 
RM  52  F  T  15  IIa  2  SSA ≠  no dysplasia  1 
MC(1) *  54  F  C  50  IIa  2­3L  TA  HGD  2 
MC(2) *      A  20  IIa  2­3L  TA  LGD   
BM  72  M  A  25  IIa  3S­3L  TA  LGD  1 
GV(2) *  79  M  A  25  IIa  3L  VA  LGD  3 
BC  47  M  A  20­25  IIa­IIc  3S­3L  MVSP ≠  no dysplasia  3 
DDR  66  M  A  12  II a  3L  MVSP  no dysplasia  1 
RA  64  F  A  15  Ip  na  TA  LGD  2 
SD  56  M  A  15  Ip  na  TA  LGD  2 
NF  79  M  A  20  Ip  na  TVA  LGD  3 
PF  27  M  A  15  Ip  na  TVA  HGD  3 
PG  40  F  S  30  Ip  na  TVA  LGD  51¹ 
MA  83  M  S  12  Ip  na  TVA  LGD  3 
MM  50  M  S  30  Ip  na  TVA  HGD  3 
SA  74  F  S  20  Ip  na  TVA  LGD  1 
GN  69  M  R  40  Ip  na  TA  LGD  3 
BA  69  M  S  30  Ip  na  TA  LGD  7 
PF  56  M  S  30  Ip  na  TA  LGD  3 
MR  58  F  D  20  Ip  na  TA  LGD  3 
SMA  52  F  S  30  Ip  na  TA  LGD  3 
PL  69  F  S  15  Ip  na  TVA  LGD  3 
BG  58  F  A  15  Ip  na  TVA  LGD  1 
GV(1) *  79  M  T  30  Ip  na  VA  LGD  3 
WE  73  M  A  30  Ip  na  TVA  HGD  1 
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Abbreviations: M, male; F, female; C, caecum; A, ascending colon; HF, hepatic flexure; T, 
transversum;  D, descending colon; S, sigma; R, rectum; na, Pit pattern not reported by the 
endoscopist; TA, tubular adenoma; TVA, tubulovillous adenoma; VA, villous adenoma; MVSP, 
microvesicular serrated polyp; SA, serrated adenoma; SSA, sessile serrated adenoma; LGD, low-
grade dysplasia; HGD, high-grade dysplasia.  
# Macroscopic appearance of neoplastic lesions was classified according to Paris Endoscopic 
Classification.  The Paris Endoscopic Classification of Superficial Neoplastic Lesions. 
Gastrointest Endosc 2003;58(suppl.):S3-S27 
º Morphological analysis of colonic crypt patterns according to Kudo's classification. Kudo S, 
Rubio CA, Teixeira CR, et al. Pit pattern in colorectal neoplasia:endoscopic magnifying view. 
Endoscopy 2001;33;367-7 
▪ Low-grade versus high-grade dysplasia as defined by the WHO classification of tumors of the 
digestive system, editorial and consensus conference in Lyon, France, November 6-9, 1999.IARC 
≠ Serrated adenomas carrying BRAF mutation, glutamic acid for valin substitution at codon 600 
(V600E) 
*Two lesions from these patients were analyzed 
¹
g
 Patient suspected of attenuated familial polyposis. The mutational analysis of APC and MYH 
enes is currently not available 
 





was  reported  having  neither  a  positive  family  history  for  colorectal  cancer  nor  a 
germ line mutation in genes which are associated with predisposition to this cancer. 
  Eighty percent  (20/25) of  the nonpolypoid  lesions presented adenomatous 












four  classes based on  their  diameter  size  (10‐20 mm; 21‐30 mm; 31‐40 mm; >40 
m). m
  The  total  number  of  synchronous  lesions  was  ≤4  in  most  of  the  patients 
(33/37),  and  4  to  16  in  three  patients.    Only  one  patient  carried  51  synchronous 
adenomas  and  was  thus  suspected  of  attenuated  familial  polyposis  (mutational 




3  lesions  (12%) with  the BRAFV600E mutation.  The  3  cases mutated  in BRAF were 
serrated (Supplementary Table 1). 
  Immunohistochemistry  analysis was  performed  to  detect  the  expression  of 
the  mismatch  repair  protein  MLH1.    This  protein  resulted  expressed  in  all  the 






  Microarray  analysis  of  303,603  probe  sets  (core  and  well‐annotated 
extended  probe  sets)  revealed  expression  levels  above  background  for  23,768 
transcript  clusters  in  at  least  one  of  the  two  main  groups  of  tissues  (42  normal 
mucosa samples and corresponding 42 precancerous lesions).  
  For  the  analysis  of  the  microarray  data  three  multivariate  approaches, 
Principal  Component  Analysis  (PCA),  Between  Group  Analysis  (BGA)  based  on 
Correspondence  Analysis  (CoA),  and  Hierarchical  Clustering  Analysis  (HCA)  were 
used to detect clusters of samples with similar expression profile and differentially 
expressed genes.   While HCA  is a commonly known tool  in  the  field of microarray 
data analysis, it is worth to mention here that PCA and CoA are dimension‐reduction 
or ordination methods which project the original data into a new low dimensional 
space.    The  dimensions  of  the  low  dimensional  space  are  derived  composite 
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variables  or  components  as  well  as  the  orthogonal  axes  of  this  new  space.    The 
objects  (i.e.  tissue  samples)  are  ordered  along  these  derived  axes.    The  distance 
between  objects  in  the  low  dimensional  space  represents  their  dissimilarity  in 
respect  of  the  original  variables,  i.e.  the  dissimilarity  in  respect  of  their  gene 
expression  profiles.    PCA,  BGA  as  well  as  HCA  showed  not  only  different  gene 
expression  profiles  for  precancerous  lesions  and  the  matched  normal  mucosa 
e two lesio  and samples, but also for th ns subtypes nonpolypoid polypoid. 
  As  depicted  in  the  PCA  score  plot  (Figure  9),  the  first  three  principal 
components  (PC1,  PC2  and  PC3)  represent  50.3%  of  the  total  variance  of  the 
original data set.   PC1 (36% of the total variance, i.e. the first principal component 
accounts for as much as possible of the variability in the original data) reflected the 
inter‐individual  (i.e.  patient‐to‐patient)  variability.  (The  patient‐to‐patient 
variability  issue will be  further discussed  in the next paragraph.)   The second axis 
(PC2  representing  the  10.3%  of  the  total  variance)  is  orthogonal  to  the  first  and 
captures  the  maximum  of  the  remaining  variance.    PC2  was  correlated  with  the 
factors responsible of the segregation of the objects ‐‐ and hence of the expression 
changes  ‐‐  among  the  3  tissue  types,  whereas  PC3  did  not  have  any  obvious 
biological  interpretation.   Based on  the ordination of  the samples along  the  first 3 
PCA axes  it was  concluded  that patient‐to‐patient  variability  explained  the  largest 
proportion (36%) and tissue type the second largest proportion (10.3%) of the total 
gene  expression  variance.    More  than  50%  of  the  total  variance  is  due  to  other 
factors and remains unexplained after PCA.   However,  the absence of  singularized 
samples  (far  away  from  any  clusters)  as  well  as  the  high  proportion  of  variance 
explained by the PCA axes 1 and 2 (as compared to a randomized PCA model which 
explains  no  more  than  17%  and  8%  of  the  total  variance  by  the  first  two  axes) 





Figure 9.  Principal Component Analysis (PCA)of log2 expression intensity values 
 
PCA score plot of the RMA (i.e Robust Multi Array) preprocessed intensity values of all 84 
specimens (red dots, normal mucosa; blue dots, nonpolypoid lesions; green dots, polypoid 
lesions). The first 3 principal components (PCs) explain 50.3% of the total variance. PC1 captures 
36% of the total variance and reflects the inter-individual variability. PC2 explains 10.3 % of the 
total variance and is associated with the variable “tissue type” (normal mucosa vs precancerous 
esions). PC3 accounts for 4.07% of the total variance and has not been associate with any 




  HCA  was  applied  to  describe  in  detail  the  relations  (similarities  and 
dissimilarities)  between  the  samples  scored  with  the  eigenvector  analysis.    To 
reduce the confounding effect of patient‐to‐patient variability, the clustering of the 
samples was based on the expression level of only 6,862 transcript clusters showing 
significant  differential  expression  between  normal  mucosa  and  lesions  [  p  value 
<0.01, FDR of 0.01 (step‐up method83, 84)].  Two main clusters, that of precancerous 
lesions  and  that  of  normal  mucosa  samples  (with  the  exception  of  2  neoplastic 
samples,  a  microvesicular  serrated  polyp  and  a  sessile  serrated  adenoma,  which 
clustered with the samples of normal mucosa) could be identified (Figure 10). The 




group  of  precancerous  lesions  presents  higher  variability  than  the  group  of  the 
normal tissue.  Two homogeneous clusters and one mixed could be identified within 








Figure 10.  Hierarchical Clustering Analysis of log2 expression intensity values 
 
The 84 tissue samples represented on the horizontal axis include 42 normal mucosa (red 
branches) and 42 precancerous lesions, grouped in nonpolypoid lesions (blue branches) and 
polypoid lesions (green branches). On the vertical axis, 6,862 transcript clusters with differential 
expression in the tissue types are displayed (p value <0.01; FDR 0.01). Each transcript cluster is 
color coded to indicate the level of expression of the gene relative to its median expression level 
across the entire tissue sample set (blue, low; red, high).  
In the precancerous lesions branch, sub branches representing individual samples and small 
groups merge at higher levels than those of the normal mucosa branch, reflecting lower level 
her variability among the precancerous lesions).  similarity (i.e. hig
Lesions characte
   
rized by serrated histology are marked by an asterisk.  
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In order  to  find the association between the most  important discriminating 
variable,  tissue  type, with other dependent  variables  (i.e.  genes),  a  between group 
analysis (CoA based) was accomplished.  BGA, in fact, attempts not only to separate 
dissimilar objects  from each other based on a multivariate profile, but  it  is also an 
exploratory method  for  the  study  of  associations  between  the multivariate  set  of 
profile  variables  and  a  co‐variables  assumed  to  be  independent  or  explanatory 
variable.  In Figure 11 A, a map of the samples score showed the efficiency of CoA in 
distinguishing  between normal mucosa  samples  and  precancerous  lesions.    There 
was however, a very strong  influence of  the patient‐to‐patient variability reflected 
in the samples dispersion (i.e. distances among samples scores) within each of the 
three  ellipses.    In  Figure  11  B,  on  axis  1  the  genes  were  plotted  that  most 
contributed  to  the  discrimination  between  these  groupings  (i.e.  normal  mucosa, 





Figure 11.  Between Group Analysis (BGA) based on Correspondence Analysis (CoA) of 
log2 expression intensity values 
 
CoA based, Between Group Analysis, of RMA preprocessed intensity values of all 84 specimens 
(red dots, normal mucosa; blue dots, nonpolypoid lesions; green dots; polypoid lesions).  
Panel A: the map of the sample scores on the first two axes shows that CoA efficiently 
discriminated between normal mucosa samples and precancerous lesions, nonpolypoid and 
polypoid, respectively. The dispersion of objects (i.e. samples) along axis 2 is indicative of high 
inter-individual (patient-to-patient) variability. Axis 1 is a discriminating component, clearly 
associated with the tissue type variable (i.e., normal mucosa vs precancerous lesions). 
Panel B: plot of the genes that most contributed to the discrimination between these groups (i.e. 
normal mucosa, nonpolypoid and polypoid lesions). At the ends of axis 1, the genes contributing 
to the segregation between normal tissue and all the precancerous lesions (nonpolypoid and 
polypoid) are plotted.  On axis 2, the genes that have different expression in nonpolypoid and 




Despite  the  efficient  discrimination  of  the  objects  in  both  PCA  and  BGA 
analyses,  samples  scores,  as already mentioned, were still much  influenced by  the 
major  variance  represented  by  the  inter‐individual  variability.    Patient‐to‐patient 
variability is commonly observed in such studies due to the high level of genetic and 
epigenetic variation among individuals in the general population.  Single nucleotide 
polymorphisms,  copy‐number  variants,  alternative  splicing,  post‐transcriptional 
and  post‐translational modifications,  and  epigenetic modifications  account  for  the 
phenotypic plasticity that allows individuals to proceed along the evolutionary path.  
Phenotypic variation is also modulated by environmental influences.  Thus, in order 
to  identify  the  variables  contributing  to  the  gene  expression  changes  we  have 
detected,  the  noise  of  the  patient‐to‐patient  variability  was  reduced  by  using  the 
log2 ratio expression values (that  is,  the expression level of any given transcript  in 
 each lesion relatively to its basal level in the corresponding normal mucosa). 
  The  first  approach  performed  to  identify  and  classify  the  variables  able  to 
explain a proportion of the total variance in the data set, was a redundancy analysis 
(RDA),  a  constrained  form  of  multivariate  analysis,  based  on  the  PCA  of  a  set  of 
independent  (explanatory) variables and a set of dependent variables  (explained). 
Here,  the  clinical  descriptors  were  seen  as  independent  variables  and  the  gene 
expression  as  a  dependent  variable  set  that  can  be  predicted  from  the  clinical 
variables.   The result of RDA  is a PCA model which  is  constrained  to optimize  the 
“prediction”  of  the  gene  expressions  from  the  clinical  variables.    The  relations 
between samples and the two variable sets are finally visualized in a series of plots, 
in particular, here, by a correlation circle for the clinical variables and a score plot 
for  the  samples.    In a  correlation circle  (Figure 12),  the position of  the uniformly 
scaled  variables  on  the  surface  of  a  multidimensional  sphere  is  shown  as  a 
projection on a plane defined by a pair of relevant ordination axes (RDA axes 1 and 
2 or 1 and 3).  The circle of correlation shows the proximity of the variables inside a 









data  set,  followed  by  the  others  as  histology  type  (adenomatous  vs  serrated 
histology), degree of dysplasia  (no  dysplasia vs  low  and high degree  of  dysplasia), 
and diameter of the lesions.    In the circle B of Figure 4, axes 1 and 3 were plotted.  
Here, the scenario is slightly different due to the added variance in agreement with 
the  increase  in axes number. The  reversed order of  the variables  relevance  in  the 
plane of RDA axes 1 and 3  (diameter, histology  type, degree of dysplasia  and  tissue 
type) corroborated the ranking of the variables inferred from the correlation circle 
in  the  plane  of  the  RDA  axes  1,  2,  and  highlighted  the  relevance  of  the  variable 
diameter in the first three dimensions of the reduced ordination space. 
 
Figure 12.  Correlation circles for clinical descriptors (variables) based on Redundancy 
Analysis (RDA) of log2 ratio expression intensity values 
 
A. Correlation circle in the dimensions of the RDA axes 1 and 2. Each clinical/pathological 
variable is represented by a vector. Vectors whose length approaches the radius of the circle (i.e. 
length approximately equal to 1) are the best represented variables in the new coordinate system. 
Vectors pointing in the same or opposite directions represent positively or negatively correlated 
variables, respectively. The order of the variables’ relevance, inferred from the length of the 
vectors, was identified as: tissue type, histologic type, degree of dysplasia and diameter of 
lesions. 
B. Correlation circle in the dimensions of the RDA axes 1 and 3.  The reversed order of the 
variables’ relevance (diameter, histologic type, degree of dysplasia and tissue type) in the plane 
of RDA axes 1 and 3 corroborates the ranking of the variables inferred from the correlation circle 
in the plane of the RDA axes 1 and 2, as well as the relevance of the variable diameter in the first 
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Figure 13. Sample 
score plots based on 
the Redundancy 
Analysis (RDA) of log2 
ratio expression 
intensity values  
 
Score plots with 
samples grouped by the 
variables considered as 
relevant in the 
correlation circles shown 
in Figure 12.  For each 
variable, tissue type, 
histologic type, diameter 
size and degree of 
dysplasia, the same 
scaled log2 ratio 
ex
(no
polypoid) lesions are 
plotted.  Score plots are 
of the BGA axes 1 and 2 
as well as 1 and 3, i.e. 
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Figure 14.  Between Group Analysis (BGA) 
of log2 ratio expression intensity values 
with the variables, tissue type 
(nonpolypoid versus polypoid), or 
istologic type (ah denomatous versus 
errated), as grouping factors 
omatous 
sions). Top genes contributing most to the 
egregation of serrated and adenomatous 





(i.e.,supervised for tissue type or histologic 
type, respectively).  
 
 
For grouping factors with two levels, only the 
scores on the first BGA axis are meaningful. 
For this reason the results of BGA for tissue 
and histologic type are visualized in 1 
dimension graph showing the BGA axis 1 
scores only.   
Panel A: 1D plot of BGA scores using tissue 
type as grouping factor. Samples are 
displayed on the axis 1 as lines,(green lines, 
polypoid lesions, blue lines, nonpolypoid 
lesions).  
Top genes contributing most to the 
segregation of the polypoid and nonpolypoid 
samples are plotted as well on axis 1.  
Panel B: 1D plot of BGA scores using 
istologic type as grouping factor. Samples 
re displayed on the axis 1 as lines [orange 













































Figure 15.  Between Group Analysis (BGA) of log2 ratio expression intensity values with 
the variables diameter and degree of dysplasia, as grouping factors (i.e, supervised for 
diameter or degree of dysplasia, respectively). 
 
For grouping factors with more than two levels, the scores on the first 2 BGA axes could be 
meaningful. For this reason, the results of BGA for diameter and degree of dysplasia are 
visualized in a biplot with BGA axes 1 and 2. 
Panel A: the 2D map of the samples score on axes 1 and 2 showed the groupings based on 
adenoma size classes. Each of the four size-related groups is delimited by an ellipse with a 
labelled centroid.  The ellipses representing the lesions with diameter < 30mm (red and blue 
ellipses) are well separated form those (green and purple ellipses) representing lesions with 
diameter >30 mm, along the axis 2.  Next to the map, along axis 2, the top genes contributing to 
the segregation of lesions with diameter > or < of 30 mm are plotted. 
Panel B: the 2D map of the samples score on axes 1 and 2 shows the groupings based on the 
degree of dysplasia (no dysplasia, low degree of dysplasia and high degree of dysplasia). Along 
axis 2, the ellipse representing the lesions with high degree of dysplasia (red ellipse) is well 
separated from the ellipse representing lesions with low and no dysplasia (blue and green 
ellipses). Next to the map, along axis 1 are plotted the genes contributing to the segregation of 
the samples based on the presence of dysplasia (no dysplasia group vs low and high dysplasia 
groups). Along axis 2, the genes contributing to the segregation of the samples based on the 





gene  transcripts  based  on  their  ability  to  distinguish  between  tissue  groups.    The 
hypothesis  tested  was  that,  under  the  assumption  that  sample  populations  are 
normally  distributed  and  have  a  homogeneous  variance,  there  is  no  difference 
between gene‐expression levels across conditions.  Three independent groups were 
tested: nonpolypoid  lesions, polypoid  lesions, and normal mucosa.   Among 23,768 












groups  of  lesions  were,  almost  invariably,  closer  and  well  separated  from  those 
found in the corresponding samples of normal mucosa.  From these data, it emerged 
that  the  transcriptomes of nonpolypoid and polypoid  lesions are rather similar, at 
least  qualitatively.    However,  a  gene  ontology  enrichment  analysis  allowed 
highlighting the dissimilarities between the two groups of precancerous lesions by 
revealing the main dysregulated pathways and processes in each group of lesions.    
Two  lists  of  significant  genes  (p  value  <  0.05)  obtained  by  the  pairwise 
comparisons  “nonpolypoid  vs  normal  mucosa”  and  “polypoid  vs  normal  mucosa”, 
were  uploaded  in  the  MetaCore  software  and  used  to  reveal  the  first  10  most 
statistically significant GeneGo pathways maps, processes and metabolic networks in 
both groups (Supplementary Table 4, Appendix).  As illustrated in Figure 16, the 
number of  the objects  falling  in  a given pathway  for  each of  the  two  comparisons 
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were  visualized  as  colored  bar  (orange,  nonpolypoid;  blue,  polypoid),  while  the 
common objects were depicted as blue­striped bars.   Several pathways of cell cycle 




cell  cycle  regulation  (cell  cycle  S  phase;  cell  cycle  core;  cell  cycle  G2­M)  were 
overrepresented  in the group of polypoid  lesions.    In contrast, a different scenario 
was observed as for the metabolic networks category (Figure 18), where almost all 







Figure 16.  GeneGo Metacore differentially affected pathways 
 
Bar graph showing the first 10 statistical differentially regulated GeneGo pathway maps between 
nonpolypoid (orange, bars) and polypoid lesions (blue, bars). The length of the horizontal orange 
and blue bars is proportional to the number of uniquely differentially expressed genes (classified 
as components of a given pathway map)  in nonpolypoid and polypoid lesions, respectively 
(compared with normal mucosa). Striped blue bars are indicative of commonly dysregulated 






Figure 17.  GeneGo differentially affected process networks 
 
Bar graph showing the first 10 statistical differentially regulated process networks between 
nonpolypoid (orange, bars) and polypoid lesions (blue, bars). The length of the horizontal orange 
and blue bars is proportional to the number of uniquely differentially expressed genes (classified 
as components of a given process network) in nonpolypoid and polypoid lesions, respectively 
(compared with normal mucosa). Striped blue bars are indicative of commonly dysregulated 





Figure 18.  GeneGo differentially affected metabolic networks 
 
Bar graph showing the first 10 statistical differentially regulated metabolic networks between 
nonpolypoid (orange, bars) and polypoid lesions (blue, bars). The length of the horizontal orange 
and blue bars is proportional to the number of uniquely differentially expressed genes (classified 
as components of a given metabolic network) in nonpolypoid and polypoid lesions, respectively 
(compared with normal mucosa). Striped blue bars are indicative of commonly dysregulated 




Among  the  genes  whose  expression  profile  clearly  showed  the  normal 
mucosa  nonpolypoid  polypoid sequence showed in Figure 29, TMIGD1 was of 
particular  interest.    This  gene  expression  change  was  detected  in  the  lists  of 
discriminating  genes  associated  with  all  the  clinical  and  pathologic  variables 
investigated, and often it was one of the top genes in these lists.  As illustrated in the 
score plot (Figure 19), TMIGD1 mRNA normalized intensity values were found to be 











Figure 19.  TMIGD1 




Score plot of TMIGD1 
RMA preprocessed log2 
intensity values for each 
sample.   
Axis 1: TMIGD1 mRNA 
intensity values; Axis 2: 
the 84 samples.   
TMIGD1 mRNA is highly 
expressed in samples of 
normal mucosa (red dots)  
but it is progressively 
downregulated in 
nonpolypoid (blue dots) 







encoding  a  predicted  membrane  protein,  whose  function  is  unknown.    The  gene 
(NCBI  GeneID  388364;  National  Center  for  Biotechnology  Information;  data  bank 
accession  code NM_206832),  is  located  on  human  chromosome  17  (17q11.2)  and 






TMIGD1 was  found  to  contain  three main domains  (a  transmembrane domain,  an 
immunoglobulin C‐2 type, and an immunoglobulin like domain), and a structure that 
is  similar  to  that of members of  the  large  Ig‐CAM  family of  adhesion molecules  (a 
tentative  structure  of  the  protein  is  shown  in Figure 20).    Beside  the  two  Ig‐like 
domains  located at  the center,  there are also  two hydrophobic helices at  the ends.  
The  orientation  between  these  four  elements  is  still  completely  arbitrary.    The 
helices are predicted to be transmembrane and hypothesized to be necessary for the 







Figure 20.  Predicted structure of the TMIGD1 protein  based on in silico analysis. 
 
Predicted structural model of the TMIGD1 protein: two Ig-like domains (white arrows for 
reference) are located in the center of the predicted structure, whereas two hydrophobic helices 
are at the ends.  The helices are predicted to be trans-membrane. Both helices could help 
keeping the protein attached to the membrane, although the N-terminal helix is predicted as a 




  Based  on  the  gene  expression  profiles  of  the  two  groups  of  colonic 
precancerous  lesions  (nonpolypoid  and  polypoid)  and  their  matched  normal 
mucosa, TMIGD1 was found to be markedly down regulated in all samples (‐19 fold 
in nonp old in poolypoid, and ‐66.3 f lypoid lesions). 
To  check whether TMIGD1  down  regulation was maintained  during  tumor 
progression,  transcriptomic  analysis  was  performed  also  in  a  few  advanced 
colorectal  cancer  samples.    Six  colon  adenocarcinomas  (3  MMR  proficient  and  3 
MMR deficient)  and  four matched normal mucosa were analyzed with  the Human 
Exon Array.  Multivariate analysis showed that TMIGD1 was 125 fold downregulated 
in the 6 cancers (Figure 21).  
Figure 21.  TMIGD1 mRNA log2 
expression intensity values in 
colorectal precancerous lesions and 
cancers. 
 
Panel A. Y axis: log2 expression 
intensity values of TMIGD1 mRNA 
detected in nonpolypoid (blue squares) 
and polypoid (green squares) lesions, 
with the Human Exon array.  Matched 
normal mucosa (red, squares) are 
grouped all together (the black lines 
indicate the correspondence between 
the lesion and its matched normal 
mucosa). X axis: samples divided in the 
three groups: polypoid, nonpolypoid and 
normal mucosa.  
For the three groups, the boxes indicate 
the distribution of TMIGD1 expression 
values, while the whiskers represent the 
shifting from the normal distribution.  
 
Panel B. Y axis: log2 expression 
intensity values of TMIGD1 mRNA 
detected with the Human Exon array in 
six colon cancers (grey, squares) and 
four matched normal mucosa (red, 
squares). 
X axis: samples divided in 2 groups, 
normal mucosa and colorectal cancer.  
For the two groups, the boxes indicate 
the distribution of TMIGD1 expression 
values, while the whiskers represent the 






These  findings  were  fully  confirmed  by  real  time  quantitative  RT‐PCR 
analysis  of mRNA  extracted  from  samples  used  for  the microarray  study  (Figure 
22).  Real time RT‐PCR data also showed that TMIGD1 mRNA is equally represented 
in  all  colon  segments  (caecum,  ascending,  transversum,  descending  and  rectum), 
and is also highly expressed in the terminal ileum(Figure 23). 
 
Figure 22.  Analysis of TMIGD1 mRNA expression in tissues and cell lines. 
 
Microarray data generated with the Affymetrix Exon array platform were validated by quantitative 
real time RT-PCR. The TMIGD1 mRNA levels in normal colonic mucosa, precancerous 
neoplasms (nonpolypoid and polypoid), and colon tumors were consistent with the microarray 
data. 
The graphic shows only tissues and cell lines where TMIGD1 was found to be expressed or 
slightly expressed. [Several normal tissues (spleen, esophagus, liver, bladder, brain, cervix, 
heart, lung, ovary, prostate, skeletal muscle, thymus and thyroid) did not express TMIGD1, as 
well as several cancer cell lines (SW480, Colo741, HT29, HT29M6, CO115, CO115 treated with 
5-AZA deoxycytidine, Sw48, CX1, SW837, HCT116, SW620, Vaco481, SW403, LnCaP, MCF7, 
Hela, Beas2B, U2OS, 293T, A2780, LAN-1, Sk-N-SH)]. 
mRNA levels were detected by amplification of the coding region of TMIGD1 and the control 
housekeeping gene GAPDH. Relative quantification analysis compares the levels of two different 
targets (target gene of interest and housekeeping gene) in a single sample and expresses the 
final result as a ratio of these targets.  
Y axis: normalized ratio: [conc.target/conc.reference]sample: [conc.target/conc.reference]calibrator.  
The calibrator is a positive sample with a stable ratio of target to reference and is used to 




Figure 23. TMIGD1 mRNA expression in different colon segments and in the small 
intestine 
 
Real time RT-PCR amplification of the coding region of TMIGD1 and the control housekeeping 
gene GAPDH, in colonic samples and ileum (terminal ileum). Except for the caecum segment, 
where TMIGD1 expression is relatively lower, TMIGD1 expression is equally represented in the 
remaining segments. 
Relative quantification analysis compares the levels of two different targets (target gene of 
interest and housekeeping gene) in a single sample and expresses the final result as a ratio of 
these targets. 




he calibrator is a positive sample with a stable ratio of target to reference and is used to 
ormalize all samples within one run. X axis: samples. 
In order to detect the TMIGD1 pattern of expression in extra‐colonic tissues, 
several  healthy  tissues  and  cancer  cell  lines  were  also  evaluated  by  real  time 
quantitative  RT‐PCR.    Three  additional  normal  tissues  (placenta,  trachea  and 
kidney) and only  few cancer cell  lines (colon cancer cell  line HCC2998 and kidney 
cancer  cell  line  CAKI‐2)  showed  expression  of  this  gene  although  at  much  lower 
level  than  in  the normal  colonic mucosa.  (Total RNAs extracted  from the different 






vector  (pcDNA  3.2/V5‐DEST)  for  the  mammalian  expression  of  TMIGD1  was 
generated  using  the  Gateway  cloning  system  (Invitrogen),  and  used  to  stably 
transfect the human SW480 colorectal cancer cell line (see Materials and Methods).  
As a negative control, the same cell line was stably transfected with the same vector 
without  the TMIGD1  cDNA.    The  stably  transfected  SW480  cell  line  (bulk  culture 
expressing  TMIGD1)  and  single‐cell  clones  were  isolated  by  neomycin  resistance 
and  their RNA analyzed by real  time RT‐PCR  for  the expression of TMIGD1.   Both, 
SW480 bulk culture and some of the clones (n°4 and n°8 clones in particular) were 
highly expressing TMIGD1 mRNA (Figure 24, A). 
  TMIGD1  expression  was  subsequently  estimated  at  the  protein  level  by 
Western blot analysis  (Figure 24, B).   The samples  so  far  tested were  the colonic 
normal  mucosa  (protein  extracts  from  isolated  colonic  crypts,  see Materials  and 
Methods),  SW480  bulk  culture  expressing  TMIGD1  and  its  derived  clones.    Two 
protein  extracts  for  each  sample  were  prepared,  total  membrane  protein  extract 
(TME)  and  total  extract  (TE)  with  the  aim  to  investigate  how  TMIGD1  was 
distributed in the cellular compartments.  Western blot analysis, in agreement with 
real time RT‐PCR data, showed a clear, sharp band corresponding to the expressed 















Figure 24.  TMIGD1 mRNA and protein expression in SW480 colon cancer cells stably 
transfected with pcDNA 3.2/V5-DEST vector carrying the full length TMIGD1 cDNA  
 
Panel A: Real time RT-PCR amplification of the coding region of TMIGD1 and the control 
housekeeping gene GAPDH in SW480 parental colorectal cell line and SW480 colon cancer cells 
stably transfected with pcDNA 3.2/V5-DEST vector carrying the full length TMIGD1 cDNA (bulk 
culture and derivative clones 8 and 4). Negative control: SW480 transfected with the empty DEST 
vector. Relative quantification analysis compares the levels of two different targets (target gene of 
interest and housekeeping gene) in a single sample and expresses the final result as a ratio of 
these targets. 
Y axis: normalized ratio: [conc.target/conc.reference]sample: [conc.target/conc.reference]calibrator.  
The calibrator is a positive sample with a stable ratio of target to reference and is used to 
normalize all samples within one run. X axis: samples. 
Panel B: Western blot analysis confirming, at the protein level, the RT-PCR data shown in panel 
A. Samples: normal colonic mucosa, SW480 colorectal cell line stably expressing TMIGD1 (bulk 
culture and its derivative clones 4 and 8), supernatant from cell culture medium of SW480 stably 
expressing TMIGD1 (bulk culture and clone 8). Negative control: SW480 cell line transfected with 
mpty DEST vector. TME, total membrane protein extract; TE, total protein extract.  The ~39 kDa 




To  gain  further  insights  into  the  protein  localization  in  the  cell,  three 
additional  approaches  were  used:  Immunocytochemistry  (ICC), 
immunohistochemistry  (IHC),  and  immunofluoresce  (IF).    In  studies  with  SW480 
cell lines, a specific membrane and cytoplasmic staining was detected in about 5% of 
the cells with both ICC (Figure 25) and IF (Figure 26) (details on staining patterns 
in  the  figure  legends).    In  immunofluorescence analysis,  cells were double  stained 
for actin (red stain), a protein localized in the cytoskeleton, and for nucleic acids [4'‐







Figure 25.  Expression of TMIGD1 in SW480 colon cancer cells stably transfected with 
pcDNA 3.2/V5-DEST carrying the full length TMIGD1 cDNA  
 
(Immunocytochemistry performed on the selected clone 8).  A. A portion of cells are strongly 
positive for TMIGD1, whereas most of them show low expression that can be appreciated in 
panel B or even no staining.  In panels C, D, and E, the intra-cytoplasmic distribution of TMIGD1 
can be easily detected: An accumulation of TMIGD1 appears in the perinuclear compartment 
(likely associated with the rough endoplasmic reticulum), however the entire cytoplasm and the 
cell membrane are also stained.  The fiber-like pattern of staining suggests that TMIGD1 might be 
associated also with the cytoskeleton. D. Negative control: SW480 cells stably transfected with 






Figure 26.  Expression of TMIGD1 in SW480 colon cancer cells stably transfected with 
pcDNA 3.2/V5 DEST vector carrying the full length TMIGD1 cDNA 
 
(immunofluorescence on the selected clone 8). Cellular proteins were stained with the specific 
primary antibody followed by the detection with the fluorochrome-conjugated secondary 
antibodies: TMIGD1 green, actin red and 4'-6-Diamidino-2-phenylindole (DAPI, blue stain) for the 
nucleus. A portion of cells are strongly positive for TMIGD1, whereas some of them show low 
expression that can be appreciated in panel B and D or even no staining.  
A and B. SW480 epithelial-type cells C and D. SW480 round-type cells.   
In all four panels, the intra-cytoplasmic distribution of TMIGD1 could be easily detected and 
nuclear staining excluded. TMIGD1 appears to concentrate at the perinuclear compartment (likely 
associated with the rough endoplasmic reticulum). The absence of co-localization between 
TMIGD1 and actin (panel B and D) indicates that TMIGD1 protein does not localize at the level of 




In  tissue  samples,  IHC showed  that  the epithelium of  the normal  colorectal 
mucosa expresses TMIGD1 (Figure 27).  The staining was cytoplasmic and present 
in the upper 2/3 of the colonic crypts where mostly differentiated cells are located.  
TMIGD1 was not detected  in  the  lower portion of  the crypts which represents  the 
stem and proliferating cells compartment.   Precancerous  lesions showed a weaker 











Figure 27.  Expression of TMIGD1 in normal and neoplastic colonic tissues  
 
(Immunohistochemistry).  A. Normal colonic mucosa showing the expression of TMIGD1 limited 
to the upper portion of the epithelial crypts where differentiated cells are located.  A higher 
magnification of the top of a crypt in panel B shows markedly positive superficial cells: As 
expected, the staining of TMIGD1 is cytoplasmic. Panel C shows that the expression of TMIGD1 
is very low in the lower crypt where the proliferative compartment resides.  D. Marked decrease of 
the TMIGD1 expression in a nonpolypoid lesion (15359 Brescia) in the left half of the picture 
(compare with the staining of the corresponding normal mucosa in the right part of the picture).  
E. Polypoid, adenomatous lesion (628 Brescia) also showing a dramatically decreased 
expression of TMIGD1. F. Two colon cancers, one (on the left) is a well differentiated 
adenocarcinoma which shows residual expression of TMIGD1, whereas the second (on the right) 






Figure 28.  Immunohistochemical expression of TMIGD1 in terminal ileum and kidney. 
 
TMIGD1 is expressed in the villi of the terminal ileum (A), where is markedly localized in the 
brush border (B).  Its expression is almost absent in the proliferative crypt compartment (C).  
Among a series of other organs analyzed, tubuli of the normal kidney showed the highest 
expression (D) and a strong localization in the brush border.  The expression of TMIGD1 was 
preserved in a papillary renal carcinoma (E), but was very low in clear cell renal carcinomas (an 





  Colorectal  tumorigenesis  is  one  of  the  most  explored  and  understood 
processes of cellular  transformation  in humans.   Decades of  in‐depth  investigation 





the  precursors  of  colorectal  cancers.    Until  recently,  two  major  forms  of 
precancerous  lesions  were  recognized:  the  adenoma  and  the  hyperplastic  polyp.  
The role of  the adenoma  in colorectal cancer development was clearly established 
when  in  1988  Volgestein  et  al47  introduced  the  concept  of  a  multistep  model  of 
carcinogenesis,  by  characterizing  the  genetic  events  occurring  in  progressive 





cancer  began  to  emerge  in  the  nineties,  when  Longacre  &  Fenoglio‐Preiser  85 
demonstrated the existence of a group of polyps showing mixed, both hyperplastic 
and  adenomatous  histologic  features.    These  lesions  were  termed  serrated 
adenomas,  and  the  authors  believed  that  they  represent  a  variant  of  villous  or 
tubulovillous adenoma.  Only later, with the study of Torlakovic & Snover86, lesions 
with serrated histology were proposed to be a variant of hyperplastic polyps.  These 
lesions  display  characteristic  molecular  alterations  not  observed  in  colorectal 
adenomas, and they might progress to colorectal cancer by means of a new pathway 
of  tumorigenesis, namely  the  serrated pathway.    (For a detailed description of  the 
histological and molecular features of this heterogenous group of lesions, as well as 
of  their  current  nomenclature,  see  Introduction  and  Figure  3  of.  Cattaneo  et  al.  
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“Pathways and crossroads  to colorectal  cancer”.    In Advances  in understanding  the 
basic  pathogenesis  and  clinical  management  of  pre­invasive  disease.  Edited  by 
Fitzegerald R., 2009, in press ‐ A reprint is included in the Appendix). 
A  second  level  of  complexity derives  from  the macroscopic  classification of 
precancerous lesions in the colorectum.  For decades, all the preinvasive colorectal 
lesions were  referred  to  as polyps  that  are  lesions protruding  into  the gut  lumen.  
Preneoplastic growths  that did not protrude  into  the  lumen were  first detected  in 
the  eighties by  Japanese  endoscopists17.   Ongoing  improvement of  the  endoscopic 
techniques (i.e. chromoendoscopy and high magnification colonoscopy) allowed the 
identification of such lesions also in other countries.   The newer and more precise 
terminology76  (see  Introduction)  refers  to  all  protruding  lesions  as  polypoid  and 
sub‐classify them as pedunculated (attached with a stalk to the mucosa) or sessile 
(attached  to  a  mucosa  by  a  broad  base).    The  counterpart  is  represented  by 





considered  in  planning  this  study.    The  sample  series  collected  for  the  study  has 
been extensively described  in both Material & Methods and Results  (see also Table 
2).  However,  few  additional  aspects  should  be  here  discussed.    Although 
nonpolypoid  lesions were collected solely  from the proximal segment of  the colon 
(the  objective  being  to  enrich  for  lesions  presumably  proceeding  through  the 
serrated  pathway,  as  previously  discussed),  only  5  (20%)  of  them  presented 




other  35%  displayed  serrated  architecture.    More  specifically  among  serrated 
lesions, 30% were MVSP, 4% were SSA, and less than 2% were SA.  Similar figures 




in  this  study  were  SSA,  and  2.4%  were  SA.    Since  the  inter‐observer  agreement 
among pathologists  in  the  classification of  serrated  lesions  is  rather  low87,  all  our 
lesions were analyzed by two pathologists with long experience in gastrointestinal 
pathology.    The  histological  diagnosis  reported  in  Table  2  reflects  the  final 
agreement  between  the  two  pathologists.    The  molecular  analysis  helped  us 
complement the histological diagnosis.  The two microvesicular serrated lesions and 
the  sessile  serrated  adenoma were  indeed  found  to  carry  the BRAFV600E mutation, 
known  to  be  associated  with  these  histological  subtypes  (see  Introduction).  
Evidence of this association was recently published by Carr et al23, who showed that, 
within the group of serrated lesions, sessile serrated adenomas and microvesicular 
serrated  lesions  were  significantly  more  likely  to  harbour  a  BRAFV600E  mutation.  
BRAF  and KRAS  oncogene mutations  are  early  and mutually  exclusive  events  that 
can even be detected in aberrant crypt foci25 71, 88‐90.   BRAF mutations are found in 
over two thirds of all MVSPs, SSAs, and dysplastic SAs, and they are also present in 
~15% of  all  adenocarcinomas, mainly  those  in  the  proximal  colon which  develop 
along the serrated pathway.  KRAS mutations are in contrast detected in 30‐40% of 
conventional adenomas and in ~1/3 of all adenocarcinomas27.  A similar prevalence 
of  KRAS  mutations  (48%)  was  also  reported  in  our  nonpolypoid  cases  (see 
Supple t A imen ary Table 1,  ppend x)  
The  last  aspect  to  be  commented  about  the  molecular  feature  of  the 




Advances  in understanding  the basic pathogenesis and  clinical management of pre­
invasive disease. Edited by Fitzegerald R., 2009, in press ‐ A reprint is included in the 
Appendix).    These  results,  in  agreement  with  those  reported  by  Sawyer  et  al91, 
confirm  that  the gain‐of‐function BRAF mutation precedes  the epigenetic  silencing 









studied  over  the  past  years92‐95,  that  of  nonpolypoid  lesions  still  remain  poorly 
investigated.  A single microarray study has compared the gene expression profile of 
these  two  types  of  precancerous  lesions96.    Eighteen  “flat‐type”  adenomas  and 
eighteen  “protruded‐type”  adenomas  were  analyzed  with  a  gene  expression 
platform including only 550 genes.   Nevertheless, the two groups could be divided 
into two major clusters by hierarchical clustering analysis, and therefore they were 




studies  differ  markedly  as  for  both  the  selection  of  samples  and  the  type  of 
microarray platform.   
Our study represents the first gene expression analysis of a large collection of 
precancerous  lesions,  carried  out  with  a  microarray  platform  that  allows 
investigating the expression level of all  the transcripts of the human genome.   The 
Exon  array  used  in  our  study  differs  from  the  previous  Affymetrix  arrays  (i.e. 




match)  probe,  but  alternatively  antigenomic  background  probes  that  are  not 
matched to any putative transcript region;   3) human Exon probes are designed to 







been  published  by  others97,  who  found  that,  in  a  comparison  between  Exon  and 
U133Plus2.0  arrays,  the  former  offers  greater  sensitivity  and  specificity  and may 








our  analysis  to  a  group  of  23,768  thousands  annotated  genes  (17,881  “core” 
transcript clusters plus 5,887 from the “extended” group) for two reasons.  First, we 
intended  to  limit  our  analysis  to  changes  in  the  expression  of  genes with  known 
function (even if only partially) and/or likely encoding proteins or regulatory RNA 
molecules. (The inclusion of tens of thousand unannotated transcript clusters from 
putatively  noncoding  genomic  regions  might  have  reduced  the  discriminatory 
power of expression changes in annotated genes between groups.)  Second, we tried 
to  reduce  the  complexity  of  our  data  set  due  to  the  rather  complicated  analytical 
tools  that are presently available  for Exon array data (such as the Partek Genomic 
Suite w ve ha e used).   
The  first  hint  that  polypoid  and  nonpolypoid  lesions  could  have  been 
distinguished  based  on  their  expression  profile  came  from  the  unsupervised 
analyses we performed (see Figures 9,10,11).  From this analysis, we could also infer 
that,  although  the  two  types  of  lesions were  segregated  in  different  clusters,  they 
were also sharing a large proportion of the gene expression changes (in comparison 
with  the normal mucosa).   An  in‐depth evaluation of  the multivariate  analyses,  as 
well as of dot plots of single‐gene intensity values, revealed that the transcriptome 
of  nonpolypoid  lesions,  although  more  similar  to  that  of  polypoid  lesions,  was 
somehow  closer  to  that  of  normal  mucosa  samples.    Examples  of  dot  plots 
emphasizing  this  phenomenon  are  reported  in  Figure  29,  where  an  expression 
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1,003  in  the  nonpolypoid  group  (683  were  concomitantly  dysregulated  in  both 
groups) (see Venn diagram in Figure 30).  The lower number of genes differentially 
expressed  only  in  nonpolypoid  lesions  (320  genes,  compared with  the  746  genes 
only dysregulated in polypoid lesions), as well as the fact that genes dysregulated in 
nonpolypoid  lesions  were  often  (68%)  dysregulated  also  in  polypoid  lesions 
(compared with 48% of  those dysregulated  in polypoid  lesions), corroborated our 
observation that up‐ or downregulations of transcript levels often followed a normal 
mucosa    nonpolypoid    polypoid  sequence  (although  expression  values  in 
nonpolypoid lesions were always closer to that of the cognate, precancerous group 
of samples).  
Figure 29.  Example of score plots 
of the expression level of four 
genes in the three groups of 
tissues 
 
Example of four score plots showing 
the general transcriptomic trend 
observed in the analysis: up- or 
downregulated genes often follow a 
normal mucosa  nonpolypoid  
polypoid sequence.  
The 2 plots in the upper panel show 
respectively genes found to be 
significantly upregulated in both  
groups of lesions, and another whose 
upregulation was significant only in 
the polypoid group,  
The 2 plots in the lower panel show 
respectively genes found to be 
significantly downregulated in both 
groups of lesions, and another whose 
downregulation was significant only 
in the polypoid group. Each dot plots 
has on the Y axis the log2 expression 
intensity values and in the X axis the 
samples groups polypoid (green 
dots), nonpolypoid (blue dots) and 





Figure 30.  Venn Diagramm illustration of the number of genes differentially and commonly 
dysregulated in precancerous lesions (compared with normal mucosa).  
 
Intersection of gene lists generated by a pairwise comparison between precancerous lesions and 
normal mucosa [nonpolypoid (NP) vs normal mucosa (NM) and polypoid (P) vs normal mucosa 
(NM)]. 
2,432 genes were significantly dysregulated in precancerous lesions (p value <0.001, FDR of 
0.001, step-down method): 1,429 of which in the polypoid group and 1,003 in the nonpolypoid 
group (683 were concomitantly dysregulated in both groups). The lower number of genes 
differentially expressed only in nonpolypoid lesions (320 genes, compared with the 746 genes 
only dysregulated only in polypoid lesions), as well as the fact that genes dysregulated in 
nonpolypoid lesions were often (68%) dysregulated also in polypoid lesions (compared with 48% 
of those dysregulated in polypoid lesions), corroborates the observation that up- or 





Constrained  analysis  allowed  us  to  identify,  among  the  clinical  and 
pathological  variables  considered  in  the  study,  those  able  to  explain  most  of  the 
variation  in  the  original  data  set.    These  variables  were  then  classified  based  on 
their  capacity  to  segregate  the  plotted  objects  (i.e.  samples).    The  most  relevant 
variable was undoubtedly the tissue type, accounting for nonpolypoid and polypoid 
lesions segregation, followed by histology type (adenomatous vs serrated), diameter 
of  the  lesions  and  the  degree  of  cytologic  dysplasia.    The  same  variables  were 




From  the  data  discussed  so  far,  it  might  emerge  that  nonpolypoid  and 
polypoid  lesions  do  not  differ  strikingly,  in  biological  terms  based  on  the 
transcriptome.    To  certain  extent,  this  was  expected,  since  both  precancerous 
lesions  arise  and  grow  in  the  same  organ,  likely  forced  to  overcome  a  series  of 
similar  selection  pressures  in  order  to  advance  along  the  transformation  process.  
However, the Gene Ontology analysis demonstrated that the two types of lesions are 
far from being identical.  By using dedicated software (GeneGO MetaCore), we could 
pinpoint  the  biological  pathways  and  process  networks  that  are most  significantly 
and differentially involved in the pathogenesis of each of the two groups of lesions.  
The cut‐offs we selected for this kind of analysis were a p value of 0.05 and an FDR 
of  0.05  (step‐up method)  in  order  to  include  a  large  number  of  gene  expression 
changes  in  the  analysis  and  thus  increase  its  sensitivity.    The  lists  generated 
included differentially  expressed  genes  in  nonpolypoid  or  polypoid  lesions  versus 
their  matched  normal  mucosa.    Differences  between  the  groups  of  lesions  were 
computed  by  counting,  for  each  pathway/process,  the  number  of  genes  found  in 
common  and  unique  for  each  experiment.    The  pathways  and  processes  likely 
involved in the transformation process in each group were identified based on how 
many  genes  of  those  representing  each  category  actually  showed  a  significant 
expres 8 and Supsion change (see Figures 16, 17, 1 plementary Table 4 of Appendix). 
A  striking  preponderance  of  cell­cycle  related  process  networks  was 
observed in the polypoid group of lesions (first three statistically significant process 
networks, Supplementary Table 4 of Appendix).  Among the genes involved in these 




pathways  that  were  differentially  affected  between  the  two  groups  of  lesions.  
Figure  16  clearly  illustrates  the  overrepresentation  of  cell‐cycle  related  genes  in 
polypoid  lesions.    The  length  of  the  horizontal  blue  bars  in  this  figure,  which  is 





bars  (i.e.  commonly  dysregulated  genes  in  both  groups).    Much  of  the  molecular 
circuitry  that  enables  normal  cells  to  respond  to  antigrowth  signals  is  associated 
with  the cell‐cycle  regulation,  specifically  the components governing  the  transit of 
the  cell  through  the  G1  phase,  which  was  the  most  over‐represented  cell‐cycle 
subcategory  in  our  polypoid  lesions.    It  could  be  hypothesized  therefore  that  in 
these lesions the cell‐cycle regulation is likely the most important mechanism being 
severely affected, leading thus to higher proliferation rates.  This abnormal function 
might  be  preponderant,  in  polypoid  lesions,  to  many  other  capabilities  usually 
acquired  by  transforming  cells,  such  as  self  sufficiency  in  growth  signals, 
insensitivity to antigrowth signals, or apoptosis evasion.   
In  contrast,  the  differentially  affected  process  networks  in  nonpolypoid 
lesions were cell adhesion_integrin mediated cell matrix adhesion and two signaling 
processes,  the reproduction_FSH­beta  signaling pathway and  the  inflammation_IL­2 
signaling.   We  argued  thus  that  nonpolypoid  lesions might  be  characterized  by  a 
greater  number  of  dysregulated  signaling  pathways  compared  with  polypoid 
lesions.    Indeed, among  the differentially affected biological pathways (Figure 16), 
development_IGF­1 receptor signaling was found to be more involved in nonpolypoid 
than polypoid lesions.  IGF­1 receptor signaling pathway is known to confer survival 




hypothesized  to  be  involved  in  tumorigenesis  101,  102.    Although we  relied  only  on 
transcritptomic  data,  we  could  hypothesize  that,  downregulation  of  most  of  the 
genes  involved  in  the  oxidative  phosphorylation,  should  impair  this  cellular 
function.    Defects  in  oxidative  phosphorylation  have  been  recently  correlated  to 
induction of apoptosis resistance103.   Severe inhibition of the respiratory chain can 
suppress  the  activation  of  the  proapoptotic  Bcl‐2  proteins  Bax  and  Bak,  either  of 



















Figure 31.  GeneGo MetaCore analysis of the transcriptome of precancerous lesions.  
The GeneGo MetaCore analysis highlighted the pathways/process networks significantly 
represented and differentially affected in the two groups of precancerous lesions, nonpolypoid 
and polypoid.  
The Wnt signaling and the cytoskeleton remodeling were found to be dysregulated in both types 
of lesions. Cell cycle regulation pathways and processes were overrepresented only in polypoid 
lesions while growth factors signaling pathways (e.g.IGF-1 signaling) were overrepresented in 
nonpolypoid lesions, as well as the oxidative phosphorylation pathway.  
This analysis pointed out that the propulsion of cell proliferation is achieved differently in the two 
types of lesions.  While polypoid lesions appear to take advantages of a profound dysregulation 
of the cell cycle, nonpolypoid lesions seem to benefit from modifications in cell survival pathways, 






how  propulsion  of  cell  proliferation  is  achieved.    While  polypoid  lesions  take 
advantages of a profound dysregulation of the cell cycle, nonpolypoid lesions seem 
to  benefit  from  modifications  in  cell  survival  pathways,  presumably  through  an 
activation  of  growth  factor  signaling  pathways  and  an  attenuation  of  apoptosis 
(Figure.31).    A  mechanism  of  apoptosis  evasion  was  also  proposed  for  serrated 
lesions by Jass J. et al.105   based on the observation that inhibition of anoikis might 
be  the  underlying mechanism  common  to  all  lesions  showing  epithelial  serration.  
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Based  on  their  hypothesis,  the  inhibition  of  apoptosis  could  be  due  either  to  an 
epigenetic  mechanism  in  response  to  tissue  injury  or  to  a  “neoplasia‐like” 
mechan vo inism in lv g a mutation of a proto‐oncogene as BRAF or KRAS106, 107. 
Figure  31  also  shows  the  biological  processes  that  are  commonly 
dysregulated  in both  types of  lesions,  such as  the Wnt signalling and cytoskeleton 
remodeling.    The  pathways  that were most  represented  in  both  groups  of  lesions 
were  indeed  cytoskeleton  remodeling, TGF­β, WNT  signaling  pathway  and  immune 
response  (Supplementary  Table  4).    Wnt  and  TGF‐  β  signalling  are  known  to  be 
abnormally dysregulated in the vast majority of colorectal neoplasms108. 
 We  also  analyzed  the  gene  expression  changes  that  might  affect  the 
metabolism  (Figure  18  and  Supplementary  Table  4).    Briefly,  while  pathways 
leading  to  lipid  synthesis  were  equally  represented  in  both  groups,  3  pathways 
involved  in  a  process  of  glucose  turnover  that  produces  NADPH  as  reducing 
equivalents and pentoses as essential part of nucleotides, were more represented in 
the group of nonpolypoid lesions.  Tumor cells must increase their cellular biomass 
prior  to cell division,  therefore metabolic  changes are necessary  to provide  tumor 
cells  with  sufficient  substrates  for  the  biosynthetic  machinery.    Some  of  the 
glycolytic  intermediates  feed  the  pentose  phosphate  pathway  leading  to  the 
synthesis of  ribose‐5‐phosphate.   Oncogenes and  tumor suppressor gene products 
play an  important  role  in diverting glycolytic metabolites  into  the branches of  the 
penthose  phosphate  pathway104,  109.    This  observation  leads  us  to  speculate  that 






We  have  recently  initiated  a  project  for  the  functional  characterization  of 
TMIGD1, a protein with unknown function whose corresponding mRNA was found 
dramatically  downregulated  in  both  nonpolypoid  and  polypoid  lesions.    By 




normal  mucosa  TMIGD1  was  expressed  in  the  upper  2/3  of  the  crypts,  were 
differentiated  absorptive  cells  are  located.    Interestingly,  in  the  proliferative 
compartment  of  the  crypts  TMIGD1  was  completely  absent.    Similar  pattern  of 
expression was observed in the small intestine (terminal ileum) were expression of 
TMIGD1  was  strictly  limited  to  the  brush  border.  The  Lieberkühn  crypts,  which 
represent  the  proliferative  compartment,  did  not  express  the  protein.    These 
evidences and the fact that TMIGD1 expression is lost progressively in the process of 
epithelial  cell  transformation  (from benign neoplasia  to cancer),  encouraged us  to 
hypoth iation. esize TMIGD1 as marker of epithelial different
We  have  also  been  successful  to  re‐express TMIGD1  in  a  colon  cancer  cell 
line, SW480, devoid of this protein (Figure 24).  Interestingly, only a small portion of 
stably‐transfected SW480 cells strongly express TMIGD1, whereas its expression is 
low  or  absent  in  the majority  of  cells.    This  finding was  associated with  a  strong 
immunodetection  signal  in  Western  blot.    One  possibility  is  that  these  cells  may 
select for loss of expression of this protein during cellular expansion.  This silencing 
process,  whatever  its  underlying  mechanism  might  be,  could  be  related  to  our 
hypothesis  that TMIGD1 may be  a marker  of  cellular  differentiation.    Therefore,  a 
highly proliferating cancer cell  line  like SW480 might take advantage by switching 
off  its  expression.    However, we  have  seen  that  the  small  percentage  of TMIGD1‐




which were designated E‐type  (i.e.  epithelial) and R‐type  (i.e.  round)  (Figure 32).  
The majority of SW480 E‐type cells,  is characterized by adhesive growth to plastic 
plates  and  typical  cuboidal  shape  of  cells  forming  epithelial  colonies.    The  less 
abundant R type cells have rounded morphology, tend to grow as piled up on each 
other  and  they  are  loosely  attached  to  the plate.    SW480  cells  harbor most  of  the 
genetic abnormalities that characterize advanced colon cancers such as activation of 
KRAS  oncogene, CMYC  amplification,  deletion  of  chromosome 18,  and mutation  of 
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APC  and p53  tumor suppressor genes.    In addition,  these cells are defective  for E‐
cadherin and express high  levels of nuclear ß‐catenin,  transforming growth  factor 
and epidermal growth factor receptors111. Compared to E‐type, isolated R‐type cells 
display  decreased  doubling  time,  loss  of  contact  inhibition,  less  adhesiveness  to 
culture  plates  and  anchorage‐independent  growth  in  soft  agar,  and  a much more 




Figure 32.  Two distinct subpopulation of the SW480 colorectal cell line 
 
Two subpopulations characterize SW480 colorectal cancerccells: Epithelial (E) type cells (green 
arrow for reference) and Round (R) type cells (red arrow for reference). SW480 E-type cells 
represent the majority and are characterized by adhesive growth to plastic plates and typical 




he R type cells, less abundant, have rounded morphology, tend to grow as piled up on each 




reported  in  the  literature), and  that both  types of cells are stained (Figure 25)  for 




and  sharp  perinuclear  staining  with  a  tendency  to  temper  in  a  surrounding 
cytoplasm  (Figure  26  A,  B),  whereas  R‐type  cells,  being  characterized  by  a  large 
nucleus and narrow cytoplasm, showed a slightly modified pattern of staining that 
was  mainly  concentrated  at  the  plasma  membrane  and/or  widespread  in  the 
cytoplasm  (Figure  26 C, D).    The  fact  that TMIGD1 was more  expressed  in E‐type 








Our  data  represent  the  first  comprehensive  transcriptomics  analysis  of 
nonpolypoid  and  polypoid  precancerous  colorectal  lesions  accomplished with  the 
Affymetrix Exon array platform.  The results reported in this dissertation regard the 
expression  level  of  the  annotated  transcript  clusters  (corresponding  to 
approximately 23,000 genes).   The gene expression analysis will be soon extended 
to  all  the  predicted  exons  (an  additional  2.5  thousands  transcript  clusters).    This 
work  should  reveal  additional  gene  expression  changes  (including  those  of 
noncoding RNAs) that might be exploited for diagnostic, prognostic and therapeutic 
applications.   The Exon array  should also  allow us  to  investigate  the  frequency of 
alternative  splicing  events  in  different  tissues.    A  first  attempt  to  analyze  this 
phenomenon  has  been  made  by  our  collaborators  (Drs.  Susanne  Pedersen, 
Lawrence  LaPointe,  Clinical  Genomics  Pty  Ltd  ,  Australia).    This  analysis  has 
highlighted  that  exon  level  gene  chip  analysis  is  complicated  due  to  data  size, 
annotations  differences  between  Ensembl  and  Affymetrix‐based  databases,  and  a 




will  be  generated  in  a metabolomics  study  recently  initiated  in  our  group.    These 
data, along with other ‐omics data available in public databases, will ultimately help 
us to generate a reliable computer replica of different types of colorectal neoplasms. 
The  functional  characterization of TMIGD1  is another priority  in our group.  
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Abbreviations:  IHC,  immunohistochemistry;TA,  tubular  adenoma; TVA,  tubulovillous  adenoma; VA, 
villous adenoma; MVSP, microvesicular serrated polyp; SA, serrated adenoma; SSA, sessile serrated 
adenoma;  LGD,  low‐grade  dysplasia;  HGD,  high‐grade  dysplasia.  POS,  positive; wt, wild‐type; mut, 
m Vutated;  Gly,  glycine;  Cys,  cysteine;  Val,  valine;Asp,  aspartate;  Ala,  alanine;  600E,  valine  to 
glutamate substitution at codon 600. 
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  Tissue type (nonpolypoid vs polypoid)  Histology type (adenomatous vs serrated) 



























1  3452417  SLC38A4  2345061  CLCA4  3638607  ANPEP  2620937  TDGF1 
2  3388807  MMP1  3751859  TMIGD1  3751859  TMIGD1  3421118  RAP1B 
3  3175971  PSAT1  2584113  GCG  2345061  CLCA4  2345023  CLCA1 
4  2659393  OSTalpha  3067250  SLC26A3  2647315  TM4SF4  3453732  TUBA1B 
5  3360401  HBB  2733483  BMP3  3016070  MUC17  2477438  QPCT 
6  3720896  CDC6  2703750  SI  2408832  GUCA2A  3452417  SLC38A4 
7  3504369  LOC729680  3332424  MS4A12  3921490  B3GALT5  3235663  LO 0 C28307
8  3490892  OLFM4  3090294  ADAMDEC1  2584113  GCG  3422144  LGR5 
9  2319340  SLC25A33  3142967  CA1  3986647  VSIG1  2849592  RBBP4 
10  4036196     3365203  TPH1  3067250  SLC26A3  3122703  DEFA6 
11  2761829  FGFBP1  3928415  CLDN8  2703750  SI  3255284  C10orf99 
12  3129149  PBK  2417008  INSL5  2324084  CDA  3856612  ZNF43 
13  3504367  LOC729680  2531908  B  3GNT7 3933559  TFF1  2561216  REG3A 
14  3690154  NETO2  3210013  TRPM6  2898986  SLC17A4  3540074  AKAP5 
15  3388830  MMP3  3890640  PCK1  3655621  ZG16  3490892  OLFM4 
16  3401786  C12orf5  3165025  RP11‐145E5.4 2751009  ANXA10  2507928  HNMT 
17  3783788  MEP1B  3237282  FAM23A  2794408  HPGD  2505419  NOC2L 
18  2833691  K  CTD16 2408832  GUCA2A  2584018  DPP4  3183206  SLC44A1 
19  3843677  NAG18  3063501  CYP3A4  3596147  GCNT3  2565935  ANKRD36B 
20  3292694  DNA2  2730746  SLC4A4  3461883  PTPRR  2941972  C6orf105 
21  3258966  CYP2C18  3204285  CCL19  2570193  MALL  3137875  GGH 
22  3670663  C  ENPN 2732508  CXCL13  2777276  ABCG2  3023803   
23  3168508  MELK  3549092  CHGA  2974592  VNN1  2872958  MGC32805 
24  3541383  ARG2  2709750  SST  3063501  CYP3A4  3875908  PLCB4 
25  2327373  LOC100129624  2779231  ADH1B  2412624  RAB3B  2880422  SPINK1 
26  3852565  ASF1B  3204301  CCL21  2514304  DHRS9  3249978  STOX1 
27  3058944  HGF  2855285  SEPP1  3598267  OSTbeta  2339334  L1TD1 
28  2333136  CDC20  2898986  SLC17A4  2633737  GPR128  3181417  A  NP32B
29  2575949  TUBA3E  3932397  C21orf88  3114512  FER1L6  3540079  AKAP5 
30  3166815  SPINK4  2440413  ITLN1  3142967  CA1  2561182  REG1B 
31  3248289  CDC2  3059667  SEMA3D  3218077  ALDOB  3392091  FAM55D 
32  3880827  GINS1  2835300  SLC26A2  2602304  TM4SF20  4013422  PGAM4 
33  3128731  PNMA2  3921490  B3GALT5  3421824  C12orf28  2402991  CHCHD3 
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34  2378937  DTL  3662150  MT1M  2730746  SLC4A4  3767480  AXIN2 
35  2469252  RRM2  3758775  PYY  3090294  ADAMDEC1  3210616  PRUNE2 
36  3011838  STEAP1  3863214  CEACAM7  3758775  PYY  2319340  SLC25A33 
37  3104758  RPSA  3982612  GPR174  3028164  LOC100124692  3389353  CASP1 
38  3607510  FANCI  3237280  FAM23A  3734517  OTOP2  3504369  LOC729680 
39  3249533  AKR1B10  3105600  CA2  2842624  PCDH24  2847967  SEMA5A 
40  3629103  KIAA0101  3323748  TMEM16E  3321361  SPON1  3498476  UNQ1829 
41  3527514  NP  2945882  CMAH  2844888  BTNL3  3253438  RPS24 
42  3703885  SLC7A5  2432336  LOC727820  3114477  FER1L6  3299467  AN 2 KRD2
43  3388785  MMP10  2598261  FN1  3405748  EMP1  2704996  SKIL 
44  2339334  L1TD1  2700244  CP  3863214  CEACAM7  3401786  C12orf5 
45  3485074  RFC3  3593931  GLDN  3365203  TPH1  3169331  ALDH1B1 
46  3944129  HMOX1  3333899  R  ARRES3 2909263  MEP1A  3292590  PBLD 
47  3725572  B4GALNT2  3960174  LGALS2  3549092  CHGA  2726542  FLJ21511 
48  3527785  SLC39A2  2854088  LIFR  2559637  NAT8B  2783715  MAD2L1 
49  3331903  FAM111B  3522327  SLC15A1  3165025  RP11‐145E5.4  3521816  OXGR1 
50  2783715  MAD2L1  3662201  MT1H  2899012  SLC17A4  2375893  SNRPE 
51  2354433  HSD3B2  3652902  SCNN1B  3783788  MEP1B  3351525  LO 3 C10013132
52  3721926  TUBG1  2584018  DPP4  3316600  MUC2  2688049  RETNLB 
53  2527253  IGFBP2  2772088  UGT2B17  3160658  SLC1A1  3195971  CBWD1 
54  3747399  KRT14  2372858  RGS2  2662435  CIDECP  3369249  APIP 
55  3324447  FIBIN  3848039  C3  2372858  RGS2  2951078  RPL35 
56  3797543  FLJ38028  2377283  CR2  3114443  FER1L6  3690154  NETO2 
57  2388219  EXO1  3443868  CD69  3475324  RHOF  3135567  LYPLA1 
58  2354634  PHGDH  2940202  F13A1  2775909  PLAC8  2828135  LYRM7 
59  3696666  NQO1  3681488  PLA2G10  3443226  MFAP5  3975431  RPSA 
60  3800245  TERF1  3321361  SPON1  2498911  SULT1C2  3512948  C13orf18 
61  3516443  FLJ25694  2374126  NR5A2  3756566  KRT20  2651835  GPR160 
62  3587457  ARHGAP11A  2779271  ADH1C  2590491  NEUROD1  3124972  KI 4 AA048
63  2548699  CYP1B1  2373336  CFH  3105600  CA2  2457691  TLR5 
64  3703112  GINS2  3761538  HOXB13  3980614  GDPD2  3409317  REP15 
65  2673085  CDC25A  2356425  PDZK1  3890640  PCK1  2781592  RBMXP4 
66  3772158  TK1  3592304  SLC28A2  3376512  HRASLS2  4042278  MMP23A 
67  3122984  SPAG11B  3617574  GOLGA8B  3693141  PLLP  3807487  RPL17 
68  3318052     2372781  RGS1  3175274  PCSK5  2435005  SELENBP1 
69  2500919  SLC20A1  3450655  CPNE8  3448088  BHLHB3  3314040  BNIP3 
70  3357397  GLB1L2  2925590  TMEM200A  2717481  MGC10981  3977646  GSPT2 
71  3377423  CDCA5  3332465  MS4A8B  3028184  LOC100124692  3315675  IFITM1 
72  3936913  CDC45L  2865390  EDIL3  2496907  IL1R2  2842561  HIGD2A 
73  3023803     3811000  RNF152  2733483  BMP3  3076489  MRPS33 
74  3689880  RAB43  2400027  PLA2G2A  4054128  LOC100132488  3348911  SDHD 
75  2540157  ODC1  2974592  VNN1  2997674  LOC641963  2999664  L  OC 702220
76  3299469  ANKRD22  3598267  OSTbeta  3028120  LOC93432  4014029  RP 6 S6KA
77  3216671  CTSL2  3031517  G  IMAP7 2409820  BEST4  3360401  HBB 
78  3186123  ORM1  3142217  PAG1  2359492  SPRR1A  2649609  MLF1 
79  3474831  OASL  2373842  PTPRC  2996970  LOC401324  2785685  L  OC646187
80  3590086  RAD51  3655621  ZG16  3811000  RNF152  3986623  LOC286440 
81  3178583  CKS2  2565935  ANKRD36B  4016319  NXF3  3711806  MEIS3P1 
82  2997376  ANLN  2337740  PRKAA2  2709750  SST  3399623  THYN1 
83  2947073  HIST1H1B  2806468  IL7R  2671936  SLC6A20  3666873  NFAT5 
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84  3477610     3351300  CD3G  3522912  ZIC5  3981735  LOC554203 
85  3228545  OBP2B  3587553  GREM1  3332424  MS4A12  2860666  TAF9 
86  3080280  XRCC2  3729419  CA4  3142217  PAG1  3304970  SH3PXD2A 
87  3593575  SLC27A2  2554018  E  FEMP1 2401251  HTR1D  3519840  SLITRK6 
88  3758317  BRCA1  3061438  SAMD9  3907556  FLJ40606  3388673  MMP7 
89  3122703  DEFA6  2635741  CD96  2501204  IL1RN  3733065  MAP2K6 
90  3886223  MYBL2  3061484  LOC253012  3933550  TFF2  2780388  CXXC4 
91  3145107  C  CNE2 2480585  RHOQ  3729419  CA4  3540076  AKAP5 
92  3761608  LOC100128010  2590491  NEUROD1  2332481  GUCA2B  2431031  HMGCS2 
93  3200648  ADFP  2870964  EPB41L4A  2381903  RP11‐452F19.2  3345415  SF  RS2B
94  2367015  FMO2  2937144  SMOC2  3808745  CCDC68  3701779  HSPC105 
95  3658980  GPT2  2777276  ABCG2  3274898  TUBAL3  2530713  CCL20 
96  3808678  SNRPG  3114022  ZHX2  3761034  ATAD4  3003143  MRPS17 
97  2953570  TREM1  3351280  CD3E  3932397  C21orf88  3955483  bA9F11.1 
98  2900091  HIST1H2AL  2647073  CPB1  3592304  SLC28A2  3635159  ST20 
99  2729821  TMPRSS11E  2601648  DOCK10  2955638  CLIC5  2877159  H  NRNPA0


















































1  3751859  TMIGD1  3204285  CCL19  3751859  T  MIGD1 2345023  CLCA1 
2  2584113  GCG  2732508  CXCL13  3638607  ANPEP  2620937  TDGF1 
3  2417008  INSL5  2773369  CXCL5  2408832  GUCA2A  2561216  REG3A 
4  2772167  U  GT2A3 2620937  TDGF1  3016070  M  UC17 3122703  DEFA6 
5  2561182  REG1B  3204301  CCL21  2647315  TM4SF4  2565935  ANKRD36B 
6  3662201  MT1H  3848039  C3  3986647  VSIG1  2688049  RETNLB 
7  3655621  ZG16  2377283  CR2  3067250  SLC26A3  2849592  RBBP4 
8  2561216  REG3A  3709744  NDEL1  2345061  CLCA4  2561182  REG1B 
9  3662247  MT1X  3851230  LOC729747  3921490  B3GALT5  3122828  DEFA5 
10  2400027  PLA2G2A  2730303  C4orf7  2324084  CDA  2339334  L1TD1 
11  3928415  CLDN8  3173479  FOXD4L3  2584113  GCG  3711806  MEIS3P1 
12  2830861  EGR1  3360724  OR56A1  2898986  SLC17A4  3210616  PRUNE2 
13  2815018  RPL7L1  3201300  IFNA6  3933559  TFF1  3422144  LGR5 
14  3917582  KRTAP6‐3  3203636  SUGT1P  2751009  ANXA10  2319340  SLC25A33 
15  3114443  FER1L6  3477993  LOC100134058 3655621  ZG16  2880422  SPINK1 
16  3544525  FOS  3789769  ONECUT2  2514304  DHRS9  3452417  SLC38A4 
17  2656379     3617574  GOLGA8B  3596147  GCNT3  2507928  HNMT 
18  3365203  TPH1  3512948  C13orf18  2412624  RAB3B  2490324  REG1A 
19  2731542  AREG  3527290  OR4N2  3598267  OSTbeta  4037778  DMBT1 
20  2501835  DPP10  2367881  GAS5  3863214  CEACAM7  3490892  OLFM4 
21  2409820  BEST4  2756238  LOC100129466 2570193  MALL  3856612  ZNF43 
22  3114512  FER1L6  3358946  CTSD  3090294  ADAMDEC1  2351809  LOC1 383 00130
23  3114477  FER1L6  2861093  FLJ40092  3105600  CA2  3351525  LOC1 323 00131
24  3991889  FAM127A  3909768     2974592  VNN1  3875908  PLCB4 
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25  2898934  SCGN  3026216  CHRM2  3376512  HRASLS2  3150281  S  AMD12
26  2490324  REG1A  3756319  CCR7  3461883  PTPRR  3409317  REP15 
27  3662150  MT1M  3370855  LOC399884  2794408  HPGD  3137875  GGH 
28  2531908  B3GNT7  2810627  LOC401188  3332424  MS4A12  2382667  D  NAH14
29  2783493  FABP2  2443450  SELL  2332481  GUCA2B  3392091  FAM55D 
30  3376512  HRASLS2  3564350  FLJ45671  3405748  EMP1  3767480  AXIN2 
31  3124972  KIAA0484  2781138  LEF1  2372858  RGS2  3421118  RAP1B 
32  3681488  PLA2G10  2439303     3142967  CA1  3540074  AKAP5 
33  3314040  BNIP3  3318443  T  RIM22 3218077  ALDOB  3975431  RPSA 
34  2525989  CPS1  2345061  CLCA4  2498911  SULT1C2  3540076  AKAP5 
35  3016070  MUC17  3768295  LOC100131307 2844888  BTNL3  3570774  PDZD11 
36  2650357  ARL14  3512275  LOC400128  2777276  ABCG2  4014029  RP 6 S6KA
37  3890640  PCK1  3422144  LGR5  2496907  IL1R2  2872958  MGC32805 
38  2572274  LOC389023  3982741  WBP11  2730746  SLC4A4  2477438  QPCT 
39  3549757  SERPINA3  3558912  LOC728755  2703750  SI  2827525  SLC12A2 
40  3443226  MFAP5  3336400  RBM14  2899012  SLC17A4  2432412  PDE4DIP 
41  2436524  TPM3  3084347  DEFB109  3475324  RHOF  3401920  GALNT8 
42  3067250  SLC26A3  3578152  TCL1A  3421824  C12orf28  3235663  L  O 0C28307
43  3182396  LOC100129070  3621002  LOC100129835 3718191  CCL8  4042278  MMP23A 
44  4022447  GPC3  2845362  SLC9A3  2359352  LCE2D  3208355  CBWD3 
45  3933559  TFF1  3688019  LOC647086  3028164  LOC 92 1001246 4055661  MAOA 
46  3061484  LOC253012  3921599  PCP4  2514926  EIF2S2  3249978  STOX1 
47  2779271  A  DH1C 3197418  LOC100128701 3890640  PCK1  2815018  RPL7L1 
48  3960174  LGALS2  3436744  TMEM132B  3443226  MFAP5  2941972  C  6orf105
49  3692999  MT1G  2759201  LOC100129623 2835119  LOC728264  2651835  G  PR160
50  4031664  RBMY2FP  3230440  RP11‐216L13.5 3114512  FER1L6  3807487  RPL17 
51  3662106  MT1DP  3167301  W  DR40A 2773972  CXCL11  3986623  LOC286440 
52  2408832  GUCA2A  3679801  GRIN2A  2401251  HTR1D  2457691  TLR5 
53  3019939  FOXP2  2849592  RBBP4  2662435  CIDECP  2868044  PCSK1 
54  3258625  GPR120  4015538  HNRPA1P5  2584018  DPP4  3827572   
55  3662130  MT1L  2457919  LOC441124  3063501  CYP3A4  3535425  TXNDC1 
56  3902379  LOC100130623  3331129  OR5AK2  2709750  SST  2847967  SEMA5A 
57  3592304  SLC28A2  2737596  BANK1  3886773  SEMG1  3061484  LO 2 C25301
58  3453732  TUBA1B  3953600  KLHL22  3693141  PLLP  3851493  ZNF799 
59  3332465  MS4A8B  2602477  LOC100132934 3165025  RP .4 11‐145E5 3023803   
60  2703750  SI  3756703  KRTAP2‐1  3894545  SDCBP2  3416907  ITGA7 
61  3522327  SLC15A1  3273846  LOC642422  3522912  ZIC5  2471351  LO 2 C28495
62  3386217  CHORDC1  2440258  SLAMF6  3204285  CCL19  3840125  ZNF766 
63  4043381  S100A1  3104489  STMN2  3549092  CHGA  3210497  PRUNE2 
64  2975014  SGK1  2731916  LOC100129865 3142217  PAG1  2461717  TOMM20 
65  2359352  LCE2D  3401786  C12orf5  2671936  SLC6A20  3519840  SLITRK6 
66  3274898  TUBAL3  3752584  ARGFXP2  2559637  NAT8B  3169331  ALDH1B1 
67  2590491  NEUROD1  2348992  VCAM1  2842624  PCDH24  2338397  LOC391044 
68  2647073  CPB1  3619157     2602304  TM4SF20  2389062  FAM36A 
69  3906886  LOC149703  4039195  HERC2P7  3175274  PCSK5  2946714  H K IST1H2B
70  3984136     3756591  KRT23  2955638  CLIC5  3105430  LRRCC1 
71  2761829  FGFBP1  2327162  LOC729973  3653677  AQP8  2405358  K  IA 9A050
72  2733498  BMP3  2523874  ICOS  2733483  BMP3  3513752  CAB39L 
73  2745065  LOC646484  3399655  LOC729860  2501204  IL1RN  3580769  CKB 
74  2951655  FKBP5  2878973  LOC729080  3756566  KRT20  3255284  C10orf99 
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75  2411569  SLC5A9  3172884  LOC100132139 3932397  C21orf88  3136294   
76  3662158  MT1JP  3372728  LOC340970  3028184  LOC 92 1001246 4010017  RP11‐167P23.2 
77  3249043  REEP3  3281429  LOC729432  3758775  PYY  2585933  SPC25 
78  2721087  GBA3  4051214  LOC100128670 2775909  PLAC8  2860666  TAF9 
79  2429235  AMPD1  3939952  DKFZP434P211 2409820  BEST4  3724432  LR 2 RC37A
80  2582124  NR4A2  2345849  LOC400759  2717481  MGC10981  3369249  APIP 
81  3059667  SEMA3D  3208327  LOC100133034 2940202  F13A1  3230440  RP1 3.5 1‐216L1
82  3579712  LOC100130955  2455191  LOC284669  3204301  CCL21  3777958  RAB12 
83  2709750  SST  2391813  SLC35E2  2845362  SLC9A3  2520429  MYO1B 
84  3937967  FLJ26056  3583541  LOC283767  3811000  RNF152  2402991  CH 3 CHD
85  2354433  HSD3B2  3558375  GZMB  2656379     2430975  LOC644237 
86  3868726  KLKP1  2379665  PROX1  2633737  GPR128  3717250  NF1 
87  3039671  SOSTDC1  3838385  CD37  3587553  GREM1  3401786  C12orf5 
88  3025433  AKR1B10  2326463  CD52  3980614  GDPD2  2783473  LOC401152 
89  2878273  HBEGF  3761164  SKAP1  3928415  CLDN8  3479289  PXMP2 
90  3900857  C20orf56  3339066  KRTAP5‐10  2939782     3181417  A  NP32B
91  3593931  GLDN  3657747  LOC100129631 2384558  TMEM78  3292694  DNA2 
92  2841165  LOC100129026  2892316  LOC285771  2898934  SCGN  2736224  ATOH1 
93  2799030  SLC6A19  3452417  SLC38A4  3907190  SLPI  2562603  LOC90784 
94  3106961  LOC286144  3340404  SPCS2  3734517  OTOP2  3060182  ABCB1 
95  3322201  LOC441453  3281311  C10orf115  3448088  BHLHB3  3333425  SCGB1D2 
96  3122828  DEFA5  3982612  GPR174  4016319  NXF3  2353283  VANGL1 
97  3715614  SLC13A2  3981829  LOC554203  2859387  HTR1A  2697490  CEP70 
98  3981701  TSIX  3961910  LOC100129648 3200031  BNC2  2425447  DPH5 
99  3974019  TSPAN7  2945741  C6orf32  3321361  SPON1  2997097   











Tissue type  p­v  Log FC  p­v 
Transcript 
ID 
Gene_assignment  Gene Symbol  p­value  ( ) NP vs. NM (N ) P vs. NM (  P vs. NM)
Log FC 
( ) P vs. NM
3326635  NM_000610 // CD44 // CD44 molecule (Indian blood group) // 11p13 // 960 /// NM_0  CD44  2.02E‐27  2.16E‐23  2.97091  6.75E‐22  3.32588 
3604147  NM_018689 // KIAA1199 // KIAA1199 // 15q24 // 57214 /// ENST00000356249 // KIAA1  KIAA1199  1.65E‐26  3.03E‐22  9.47069  2.44E‐21  13.1131 
3697746  NM_015020 // PHLPPL // PH domain and leucine rich repeat protein phosphatase‐lik  PHLPPL  3.96E‐26  1.04E‐21  ‐2.91885  3.63E‐21  ‐3.5068 
2733483  NM_001201 // BMP3 // bone morphogenetic protein 3 // 4q21 // 651 /// ENST0000028  BMP3  4.00E‐26  6.75E‐18  ‐4.81337  6.04E‐24  ‐16.7064 
3751859  NM_206832 // TMIGD1 // transmembrane and immunoglobulin domain containing 1 // 1  TMIGD1  1.76E‐25  1.75E‐19  ‐18.959  5.44E‐22  ‐66.3636 
3729419  NM_000717 // CA4 // carbonic anhydrase IV // 17q23 // 762 /// ENST00000300900 //  CA4  2.89E‐24  3.27E‐19  ‐5.5067  4.03E‐20  ‐8.9876 
3165025  NR_003529 // RP11‐145E5.4 // antisense noncoding RNA in the INK4 locus // 9p21.3  RP11‐145E5.4  3.75E‐24  1.07E‐15  ‐3.15355  3.05E‐22  ‐8.62233 
3719210  NM_024308 // MGC4172 // short‐chain dehydrogenase/reductase // 17q12 // 79154 //  MGC4172  3.76E‐24  5.57E‐20  ‐3.47596  3.84E‐19  ‐4.17803 
3921933  NM_012105 // BACE2 // beta‐site APP‐cleaving enzyme 2 // 21q22.3 // 25825 /// NM  BACE2  3.83E‐24  1.74E‐18  1.91813  1.59E‐20  2.46748 
3774906  NM_003004 // SECTM1 // secreted and transmembrane 1 // 17q25 // 6398 /// ENST000  SECTM1  1.17E‐23  2.83E‐18  ‐2.9147  7.18E‐20  ‐4.22882 
2408832  NM_033553 // GUCA2A // guanylate cyclase activator 2A (guanylin) // 1p35‐p34 //   GUCA2A  1.37E‐23  2.57E‐18  ‐9.85327  1.02E‐19  ‐21.0042 
2777276  NM_004827 // ABCG2 // ATP‐binding cassette, sub‐family G (WHITE), member 2 // 4q  ABCG2  2.10E‐23  9.28E‐19  ‐7.08986  5.57E‐19  ‐11.1396 
2456687  NM_018713 // SLC30A10 // solute carrier family 30, member 10 // 1q41 // 55532 //  SLC30A10  2.71E‐23  8.16E‐20  ‐6.44879  1.41E‐17  ‐7.00735 
2409820  NM_153274 // BEST4 // bestrophin 4 // 1p33‐p32.3 // 266675 /// ENST00000372207 /  BEST4  1.04E‐22  5.00E‐18  ‐4.7066  2.07E‐18  ‐6.87213 
3469319  NM_018171 // APPL2 // adaptor protein, phosphotyrosine interaction, PH domain an  APPL2  1.73E‐22  2.31E‐17  ‐1.83577  1.26E‐18  ‐2.23045 
3666366  NM_001793 // CDH3 // cadherin 3, type 1, P‐cadherin (placental) // 16q22.1 // 10  CDH3  3.22E‐22  6.97E‐19  4.78051  1.73E‐16  5.01246 
3764399  NM_017763 // RNF43 // ring finger protein 43 // 17q22 // 54894 /// ENST000003762  RNF43  3.51E‐22  1.30E‐18  2.87397  9.42E‐17  3.08975 
3454892  NM_007210 // GALNT6 // UDP‐N‐acetyl‐alpha‐D‐galactosamine:polypeptide N‐acetylga  GALNT6  3.72E‐22  3.38E‐18  2.66274  3.43E‐17  3.03189 
3734517  NM_178160 // OTOP2 // otopetrin 2 // 17q25.1 // 92736 /// ENST00000331427 // OTO  OTOP2  5.99E‐22  3.24E‐17  ‐5.16622  8.26E‐18  ‐7.954 
2908423  NM_001078177 // SLC29A1 // solute carrier family 29 (nucleoside transporters), m  SLC29A1  6.15E‐22  2.67E‐18  2.39115  1.23E‐16  2.56919 
2898986  NM_005495 // SLC17A4 // solute carrier family 17 (sodium phosphate), member 4 //  SLC17A4  7.74E‐22  8.16E‐15  ‐3.46903  2.06E‐19  ‐7.94106 
3598267  NM_178859 // OSTbeta // organic solute transporter beta // 15q22.31 // 123264 //  OSTbeta  9.49E‐22  2.81E‐17  ‐7.95725  2.18E‐17  ‐12.6067 
3653677  NM_001169 // AQP8 // aquaporin 8 // 16p12 // 343 /// ENST00000219660 // AQP8 //   AQP8  9.62E‐22  6.26E‐18  ‐12.7823  1.11E‐16  ‐17.0548 
3816778  NM_002067 // GNA11 // guanine nucleotide binding protein (G protein), alpha 11 (  GNA11  1.23E‐21  8.54E‐19  ‐2.0249  2.56E‐15  ‐1.96021 
2835848  NM_078483 // SLC36A1 // solute carrier family 36 (proton/amino acid symporter),   SLC36A1  1.36E‐21  1.00E‐15  ‐1.75779  1.94E‐18  ‐2.28137 
3280573  NM_006393 // NEBL // nebulette // 10p12 // 10529 /// NM_213569 // NEBL // nebule  NEBL  1.64E‐21  4.15E‐19  5.09268  1.59E‐14  4.20095 





2520069  NM_001042521 // MGC13057 // hypothetical protein MGC13057 // 2q32.2 // 84281 ///  MGC13057  2.15E‐21  4.50E‐17  ‐2.63313  6.16E‐17  ‐3.19984 
3791782  NM_002639 // SERPINB5 // serpin peptidase inhibitor, clade B (ovalbumin), member  SERPINB5  2.26E‐21  5.39E‐19  6.47402  2.29E‐14  5.15621 
3767480  NM_004655 // AXIN2 // axin 2 // 17q23‐q24 // 8313 /// ENST00000307078 // AXIN2 /  AXIN2  2.30E‐21  6.66E‐17  3.64005  4.69E‐17  4.87107 
3142217  NM_018440 // PAG1 // phosphoprotein associated with glycosphingolipid microdomai  PAG1  2.68E‐21  5.47E‐14  ‐2.25257  4.18E‐19  ‐4.09289 
2862696  NM_003633 // ENC1 // ectodermal‐neural cortex (with BTB‐like domain) // 5q12‐q13  ENC1  2.88E‐21  7.27E‐17  2.37842  6.48E‐17  2.87009 
3549092  NM_001275 // CHGA // chromogranin A (parathyroid secretory protein 1) // 14q32 /  CHGA  3.49E‐21  6.28E‐14  ‐3.31257  5.65E‐19  ‐7.9226 
3220384  NM_057159 // LPAR1 // lysophosphatidic acid receptor 1 // 9q31.3 // 1902 /// NM_  LPAR1  3.64E‐21  1.21E‐14  ‐1.88395  1.61E‐18  ‐2.73665 
2815220  NM_173490 // TMEM171 // transmembrane protein 171 // 5q13.2 // 134285 /// ENST00  TMEM171  4.43E‐21  1.21E‐17  ‐2.60159  1.11E‐15  ‐2.74937 
3201488  NM_078487 // CDKN2B // cyclin‐dependent kinase inhibitor 2B (p15, inhibits CDK4)  CDKN2B  5.45E‐21  5.01E‐15  ‐2.01277  5.42E‐18  ‐2.83972 
3592755  NM_153618 // SEMA6D // sema domain, transmembrane domain (TM), and cytoplasmic d  SEMA6D  5.90E‐21  5.62E‐15  ‐2.76674  5.66E‐18  ‐4.58128 
3891447  NM_207032 // EDN3 // endothelin 3 // 20q13.2‐q13.3 // 1908 /// NM_207034 // EDN3  EDN3  7.90E‐21  4.13E‐13  ‐1.98888  6.51E‐19  ‐3.52459 
2894573  NM_145649 // GCNT2 // glucosaminyl (N‐acetyl) transferase 2, I‐branching enzyme   GCNT2  8.16E‐21  3.05E‐17  ‐3.31505  1.24E‐15  ‐3.66376 
2494709  NM_020184 // CNNM4 // cyclin M4 // 2p12‐p11.2 // 26504 /// ENST00000377075 // CN  CNNM4  8.57E‐21  2.17E‐16  ‐1.66642  1.61E‐16  ‐1.86809 
3883013  NM_021202 // TP53INP2 // tumor protein p53 inducible nuclear protein 2 // 20q11.  TP53INP2  8.95E‐21  5.23E‐16  ‐1.96408  7.55E‐17  ‐2.38257 
3622176  NM_014080 // DUOX2 // dual oxidase 2 // 15q15.3 // 50506 /// ENST00000389039 //   DUOX2  1.05E‐20  7.19E‐19  9.26465  7.30E‐13  5.79995 
3175274  NM_006200 // PCSK5 // proprotein convertase subtilisin/kexin type 5 // 9q21.3 //  PCSK5  1.06E‐20  1.12E‐14  ‐2.7632  8.69E‐18  ‐4.63863 
3741875  NM_015113 // ZZEF1 // zinc finger, ZZ‐type with EF‐hand domain 1 // 17p13.2 // 2  ZZEF1  1.30E‐20  3.35E‐15  ‐1.60916  2.96E‐17  ‐1.94756 
2923868  NM_181794 // PKIB // protein kinase (cAMP‐dependent, catalytic) inhibitor beta /  PKIB  1.33E‐20  6.29E‐17  ‐2.3143  1.40E‐15  ‐2.52327 
2360257  NM_000565 // IL6R // interleukin 6 receptor // 1q21 // 3570 /// NM_181359 // IL6  IL6R  1.39E‐20  8.47E‐17  ‐2.16291  1.08E‐15  ‐2.37665 
3677913  NM_001116 // ADCY9 // adenylate cyclase 9 // 16p13.3 // 115 /// ENST00000294016   ADCY9  1.47E‐20  6.24E‐16  ‐1.54728  1.54E‐16  ‐1.73747 
2730746  NM_001098484 // SLC4A4 // solute carrier family 4, sodium bicarbonate cotranspor  SLC4A4  1.52E‐20  1.29E‐13  ‐3.67611  3.10E‐18  ‐8.95996 
3653098  NM_022097 // CHP2 // calcineurin B homologous protein 2 // 16p12.1 // 63928 ///   CHP2  1.53E‐20  8.06E‐17  ‐3.56768  1.39E‐15  ‐4.11255 
3883064  NM_018677 // ACSS2 // acyl‐CoA synthetase short‐chain family member 2 // 20q11.2  ACSS2  1.73E‐20  2.79E‐17  ‐2.0013  6.53E‐15  ‐2.03768 
3090294  NM_014479 // ADAMDEC1 // ADAM‐like, decysin 1 // 8p21.2 // 27299 /// ENST0000025  ADAMDEC1  1.74E‐20  5.03E‐12  ‐3.33561  5.71E‐19  ‐11.1878 
2332481  NM_007102 // GUCA2B // guanylate cyclase activator 2B (uroguanylin) // 1p34‐p33   GUCA2B  2.06E‐20  4.31E‐16  ‐4.90869  4.00E‐16  ‐6.91611 
3936442  NM_001127649 // PEX26 // peroxisomal biogenesis factor 26 // 22q11.21 // 55670 /  PEX26  2.24E‐20  7.91E‐17  ‐1.7826  2.99E‐15  ‐1.87216 
3664924  NM_005182 // CA7 // carbonic anhydrase VII // 16q22.1 // 766 /// NM_001014435 //  CA7  2.26E‐20  9.27E‐16  ‐3.45957  2.26E‐16  ‐4.81441 
3388673  NM_002423 // MMP7 // matrix metallopeptidase 7 (matrilysin, uterine) // 11q21‐q2  MMP7  2.40E‐20  2.33E‐16  8.40838  1.01E‐15  11.8027 
3654669  NM_177528 // SULT1A2 // sulfotransferase family, cytosolic, 1A, phenol‐preferrin  SULT1A2  2.41E‐20  1.26E‐15  ‐2.41724  1.91E‐16  ‐3.10827 
2773872  NM_014435 // NAAA // N‐acylethanolamine acid amidase // 4q21.1 // 27163 /// NM_0  NAAA  2.41E‐20  2.23E‐14  ‐1.62938  1.92E‐17  ‐2.0872 
2765865  NM_001085400 // RELL1 // RELT‐like 1 // 4p14 // 768211 /// NM_001085399 // RELL1  RELL1  2.48E‐20  8.50E‐16  ‐1.75761  2.90E‐16  ‐2.02761 
3887117  NM_001127695 // CTSA // cathepsin A // 20q13.1 // 5476 /// NM_000308 // CTSA //   CTSA  2.52E‐20  2.31E‐16  ‐1.63626  1.11E‐15  ‐1.76647 
3894545  NM_080489 // SDCBP2 // syndecan binding protein (syntenin) 2 // 20p13 // 27111 /  SDCBP2  2.67E‐20  4.25E‐16  ‐2.66247  6.54E‐16  ‐3.22801 
3456081  NM_000966 // RARG // retinoic acid receptor, gamma // 12q13 // 5916 /// NM_00104  RARG  2.82E‐20  7.78E‐17  1.67517  4.88E‐15  1.73472 
3569814  NM_001102 // ACTN1 // actinin, alpha 1 // 14q24.1‐q24.2|14q24|14q22‐q24 // 87 //  ACTN1  2.98E‐20  1.27E‐14  1.56834  4.04E‐17  1.91857 
2334476  NM_015112 // MAST2 // microtubule associated serine/threonine kinase 2 // 1p34.1  MAST2  3.74E‐20  2.03E‐15  ‐1.46897  2.66E‐16  ‐1.64291 
3190190  NM_005564 // LCN2 // lipocalin 2 // 9q34 // 3934 /// ENST00000373017 // LCN2 //   LCN2  3.79E‐20  3.40E‐16  5.01332  1.58E‐15  6.4521 
3896621  NM_017671 // FERMT1 // fermitin family homolog 1 (Drosophila) // 20p12.3 // 5561  FERMT1  4.63E‐20  4.47E‐16  2.3922  1.73E‐15  2.75792 
3020343  NM_001127500 // MET // met proto‐oncogene (hepatocyte growth factor receptor) //  MET  5.18E‐20  1.22E‐16  2.83635  9.60E‐15  3.01721 
2398820  NM_007365 // PADI2 // peptidyl arginine deiminase, type II // 1p36.13 // 11240 /  PADI2  5.69E‐20  8.89E‐16  ‐1.93303  1.23E‐15  ‐2.20615 
2828520  NM_003060 // SLC22A5 // solute carrier family 22 (organic cation/carnitine trans  SLC22A5  6.21E‐20  2.46E‐16  ‐1.94241  5.92E‐15  ‐2.07408 




3768627  NM_007168 // ABCA8 // ATP‐binding cassette, sub‐family A (ABC1), member 8 // 17q  ABCA8  8.01E‐20  9.93E‐15  ‐3.54385  2.44E‐16  ‐5.59519 
3265224  NM_198496 // VWA2 // von Willebrand factor A domain containing 2 // 10q25.3 // 3  VWA2  8.42E‐20  1.29E‐15  2.81899  1.72E‐15  3.47543 
2952834  NM_003740 // KCNK5 // potassium channel, subfamily K, member 5 // 6p21 // 8645 /  KCNK5  9.63E‐20  3.17E‐16  ‐1.77378  1.04E‐14  ‐1.86514 
3745571  BC015790 // LOC400573 // hypothetical gene supported by BC015790; BC041634 // 17  LOC400573  1.16E‐19  4.82E‐17  ‐1.668  1.95E‐13  ‐1.61257 
3986346  NM_020384 // CLDN2 // claudin 2 // Xq22.3‐q23 // 9075 /// ENST00000336803 // CLD  CLDN2  1.22E‐19  8.39E‐17  3.53132  9.59E‐14  3.40982 
3365203  NM_004179 // TPH1 // tryptophan hydroxylase 1 // 11p15.3‐p14 // 7166 /// ENST000  TPH1  1.26E‐19  3.98E‐13  ‐4.95187  3.45E‐17  ‐13.541 
3396883  NM_032795 // RPUSD4 // RNA pseudouridylate synthase domain containing 4 // 11q24  RPUSD4  1.35E‐19  1.87E‐14  1.40888  3.43E‐16  1.60175 
3557851  NM_024658 // IPO4 // importin 4 // 14q12 // 79711 /// ENST00000354464 // IPO4 //  IPO4  1.40E‐19  4.20E‐11  1.35879  3.42E‐18  1.8777 
2709750  NM_001048 // SST // somatostatin // 3q28 // 6750 /// ENST00000287641 // SST // s  SST  1.47E‐19  2.23E‐12  ‐3.12595  1.56E‐17  ‐7.50679 
2345061  NM_012128 // CLCA4 // chloride channel, calcium activated, family member 4 // 1p  CLCA4  1.50E‐19  1.60E‐12  ‐8.41057  1.94E‐17  ‐40.453 
3871192  NM_002842 // PTPRH // protein tyrosine phosphatase, receptor type, H // 19q13.4   PTPRH  1.51E‐19  2.68E‐15  ‐1.75496  2.39E‐15  ‐1.98273 
3202224  NM_022901 // LRRC19 // leucine rich repeat containing 19 // 9p21.2 // 64922 ///   LRRC19  1.61E‐19  1.85E‐14  ‐2.57522  4.60E‐16  ‐3.6252 
2374126  NM_205860 // NR5A2 // nuclear receptor subfamily 5, group A, member 2 // 1q32.1   NR5A2  2.01E‐19  1.93E‐11  ‐2.03239  7.86E‐18  ‐3.98378 
3811000  NM_173557 // RNF152 // ring finger protein 152 // 18q21.33 // 220441 /// ENST000  RNF152  2.36E‐19  4.55E‐13  ‐2.68905  7.97E‐17  ‐4.84713 
3133345  NM_006749 // SLC20A2 // solute carrier family 20 (phosphate transporter), member  SLC20A2  3.43E‐19  4.91E‐15  ‐1.67612  5.72E‐15  ‐1.86509 
3835035  NM_020406 // CD177 // CD177 molecule // 19q13.2 // 57126 /// AF146747 // CD177 /  CD177  3.65E‐19  1.42E‐14  ‐4.21549  2.30E‐15  ‐6.34905 
3847873  NM_024103 // SLC25A23 // solute carrier family 25 (mitochondrial carrier; phosph  SLC25A23  3.95E‐19  2.71E‐15  ‐1.6352  1.38E‐14  ‐1.76193 
3705491  NM_024792 // FAM57A // family with sequence similarity 57, member A // 17p13.3 /  FAM57A  4.58E‐19  6.92E‐13  1.77331  1.62E‐16  2.47785 
3359448  BC030237 // SLC22A18AS // solute carrier family 22 (organic cation transporter),  SLC22A18AS  7.97E‐19  3.28E‐15  ‐2.35834  4.21E‐14  ‐2.60909 
3075531  NM_080660 // ZC3HAV1L // zinc finger CCCH‐type, antiviral 1‐like // 7q34 // 9209  ZC3HAV1L  8.35E‐19  7.52E‐14  1.70851  2.16E‐15  2.07006 
2708457  NM_004366 // CLCN2 // chloride channel 2 // 3q27‐q28 // 1181 /// ENST00000265593  CLCN2  8.48E‐19  2.70E‐15  ‐1.98718  5.95E‐14  ‐2.12637 
2731986  NM_003943 // STBD1 // starch binding domain 1 // 4q24‐q25 // 8987 /// ENST000002  STBD1  9.25E‐19  4.13E‐15  ‐2.11567  4.32E‐14  ‐2.32334 
3394356  NM_004205 // USP2 // ubiquitin specific peptidase 2 // 11q23.3 // 9099 /// NM_17  USP2  9.38E‐19  1.83E‐16  ‐3.0384  2.99E‐12  ‐2.67681 
3450655  NM_153634 // CPNE8 // copine VIII // 12q12 // 144402 /// ENST00000331366 // CPNE  CPNE8  1.04E‐18  5.08E‐12  ‐2.39744  1.55E‐16  ‐4.42049 
2458513  NM_014698 // TMEM63A // transmembrane protein 63A // 1q42.12 // 9725 /// ENST000  TMEM63A  1.08E‐18  1.97E‐16  1.83059  3.73E‐12  1.70349 
2463482  NM_014322 // OPN3 // opsin 3 // 1q43 // 23596 /// NM_001821 // CHML // choroider  OPN3  1.09E‐18  1.98E‐15  ‐1.60998  1.42E‐13  ‐1.65452 
3677752  NM_016292 // TRAP1 // TNF receptor‐associated protein 1 // 16p13.3 // 10131 ///   TRAP1  1.43E‐18  2.75E‐09  1.36306  1.17E‐17  2.06072 
3758775  NM_004160 // PYY // peptide YY // 17q21.1 // 5697 /// ENST00000360085 // PYY //   PYY  1.46E‐18  1.97E‐11  ‐2.76827  1.14E‐16  ‐6.25616 
2998638  AK299133 // C7orf10 // chromosome 7 open reading frame 10 // 7p14.1 // 79783 ///  C7orf10  1.61E‐18  9.52E‐16  ‐3.08379  8.39E‐13  ‐2.99347 
3441849  NM_001065 // TNFRSF1A // tumor necrosis factor receptor superfamily, member 1A /  TNFRSF1A  1.63E‐18  3.12E‐16  ‐1.38092  4.60E‐12  ‐1.33141 
3332424  NM_017716 // MS4A12 // membrane‐spanning 4‐domains, subfamily A, member 12 // 11  MS4A12  1.74E‐18  5.06E‐13  ‐8.90193  1.55E‐15  ‐24.4702 
2679406  NM_003716 // CADPS // Ca++‐dependent secretion activator // 3p14.2 // 8618 /// N  CADPS  1.80E‐18  1.61E‐15  3.01273  5.14E‐13  3.03332 
3974019  NM_004615 // TSPAN7 // tetraspanin 7 // Xp11.4 // 7102 /// ENST00000378482 // TS  TSPAN7  1.80E‐18  9.21E‐14  ‐3.04301  6.47E‐15  ‐4.35017 
2565246  NM_017849 // TMEM127 // transmembrane protein 127 // 2q11.2 // 55654 /// ENST000  TMEM127  1.85E‐18  9.77E‐14  ‐1.37484  6.45E‐15  ‐1.52413 
2562233  NM_017750 // RETSAT // retinol saturase (all‐trans‐retinol 13,14‐reductase) // 2  RETSAT  1.89E‐18  1.05E‐14  ‐1.96061  5.93E‐14  ‐2.16412 
3886143  NM_016276 // SGK2 // serum/glucocorticoid regulated kinase 2 // 20q13.2 // 10110  SGK2  2.01E‐18  1.41E‐15  ‐1.94459  7.78E‐13  ‐1.92912 
3746845  NM_006470 // TRIM16 // tripartite motif‐containing 16 // 17p11.2 // 10626 /// NM  TRIM16  2.14E‐18  6.19E‐13  1.62571  1.83E‐15  2.03773 
3816803  BC001528 // GNA11 // guanine nucleotide binding protein (G protein), alpha 11 (G  GNA11  2.31E‐18  1.83E‐16  ‐2.2005  2.67E‐11  ‐1.90791 
3710108  NM_004246 // GLP2R // glucagon‐like peptide 2 receptor // 17p13.3 // 9340 /// EN  GLP2R  2.39E‐18  2.58E‐15  ‐2.01826  4.96E‐13  ‐2.05009 
3142967  NM_001128829 // CA1 // carbonic anhydrase I // 8q13‐q22.1 // 759 /// NM_001738 /  CA1  2.39E‐18  1.41E‐12  ‐6.60221  1.20E‐15  ‐17.8465 
3064293  NM_004444 // EPHB4 // EPH receptor B4 // 7q22 // 2050 /// ENST00000358173 // EPH  EPHB4  2.48E‐18  9.05E‐14  1.61235  1.13E‐14  1.85837 




3655621  NM_152338 // ZG16 // zymogen granule protein 16 // 16p13.3 // 123887 /// ENST000  ZG16  2.57E‐18  3.36E‐14  ‐8.14808  3.07E‐14  ‐12.8235 
3544625  NM_017791 // FLVCR2 // feline leukemia virus subgroup C cellular receptor family  FLVCR2  2.69E‐18  2.73E‐15  ‐2.31361  5.90E‐13  ‐2.3491 
3914786  NR_003087 // ABCC13 // ATP‐binding cassette, sub‐family C (CFTR/MRP), member 13   ABCC13  2.99E‐18  2.89E‐13  ‐1.86401  5.67E‐15  ‐2.35872 
2611848  NM_003043 // SLC6A6 // solute carrier family 6 (neurotransmitter transporter, ta  SLC6A6  3.20E‐18  4.99E‐15  3.13709  3.85E‐13  3.33189 
3374890  NM_001062 // TCN1 // transcobalamin I (vitamin B12 binding protein, R binder fam  TCN1  3.35E‐18  5.31E‐14  12.4668  3.13E‐14  22.4812 
3592196  NM_207581 // DUOXA2 // dual oxidase maturation factor 2 // 15q15.1 // 405753 ///  DUOXA2  3.36E‐18  1.16E‐14  4.74527  1.56E‐13  5.67225 
3652902  NM_000336 // SCNN1B // sodium channel, nonvoltage‐gated 1, beta // 16p12.2‐p12.1  SCNN1B  3.38E‐18  1.19E‐11  ‐2.61999  4.98E‐16  ‐5.09646 
3662808  NM_201524 // GPR56 // G protein‐coupled receptor 56 // 16q12.2‐q21 // 9289 /// N  GPR56  3.68E‐18  2.94E‐14  1.68485  6.70E‐14  1.85133 
2955638  NM_001114086 // CLIC5 // chloride intracellular channel 5 // 6p21.1‐p12.1 // 534  CLIC5  3.70E‐18  1.18E‐11  ‐2.23474  5.69E‐16  ‐3.87173 
2358320  NM_025150 // TARS2 // threonyl‐tRNA synthetase 2, mitochondrial (putative) // 1q  TARS2  3.79E‐18  1.31E‐12  1.21229  2.55E‐15  1.33159 
2460325  BC066649 // C1orf198 // chromosome 1 open reading frame 198 // 1q42.13‐q43 // 84  C1orf198  3.96E‐18  1.07E‐13  1.42476  2.14E‐14  1.57219 
2871617  NM_018700 // TRIM36 // tripartite motif‐containing 36 // 5q22.3 // 55521 /// NM_  TRIM36  4.14E‐18  6.07E‐14  ‐2.10051  3.97E‐14  ‐2.49064 
4012299  NM_002637 // PHKA1 // phosphorylase kinase, alpha 1 (muscle) // Xq12‐q13 // 5255  PHKA1  4.60E‐18  1.44E‐13  1.97292  2.11E‐14  2.4041 
2673773  NM_000387 // SLC25A20 // solute carrier family 25 (carnitine/acylcarnitine trans  SLC25A20  4.62E‐18  2.11E‐15  ‐1.9389  2.60E‐12  ‐1.88794 
3664982  NM_003869 // CES2 // carboxylesterase 2 (intestine, liver) // 16q22.1 // 8824 //  CES2  4.67E‐18  1.03E‐13  ‐2.13948  2.96E‐14  ‐2.61288 
3797032  NM_012307 // EPB41L3 // erythrocyte membrane protein band 4.1‐like 3 // 18p11.32  EPB41L3  4.84E‐18  2.61E‐14  ‐2.32493  1.25E‐13  ‐2.64319 
3753966  NM_032962 // CCL14 // chemokine (C‐C motif) ligand 14 // 17q11.2 // 6358 /// NM_  CCL14  4.90E‐18  1.01E‐13  ‐1.79876  3.27E‐14  ‐2.09303 
2381249  NM_024709 // C1orf115 // chromosome 1 open reading frame 115 // 1q41 // 79762 //  C1orf115  5.21E‐18  1.09E‐13  ‐1.63602  3.36E‐14  ‐1.85975 
2358949  NM_020770 // CGN // cingulin // 1q21 // 57530 /// ENST00000271636 // CGN // cing  CGN  5.54E‐18  3.25E‐14  ‐1.56303  1.27E‐13  ‐1.67874 
3830002  NM_020895 // GRAMD1A // GRAM domain containing 1A // 19q13.11 // 57655 /// ENST0  GRAMD1A  5.64E‐18  2.78E‐14  1.67728  1.55E‐13  1.80905 
3756566  NM_019010 // KRT20 // keratin 20 // 17q21.2 // 54474 /// ENST00000167588 // KRT2  KRT20  5.73E‐18  8.41E‐14  ‐2.98126  5.11E‐14  ‐3.84374 
3154317  NM_006096 // NDRG1 // N‐myc downstream regulated gene 1 // 8q24.3 // 10397 /// E  NDRG1  5.77E‐18  1.06E‐14  ‐1.99527  4.95E‐13  ‐2.09257 
3767339  NM_006572 // GNA13 // guanine nucleotide binding protein (G protein), alpha 13 /  GNA13  5.91E‐18  5.03E‐13  ‐1.55948  1.08E‐14  ‐1.8427 
3960478  NM_001894 // CSNK1E // casein kinase 1, epsilon // 22q13.1 // 1454 /// NM_152221  CSNK1E  6.42E‐18  4.21E‐13  1.36492  1.43E‐14  1.5243 
2607923  NM_175607 // CNTN4 // contactin 4 // 3p26‐p25 // 152330 /// NM_175613 // CNTN4 /  CNTN4  6.56E‐18  4.02E‐15  ‐2.09845  2.22E‐12  ‐2.07487 
3671076  NM_002153 // HSD17B2 // hydroxysteroid (17‐beta) dehydrogenase 2 // 16q24.1‐q24.  HSD17B2  6.79E‐18  3.60E‐13  ‐2.98048  1.80E‐14  ‐4.3113 
3023384  NM_015328 // AHCYL2 // S‐adenosylhomocysteine hydrolase‐like 2 // 7q32.1 // 2338  AHCYL2  6.89E‐18  1.55E‐14  ‐2.27651  4.41E‐13  ‐2.44406 
3886453  NM_000457 // HNF4A // hepatocyte nuclear factor 4, alpha // 20q12‐q13.1 // 3172   HNF4A  8.00E‐18  4.44E‐13  ‐1.37019  1.96E‐14  ‐1.52688 
2910868  NM_014464 // TINAG // tubulointerstitial nephritis antigen // 6p11.2‐p12 // 2728  TINAG  8.92E‐18  1.76E‐13  ‐2.3028  5.41E‐14  ‐2.86204 
3264948  NM_033338 // CASP7 // caspase 7, apoptosis‐related cysteine peptidase // 10q25 /  CASP7  9.06E‐18  2.79E‐16  ‐1.61622  4.10E‐10  ‐1.4321 
2794408  NM_000860 // HPGD // hydroxyprostaglandin dehydrogenase 15‐(NAD) // 4q34‐q35 //   HPGD  9.12E‐18  3.81E‐13  ‐3.63251  2.78E‐14  ‐5.50215 
2584113  NM_002054 // GCG // glucagon // 2q36‐q37 // 2641 /// ENST00000375497 // GCG // g  GCG  9.56E‐18  8.47E‐11  ‐5.92818  6.83E‐16  ‐24.62 
2411173  NM_005764 // PDZK1IP1 // PDZK1 interacting protein 1 // 1p33 // 10158 /// ENST00  PDZK1IP1  9.64E‐18  8.45E‐16  3.14585  5.93E‐11  2.59914 
3756262  NM_032865 // TNS4 // tensin 4 // 17q21.2 // 84951 /// ENST00000254051 // TNS4 //  TNS4  9.94E‐18  4.46E‐15  3.42481  4.63E‐12  3.27186 
3390641  NM_020809 // ARHGAP20 // Rho GTPase activating protein 20 // 11q22.3‐q23.1 // 57  ARHGAP20  9.98E‐18  1.78E‐15  ‐1.64208  1.86E‐11  ‐1.55492 
2891556  NM_033260 // FOXQ1 // forkhead box Q1 // 6p25 // 94234 /// ENST00000296839 // FO  FOXQ1  1.01E‐17  4.09E‐15  2.08792  5.43E‐12  2.01969 
3767465  NM_004655 // AXIN2 // axin 2 // 17q23‐q24 // 8313 /// ENST00000307078 // AXIN2 /  AXIN2  1.35E‐17  4.03E‐13  1.62933  5.09E‐14  1.88516 
2958172  NM_021073 // BMP5 // bone morphogenetic protein 5 // 6p12.1 // 653 /// ENST00000  BMP5  1.38E‐17  2.36E‐12  ‐2.04955  1.21E‐14  ‐2.82044 
2889486  NM_153373 // AGXT2L2 // alanine‐glyoxylate aminotransferase 2‐like 2 // 5q35.3 /  AGXT2L2  1.47E‐17  8.40E‐13  ‐1.38559  3.10E‐14  ‐1.5547 
3131563  XM_001718074 // LOC100128034 // hypothetical protein LOC100128034 // 8p12 // 100  LOC100128034  1.55E‐17  3.42E‐14  2.75304  8.19E‐13  3.01961 
3002420  NM_182546 // VSTM2A // V‐set and transmembrane domain containing 2A // 7p11.2 //  VSTM2A  1.58E‐17  6.68E‐15  ‐1.87468  7.06E‐12  ‐1.82903 




3461883  NM_002849 // PTPRR // protein tyrosine phosphatase, receptor type, R // 12q15 //  PTPRR  1.66E‐17  3.85E‐12  ‐2.82306  1.12E‐14  ‐4.61663 
3911767  NM_001336 // CTSZ // cathepsin Z // 20q13 // 1522 /// ENST00000217131 // CTSZ //  CTSZ  1.87E‐17  1.57E‐13  ‐1.48189  2.20E‐13  ‐1.60254 
2700244  NM_000096 // CP // ceruloplasmin (ferroxidase) // 3q23‐q25 // 1356 /// ENST00000  CP  1.91E‐17  5.54E‐10  ‐2.19528  6.45E‐16  ‐4.59291 
3795733  NM_130386 // COLEC12 // collectin sub‐family member 12 // 18pter‐p11.3 // 81035   COLEC12  1.95E‐17  1.76E‐14  ‐1.99586  2.93E‐12  ‐2.02665 
2371346  NM_015149 // RGL1 // ral guanine nucleotide dissociation stimulator‐like 1 // 1q  RGL1  1.99E‐17  5.40E‐12  ‐1.57257  1.15E‐14  ‐1.96343 
3325839  NM_018393 // TCP11L1 // t‐complex 11 (mouse)‐like 1 // 11p13 // 55346 /// ENST00  TCP11L1  2.07E‐17  7.56E‐11  ‐1.40212  2.13E‐15  ‐1.79458 
3439178  NM_018663 // PXMP2 // peroxisomal membrane protein 2, 22kDa // 12q24.33 // 5827   PXMP2  2.19E‐17  6.56E‐16  ‐1.77964  7.61E‐10  ‐1.54021 
2692447  NM_053025 // MYLK // myosin light chain kinase // 3q21 // 4638 /// NM_053026 //   MYLK  2.22E‐17  9.24E‐10  ‐1.64536  6.08E‐16  ‐2.68367 
2721087  NM_020973 // GBA3 // glucosidase, beta, acid 3 (cytosolic) // 4p15.31 // 57733 /  GBA3  2.23E‐17  7.35E‐14  ‐5.98194  6.83E‐13  ‐7.49077 
3338192  NM_053056 // CCND1 // cyclin D1 // 11q13 // 595 /// ENST00000227507 // CCND1 //   CCND1  2.40E‐17  1.34E‐11  1.44033  7.95E‐15  1.76529 
3174121  NM_153267 // MAMDC2 // MAM domain containing 2 // 9q21.11 // 256691 /// NM_00098  MAMDC2  2.60E‐17  6.46E‐12  ‐2.65618  1.51E‐14  ‐4.273 
3757630  NM_021078 // KAT2A // K(lysine) acetyltransferase 2A // 17q21 // 2648 /// ENST00  KAT2A  2.64E‐17  3.64E‐12  1.44903  2.39E‐14  1.703 
3299469  NM_144590 // ANKRD22 // ankyrin repeat domain 22 // 10q23.31 // 118932 /// ENST0  ANKRD22  2.71E‐17  1.40E‐10  2.02768  2.17E‐15  3.49506 
3340665  NM_032564 // DGAT2 // diacylglycerol O‐acyltransferase homolog 2 (mouse) // 11q1  DGAT2  2.94E‐17  1.78E‐12  1.792  5.05E‐14  2.21925 
3980614  NM_017711 // GDPD2 // glycerophosphodiester phosphodiesterase domain containing   GDPD2  3.07E‐17  1.49E‐13  ‐2.45404  5.65E‐13  ‐2.83245 
3545311  NM_033426 // KIAA1737 // KIAA1737 // 14q24.3 // 85457 /// ENST00000361786 // KIA  KIAA1737  3.08E‐17  3.13E‐12  ‐1.38707  3.42E‐14  ‐1.58703 
3115504  NM_002467 // MYC // v‐myc myelocytomatosis viral oncogene homolog (avian) // 8q2  MYC  3.20E‐17  7.91E‐13  1.85397  1.18E‐13  2.22125 
3734453  NM_004252 // SLC9A3R1 // solute carrier family 9 (sodium/hydrogen exchanger), me  SLC9A3R1  3.22E‐17  1.95E‐13  ‐1.93175  4.64E‐13  ‐2.17181 
3839346  NM_003121 // SPIB // Spi‐B transcription factor (Spi‐1/PU.1 related) // 19q13.3‐  SPIB  3.26E‐17  6.16E‐11  ‐2.12415  4.57E‐15  ‐3.53591 
2621122  NM_015175 // NBEAL2 // neurobeachin‐like 2 // 3p21.31 // 23218 /// AY358455 // N  NBEAL2  3.31E‐17  8.41E‐13  1.42156  1.18E‐13  1.57722 
2930007  NM_001030060 // SAMD5 // sterile alpha motif domain containing 5 // 6q24.3 // 38  SAMD5  3.41E‐17  5.89E‐14  1.97539  1.96E‐12  2.08281 
2865327  NM_001884 // HAPLN1 // hyaluronan and proteoglycan link protein 1 // 5q14.3 // 1  HAPLN1  3.67E‐17  5.36E‐12  ‐2.13696  2.95E‐14  ‐2.99693 
3067250  NM_000111 // SLC26A3 // solute carrier family 26, member 3 // 7q31 // 1811 /// E  SLC26A3  3.77E‐17  3.98E‐10  ‐5.16429  1.90E‐15  ‐20.8777 
3558418  NM_014178 // STXBP6 // syntaxin binding protein 6 (amisyn) // 14q12 // 29091 ///  STXBP6  3.78E‐17  3.31E‐14  1.6508  4.91E‐12  1.67111 
2829947  NM_000358 // TGFBI // transforming growth factor, beta‐induced, 68kDa // 5q31 //  TGFBI  3.81E‐17  1.36E‐13  3.33429  9.29E‐13  3.93117 
3258772  NM_153226 // TMEM20 // transmembrane protein 20 // 10q23.33 // 159371 /// ENST00  TMEM20  3.94E‐17  2.28E‐15  ‐2.05802  3.17E‐10  ‐1.78952 
3557209  NM_012244 // SLC7A8 // solute carrier family 7 (cationic amino acid transporter,  SLC7A8  4.34E‐17  2.05E‐14  1.61413  1.23E‐11  1.59595 
3958658  NM_004737 // LARGE // like‐glycosyltransferase // 22q12.3 // 9215 /// NM_133642   LARGE  4.35E‐17  3.82E‐14  ‐1.41715  5.40E‐12  ‐1.42991 
2474341  NM_004341 // CAD // carbamoyl‐phosphate synthetase 2, aspartate transcarbamylase  CAD  4.69E‐17  8.27E‐11  1.36363  6.39E‐15  1.68229 
2619265  NM_004624 // VIPR1 // vasoactive intestinal peptide receptor 1 // 3p22 // 7433 /  VIPR1  4.70E‐17  4.30E‐10  ‐1.39589  2.45E‐15  ‐1.84825 
3144973  NM_012415 // RAD54B // RAD54 homolog B (S. cerevisiae) // 8q21.3‐q22 // 25788 //  RAD54B  5.10E‐17  2.61E‐12  1.62136  8.88E‐14  1.92911 
2676671  NM_001064 // TKT // transketolase // 3p14.3 // 7086 /// ENST00000296289 // TKT /  TKT  5.56E‐17  2.09E‐11  1.51138  2.04E‐14  1.88594 
2865390  NM_005711 // EDIL3 // EGF‐like repeats and discoidin I‐like domains 3 // 5q14 //  EDIL3  5.88E‐17  3.07E‐10  ‐2.17733  4.01E‐15  ‐4.02477 
3445326  NM_000834 // GRIN2B // glutamate receptor, ionotropic, N‐methyl D‐aspartate 2B /  GRIN2B  6.19E‐17  1.84E‐13  2.24464  1.62E‐12  2.4863 
3907111  NM_006809 // TOMM34 // translocase of outer mitochondrial membrane 34 // ‐‐‐ //   TOMM34  6.33E‐17  1.01E‐07  1.23933  3.03E‐16  1.70461 
3663181  NM_014157 // CCDC113 // coiled‐coil domain containing 113 // 16q21 // 29070 ///   CCDC113  6.45E‐17  9.93E‐12  1.71773  4.40E‐14  2.20135 
2669488  NM_006225 // PLCD1 // phospholipase C, delta 1 // 3p22‐p21.3 // 5333 /// ENST000  PLCD1  6.80E‐17  5.83E‐13  ‐1.52152  5.70E‐13  ‐1.66421 
2910680  NM_018214 // LRRC1 // leucine rich repeat containing 1 // 6p12.1 // 55227 /// EN  LRRC1  6.80E‐17  4.45E‐12  ‐1.55496  9.03E‐14  ‐1.84264 
3740998  NM_018128 // TSR1 // TSR1, 20S rRNA accumulation, homolog (S. cerevisiae) // 17p  TSR1  6.94E‐17  5.90E‐11  1.37803  1.39E‐14  1.67877 
2580802  NM_005168 // RND3 // Rho family GTPase 3 // 2q23.3 // 390 /// ENST00000375734 //  RND3  7.47E‐17  9.10E‐14  ‐1.76668  5.28E‐12  ‐1.8239 
3356038  NM_138788 // TMEM45B // transmembrane protein 45B // 11q24.3 // 120224 /// ENST0  TMEM45B  8.23E‐17  2.73E‐13  ‐1.84561  1.77E‐12  ‐2.00842 




2732844  NM_005139 // ANXA3 // annexin A3 // 4q13‐q22 // 306 /// ENST00000264908 // ANXA3  ANXA3  8.41E‐17  1.47E‐13  2.73485  3.73E‐12  2.98218 
3864430  NM_014297 // ETHE1 // ethylmalonic encephalopathy 1 // 19q13.31 // 23474 /// ENS  ETHE1  8.63E‐17  2.91E‐14  ‐1.88412  3.18E‐11  ‐1.82978 
3358201  NM_021924 // MUPCDH // mucin‐like protocadherin // 11p15.5 // 53841 /// NM_03126  MUPCDH  8.69E‐17  2.94E‐11  ‐1.69923  3.11E‐14  ‐2.25565 
2717078  NM_005980 // S100P // S100 calcium binding protein P // 4p16 // 6286 /// ENST000  S100P  8.73E‐17  1.27E‐13  2.8937  4.77E‐12  3.12227 
2734047  NM_032717 // AGPAT9 // 1‐acylglycerol‐3‐phosphate O‐acyltransferase 9 // 4q21.23  AGPAT9  8.83E‐17  7.02E‐14  ‐2.48539  1.02E‐11  ‐2.53796 
2400177  NM_018584 // CAMK2N1 // calcium/calmodulin‐dependent protein kinase II inhibitor  CAMK2N1  9.09E‐17  2.68E‐11  ‐1.59321  3.55E‐14  ‐2.03219 
3863669  NM_001712 // CEACAM1 // carcinoembryonic antigen‐related cell adhesion molecule   CEACAM1  9.18E‐17  4.82E‐14  ‐2.88839  1.80E‐11  ‐2.85705 
3150844  NM_021021 // SNTB1 // syntrophin, beta 1 (dystrophin‐associated protein A1, 59kD  SNTB1  9.27E‐17  3.64E‐12  1.52544  1.76E‐13  1.76463 
3084950  NM_194284 // CLDN23 // claudin 23 // 8p23.1 // 137075 /// BC125148 // CLDN23 //   CLDN23  1.01E‐16  4.93E‐13  ‐1.81667  1.36E‐12  ‐2.01234 
3104489  NM_007029 // STMN2 // stathmin‐like 2 // 8q21.13 // 11075 /// ENST00000220876 //  STMN2  1.02E‐16  5.06E‐14  ‐3.36563  2.10E‐11  ‐3.30824 
3274898  NM_024803 // TUBAL3 // tubulin, alpha‐like 3 // 10p15.1 // 79861 /// ENST0000038  TUBAL3  1.04E‐16  1.04E‐13  ‐2.85884  8.51E‐12  ‐2.99011 
3946510  NM_022098 // XPNPEP3 // X‐prolyl aminopeptidase (aminopeptidase P) 3, putative /  XPNPEP3  1.12E‐16  2.00E‐09  1.28182  3.46E‐15  1.61798 
2897899  NM_003107 // SOX4 // SRY (sex determining region Y)‐box 4 // 6p22.3 // 6659 ///   SOX4  1.16E‐16  9.06E‐15  1.47197  3.81E‐10  1.38156 
3568603  NM_002083 // GPX2 // glutathione peroxidase 2 (gastrointestinal) // 14q24.1 // 2  GPX2  1.17E‐16  4.93E‐13  1.96158  1.78E‐12  2.18565 
3394660  NM_012101 // TRIM29 // tripartite motif‐containing 29 // 11q22‐q23 // 23650 ///   TRIM29  1.18E‐16  6.15E‐14  2.90077  2.17E‐11  2.87299 
2570193  NM_005434 // MALL // mal, T‐cell differentiation protein‐like // 2q13 // 7851 //  MALL  1.21E‐16  1.12E‐12  ‐3.09693  8.11E‐13  ‐3.99988 
3976341  NM_003254 // TIMP1 // TIMP metallopeptidase inhibitor 1 // Xp11.3‐p11.23 // 7076  TIMP1  1.24E‐16  8.17E‐14  2.49606  1.64E‐11  2.52015 
3452818  NM_001017535 // VDR // vitamin D (1,25‐ dihydroxyvitamin D3) receptor // 12q13.1  VDR  1.25E‐16  3.26E‐13  ‐1.52086  3.14E‐12  ‐1.60078 
3786471  NM_015559 // SETBP1 // SET binding protein 1 // 18q21.1 // 26040 /// BC146776 //  SETBP1  1.34E‐16  3.18E‐11  ‐1.39868  5.61E‐14  ‐1.65941 
2579572  NM_014795 // ZEB2 // zinc finger E‐box binding homeobox 2 // 2q22 // 9839 /// EN  ZEB2  1.36E‐16  7.76E‐11  ‐1.68786  3.07E‐14  ‐2.30002 
3208327  ENST00000377415 // LOC100132426 // similar to hCG1742442 // 9q12 // 100132426  LOC100132426  1.38E‐16  4.36E‐13  7.82385  2.74E‐12  10.404 
3222128  NM_005118 // TNFSF15 // tumor necrosis factor (ligand) superfamily, member 15 //  TNFSF15  1.39E‐16  3.20E‐13  2.21241  3.90E‐12  2.41992 
2670948  NM_001099668 // HIGD1A // HIG1 domain family, member 1A // 3p22.1 // 25994 /// N  HIGD1A  1.45E‐16  1.02E‐13  ‐1.88807  1.69E‐11  ‐1.90823 
3823410  DQ249310 // UCA1 // urothelial cancer associated 1 // 19p13 // 652995  UCA1  1.46E‐16  2.51E‐12  2.85402  5.18E‐13  3.82869 
2655845  NM_004443 // EPHB3 // EPH receptor B3 // 3q21‐qter // 2049 /// ENST00000330394 /  EPHB3  1.49E‐16  2.10E‐12  2.23182  6.27E‐13  2.75895 
3622436  NM_013309 // SLC30A4 // solute carrier family 30 (zinc transporter), member 4 //  SLC30A4  1.55E‐16  1.33E‐11  ‐1.82339  1.37E‐13  ‐2.34669 
2924330  NM_001003395 // TPD52L1 // tumor protein D52‐like 1 // 6q22‐q23 // 7164 /// NM_0  TPD52L1  1.57E‐16  1.79E‐13  1.74361  9.68E‐12  1.7996 
3444252  NM_003651 // CSDA // cold shock domain protein A // 12p13.1 // 8531 /// ENST0000  CSDA  1.57E‐16  3.09E‐11  1.41226  7.30E‐14  1.67537 
3985717  NM_001128834 // PLP1 // proteolipid protein 1 // Xq22 // 5354 /// NM_000533 // P  PLP1  1.67E‐16  1.08E‐11  ‐2.44745  1.81E‐13  ‐3.48953 
3592109  NM_003104 // SORD // sorbitol dehydrogenase // 15q15.3 // 6652 /// ENST000002678  SORD  1.70E‐16  2.39E‐11  1.72552  9.96E‐14  2.22489 
2487549  NM_002357 // MXD1 // MAX dimerization protein 1 // 2p13‐p12 // 4084 /// ENST0000  MXD1  1.80E‐16  6.08E‐12  ‐1.9204  3.31E‐13  ‐2.39858 
3015603  NM_006076 // HRBL // HIV‐1 Rev binding protein‐like // 7q22.1 // 3268 /// ENST00  HRBL  1.82E‐16  5.03E‐15  ‐1.59863  3.37E‐09  ‐1.42252 
3379644  NM_001876 // CPT1A // carnitine palmitoyltransferase 1A (liver) // 11q13.1‐q13.2  CPT1A  1.83E‐16  5.11E‐14  ‐1.70197  6.95E‐11  ‐1.65162 
3317915  NM_003156 // STIM1 // stromal interaction molecule 1 // 11p15.5 // 6786 /// ENST  STIM1  1.87E‐16  1.20E‐10  ‐1.30844  3.66E‐14  ‐1.54085 
2404999  NM_023009 // MARCKSL1 // MARCKS‐like 1 // 1p35.1 // 65108 /// ENST00000329421 //  MARCKSL1  1.88E‐16  5.21E‐15  1.33124  3.42E‐09  1.23991 
3771215  NM_004035 // ACOX1 // acyl‐Coenzyme A oxidase 1, palmitoyl // 17q24‐q25|17q25.1   ACOX1  2.08E‐16  1.96E‐14  ‐1.77432  4.03E‐10  ‐1.63284 
3556990  NM_032876 // JUB // jub, ajuba homolog (Xenopus laevis) // 14q11.2 // 84962 ///   JUB  2.12E‐16  8.25E‐12  1.72847  3.31E‐13  2.09958 
3204833  NM_020944 // GBA2 // glucosidase, beta (bile acid) 2 // 9p13.3 // 57704 /// ENST  GBA2  2.18E‐16  2.31E‐13  ‐1.48476  1.34E‐11  ‐1.51645 
3907473  NM_005469 // ACOT8 // acyl‐CoA thioesterase 8 // 20q13.12 // 10005 /// NM_183386  ACOT8  2.32E‐16  2.38E‐14  ‐1.43677  3.75E‐10  ‐1.36712 
2955556  NM_001114086 // CLIC5 // chloride intracellular channel 5 // 6p21.1‐p12.1 // 534  CLIC5  2.35E‐16  5.31E‐10  ‐1.64695  1.97E‐14  ‐2.38046 
2857204  NM_003711 // PPAP2A // phosphatidic acid phosphatase type 2A // 5q11 // 8611 ///  PPAP2A  2.43E‐16  5.49E‐12  ‐1.81201  5.90E‐13  ‐2.17878 




2965206  NM_004440 // EPHA7 // EPH receptor A7 // 6q16.1 // 2045 /// ENST00000369303 // E  EPHA7  2.85E‐16  5.39E‐10  ‐1.61893  2.54E‐14  ‐2.29594 
3507465  NM_181785 // SLC46A3 // solute carrier family 46, member 3 // 13q12.3 // 283537   SLC46A3  2.88E‐16  9.21E‐13  ‐2.37154  4.58E‐12  ‐2.69246 
3302240  NM_015179 // RRP12 // ribosomal RNA processing 12 homolog (S. cerevisiae) // 10q  RRP12  2.90E‐16  4.91E‐10  1.28091  2.77E‐14  1.52864 
2324919  NM_017449 // EPHB2 // EPH receptor B2 // 1p36.1‐p35 // 2048 /// NM_004442 // EPH  EPHB2  3.21E‐16  1.41E‐12  1.83119  3.52E‐12  2.03525 
2842101  NM_022754 // SFXN1 // sideroflexin 1 // ‐‐‐ // 94081 /// ENST00000321442 // SFXN  SFXN1  3.42E‐16  1.79E‐14  ‐2.11867  1.50E‐09  ‐1.83545 
2835715  NM_002084 // GPX3 // glutathione peroxidase 3 (plasma) // 5q23 // 2878 /// ENST0  GPX3  3.43E‐16  2.09E‐13  ‐1.75721  3.67E‐11  ‐1.76923 
3868841  NM_144947 // KLK11 // kallikrein‐related peptidase 11 // 19q13.3‐q13.4 // 11012   KLK11  3.53E‐16  2.67E‐13  2.0969  2.85E‐11  2.14401 
4008275  NM_020717 // SHROOM4 // shroom family member 4 // Xp11.22 // 57477 /// ENST00000  SHROOM4  3.59E‐16  2.58E‐12  1.63694  2.31E‐12  1.82205 
3781654  NM_003831 // RIOK3 // RIO kinase 3 (yeast) // 18q11.2 // 8780 /// ENST0000033948  RIOK3  3.63E‐16  3.02E‐11  ‐1.62797  2.66E‐13  ‐2.00847 
2831350  NM_016463 // CXXC5 // CXXC finger 5 // 5q31.3 // 51523 /// ENST00000302517 // CX  CXXC5  3.67E‐16  3.10E‐14  1.60386  6.95E‐10  1.49359 
3606034  NM_002605 // PDE8A // phosphodiesterase 8A // 15q25.3 // 5151 /// NM_173454 // P  PDE8A  3.69E‐16  2.45E‐13  ‐1.68362  3.46E‐11  ‐1.70099 
2512790  NM_022058 // SLC4A10 // solute carrier family 4, sodium bicarbonate transporter‐  SLC4A10  3.74E‐16  1.01E‐14  ‐2.82028  5.39E‐09  ‐2.18328 
3010503  NM_001001548 // CD36 // CD36 molecule (thrombospondin receptor) // 7q11.2 // 948  CD36  3.82E‐16  4.00E‐10  ‐2.0379  4.63E‐14  ‐3.28857 
3105600  NM_000067 // CA2 // carbonic anhydrase II // 8q22 // 760 /// ENST00000285379 //   CA2  3.97E‐16  6.20E‐11  ‐4.34241  1.76E‐13  ‐8.9188 
2923939  NM_006714 // SMPDL3A // sphingomyelin phosphodiesterase, acid‐like 3A // 6q22.31  SMPDL3A  4.67E‐16  6.94E‐09  ‐1.77807  1.19E‐14  ‐3.09695 
3261971  NM_017649 // CNNM2 // cyclin M2 // 10q24.32 // 54805 /// NM_199076 // CNNM2 // c  CNNM2  4.68E‐16  2.70E‐09  ‐1.46666  1.97E‐14  ‐2.03647 
3930235  NM_004414 // RCAN1 // regulator of calcineurin 1 // 21q22.1‐q22.2|21q22.12 // 18  RCAN1  4.70E‐16  9.81E‐14  ‐1.57703  2.00E‐10  ‐1.52469 
2533493  NM_014521 // SH3BP4 // SH3‐domain binding protein 4 // 2q37.1‐q37.2 // 23677 ///  SH3BP4  4.94E‐16  3.06E‐13  1.52406  4.64E‐11  1.53448 
3599758  NM_001104554 // PAQR5 // progestin and adipoQ receptor family member V // 15q23   PAQR5  5.39E‐16  9.80E‐14  ‐2.14706  2.68E‐10  ‐2.01281 
3707812  NM_015253 // WSCD1 // WSC domain containing 1 // 17p13.2 // 23302 /// ENST000003  WSCD1  5.55E‐16  9.29E‐14  ‐1.9179  3.09E‐10  ‐1.80734 
3407453  NM_000921 // PDE3A // phosphodiesterase 3A, cGMP‐inhibited // 12p12 // 5139 ///   PDE3A  5.72E‐16  6.09E‐12  ‐3.39657  2.22E‐12  ‐4.64774 
3509842  NM_001127217 // SMAD9 // SMAD family member 9 // 13q12‐q14 // 4093 /// NM_005905 SMAD9  6.36E‐16  3.80E‐10  1.68729  9.85E‐14  2.34364 
3687475  NM_024307 // GDPD3 // glycerophosphodiester phosphodiesterase domain containing   GDPD3  6.41E‐16  4.73E‐14  ‐2.42352  1.24E‐09  ‐2.10583 
3062082  NM_002612 // PDK4 // pyruvate dehydrogenase kinase, isozyme 4 // 7q21.3 // 5166   PDK4  6.42E‐16  2.52E‐10  ‐1.95483  1.32E‐13  ‐2.8972 
2931391  NM_015440 // MTHFD1L // methylenetetrahydrofolate dehydrogenase (NADP+ dependent  MTHFD1L  6.44E‐16  2.99E‐10  1.46554  1.18E‐13  1.84578 
3449760  NM_144973 // DENND5B // DENN/MADD domain containing 5B // 12p11.21 // 160518 /// DENND5B  6.46E‐16  8.62E‐11  ‐1.75755  2.86E‐13  ‐2.30954 
3563861  NM_004196 // CDKL1 // cyclin‐dependent kinase‐like 1 (CDC2‐related kinase) // 14  CDKL1  6.63E‐16  4.95E‐13  ‐1.37107  4.47E‐11  ‐1.38595 
2585476  NM_002976 // SCN7A // sodium channel, voltage‐gated, type VII, alpha // 2q21‐q23  SCN7A  6.90E‐16  8.55E‐11  ‐2.24178  3.18E‐13  ‐3.29935 
3571667  NM_001249 // ENTPD5 // ectonucleoside triphosphate diphosphohydrolase 5 // 14q24  ENTPD5  6.97E‐16  1.94E‐12  ‐1.95722  1.00E‐11  ‐2.15671 
3327057  NM_024841 // FLJ14213 // protor‐2 // 11p13‐p12 // 79899 /// ENST00000378867 // F  FLJ14213  7.06E‐16  5.35E‐14  ‐1.69346  1.26E‐09  ‐1.55989 
3665501  NM_000196 // HSD11B2 // hydroxysteroid (11‐beta) dehydrogenase 2 // 16q22 // 329  HSD11B2  7.19E‐16  1.00E‐14  ‐2.00033  3.05E‐08  ‐1.62194 
3846709  NM_017720 // STAP2 // signal transducing adaptor family member 2 // 19p13.3 // 5  STAP2  7.45E‐16  1.42E‐13  ‐1.59135  3.10E‐10  ‐1.53433 
2954355  NM_014780 // CUL7 // cullin 7 // 6p21.1 // 9820 /// ENST00000265348 // CUL7 // c  CUL7  7.45E‐16  4.31E‐12  1.28116  4.87E‐12  1.34874 
3217361  NM_173551 // ANKS6 // ankyrin repeat and sterile alpha motif domain containing 6  ANKS6  7.85E‐16  7.14E‐12  1.39379  3.24E‐12  1.51292 
3470964  NM_016433 // GLTP // glycolipid transfer protein // 12q24.11 // 51228 /// ENST00  GLTP  8.22E‐16  2.36E‐13  ‐1.63843  1.83E‐10  ‐1.60375 
2635184  NM_007072 // HHLA2 // HERV‐H LTR‐associating 2 // 3q13.13 // 11148 /// ENST00000  HHLA2  8.33E‐16  8.30E‐11  ‐2.8921  4.33E‐13  ‐4.72237 
2673873  NM_000884 // IMPDH2 // IMP (inosine monophosphate) dehydrogenase 2 // 3p21.2 //   IMPDH2  8.62E‐16  2.80E‐11  1.78166  1.10E‐12  2.19372 
3595691  NM_000236 // LIPC // lipase, hepatic // 15q21‐q23 // 3990 /// ENST00000356113 //  LIPC  8.72E‐16  1.85E‐13  ‐2.05875  2.92E‐10  ‐1.95998 
3890640  NM_002591 // PCK1 // phosphoenolpyruvate carboxykinase 1 (soluble) // 20q13.31 /  PCK1  9.13E‐16  7.70E‐09  ‐3.09548  2.71E‐14  ‐8.76711 
3783565  NM_000371 // TTR // transthyretin // 18q12.1 // 7276 /// ENST00000237014 // TTR   TTR  9.23E‐16  1.38E‐06  ‐1.38075  2.78E‐15  ‐2.35275 
2486178  NM_002398 // MEIS1 // Meis homeobox 1 // 2p14‐p13 // 4211 /// BC036511 // MEIS1   MEIS1  9.31E‐16  5.09E‐10  ‐2.06967  1.40E‐13  ‐3.26794 




3649890  NM_004996 // ABCC1 // ATP‐binding cassette, sub‐family C (CFTR/MRP), member 1 //  ABCC1  1.01E‐15  3.14E‐10  1.39423  2.18E‐13  1.68727 
3824993  NM_004864 // GDF15 // growth differentiation factor 15 // 19p13.11 // 9518 /// E  GDF15  1.08E‐15  2.38E‐12  2.54824  1.74E‐11  2.87763 
2944491  NM_001080480 // MBOAT1 // membrane bound O‐acyltransferase domain containing 1 /  MBOAT1  1.10E‐15  2.09E‐10  ‐1.56313  3.28E‐13  ‐1.97925 
2409275  NM_182517 // C1orf210 // chromosome 1 open reading frame 210 // 1p34.2 // 149466  C1orf210  1.12E‐15  5.87E‐13  ‐1.62478  1.00E‐10  ‐1.632 
2975014  NM_005627 // SGK1 // serum/glucocorticoid regulated kinase 1 // 6q23 // 6446 ///  SGK1  1.14E‐15  2.32E‐12  ‐2.70061  1.99E‐11  ‐3.05284 
3776583  BC137437 // FLJ35776 // hypothetical LOC649446 // 18p11.31 // 649446 /// NM_0010  FLJ35776  1.15E‐15  1.62E‐11  1.68129  2.83E‐12  1.95496 
2470470  NM_145175 // FAM84A // family with sequence similarity 84, member A // 2p24.3 //  FAM84A  1.17E‐15  2.32E‐11  1.37699  2.11E‐12  1.52581 
3472183  NM_004658 // RASAL1 // RAS protein activator like 1 (GAP1 like) // 12q23‐q24 //   RASAL1  1.17E‐15  5.77E‐12  1.42772  7.93E‐12  1.53259 
2898934  NM_006998 // SCGN // secretagogin, EF‐hand calcium binding protein // 6p22.3‐p22  SCGN  1.19E‐15  1.28E‐10  ‐2.48147  5.30E‐13  ‐3.82462 
2590491  NM_002500 // NEUROD1 // neurogenic differentiation 1 // 2q32 // 4760 /// ENST000  NEUROD1  1.20E‐15  3.34E‐10  ‐2.67774  2.68E‐13  ‐4.68067 
2566414  NM_012214 // MGAT4A // mannosyl (alpha‐1,3‐)‐glycoprotein beta‐1,4‐N‐acetylgluco  MGAT4A  1.21E‐15  1.14E‐10  ‐2.20198  5.97E‐13  ‐3.17424 
3184710  NM_005592 // MUSK // muscle, skeletal, receptor tyrosine kinase // 9q31.3‐q32 //  MUSK  1.22E‐15  2.41E‐10  ‐1.72075  3.44E‐13  ‐2.29971 
2809245  NM_002203 // ITGA2 // integrin, alpha 2 (CD49B, alpha 2 subunit of VLA‐2 recepto  ITGA2  1.24E‐15  3.44E‐13  2.31059  2.52E‐10  2.22852 
3444216  NM_018423 // STYK1 // serine/threonine/tyrosine kinase 1 // 12p13.2 // 55359 ///  STYK1  1.30E‐15  1.24E‐10  ‐1.52976  6.26E‐13  ‐1.86452 
3768791  NM_080284 // ABCA6 // ATP‐binding cassette, sub‐family A (ABC1), member 6 // 17q  ABCA6  1.33E‐15  7.11E‐12  ‐1.85425  7.96E‐12  ‐2.10814 
2367086  NM_002022 // FMO4 // flavin containing monooxygenase 4 // 1q23‐q25 // 2329 /// N  FMO4  1.36E‐15  5.20E‐12  ‐1.83029  1.14E‐11  ‐2.03977 
2558150  NM_014911 // AAK1 // AP2 associated kinase 1 // 2p14 // 22848 /// NR_003705 // S  AAK1  1.40E‐15  7.12E‐07  ‐1.29064  5.86E‐15  ‐1.89257 
2827057  NM_023927 // GRAMD3 // GRAM domain containing 3 // 5q23.2 // 65983 /// ENST00000  GRAMD3  1.41E‐15  1.25E‐12  ‐1.93989  6.06E‐11  ‐2.01261 
3472755  NM_016569 // TBX3 // T‐box 3 // 12q24.1 // 6926 /// NM_005996 // TBX3 // T‐box 3  TBX3  1.42E‐15  9.85E‐12  1.80085  6.46E‐12  2.06301 
3157385  NM_052963 // TOP1MT // topoisomerase (DNA) I, mitochondrial // 8q24.3 // 116447   TOP1MT  1.45E‐15  3.24E‐12  1.53748  2.11E‐11  1.62883 
2429235  NM_000036 // AMPD1 // adenosine monophosphate deaminase 1 (isoform M) // 1p13 //  AMPD1  1.45E‐15  4.00E‐11  ‐2.78392  1.85E‐12  ‐3.99804 
3210013  NM_017662 // TRPM6 // transient receptor potential cation channel, subfamily M,   TRPM6  1.46E‐15  3.35E‐08  ‐2.79135  2.34E‐14  ‐8.29021 
3212420  NM_022127 // SLC28A3 // solute carrier family 28 (sodium‐coupled nucleoside tran  SLC28A3  1.46E‐15  2.16E‐13  2.60444  6.97E‐10  2.37835 
2740067  NM_001148 // ANK2 // ankyrin 2, neuronal // 4q25‐q27 // 287 /// NM_001127493 //   ANK2  1.51E‐15  7.16E‐11  ‐1.5989  1.22E‐12  ‐1.93216 
2424524  NM_000110 // DPYD // dihydropyrimidine dehydrogenase // 1p22 // 1806 /// ENST000  DPYD  1.54E‐15  7.41E‐09  ‐1.68557  5.50E‐14  ‐2.66114 
2531589  NM_030926 // ITM2C // integral membrane protein 2C // 2q37 // 81618 /// NM_00101  ITM2C  1.57E‐15  9.27E‐11  ‐1.45714  1.04E‐12  ‐1.70968 
2367743  NM_004905 // PRDX6 // peroxiredoxin 6 // 1q25.1 // 9588 /// ENST00000340385 // P  PRDX6  1.59E‐15  3.67E‐11  ‐1.82802  2.32E‐12  ‐2.24248 
3091301  NM_173174 // PTK2B // PTK2B protein tyrosine kinase 2 beta // 8p21.1 // 2185 ///  PTK2B  1.65E‐15  4.21E‐10  ‐1.29511  3.63E‐13  ‐1.49896 
3219215  NM_004235 // KLF4 // Kruppel‐like factor 4 (gut) // 9q31 // 9314 /// ENST0000037  KLF4  1.65E‐15  1.12E‐11  ‐2.07622  7.32E‐12  ‐2.4585 
3742130  NM_014520 // MYBBP1A // MYB binding protein (P160) 1a // 17p13.3 // 10514 /// NM  MYBBP1A  1.67E‐15  5.33E‐09  1.22981  7.39E‐14  1.46035 
2669052  NM_014831 // LBA1 // lupus brain antigen 1 // 3p22.2 // 9881  LBA1  1.69E‐15  5.27E‐08  ‐1.62476  2.27E‐14  ‐2.77937 
3376235  NM_018093 // WDR74 // WD repeat domain 74 // 11q12.3 // 54663 /// ENST0000027885  WDR74  1.70E‐15  1.10E‐08  1.32977  5.07E‐14  1.72448 
3540552  NM_178155 // FUT8 // fucosyltransferase 8 (alpha (1,6) fucosyltransferase) // 14  FUT8  1.73E‐15  2.40E‐12  1.8233  4.11E‐11  1.93052 
3892812  NM_016354 // SLCO4A1 // solute carrier organic anion transporter family, member   SLCO4A1  1.84E‐15  9.95E‐10  1.56228  2.36E‐13  2.08159 
2835300  NM_000112 // SLC26A2 // solute carrier family 26 (sulfate transporter), member 2  SLC26A2  1.84E‐15  4.22E‐10  ‐3.94644  4.26E‐13  ‐8.47779 
2453370  NM_025179 // PLXNA2 // plexin A2 // 1q32.2 // 5362 /// ENST00000367033 // PLXNA2  PLXNA2  1.86E‐15  3.54E‐09  ‐1.30569  1.08E‐13  ‐1.60627 
3739162  NM_005993 // TBCD // tubulin folding cofactor D // 17q25.3 // 6904 /// ENST00000  TBCD  1.86E‐15  5.43E‐09  1.23301  8.47E‐14  1.46525 
3815399  NM_004368 // CNN2 // calponin 2 // 19p13.3 // 1265 /// NM_201277 // CNN2 // calp  CNN2  1.88E‐15  3.73E‐12  1.57484  2.91E‐11  1.66798 
3987029  NM_032227 // TMEM164 // transmembrane protein 164 // Xq22.3 // 84187 /// ENST000  TMEM164  1.89E‐15  1.11E‐11  ‐1.45727  9.35E‐12  ‐1.58318 
3687277  NM_012410 // SEZ6L2 // seizure related 6 homolog (mouse)‐like 2 // 16p11.2 // 26  SEZ6L2  1.90E‐15  4.44E‐13  1.62546  4.23E‐10  1.58316 
3375307  NM_153611 // CYBASC3 // cytochrome b, ascorbate dependent 3 // 11q12.2 // 220002  CYBASC3  1.98E‐15  6.39E‐15  ‐1.56246  1.65E‐06  ‐1.28598 




3864352  XM_001724326 // LOC100131563 // hypothetical protein LOC100131563 // 19q13.31 //  LOC100131563  2.00E‐15  7.54E‐11  ‐1.85207  1.80E‐12  ‐2.35138 
3875423  NM_001200 // BMP2 // bone morphogenetic protein 2 // 20p12 // 650 /// ENST000003  BMP2  2.24E‐15  7.71E‐13  ‐1.63113  2.76E‐10  ‐1.61509 
2775909  NM_016619 // PLAC8 // placenta‐specific 8 // 4q21.22 // 51316 /// ENST0000031150  PLAC8  2.45E‐15  1.12E‐09  ‐2.24619  3.28E‐13  ‐3.74924 
2854092  NM_002310 // LIFR // leukemia inhibitory factor receptor alpha // 5p13‐p12 // 39  LIFR  2.58E‐15  6.22E‐09  ‐2.01201  1.22E‐13  ‐3.55131 
3808745  NM_025214 // CCDC68 // coiled‐coil domain containing 68 // 18q21 // 80323 /// EN  CCDC68  2.59E‐15  1.27E‐09  ‐2.07949  3.27E‐13  ‐3.32645 
3758510  NM_001986 // ETV4 // ets variant gene 4 (E1A enhancer binding protein, E1AF) //   ETV4  2.59E‐15  1.07E‐11  3.06352  1.66E‐11  3.80566 
2401384  NM_017707 // DDEFL1 // development and differentiation enhancing factor‐like 1 /  DDEFL1  2.59E‐15  1.66E‐13  ‐1.39966  3.74E‐09  ‐1.32522 
2693357  NM_017836 // SLC41A3 // solute carrier family 41, member 3 // 3q21.2 // 54946 //  SLC41A3  2.60E‐15  1.79E‐12  1.28638  1.25E‐10  1.29938 
2845351  AK023178 // LOC25845 // hypothetical LOC25845 // 5p15.33 // 25845 /// BC086861 /  LOC25845  2.63E‐15  3.39E‐13  ‐4.37695  1.25E‐09  ‐3.76276 
2766788  NM_001098634 // RBM47 // RNA binding motif protein 47 // 4p13‐p12 // 54502 /// N  RBM47  2.64E‐15  4.40E‐12  ‐1.49649  4.44E‐11  ‐1.56782 
3949162  NM_015124 // GRAMD4 // GRAM domain containing 4 // 22q13.31 // 23151 /// ENST000  GRAMD4  2.69E‐15  2.37E‐12  ‐1.51226  9.44E‐11  ‐1.551 
3064501  NM_178176 // MOGAT3 // monoacylglycerol O‐acyltransferase 3 // 7q22.1 // 346606   MOGAT3  2.80E‐15  6.73E‐13  ‐2.0024  5.24E‐10  ‐1.93555 
3945545  NM_004900 // APOBEC3B // apolipoprotein B mRNA editing enzyme, catalytic polypep  APOBEC3B  2.81E‐15  1.71E‐14  ‐2.29344  3.99E‐07  ‐1.68288 
2682088  NM_173359 // EIF4E3 // eukaryotic translation initiation factor 4E family member  EIF4E3  2.84E‐15  3.98E‐08  ‐1.3252  5.06E‐14  ‐1.76889 
2899012  BC109207 // SLC17A4 // solute carrier family 17 (sodium phosphate), member 4 //   SLC17A4  2.94E‐15  2.17E‐09  ‐2.06443  2.76E‐13  ‐3.39848 
3962678  NM_007229 // PACSIN2 // protein kinase C and casein kinase substrate in neurons   PACSIN2  3.18E‐15  1.17E‐11  ‐1.32941  2.15E‐11  ‐1.40181 
3674886  NM_001077350 // C16orf35 // chromosome 16 open reading frame 35 // 16p13.3 // 81  C16orf35  3.28E‐15  5.59E‐09  1.20437  1.79E‐13  1.39277 
3527935  XM_001716933 // C14orf176 // chromosome 14 open reading frame 176 // 14q11.2 //   C14orf176  3.39E‐15  3.60E‐11  ‐2.04602  8.00E‐12  ‐2.50138 
3716950  NM_018404 // CENTA2 // centaurin, alpha 2 // 17q11.2 // 55803 /// ENST0000033088  CENTA2  3.41E‐15  3.39E‐12  ‐1.56044  9.61E‐11  ‐1.6126 
2560076  NM_033046 // RTKN // rhotekin // 2p13.1 // 6242 /// NM_001015055 // RTKN // rhot  RTKN  3.76E‐15  3.80E‐09  1.23543  2.73E‐13  1.44108 
2334986  NM_178033 // CYP4X1 // cytochrome P450, family 4, subfamily X, polypeptide 1 //   CYP4X1  3.84E‐15  4.62E‐13  3.45601  1.75E‐09  3.03242 
3816815  NM_002068 // GNA15 // guanine nucleotide binding protein (G protein), alpha 15 (  GNA15  3.93E‐15  5.62E‐09  1.47792  2.28E‐13  1.99463 
2694123  NM_003707 // RUVBL1 // RuvB‐like 1 (E. coli) // 3q21 // 8607 /// ENST00000322623  RUVBL1  4.14E‐15  2.62E‐10  1.45722  2.02E‐12  1.72556 
2827525  NM_001046 // SLC12A2 // solute carrier family 12 (sodium/potassium/chloride tran  SLC12A2  4.30E‐15  2.45E‐12  2.56241  2.21E‐10  2.63174 
2645764  NM_001679 // ATP1B3 // ATPase, Na+/K+ transporting, beta 3 polypeptide // 3q23 /  ATP1B3  4.44E‐15  4.63E‐12  ‐1.92205  1.08E‐10  ‐2.02611 
3422144  NM_003667 // LGR5 // leucine‐rich repeat‐containing G protein‐coupled receptor 5  LGR5  4.45E‐15  2.89E‐13  6.25522  5.04E‐09  4.68667 
3787855  NM_006033 // LIPG // lipase, endothelial // 18q21.1 // 9388 /// ENST00000261292   LIPG  4.46E‐15  2.90E‐11  1.79937  1.54E‐11  2.07291 
2926447  NM_003206 // TCF21 // transcription factor 21 // 6pter‐qter // 6943 /// NM_19839  TCF21  4.54E‐15  7.81E‐11  ‐2.01433  6.37E‐12  ‐2.53609 
3409127  NM_020183 // ARNTL2 // aryl hydrocarbon receptor nuclear translocator‐like 2 //   ARNTL2  4.85E‐15  1.96E‐09  1.73446  5.95E‐13  2.46398 
3829751  NM_032346 // PDCD2L // programmed cell death 2‐like // 19q13.11 // 84306 /// ENS  PDCD2L  4.97E‐15  3.43E‐09  1.37132  4.28E‐13  1.70779 
3341155  NM_004055 // CAPN5 // calpain 5 // 11q14 // 726 /// ENST00000278559 // CAPN5 //   CAPN5  5.02E‐15  6.23E‐12  ‐1.39714  9.62E‐11  ‐1.44325 
2414366  NM_003713 // PPAP2B // phosphatidic acid phosphatase type 2B // 1pter‐p22.1 // 8  PPAP2B  5.04E‐15  1.09E‐11  ‐1.50068  5.22E‐11  ‐1.59167 
3972929  NM_001128127 // GK // glycerol kinase // Xp21.3 // 2710 /// NM_203391 // GK // g  GK  5.09E‐15  4.96E‐13  ‐1.86201  2.86E‐09  ‐1.72667 
3383130  NM_023930 // KCTD14 // potassium channel tetramerisation domain containing 14 //  KCTD14  5.13E‐15  1.57E‐11  1.77477  3.63E‐11  1.96335 
3091746  NM_017412 // FZD3 // frizzled homolog 3 (Drosophila) // 8p21 // 7976 /// ENST000  FZD3  5.16E‐15  4.31E‐12  2.09448  1.56E‐10  2.19458 
3375049  NM_014502 // PRPF19 // PRP19/PSO4 pre‐mRNA processing factor 19 homolog (S. cere  PRPF19  5.16E‐15  3.64E‐09  1.23572  4.34E‐13  1.43257 
3115530  M34428 // PVT1 // Pvt1 oncogene (non‐protein coding) // 8q24 // 5820 /// M34429   PVT1  5.33E‐15  5.21E‐13  1.66471  2.94E‐09  1.56526 
3450899  NM_052885 // SLC2A13 // solute carrier family 2 (facilitated glucose transporter  SLC2A13  5.38E‐15  3.99E‐10  ‐1.39953  2.16E‐12  ‐1.63873 
2675763  NM_004704 // RRP9 // ribosomal RNA processing 9, small subunit (SSU) processome   RRP9  5.76E‐15  4.06E‐06  1.18323  1.59E‐14  1.56635 
3237280  NM_001098844 // FAM23A // family with sequence similarity 23, member A // 10p12.  FAM23A  5.86E‐15  1.17E‐09  ‐3.69581  1.11E‐12  ‐7.78262 
2775994  NM_001098540 // HPSE // heparanase // 4q21.3 // 10855 /// NM_006665 // HPSE // h  HPSE  5.87E‐15  1.25E‐12  ‐1.4445  9.92E‐10  ‐1.41665 




2879312  NM_000176 // NR3C1 // nuclear receptor subfamily 3, group C, member 1 (glucocort  NR3C1  6.19E‐15  3.01E‐08  ‐1.61006  1.60E‐13  ‐2.50212 
3458783  NM_000075 // CDK4 // cyclin‐dependent kinase 4 // 12q14 // 1019 /// ENST00000257  CDK4  6.26E‐15  2.36E‐06  1.30762  2.16E‐14  1.98685 
3594031  NM_014548 // TMOD2 // tropomodulin 2 (neuronal) // 15q21.1‐q21.2 // 29767 /// EN  TMOD2  6.49E‐15  9.75E‐10  ‐1.42568  1.47E‐12  ‐1.72865 
3318666  NM_000543 // SMPD1 // sphingomyelin phosphodiesterase 1, acid lysosomal // 11p15  SMPD1  6.53E‐15  9.20E‐13  ‐1.87047  1.92E‐09  ‐1.77046 
3430959  NM_001093 // ACACB // acetyl‐Coenzyme A carboxylase beta // 12q24.11 // 32 /// E  ACACB  6.66E‐15  3.91E‐10  ‐1.42284  3.03E‐12  ‐1.66829 
2461037  NM_014801 // PCNXL2 // pecanex‐like 2 (Drosophila) // 1q42.2 // 80003 /// ENST00  PCNXL2  6.69E‐15  3.06E‐14  1.60954  1.21E‐06  1.3323 
3973768  NM_198511 // LANCL3 // LanC lantibiotic synthetase component C‐like 3 (bacterial  LANCL3  7.02E‐15  6.54E‐14  ‐1.63753  2.46E‐07  ‐1.39236 
3057955  NM_006682 // FGL2 // fibrinogen‐like 2 // 7q11.23 // 10875 /// ENST00000248598 /  FGL2  7.04E‐15  2.54E‐08  ‐1.78782  2.08E‐13  ‐3.00584 
3723348  NM_006460 // HEXIM1 // hexamethylene bis‐acetamide inducible 1 // 17q21.31 // 10  HEXIM1  7.14E‐15  2.19E‐11  ‐1.41792  4.56E‐11  ‐1.51004 
3517251  NM_080759 // DACH1 // dachshund homolog 1 (Drosophila) // 13q22 // 1602 /// NM_0  DACH1  7.17E‐15  4.29E‐11  1.78648  2.34E‐11  2.05352 
3168938  NM_022490 // POLR1E // polymerase (RNA) I polypeptide E, 53kDa // 9p13.2 // 6442  POLR1E  7.32E‐15  5.59E‐09  1.40921  5.37E‐13  1.80224 
3190061  NM_004957 // FPGS // folylpolyglutamate synthase // 9q34.1 // 2356 /// NM_001018  FPGS  7.37E‐15  1.29E‐07  1.20879  9.46E‐14  1.48838 
2976768  NM_006079 // CITED2 // Cbp/p300‐interacting transactivator, with Glu/Asp‐rich ca  CITED2  7.44E‐15  1.59E‐09  ‐1.44366  1.26E‐12  ‐1.78789 
2841964  NM_002449 // MSX2 // msh homeobox 2 // 5q34‐q35 // 4488 /// NR_002307 // MSX2P1   MSX2  7.56E‐15  2.37E‐11  2.68766  4.64E‐11  3.22071 
3929076  NR_002996 // SNORA80 // small nucleolar RNA, H/ACA box 80 // 21q22.11 // 677846   SNORA80  7.58E‐15  1.97E‐09  1.38785  1.12E‐12  1.69131 
3417309  NM_006191 // PA2G4 // proliferation‐associated 2G4, 38kDa // 12q13.2 // 5036 ///  PA2G4  7.59E‐15  9.35E‐06  1.24739  1.61E‐14  1.85805 
2945882  NR_002174 // CMAH // cytidine monophosphate‐N‐acetylneuraminic acid hydroxylase   CMAH  7.60E‐15  8.87E‐05  ‐1.4437  7.62E‐15  ‐3.41036 
3817116  NM_014428 // TJP3 // tight junction protein 3 (zona occludens 3) // 19p13.3 // 2  TJP3  8.15E‐15  8.89E‐12  ‐1.41507  1.54E‐10  ‐1.46063 
3903361  NM_000687 // AHCY // S‐adenosylhomocysteine hydrolase // 20cen‐q13.1 // 191 ///   AHCY  8.38E‐15  1.27E‐07  1.32438  1.12E‐13  1.79608 
2927604  NM_020340 // KIAA1244 // KIAA1244 // 6q23.3 // 57221 /// ENST00000251691 // KIAA  KIAA1244  8.44E‐15  3.25E‐12  1.87107  5.64E‐10  1.87248 
3129175  NM_173833 // SCARA5 // scavenger receptor class A, member 5 (putative) // 8p21.1  SCARA5  8.66E‐15  1.03E‐12  ‐1.74762  2.92E‐09  ‐1.65284 
3468345  NM_001111283 // IGF1 // insulin‐like growth factor 1 (somatomedin C) // 12q22‐q2  IGF1  8.68E‐15  8.70E‐10  ‐1.77638  2.44E‐12  ‐2.38037 
3202316  NM_024761 // MOBKL2B // MOB1, Mps One Binder kinase activator‐like 2B (yeast) //  MOBKL2B  8.83E‐15  2.07E‐11  ‐1.47708  6.99E‐11  ‐1.57179 
2585400  NM_002977 // SCN9A // sodium channel, voltage‐gated, type IX, alpha subunit // 2  SCN9A  8.88E‐15  4.78E‐09  ‐2.03233  7.75E‐13  ‐3.30229 
3127703  NM_003842 // TNFRSF10B // tumor necrosis factor receptor superfamily, member 10b  TNFRSF10B  9.39E‐15  2.30E‐10  1.53674  7.89E‐12  1.80476 
3142485  NM_005536 // IMPA1 // inositol(myo)‐1(or 4)‐monophosphatase 1 // 8q21.13‐q21.3 /  IMPA1  9.82E‐15  2.24E‐10  ‐1.62851  8.64E‐12  ‐1.94905 
2854088  NM_001127671 // LIFR // leukemia inhibitory factor receptor alpha // 5p13‐p12 //  LIFR  9.83E‐15  1.23E‐07  ‐1.95536  1.39E‐13  ‐3.99792 
2450668  NM_016456 // TMEM9 // transmembrane protein 9 // ‐‐‐ // 252839 /// ENST000003673  TMEM9  9.88E‐15  2.41E‐10  1.38228  8.20E‐12  1.56066 
3230697  NM_015392 // NPDC1 // neural proliferation, differentiation and control, 1 // 9q  NPDC1  9.98E‐15  1.52E‐08  1.42292  4.45E‐13  1.88996 
3535628  NM_053064 // GNG2 // guanine nucleotide binding protein (G protein), gamma 2 //   GNG2  1.00E‐14  9.88E‐11  ‐1.86905  1.84E‐11  ‐2.24145 
3540007  NM_005956 // MTHFD1 // methylenetetrahydrofolate dehydrogenase (NADP+ dependent)  MTHFD1  1.00E‐14  6.41E‐07  1.31914  6.56E‐14  1.89129 
3638607  NM_001150 // ANPEP // alanyl (membrane) aminopeptidase // 15q25‐q26 // 290 /// E  ANPEP  1.01E‐14  4.66E‐11  ‐7.01314  3.82E‐11  ‐10.8 
2880679  NM_024577 // SH3TC2 // SH3 domain and tetratricopeptide repeats 2 // 5q32 // 796  SH3TC2  1.07E‐14  1.02E‐12  2.28499  4.68E‐09  2.07268 
2835531  NM_001543 // NDST1 // N‐deacetylase/N‐sulfotransferase (heparan glucosaminyl) 1   NDST1  1.07E‐14  3.21E‐12  ‐1.37261  9.17E‐10  ‐1.36463 
2841120  AK096661 // LOC54492 // hypothetical LOC54492 // 5q35.1 // 54492  LOC54492  1.09E‐14  2.34E‐12  ‐2.20018  1.45E‐09  ‐2.12002 
3718191  NM_005623 // CCL8 // chemokine (C‐C motif) ligand 8 // 17q11.2 // 6355 /// ENST0  CCL8  1.11E‐14  5.86E‐12  ‐4.75041  4.54E‐10  ‐4.9865 
2763912  NM_173463 // CCDC149 // coiled‐coil domain containing 149 // 4p15.2 // 91050 ///  CCDC149  1.13E‐14  2.71E‐12  1.38013  1.27E‐09  1.36377 
2735409  NM_016323 // HERC5 // hect domain and RLD 5 // 4q22.1 // 51191 /// ENST000002643  HERC5  1.14E‐14  1.61E‐10  ‐1.32058  1.47E‐11  ‐1.44574 
2463173  NM_022469 // GREM2 // gremlin 2, cysteine knot superfamily, homolog (Xenopus lae  GREM2  1.16E‐14  2.46E‐09  ‐2.21062  1.77E‐12  ‐3.53723 
3414739  NM_014033 // METTL7A // methyltransferase like 7A // 12q13.13 // 25840 /// ENST0  METTL7A  1.19E‐14  7.05E‐11  ‐2.041  3.33E‐11  ‐2.43425 
3442427  NM_005768 // LPCAT3 // lysophosphatidylcholine acyltransferase 3 // 12p13 // 101  LPCAT3  1.22E‐14  1.59E‐13  ‐1.74665  1.64E‐07  ‐1.4816 




3874636  NM_175839 // SMOX // spermine oxidase // 20p13 // 54498 /// NM_175842 // SMOX //  SMOX  1.28E‐14  1.04E‐11  1.52681  2.94E‐10  1.57298 
3933331  NM_015500 // C2CD2 // C2 calcium‐dependent domain containing 2 // 21q22.3 // 259  C2CD2  1.31E‐14  3.11E‐12  1.29898  1.41E‐09  1.28671 
3496637  NM_005708 // GPC6 // glypican 6 // 13q32 // 10082 /// ENST00000377047 // GPC6 //  GPC6  1.33E‐14  4.59E‐09  ‐1.52922  1.39E‐12  ‐2.01394 
2990404  NM_001112706 // SCIN // scinderin // 7p21.3 // 85477 /// NM_033128 // SCIN // sc  SCIN  1.37E‐14  2.16E‐10  ‐2.63493  1.50E‐11  ‐3.66164 
2514304  NM_005771 // DHRS9 // dehydrogenase/reductase (SDR family) member 9 // 2q31.1 //  DHRS9  1.38E‐14  7.72E‐12  ‐3.53013  4.86E‐10  ‐3.70537 
4021433  NM_001421 // ELF4 // E74‐like factor 4 (ets domain transcription factor) // Xq26  ELF4  1.39E‐14  1.26E‐11  ‐1.45405  2.73E‐10  ‐1.49885 
4000155  NM_001001995 // GPM6B // glycoprotein M6B // Xp22.2 // 2824 /// NM_001001996 //   GPM6B  1.43E‐14  7.99E‐11  ‐1.79037  4.01E‐11  ‐2.06407 
3346453  NM_006106 // YAP1 // Yes‐associated protein 1, 65kDa // 11q13 // 10413 /// ENST0  YAP1  1.53E‐14  1.48E‐11  1.40308  2.69E‐10  1.44551 
2339872  NM_005012 // ROR1 // receptor tyrosine kinase‐like orphan receptor 1 // 1p32‐p31  ROR1  1.53E‐14  2.63E‐06  ‐1.30485  5.98E‐14  ‐1.94085 
3960722  ENST00000406767 // RP1‐199H16.1 // hypothetical LOC388900 // 22q13.1 // 388900  RP1‐199H16.1  1.59E‐14  4.41E‐12  1.42704  1.30E‐09  1.4163 
2374422  BC106877 // C1orf106 // chromosome 1 open reading frame 106 // 1q32.1 // 55765 /  C1orf106  1.61E‐14  2.75E‐08  ‐1.26149  5.94E‐13  ‐1.53162 
3596147  NM_004751 // GCNT3 // glucosaminyl (N‐acetyl) transferase 3, mucin type // 15q21  GCNT3  1.67E‐14  7.55E‐11  ‐3.03652  5.49E‐11  ‐3.9084 
2515933  NM_016653 // ZAK // sterile alpha motif and leucine zipper containing kinase AZK  ZAK  1.75E‐14  3.70E‐10  1.56737  1.39E‐11  1.85235 
3940360  ENST00000406486 // CTA‐221G9.4 // KIAA1671 protein // 22q11.23 // 85379 /// AL83  CTA‐221G9.4  1.80E‐14  2.68E‐11  ‐1.25682  1.83E‐10  ‐1.29421 
2949524  NM_006709 // EHMT2 // euchromatic histone‐lysine N‐methyltransferase 2 // 6p21.3  EHMT2  1.88E‐14  1.57E‐09  1.18089  4.91E‐12  1.28503 
2459616  NM_033445 // HIST3H2A // histone cluster 3, H2a // 1q42.13 // 92815 /// ENST0000  HIST3H2A  1.90E‐14  1.76E‐10  1.52814  3.05E‐11  1.732 
3299463  NM_144590 // ANKRD22 // ankyrin repeat domain 22 // 10q23.31 // 118932 /// ENST0  ANKRD22  1.93E‐14  2.55E‐10  2.38637  2.23E‐11  3.17721 
3832114  NM_015073 // SIPA1L3 // signal‐induced proliferation‐associated 1 like 3 // 19q1  SIPA1L3  1.95E‐14  9.09E‐11  ‐1.34287  5.95E‐11  ‐1.438 
3800834  NM_138340 // ABHD3 // abhydrolase domain containing 3 // 18q11.2 // 171586 /// E  ABHD3  1.97E‐14  2.65E‐11  ‐1.48579  2.18E‐10  ‐1.55831 
3948259  NM_001017526 // ARHGAP8 // Rho GTPase activating protein 8 // 22q13.31 // 23779   ARHGAP8  1.97E‐14  2.96E‐11  1.29184  1.93E‐10  1.33562 
3256590  NM_004670 // PAPSS2 // 3'‐phosphoadenosine 5'‐phosphosulfate synthase 2 // 10q23  PAPSS2  2.12E‐14  8.67E‐11  ‐1.82895  7.12E‐11  ‐2.09085 
2612813  NM_015184 // PLCL2 // phospholipase C‐like 2 // 3p24.3 // 23228 /// ENST00000285  PLCL2  2.12E‐14  2.69E‐09  ‐1.55746  3.93E‐12  ‐1.99113 
3868659  NM_199249 // C19orf48 // chromosome 19 open reading frame 48 // 19q13.33 // 8479  C19orf48  2.15E‐14  5.64E‐08  1.50148  5.77E‐13  2.16341 
2563536  NM_001443 // FABP1 // fatty acid binding protein 1, liver // 2p11 // 2168 /// EN  FABP1  2.16E‐14  6.31E‐11  ‐2.76414  1.02E‐10  ‐3.35726 
4011008  NM_007268 // VSIG4 // V‐set and immunoglobulin domain containing 4 // Xq12‐q13.3  VSIG4  2.25E‐14  7.54E‐10  ‐1.90028  1.13E‐11  ‐2.49059 
3029129  NM_003461 // ZYX // zyxin // 7q32 // 7791 /// NM_001010972 // ZYX // zyxin // 7q  ZYX  2.34E‐14  8.46E‐11  1.33546  8.63E‐11  1.41984 
3674659  NR_023348 // GAS8 // growth arrest‐specific 8 // 16q24.3 // 2622 /// NM_001481 /  GAS8  2.35E‐14  2.91E‐10  1.29534  2.72E‐11  1.40943 
3189864  NM_138361 // LRSAM1 // leucine rich repeat and sterile alpha motif containing 1   LRSAM1  2.36E‐14  1.09E‐09  1.24174  9.05E‐12  1.37006 
2757427  NM_012318 // LETM1 // leucine zipper‐EF‐hand containing transmembrane protein 1   LETM1  2.45E‐14  6.15E‐14  ‐1.6283  9.76E‐06  ‐1.30531 
2488680  NM_006062 // SMYD5 // SMYD family member 5 // 2p13.2 // 10322 /// ENST0000038950  SMYD5  2.45E‐14  3.05E‐09  1.23703  4.42E‐12  1.39236 
3434760  NM_002560 // P2RX4 // purinergic receptor P2X, ligand‐gated ion channel, 4 // 12  P2RX4  2.45E‐14  4.33E‐11  ‐1.50671  1.88E‐10  ‐1.60059 
3863060  NM_020158 // EXOSC5 // exosome component 5 // 19q13.1 // 56915 /// ENST000002212  EXOSC5  2.56E‐14  4.32E‐07  1.28719  2.50E‐13  1.72369 
3959918  NM_003312 // TST // thiosulfate sulfurtransferase (rhodanese) // 22q13.1 // 7263  TST  2.62E‐14  2.48E‐13  ‐1.96582  4.66E‐07  ‐1.58238 
3260937  NM_021830 // C10orf2 // chromosome 10 open reading frame 2 // 10q23.3‐q24.3 // 5  C10orf2  2.65E‐14  5.04E‐08  1.29637  8.10E‐13  1.62358 
2945645  NM_016614 // TTRAP // TRAF and TNF receptor associated protein // 6p22.3‐p22.1 /  TTRAP  2.68E‐14  7.10E‐11  ‐1.67215  1.29E‐10  ‐1.83945 
3975227  NM_000240 // MAOA // monoamine oxidase A // Xp11.3 // 4128 /// ENST00000338702 /  MAOA  2.72E‐14  4.54E‐11  ‐2.09478  2.13E‐10  ‐2.32969 
3964154  NM_022766 // CERK // ceramide kinase // 22q13.31 // 64781 /// ENST00000216264 //  CERK  2.77E‐14  1.46E‐08  ‐1.44048  1.82E‐12  ‐1.87105 
3590341  NM_007236 // CHP // calcium binding protein P22 // 15q13.3 // 11261 /// ENST0000  CHP  2.80E‐14  5.63E‐13  ‐1.52513  1.10E‐07  ‐1.37235 
3151883  NM_194291 // TMEM65 // transmembrane protein 65 // 8q24.13 // 157378 /// ENST000  TMEM65  2.81E‐14  1.98E‐11  ‐1.44817  5.78E‐10  ‐1.48456 
4015548  NM_212559 // XKRX // XK, Kell blood group complex subunit‐related, X‐linked // X  XKRX  2.81E‐14  4.53E‐10  1.74205  2.44E‐11  2.1211 
3688254  NM_002773 // PRSS8 // protease, serine, 8 // 16p11.2 // 5652 /// ENST00000317508  PRSS8  3.03E‐14  3.48E‐11  ‐1.61136  3.44E‐10  ‐1.69958 




2908052  NM_203290 // POLR1C // polymerase (RNA) I polypeptide C, 30kDa // 6p21.1 // 9533  POLR1C  3.07E‐14  6.00E‐09  1.33172  3.79E‐12  1.58604 
3743551  NM_001307 // CLDN7 // claudin 7 // 17p13 // 1366 /// ENST00000360325 // CLDN7 //  CLDN7  3.19E‐14  4.25E‐12  ‐1.52038  5.47E‐09  ‐1.47067 
3431376  NM_033121 // ANKRD13A // ankyrin repeat domain 13A // 12q24.11 // 88455 /// ENST  ANKRD13A  3.24E‐14  1.14E‐08  ‐1.36973  2.66E‐12  ‐1.69417 
3416921  NM_002905 // RDH5 // retinol dehydrogenase 5 (11‐cis/9‐cis) // 12q13‐q14 // 5959  RDH5  3.33E‐14  2.17E‐12  ‐1.62664  1.64E‐08  ‐1.51758 
3761451  NM_024017 // HOXB9 // homeobox B9 // 17q21.3 // 3219 /// ENST00000311177 // HOXB HOXB9  3.36E‐14  3.96E‐08  1.45556  1.28E‐12  1.97848 
4015312  NM_001105243 // PCDH19 // protocadherin 19 // Xq13.3 // 57526 /// NM_020766 // P  PCDH19  3.38E‐14  5.81E‐09  ‐1.40561  4.43E‐12  ‐1.72361 
2893895  NM_001718 // BMP6 // bone morphogenetic protein 6 // 6p24‐p23 // 654 /// ENST000  BMP6  3.40E‐14  3.76E‐12  ‐1.72141  7.45E‐09  ‐1.63456 
3720817  NM_016339 // RAPGEFL1 // Rap guanine nucleotide exchange factor (GEF)‐like 1 //   RAPGEFL1  3.48E‐14  5.47E‐10  ‐1.55469  2.89E‐11  ‐1.81952 
3535515  NM_001042481 // FRMD6 // FERM domain containing 6 // 14q22.1 // 122786 /// NM_15  FRMD6  3.51E‐14  8.36E‐11  ‐1.47999  1.73E‐10  ‐1.58794 
2659393  NM_152672 // OSTalpha // organic solute transporter alpha // 3q29 // 200931 ///   OSTalpha  3.55E‐14  1.02E‐13  ‐4.1584  8.21E‐06  ‐2.22614 
2787096  NM_015130 // TBC1D9 // TBC1 domain family, member 9 (with GRAM domain) // 4q31.2  TBC1D9  3.61E‐14  1.29E‐09  ‐1.6496  1.50E‐11  ‐2.05372 
3571553  NM_194278 // C14orf43 // chromosome 14 open reading frame 43 // 14q24.3 // 91748  C14orf43  3.67E‐14  1.96E‐10  ‐1.34091  8.00E‐11  ‐1.44495 
2909263  NM_005588 // MEP1A // meprin A, alpha (PABA peptide hydrolase) // 6p12‐p11 // 42  MEP1A  3.69E‐14  2.84E‐09  ‐2.7035  8.43E‐12  ‐4.51845 
3957445  NM_014303 // PES1 // pescadillo homolog 1, containing BRCT domain (zebrafish) //  PES1  3.70E‐14  7.36E‐08  1.25617  1.01E‐12  1.53742 
3434594  NM_000017 // ACADS // acyl‐Coenzyme A dehydrogenase, C‐2 to C‐3 short chain // 1  ACADS  3.70E‐14  3.28E‐13  ‐1.90256  6.35E‐07  ‐1.54315 
2427930  NM_024102 // WDR77 // WD repeat domain 77 // 1p13.2 // 79084 /// ENST00000235090  WDR77  3.71E‐14  4.38E‐08  1.46664  1.37E‐12  2.00914 
2728938  NM_015236 // LPHN3 // latrophilin 3 // 4q13.1 // 23284 /// ENST00000295349 // LP  LPHN3  3.77E‐14  3.11E‐09  ‐1.52565  8.13E‐12  ‐1.90376 
3941683  NM_032173 // ZNRF3 // zinc and ring finger 3 // 22q12.1 // 84133 /// ENST0000033  ZNRF3  3.81E‐14  9.69E‐11  1.75644  1.71E‐10  1.95135 
3978760  NM_014061 // MAGEH1 // melanoma antigen family H, 1 // Xp11.21 // 28986 /// ENST  MAGEH1  3.84E‐14  1.09E‐09  ‐1.50878  1.90E‐11  ‐1.79015 
3359224  NM_005170 // ASCL2 // achaete‐scute complex homolog 2 (Drosophila) // 11p15.5 //  ASCL2  3.88E‐14  1.74E‐10  1.95848  9.81E‐11  2.30041 
2594627  BC039295 // FAM126B // family with sequence similarity 126, member B // 2q33.1 /  FAM126B  3.91E‐14  1.71E‐10  ‐1.52204  1.01E‐10  ‐1.68163 
3444086  NM_007360 // KLRK1 // killer cell lectin‐like receptor subfamily K, member 1 //   KLRK1  3.96E‐14  2.00E‐06  ‐1.48848  2.09E‐13  ‐2.55173 
2371139  NM_005562 // LAMC2 // laminin, gamma 2 // 1q25‐q31 // 3918 /// NM_018891 // LAMC  LAMC2  3.98E‐14  4.72E‐12  2.0111  7.42E‐09  1.89131 
2500919  NM_005415 // SLC20A1 // solute carrier family 20 (phosphate transporter), member  SLC20A1  4.00E‐14  5.24E‐13  ‐3.8984  3.00E‐07  ‐2.63495 
3347615  NM_000019 // ACAT1 // acetyl‐Coenzyme A acetyltransferase 1 // 11q22.3‐q23.1 //   ACAT1  4.03E‐14  3.19E‐11  ‐1.92768  6.35E‐10  ‐2.03378 
2619666  NM_017719 // SNRK // SNF related kinase // 3p22.1 // 54861 /// NM_001100594 // S  SNRK  4.16E‐14  2.31E‐09  ‐1.26009  1.17E‐11  ‐1.40982 
2615060  NM_001003793 // RBMS3 // RNA binding motif, single stranded interacting protein   RBMS3  4.23E‐14  1.75E‐09  ‐1.53787  1.49E‐11  ‐1.87129 
2445982  NM_004673 // ANGPTL1 // angiopoietin‐like 1 // 1q25.2 // 9068 /// ENST0000023481  ANGPTL1  4.50E‐14  9.45E‐09  ‐1.73988  4.74E‐12  ‐2.46485 
2955761  NM_016593 // CYP39A1 // cytochrome P450, family 39, subfamily A, polypeptide 1 /  CYP39A1  4.55E‐14  2.05E‐10  1.68902  1.09E‐10  1.91788 
2866225  NM_002397 // MEF2C // myocyte enhancer factor 2C // 5q14 // 4208 /// ENST0000034  MEF2C  4.59E‐14  7.56E‐10  ‐1.86053  3.36E‐11  ‐2.33569 
2992814  NM_001005340 // GPNMB // glycoprotein (transmembrane) nmb // 7p15 // 10457 /// N  GPNMB  4.72E‐14  5.06E‐10  ‐2.30828  5.00E‐11  ‐3.02984 
3070712  NM_003941 // WASL // Wiskott‐Aldrich syndrome‐like // 7q31.3 // 8976 /// ENST000  WASL  4.82E‐14  8.65E‐10  ‐1.43973  3.24E‐11  ‐1.65101 
3960782  NM_014876 // JOSD1 // Josephin domain containing 1 // 22q13.1 // 9929 /// ENST00  JOSD1  4.86E‐14  2.09E‐12  ‐1.70088  3.98E‐08  ‐1.54806 
2778440  NM_003728 // UNC5C // unc‐5 homolog C (C. elegans) // 4q21‐q23 // 8633 /// ENST0  UNC5C  5.12E‐14  5.76E‐10  ‐1.44053  5.05E‐11  ‐1.62578 
3190659  NM_001122821 // SET // SET nuclear oncogene // 9q34 // 6418 /// NM_003011 // SET  SET  5.23E‐14  3.54E‐09  1.39024  1.19E‐11  1.6456 
3231846  NM_014023 // WDR37 // WD repeat domain 37 // 10p15.3 // 22884 /// ENST0000035822  WDR37  5.25E‐14  3.00E‐09  ‐1.16059  1.35E‐11  ‐1.24925 
2429914  NM_001542 // IGSF3 // immunoglobulin superfamily, member 3 // 1p13 // 3321 /// N  IGSF3  5.47E‐14  1.42E‐09  ‐1.39908  2.60E‐11  ‐1.60818 
3329649  NM_000107 // DDB2 // damage‐specific DNA binding protein 2, 48kDa // 11p12‐p11 /  DDB2  5.69E‐14  1.77E‐10  1.48256  1.82E‐10  1.61123 
3685610  NM_001006634 // ARHGAP17 // Rho GTPase activating protein 17 // 16p12.1 // 55114  ARHGAP17  5.92E‐14  4.33E‐09  ‐1.28637  1.22E‐11  ‐1.46741 
3337168  NM_000852 // GSTP1 // glutathione S‐transferase pi 1 // 11q13 // 2950 /// ENST00  GSTP1  5.96E‐14  3.26E‐08  1.4156  3.11E‐12  1.83523 
3555340  NM_007110 // TEP1 // telomerase‐associated protein 1 // 14q11.2 // 7011 /// ENST  TEP1  6.03E‐14  6.83E‐10  ‐1.29236  5.62E‐11  ‐1.40835 




3695699  NM_004691 // ATP6V0D1 // ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1  ATP6V0D1  6.47E‐14  8.51E‐14  ‐1.65064  8.38E‐05  ‐1.27058 
3783788  NM_005925 // MEP1B // meprin A, beta // 18q12.2‐q12.3 // 4225 /// ENST0000026920  MEP1B  6.52E‐14  2.29E‐12  ‐8.89031  6.53E‐08  ‐5.82649 
3622282  NM_138356 // SHF // Src homology 2 domain containing F // 15q21.1 // 90525 /// E  SHF  6.55E‐14  1.49E‐10  1.67082  2.74E‐10  1.83679 
3442641  NM_174941 // CD163L1 // CD163 molecule‐like 1 // 12p13.3 // 283316 /// ENST00000  CD163L1  6.59E‐14  5.69E‐10  ‐2.10647  7.61E‐11  ‐2.65484 
2502842  NM_183240 // TMEM37 // transmembrane protein 37 // 2q14.2 // 140738 /// ENST0000  TMEM37  6.70E‐14  9.98E‐10  ‐1.81068  4.75E‐11  ‐2.24766 
4021341  NM_016032 // ZDHHC9 // zinc finger, DHHC‐type containing 9 // Xq26.1 // 51114 //  ZDHHC9  6.75E‐14  5.98E‐10  1.34826  7.54E‐11  1.48072 
2979111  NM_032832 // LRP11 // low density lipoprotein receptor‐related protein 11 // 6q2  LRP11  6.84E‐14  1.59E‐07  1.1918  1.46E‐12  1.40359 
2348896  NM_003672 // CDC14A // CDC14 cell division cycle 14 homolog A (S. cerevisiae) //  CDC14A  6.91E‐14  1.08E‐07  ‐1.46834  1.85E‐12  ‐2.0596 
3742285  NM_022059 // CXCL16 // chemokine (C‐X‐C motif) ligand 16 // 17p13 // 58191 /// N  CXCL16  7.16E‐14  4.57E‐11  1.56965  1.18E‐09  1.61936 
2571217  NM_032494 // ZC3H8 // zinc finger CCCH‐type containing 8 // 2q13 // 84524 /// EN  ZC3H8  7.24E‐14  5.55E‐10  1.34446  9.03E‐11  1.46967 
3228191  NM_022779 // DDX31 // DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 31 // 9q34.13 // 64  DDX31  7.30E‐14  2.63E‐09  1.34399  2.44E‐11  1.53725 
3458248  NM_005379 // MYO1A // myosin IA // 12q13‐q14 // 4640 /// ENST00000300119 // MYO1  MYO1A  7.41E‐14  1.15E‐09  ‐1.92402  4.93E‐11  ‐2.45112 
3823340  NM_023944 // CYP4F12 // cytochrome P450, family 4, subfamily F, polypeptide 12 /  CYP4F12  7.89E‐14  2.63E‐10  ‐1.92807  2.10E‐10  ‐2.23244 
2327482  NM_001048194 // RCC1 // regulator of chromosome condensation 1 // 1p36.1 // 1104  RCC1  7.91E‐14  7.35E‐08  1.2951  2.76E‐12  1.60166 
3961842  NM_002883 // RANGAP1 // Ran GTPase activating protein 1 // 22q13 // 5905 /// ENS  RANGAP1  7.96E‐14  1.57E‐06  1.26794  5.46E‐13  1.70592 
2907623  NM_201523 // KLC4 // kinesin light chain 4 // 6p21.1 // 89953 /// NM_201522 // K  KLC4  8.08E‐14  8.99E‐10  ‐1.2501  6.96E‐11  ‐1.34844 
3670918  NM_002661 // PLCG2 // phospholipase C, gamma 2 (phosphatidylinositol‐specific) /  PLCG2  8.10E‐14  1.72E‐09  ‐1.46265  4.01E‐11  ‐1.70518 
3060300  NM_003130 // SRI // sorcin // 7q21.1 // 6717 /// NM_198901 // SRI // sorcin // 7  SRI  8.11E‐14  5.89E‐10  ‐1.70754  1.02E‐10  ‐2.00246 
3665410  NM_015432 // PLEKHG4 // pleckstrin homology domain containing, family G (with Rh  PLEKHG4  8.14E‐14  6.25E‐10  1.31673  9.77E‐11  1.43125 
2382117  NM_001748 // CAPN2 // calpain 2, (m/II) large subunit // 1q41‐q42 // 824 /// ENS  CAPN2  8.36E‐14  2.51E‐09  ‐1.50357  3.10E‐11  ‐1.79849 
3333443  NM_001083926 // ASRGL1 // asparaginase like 1 // 11q12.3 // 80150 /// NM_025080   ASRGL1  8.49E‐14  4.44E‐08  1.62473  4.13E‐12  2.34287 
3332548  NM_024098 // CCDC86 // coiled‐coil domain containing 86 // 11q12.2 // 79080 ///   CCDC86  8.49E‐14  1.41E‐06  1.20669  6.23E‐13  1.51935 
4004044  NM_000109 // DMD // dystrophin // Xp21.2 // 1756 /// NM_004010 // DMD // dystrop  DMD  8.60E‐14  4.47E‐09  ‐1.49058  2.06E‐11  ‐1.81737 
2995491  NM_032222 // FLJ22374 // hypothetical protein FLJ22374 // 7p15.1 // 84182 /// EN  FLJ22374  8.64E‐14  5.90E‐10  1.38312  1.13E‐10  1.52102 
3502156  NM_015205 // ATP11A // ATPase, class VI, type 11A // 13q34 // 23250 /// NM_03218  ATP11A  8.77E‐14  1.11E‐10  1.41687  6.17E‐10  1.4849 
2515627  NM_000210 // ITGA6 // integrin, alpha 6 // 2q31.1 // 3655 /// NM_001079818 // IT  ITGA6  8.85E‐14  3.38E‐10  1.9065  1.99E‐10  2.22265 
2398894  NM_018715 // RCC2 // regulator of chromosome condensation 2 // 1p36.13 // 55920   RCC2  8.85E‐14  6.58E‐10  1.40167  1.06E‐10  1.55196 
3865301  NM_000400 // ERCC2 // excision repair cross‐complementing rodent repair deficien  ERCC2  8.97E‐14  7.90E‐06  1.14194  3.07E‐13  1.39693 
3717034  BC062632 // LOC400590 // hypothetical LOC400590 // 17q11.2 // 400590  LOC400590  9.06E‐14  6.60E‐10  ‐1.755  1.10E‐10  ‐2.0778 
3742727  NM_020162 // DHX33 // DEAH (Asp‐Glu‐Ala‐His) box polypeptide 33 // 17p13.2 // 56  DHX33  9.13E‐14  1.83E‐07  1.24641  1.96E‐12  1.52838 
2594951  NM_001044385 // ALS2CR4 // amyotrophic lateral sclerosis 2 (juvenile) chromosome  ALS2CR4  9.19E‐14  4.20E‐08  1.28354  4.76E‐12  1.54434 
2323559  NM_016183 // MRTO4 // mRNA turnover 4 homolog (S. cerevisiae) // 1p36.13 // 5115  MRTO4  9.28E‐14  7.46E‐06  1.27303  3.27E‐13  1.83044 
3667652  NM_001017967 // MARVELD3 // MARVEL domain containing 3 // 16q22.3 // 91862 /// N  MARVELD3  9.78E‐14  1.40E‐11  ‐1.41745  9.70E‐09  ‐1.38673 
3820571  NM_032885 // ATG4D // ATG4 autophagy related 4 homolog D (S. cerevisiae) // 19p1  ATG4D  9.81E‐14  8.72E‐13  ‐1.48721  1.01E‐06  ‐1.30991 
2776670  NM_138980 // MAPK10 // mitogen‐activated protein kinase 10 // 4q22.1‐q23 // 5602  MAPK10  9.97E‐14  2.61E‐09  ‐1.3346  3.91E‐11  ‐1.51066 
2699623  NM_001128304 // PLSCR4 // phospholipid scramblase 4 // 3q24 // 57088 /// NM_0011  PLSCR4  1.01E‐13  8.36E‐06  ‐1.25648  3.46E‐13  ‐1.77664 
3377385  NM_005468 // NAALADL1 // N‐acetylated alpha‐linked acidic dipeptidase‐like 1 //   NAALADL1  1.03E‐13  2.64E‐09  ‐2.07747  4.08E‐11  ‐2.84021 
3699581  NM_145254 // TMEM170A // transmembrane protein 170A // 16q23.1 // 124491 /// ENS  TMEM170A  1.04E‐13  2.31E‐11  ‐1.58093  5.52E‐09  ‐1.56504 
3364525  NM_175058 // PLEKHA7 // pleckstrin homology domain containing, family A member 7  PLEKHA7  1.05E‐13  1.29E‐09  ‐1.34006  7.64E‐11  ‐1.48634 
3676002  NM_014714 // IFT140 // intraflagellar transport 140 homolog (Chlamydomonas) // 1  IFT140  1.06E‐13  2.42E‐10  1.32921  3.74E‐10  1.40401 
2788926  NM_000901 // NR3C2 // nuclear receptor subfamily 3, group C, member 2 // 4q31.1   NR3C2  1.06E‐13  8.13E‐08  ‐1.45256  3.84E‐12  ‐1.96481 




2439861  NM_020789 // IGSF9 // immunoglobulin superfamily, member 9 // 1q22‐q23 // 57549   IGSF9  1.12E‐13  1.00E‐10  ‐1.52504  1.06E‐09  ‐1.59472 
2433371  NM_016361 // ACP6 // acid phosphatase 6, lysophosphatidic // 1q21 // 51205 /// E  ACP6  1.12E‐13  8.88E‐11  1.41343  1.22E‐09  1.4604 
3742182  NM_001122890 // GGT6 // gamma‐glutamyltransferase 6 // 17p13.2 // 124975 /// NM_  GGT6  1.15E‐13  8.56E‐12  ‐1.46269  2.71E‐08  ‐1.39736 
2515240  NM_024843 // CYBRD1 // cytochrome b reductase 1 // 2q31.1 // 79901 /// NM_001127  CYBRD1  1.18E‐13  5.20E‐08  ‐1.97017  5.82E‐12  ‐3.2671 
3300242  NM_014912 // CPEB3 // cytoplasmic polyadenylation element binding protein 3 // 1  CPEB3  1.25E‐13  4.20E‐09  ‐1.35026  3.74E‐11  ‐1.55046 
2758076  NM_003703 // NOL14 // nucleolar protein 14 // 4p16.3 // 8602 /// ENST00000314262  NOL14  1.31E‐13  1.16E‐09  1.40427  1.18E‐10  1.56893 
3830166  NM_021910 // FXYD3 // FXYD domain containing ion transport regulator 3 // 19q13.  FXYD3  1.33E‐13  2.42E‐11  ‐1.83094  8.27E‐09  ‐1.79025 
3956781  NM_001127 // AP1B1 // adaptor‐related protein complex 1, beta 1 subunit // 22q12  AP1B1  1.34E‐13  2.61E‐13  ‐1.4033  3.75E‐05  ‐1.19477 
2619761  NM_016006 // ABHD5 // abhydrolase domain containing 5 // 3p21 // 51099 /// ENST0  ABHD5  1.34E‐13  3.37E‐13  ‐1.6502  1.97E‐05  ‐1.31911 
2497301  NM_144632 // TMEM182 // transmembrane protein 182 // 2q12.1 // 130827 /// ENST00  TMEM182  1.35E‐13  2.93E‐08  1.28303  1.01E‐11  1.51513 
3959631  NM_003753 // EIF3D // eukaryotic translation initiation factor 3, subunit D // 2  EIF3D  1.37E‐13  5.23E‐10  1.3019  2.65E‐10  1.38897 
2699145  NM_173653 // SLC9A9 // solute carrier family 9 (sodium/hydrogen exchanger), memb  SLC9A9  1.38E‐13  2.09E‐09  ‐1.79942  7.70E‐11  ‐2.25049 
3190925  NM_020438 // DOLPP1 // dolichyl pyrophosphate phosphatase 1 // 9q34.1 // 57171 /  DOLPP1  1.41E‐13  7.34E‐13  ‐1.48825  3.70E‐06  ‐1.28421 
2971564  NM_001042475 // C6orf204 // chromosome 6 open reading frame 204 // 6q22 // 38711  C6orf204  1.44E‐13  5.34E‐07  ‐1.36388  1.96E‐12  ‐1.87915 
3815014  NM_001728 // BSG // basigin (Ok blood group) // 19p13.3 // 682 /// NM_198589 //   BSG  1.51E‐13  3.60E‐13  ‐1.59092  2.35E‐05  ‐1.28964 
3190463  NM_002540 // ODF2 // outer dense fiber of sperm tails 2 // 9q34.11 // 4957 /// N  ODF2  1.51E‐13  9.19E‐08  1.20306  5.70E‐12  1.39339 
3475324  NM_019034 // RHOF // ras homolog gene family, member F (in filopodia) // 12q24.3  RHOF  1.53E‐13  2.05E‐11  ‐2.74153  1.37E‐08  ‐2.57021 
2926969  NM_018945 // PDE7B // phosphodiesterase 7B // 6q23‐q24 // 27115 /// ENST00000308  PDE7B  1.54E‐13  2.90E‐09  ‐1.54003  6.88E‐11  ‐1.83472 
3416895  NM_152637 // METTL7B // methyltransferase like 7B // 12q13.2 // 196410 /// ENST0  METTL7B  1.58E‐13  7.55E‐13  ‐1.78931  4.74E‐06  ‐1.43495 
2480383  NM_001430 // EPAS1 // endothelial PAS domain protein 1 // 2p21‐p16 // 2034 /// E  EPAS1  1.62E‐13  1.92E‐09  ‐1.42244  1.06E‐10  ‐1.61457 
3470689  NM_001001655 // ALKBH2 // alkB, alkylation repair homolog 2 (E. coli) // 12q24.1  ALKBH2  1.63E‐13  5.16E‐09  1.39903  4.71E‐11  1.633 
3740651  ENST00000330676 // TLCD2 // TLC domain containing 2 // 17p13.3 // 727910  TLCD2  1.64E‐13  8.07E‐13  ‐1.56226  4.45E‐06  ‐1.32123 
3555300  NM_021178 // CCNB1IP1 // cyclin B1 interacting protein 1 // 14q11.2 // 57820 ///  CCNB1IP1  1.70E‐13  1.20E‐08  1.33769  2.63E‐11  1.56882 
3955815  NM_022081 // HPS4 // Hermansky‐Pudlak syndrome 4 // 22cen‐q12.3 // 89781 /// NM_  HPS4  1.82E‐13  5.20E‐11  1.31359  5.56E‐09  1.31621 
3602004  NM_138967 // SCAMP5 // secretory carrier membrane protein 5 // 15q24.1‐q24.2 //   SCAMP5  1.85E‐13  4.04E‐11  ‐1.5724  7.97E‐09  ‐1.56014 
2447066  NM_002065 // GLUL // glutamate‐ammonia ligase (glutamine synthetase) // 1q31 //   GLUL  1.87E‐13  4.06E‐11  1.32456  8.09E‐09  1.31795 
3876645  NM_014962 // BTBD3 // BTB (POZ) domain containing 3 // 20p12.2 // 22903 /// NM_1  BTBD3  1.90E‐13  6.54E‐11  ‐1.59489  4.53E‐09  ‐1.61353 
2731381  NM_001511 // CXCL1 // chemokine (C‐X‐C motif) ligand 1 (melanoma growth stimulat  CXCL1  1.91E‐13  1.30E‐09  2.15456  1.91E‐10  2.72972 
3411721  NM_001843 // CNTN1 // contactin 1 // 12q11‐q12 // 1272 /// NM_175038 // CNTN1 //  CNTN1  1.91E‐13  5.57E‐09  ‐1.51991  5.61E‐11  ‐1.83949 
2601648  NM_014689 // DOCK10 // dedicator of cytokinesis 10 // 2q36.2 // 55619 /// ENST00  DOCK10  1.93E‐13  3.60E‐05  ‐1.41883  4.05E‐13  ‐2.61861 
3264997  NM_024889 // C10orf81 // chromosome 10 open reading frame 81 // 10q25.3 // 79949  C10orf81  1.94E‐13  1.30E‐11  2.99154  4.29E‐08  2.60736 
3575906  NM_145231 // C14orf143 // chromosome 14 open reading frame 143 // 14q32.11 // 90  C14orf143  1.95E‐13  0.00766766  1.06996  7.10E‐14  1.38595 
3323052  NM_182964 // NAV2 // neuron navigator 2 // 11p15.1 // 89797 /// NM_145117 // NAV  NAV2  1.97E‐13  2.27E‐08  1.32265  2.04E‐11  1.56726 
3407629  NM_019844 // SLCO1B3 // solute carrier organic anion transporter family, member   SLCO1B3  2.03E‐13  2.79E‐11  5.66455  1.57E‐08  5.11442 
3739812  NM_015721 // GEMIN4 // gem (nuclear organelle) associated protein 4 // 17p13 //   GEMIN4  2.04E‐13  1.72E‐07  1.2889  5.83E‐12  1.59847 
3003228  NM_001042468 // SUMF2 // sulfatase modifying factor 2 // 7q11.1 // 25870 /// NM_  SUMF2  2.09E‐13  3.95E‐09  1.36301  8.44E‐11  1.54901 
3818732  NM_015318 // ARHGEF18 // rho/rac guanine nucleotide exchange factor (GEF) 18 //   ARHGEF18  2.09E‐13  4.37E‐10  ‐1.31484  6.35E‐10  ‐1.38684 
3120653  NM_005309 // GPT // glutamic‐pyruvate transaminase (alanine aminotransferase) //  GPT  2.09E‐13  1.69E‐11  ‐1.81793  3.37E‐08  ‐1.70514 
2562932  NM_001768 // CD8A // CD8a molecule // 2p12 // 925 /// NM_171827 // CD8A // CD8a   CD8A  2.09E‐13  7.36E‐06  ‐1.20225  8.64E‐13  ‐1.56207 
3863214  L31792 // CEACAM7 // carcinoembryonic antigen‐related cell adhesion molecule 7 /  CEACAM7  2.12E‐13  1.34E‐08  ‐4.00819  3.32E‐11  ‐8.50563 
3262198  NM_014976 // PDCD11 // programmed cell death 11 // 10q24.33 // 22984 /// ENST000  PDCD11  2.21E‐13  2.79E‐09  1.34384  1.23E‐10  1.50033 




3257246  NM_001548 // IFIT1 // interferon‐induced protein with tetratricopeptide repeats   IFIT1  2.24E‐13  1.09E‐07  ‐1.85346  8.69E‐12  ‐3.0028 
3464983  NM_001001323 // ATP2B1 // ATPase, Ca++ transporting, plasma membrane 1 // 12q21.  ATP2B1  2.31E‐13  2.99E‐09  ‐1.57709  1.24E‐10  ‐1.87212 
3678000  NM_003223 // TFAP4 // transcription factor AP‐4 (activating enhancer binding pro  TFAP4  2.31E‐13  7.95E‐09  1.34065  5.59E‐11  1.54253 
2881083  NM_000440 // PDE6A // phosphodiesterase 6A, cGMP‐specific, rod, alpha // 5q31.2‐  PDE6A  2.31E‐13  2.37E‐11  ‐1.64721  2.54E‐08  ‐1.5792 
2403261  NM_002038 // IFI6 // interferon, alpha‐inducible protein 6 // 1p35 // 2537 /// N  IFI6  2.35E‐13  6.14E‐08  1.74213  1.33E‐11  2.58083 
2477438  NM_012413 // QPCT // glutaminyl‐peptide cyclotransferase // 2p22.2 // 25797 ///   QPCT  2.35E‐13  3.38E‐09  2.57363  1.15E‐10  3.71226 
2440586  NM_030916 // PVRL4 // poliovirus receptor‐related 4 // 1q22‐q23.2 // 81607 /// E  PVRL4  2.39E‐13  3.63E‐10  1.58611  9.65E‐10  1.71273 
2613293  NM_144633 // KCNH8 // potassium voltage‐gated channel, subfamily H (eag‐related)  KCNH8  2.53E‐13  4.28E‐12  2.08029  4.73E‐07  1.72978 
3946889  NM_001098 // ACO2 // aconitase 2, mitochondrial // 22q11.2‐q13.31|22q13.2|22q13.  ACO2  2.56E‐13  8.05E‐12  ‐1.44246  1.65E‐07  ‐1.34375 
2410158  NM_007170 // TESK2 // testis‐specific kinase 2 // 1p32 // 10420 /// ENST00000372  TESK2  2.57E‐13  1.27E‐05  ‐1.21933  8.66E‐13  ‐1.64314 
2572274  BC032913 // LOC389023 // hypothetical gene supported by BC032913; BC048425 // 2q  LOC389023  2.72E‐13  1.02E‐09  ‐2.65719  4.22E‐10  ‐3.41305 
3660075  NM_033119 // NKD1 // naked cuticle homolog 1 (Drosophila) // 16q12 // 85407 ///   NKD1  2.77E‐13  1.80E‐09  2.19965  2.57E‐10  2.80964 
3751042  NM_138463 // TLCD1 // TLC domain containing 1 // 17q11.2 // 116238 /// ENST00000  TLCD1  2.81E‐13  0.021913  1.08317  7.95E‐14  1.57201 
3748798  NM_002404 // MFAP4 // microfibrillar‐associated protein 4 // 17p11.2 // 4239 ///  MFAP4  2.88E‐13  8.28E‐08  ‐1.98913  1.44E‐11  ‐3.27975 
3837759  NM_000836 // GRIN2D // glutamate receptor, ionotropic, N‐methyl D‐aspartate 2D /  GRIN2D  2.89E‐13  1.56E‐10  1.71334  3.42E‐09  1.78087 
3975893  NM_014735 // PHF16 // PHD finger protein 16 // Xp11.3 // 9767 /// NM_001077445 /  PHF16  2.90E‐13  1.51E‐09  1.44417  3.25E‐10  1.6062 
3588658  ENST00000330188 // TPM3 // tropomyosin 3 // 1q21.2 // 7170 /// BC006254 // C15or  TPM3  2.92E‐13  1.16E‐08  1.31288  5.86E‐11  1.50451 
3773244  NM_019020 // TBC1D16 // TBC1 domain family, member 16 // 17q25.3 // 125058 /// E  TBC1D16  2.94E‐13  1.09E‐08  1.31163  6.21E‐11  1.49937 
2766419  NM_001024921 // RPL9 // ribosomal protein L9 // 4p13 // 6133 /// NM_000661 // RP  RPL9  2.99E‐13  0.000127479 1.22334  4.11E‐13  1.83606 
3140920  NM_020647 // JPH1 // junctophilin 1 // 8q21 // 56704 /// ENST00000342232 // JPH1  JPH1  3.09E‐13  2.58E‐09  1.69361  2.20E‐10  2.0239 
2413886  NM_001114108 // TTC22 // tetratricopeptide repeat domain 22 // 1p32.3 // 55001 /  TTC22  3.11E‐13  4.75E‐09  ‐1.45931  1.31E‐10  ‐1.69772 
3937092  NM_000754 // COMT // catechol‐O‐methyltransferase // 22q11.21‐q11.23|22q11.21 //  COMT  3.11E‐13  4.73E‐07  1.29711  5.59E‐12  1.65959 
3911217  NM_020182 // PMEPA1 // prostate transmembrane protein, androgen induced 1 // 20q  PMEPA1  3.11E‐13  2.92E‐12  2.02463  1.58E‐06  1.62948 
3168385  NM_022343 // GLIPR2 // GLI pathogenesis‐related 2 // 9p13‐p12 // 152007 /// ENST  GLIPR2  3.12E‐13  4.88E‐10  ‐1.95988  1.11E‐09  ‐2.20259 
3011409  NM_138290 // RUNDC3B // RUN domain containing 3B // 7q21.12 // 154661 /// ENST00  RUNDC3B  3.14E‐13  4.98E‐08  ‐1.59556  2.28E‐11  ‐2.17079 
3193900  NM_016034 // MRPS2 // mitochondrial ribosomal protein S2 // 9q34 // 51116 /// EN  MRPS2  3.14E‐13  8.04E‐05  1.16243  5.16E‐13  1.54476 
2890239  NM_054013 // MGAT4B // mannosyl (alpha‐1,3‐)‐glycoprotein beta‐1,4‐N‐acetylgluco  MGAT4B  3.17E‐13  4.69E‐11  ‐1.36196  1.83E‐08  ‐1.3422 
3355114  NM_014026 // DCPS // decapping enzyme, scavenger // 11q24.2 // 28960 /// ENST000  DCPS  3.18E‐13  1.06E‐08  1.29556  7.13E‐11  1.46838 
3326252  NM_024662 // NAT10 // N‐acetyltransferase 10 // 11p13 // 55226 /// ENST000002578  NAT10  3.23E‐13  6.81E‐08  1.36987  1.92E‐11  1.70406 
3725035  NM_003204 // NFE2L1 // nuclear factor (erythroid‐derived 2)‐like 1 // 17q21.3 //  NFE2L1  3.29E‐13  8.48E‐11  ‐1.35207  9.09E‐09  ‐1.3539 
3666566  NM_032830 // CIRH1A // cirrhosis, autosomal recessive 1A (cirhin) // 16q22.1 //   CIRH1A  3.32E‐13  2.88E‐06  1.43117  2.34E‐12  2.21167 
3745525  NM_001004313 // TMEM220 // transmembrane protein 220 // 17p13.1 // 388335 /// EN  TMEM220  3.38E‐13  8.14E‐09  ‐1.7271  9.60E‐11  ‐2.20882 
3223687  NM_015651 // PHF19 // PHD finger protein 19 // 9q33.2 // 26147 /// NM_001009936   PHF19  3.43E‐13  3.62E‐07  1.32907  7.40E‐12  1.71773 
3455134  NM_182507 // KRT80 // keratin 80 // 12q13.13 // 144501 /// NM_001081492 // KRT80  KRT80  3.46E‐13  1.99E‐09  1.63542  3.32E‐10  1.89819 
3951768  AK292689 // CECR1 // cat eye syndrome chromosome region, candidate 1 // 22q11.2   CECR1  3.48E‐13  8.30E‐09  ‐1.60666  9.89E‐11  ‐1.98859 
3988165  NM_007231 // SLC6A14 // solute carrier family 6 (amino acid transporter), member  SLC6A14  3.52E‐13  2.84E‐11  5.02968  4.54E‐08  4.2623 
3855596  NM_176880 // NR2C2AP // nuclear receptor 2C2‐associated protein // 19p13.11 // 1  NR2C2AP  3.55E‐13  0.000101883 1.19996  5.43E‐13  1.70765 
2984616  NM_016098 // BRP44L // brain protein 44‐like // 6q27 // 51660 /// ENST0000034175  BRP44L  3.56E‐13  4.35E‐11  ‐1.69509  2.54E‐08  ‐1.63897 
2427981  NM_020683 // ADORA3 // adenosine A3 receptor // 1p13.2 // 140 /// NM_001081976 /  ADORA3  3.56E‐13  9.71E‐11  ‐1.62488  8.87E‐09  ‐1.63336 
3874438  NM_021873 // CDC25B // cell division cycle 25 homolog B (S. pombe) // 20p13 // 9  CDC25B  3.57E‐13  1.48E‐06  1.37543  3.59E‐12  1.95408 
3996667  NM_001363 // DKC1 // dyskeratosis congenita 1, dyskerin // Xq28 // 1736 /// NR_0  DKC1  3.64E‐13  3.40E‐07  1.36624  8.27E‐12  1.8027 




3464967  NM_003774 // GALNT4 // UDP‐N‐acetyl‐alpha‐D‐galactosamine:polypeptide N‐acetylga  GALNT4  3.68E‐13  1.20E‐10  1.74426  7.22E‐09  1.77163 
3762443  BC128165 // C17orf73 // chromosome 17 open reading frame 73 // 17q21.33 // 55018  C17orf73  3.83E‐13  2.91E‐10  ‐1.87647  2.75E‐09  ‐2.00822 
3203582  NM_022917 // NOL6 // nucleolar protein family 6 (RNA‐associated) // 9p13.3 // 65  NOL6  3.85E‐13  2.76E‐06  1.2408  2.87E‐12  1.60496 
3875908  NM_000933 // PLCB4 // phospholipase C, beta 4 // 20p12 // 5332 /// NM_182797 //   PLCB4  3.93E‐13  2.87E‐10  2.9427  2.92E‐09  3.29405 
2485257  NM_001001521 // UGP2 // UDP‐glucose pyrophosphorylase 2 // 2p14‐p13 // 7360 ///   UGP2  3.94E‐13  7.92E‐10  ‐2.04606  9.91E‐10  ‐2.3641 
2634494  NM_001627 // ALCAM // activated leukocyte cell adhesion molecule // 3q13.1 // 21  ALCAM  3.98E‐13  6.49E‐11  1.94518  1.83E‐08  1.8995 
3263944  NM_145341 // PDCD4 // programmed cell death 4 (neoplastic transformation inhibit  PDCD4  4.01E‐13  2.84E‐07  ‐1.56441  1.05E‐11  ‐2.29432 
4018454  NM_133265 // AMOT // angiomotin // Xq23 // 154796 /// NM_001113490 // AMOT // an  AMOT  4.05E‐13  2.85E‐09  1.45617  3.07E‐10  1.64627 
2816494  NM_005242 // F2RL1 // coagulation factor II (thrombin) receptor‐like 1 // 5q13 /  F2RL1  4.07E‐13  1.40E‐09  ‐1.43094  5.94E‐10  ‐1.56806 
3855506  NM_017814 // TMEM161A // transmembrane protein 161A // 19p13.11 // 54929 /// ENS  TMEM161A  4.07E‐13  0.00043414  1.15112  3.75E‐13  1.60082 
3776504  NM_170695 // TGIF1 // TGFB‐induced factor homeobox 1 // 18p11.3 // 7050 /// NM_1  TGIF1  4.08E‐13  8.36E‐09  1.26881  1.24E‐10  1.40814 
3204149  NM_147164 // CNTFR // ciliary neurotrophic factor receptor // 9p13 // 1271 /// N  CNTFR  4.12E‐13  5.14E‐12  ‐2.01777  1.06E‐06  ‐1.65973 
2616166  NM_006371 // CRTAP // cartilage associated protein // 3p22.3 // 10491 /// ENST00  CRTAP  4.16E‐13  2.35E‐08  1.18665  5.76E‐11  1.30355 
2379665  NM_002763 // PROX1 // prospero homeobox 1 // 1q32.2‐q32.3 // 5629 /// ENST000003  PROX1  4.27E‐13  1.19E‐11  2.20547  2.64E‐07  1.8813 
3603199  NM_005530 // IDH3A // isocitrate dehydrogenase 3 (NAD+) alpha // 15q25.1‐q25.2 /  IDH3A  4.42E‐13  7.78E‐12  ‐1.79301  5.84E‐07  ‐1.55475 
3203990  NM_020702 // KIAA1161 // KIAA1161 // 9p13.3 // 57462 /// ENST00000297625 // KIAA  KIAA1161  4.48E‐13  5.47E‐10  ‐1.68283  1.80E‐09  ‐1.82492 
3041875  NM_015550 // OSBPL3 // oxysterol binding protein‐like 3 // 7p15 // 26031 /// NM_  OSBPL3  4.67E‐13  1.15E‐08  1.42597  1.18E‐10  1.67929 
3896524  NM_015939 // TRMT6 // tRNA methyltransferase 6 homolog (S. cerevisiae) // 20p12.  TRMT6  4.81E‐13  1.73E‐07  1.22917  1.80E‐11  1.4425 
2872047  NM_020796 // SEMA6A // sema domain, transmembrane domain (TM), and cytoplasmic d  SEMA6A  4.82E‐13  1.30E‐07  ‐1.84215  2.17E‐11  ‐2.89285 
3757399  NM_052935 // NT5C3L // 5'‐nucleotidase, cytosolic III‐like // 17q21.2 // 115024   NT5C3L  4.83E‐13  8.36E‐09  1.2735  1.60E‐10  1.411 
2326496  NM_024887 // DHDDS // dehydrodolichyl diphosphate synthase // 1p36.11 // 79947 /  DHDDS  4.88E‐13  1.51E‐10  ‐1.49707  9.12E‐09  ‐1.51318 
3244460  AB235418 // TMEM72 // transmembrane protein 72 // 10q11.21 // 643236 /// BC12779  TMEM72  4.88E‐13  2.44E‐08  ‐1.80257  7.00E‐11  ‐2.47852 
2985368  NM_024919 // FRMD1 // FERM domain containing 1 // 6q27 // 79981 /// NM_001122841  FRMD1  5.10E‐13  6.89E‐10  ‐1.48356  1.76E‐09  ‐1.585 
3699335  NM_153486 // LDHD // lactate dehydrogenase D // 16q23.1 // 197257 /// NM_194436   LDHD  5.12E‐13  1.12E‐10  ‐1.58566  1.45E‐08  ‐1.5816 
3027204  NM_001061 // TBXAS1 // thromboxane A synthase 1 (platelet) // 7q34‐q35 // 6916 /  TBXAS1  5.23E‐13  9.89E‐09  1.41508  1.57E‐10  1.64607 
3712098  NR_002744 // SNORD49A // small nucleolar RNA, C/D box 49A // 17p11.2 // 26800 //  SNORD49A  5.38E‐13  4.69E‐09  1.26949  3.06E‐10  1.38161 
3645477  NM_152341 // PAQR4 // progestin and adipoQ receptor family member IV // 16p13.3   PAQR4  5.41E‐13  3.46E‐05  1.23199  1.35E‐12  1.73227 
3263624  NM_005962 // MXI1 // MAX interactor 1 // 10q24‐q25 // 4601 /// NM_130439 // MXI1  MXI1  5.55E‐13  2.21E‐09  ‐1.49539  6.34E‐10  ‐1.67078 
2438657  NM_198236 // ARHGEF11 // Rho guanine nucleotide exchange factor (GEF) 11 // 1q21  ARHGEF11  5.59E‐13  3.82E‐08  ‐1.1588  6.13E‐11  ‐1.2622 
3414885  NM_001039960 // SLC4A8 // solute carrier family 4, sodium bicarbonate cotranspor  SLC4A8  5.62E‐13  6.28E‐10  1.67266  2.28E‐09  1.80774 
2793441  NM_016228 // AADAT // aminoadipate aminotransferase // 4q33 // 51166 /// NM_1826  AADAT  5.62E‐13  5.06E‐08  1.48265  5.05E‐11  1.88682 
3173673  NM_003558 // PIP5K1B // phosphatidylinositol‐4‐phosphate 5‐kinase, type I, beta   PIP5K1B  5.65E‐13  2.71E‐08  ‐1.46081  8.02E‐11  ‐1.79235 
3461341  NM_001874 // CPM // carboxypeptidase M // 12q14.3 // 1368 /// NM_198320 // CPM /  CPM  5.72E‐13  2.29E‐07  ‐1.79156  1.90E‐11  ‐2.85052 
2375144  NM_001017403 // LGR6 // leucine‐rich repeat‐containing G protein‐coupled recepto  LGR6  5.73E‐13  2.63E‐11  1.994  1.38E‐07  1.79672 
3134511  NM_003068 // SNAI2 // snail homolog 2 (Drosophila) // 8q11 // 6591 /// ENST00000  SNAI2  6.07E‐13  1.52E‐09  ‐2.22141  1.05E‐09  ‐2.6712 
3361116  NM_022061 // MRPL17 // mitochondrial ribosomal protein L17 // 11p15.5‐p15.4 // 6  MRPL17  6.19E‐13  7.15E‐07  1.20287  1.07E‐11  1.43203 
3299465  NM_144590 // ANKRD22 // ankyrin repeat domain 22 // 10q23.31 // 118932 /// ENST0  ANKRD22  6.41E‐13  4.15E‐09  2.12475  4.46E‐10  2.7208 
3321150  NM_001178 // ARNTL // aryl hydrocarbon receptor nuclear translocator‐like // 11p  ARNTL  6.50E‐13  3.00E‐10  ‐1.55829  6.70E‐09  ‐1.60619 
3057520  NM_031925 // TMEM120A // transmembrane protein 120A // 7q11.23 // 83862 /// ENST  TMEM120A  6.57E‐13  7.78E‐10  ‐1.48819  2.36E‐09  ‐1.58532 
3692516  AF275804 // hCG_1815491 // hCG1815491 // 16q12.2 // 643911  hCG_1815491  6.59E‐13  2.21E‐10  2.14577  9.87E‐09  2.20928 
3376512  NM_017878 // HRASLS2 // HRAS‐like suppressor 2 // 11q12.3 // 54979 /// ENST00000  HRASLS2  6.64E‐13  1.40E‐10  ‐2.99987  1.76E‐08  ‐2.98147 




2991395  NM_178423 // HDAC9 // histone deacetylase 9 // 7p21.1 // 9734 /// NM_178425 // H  HDAC9  6.82E‐13  8.63E‐08  ‐1.37605  4.55E‐11  ‐1.69845 
3838624  NM_004107 // FCGRT // Fc fragment of IgG, receptor, transporter, alpha // 19q13.  FCGRT  6.86E‐13  5.93E‐10  ‐1.82022  3.40E‐09  ‐1.96682 
3276135  NM_001029880 // SFMBT2 // Scm‐like with four mbt domains 2 // 10p14 // 57713 ///  SFMBT2  6.95E‐13  8.44E‐09  ‐1.40491  2.72E‐10  ‐1.60712 
2979267  NM_024518 // ULBP3 // UL16 binding protein 3 // 6q25 // 79465 /// ENST0000036733  ULBP3  7.00E‐13  2.15E‐09  1.61616  9.38E‐10  1.82615 
2727762  NM_024592 // SRD5A3 // steroid 5 alpha‐reductase 3 // 4q12 // 79644 /// ENST0000  SRD5A3  7.07E‐13  8.82E‐10  1.54402  2.34E‐09  1.65902 
3875179  NM_001819 // CHGB // chromogranin B (secretogranin 1) // 20pter‐p12 // 1114 ///   CHGB  7.25E‐13  2.37E‐09  ‐2.32433  9.09E‐10  ‐2.89662 
3077321  NM_005232 // EPHA1 // EPH receptor A1 // 7q34 // 2041 /// ENST00000275815 // EPH  EPHA1  7.33E‐13  3.40E‐09  1.3026  6.57E‐10  1.40895 
2976041  NM_014432 // IL20RA // interleukin 20 receptor, alpha // 6q22.33‐q23.1 // 53832   IL20RA  7.39E‐13  4.05E‐08  1.50866  8.70E‐11  1.90201 
3286602  NM_000609 // CXCL12 // chemokine (C‐X‐C motif) ligand 12 (stromal cell‐derived f  CXCL12  7.59E‐13  1.46E‐08  ‐1.95567  1.97E‐10  ‐2.64036 
3048749  NM_019082 // DDX56 // DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 56 // 7p13 // 54606  DDX56  7.61E‐13  6.36E‐06  1.17679  4.37E‐12  1.44678 
3335697  NM_001335 // CTSW // cathepsin W // 11q13.1 // 1521 /// ENST00000307886 // CTSW   CTSW  7.68E‐13  1.15E‐09  ‐1.57771  2.04E‐09  ‐1.71606 
3191695  NM_014285 // EXOSC2 // exosome component 2 // 9q34 // 23404 /// ENST00000372358   EXOSC2  7.87E‐13  0.00011332  1.21903  1.29E‐12  1.76664 
3726934  NM_198175 // NME1 // non‐metastatic cells 1, protein (NM23A) expressed in // 17q  NME1  7.94E‐13  3.77E‐05  1.29798  2.04E‐12  1.97612 
3550307  NM_000710 // BDKRB1 // bradykinin receptor B1 // 14q32.1‐q32.2 // 623 /// ENST00  BDKRB1  8.00E‐13  4.10E‐11  ‐2.22031  1.39E‐07  ‐1.99009 
2500275  NM_138621 // BCL2L11 // BCL2‐like 11 (apoptosis facilitator) // 2q13 // 10018 //  BCL2L11  8.09E‐13  1.95E‐07  ‐1.3343  3.34E‐11  ‐1.65445 
2886130  NM_024594 // PANK3 // pantothenate kinase 3 // 5q34 // 79646 /// ENST00000239231  PANK3  8.37E‐13  9.51E‐10  ‐1.29154  2.86E‐09  ‐1.34522 
2531908  NM_145236 // B3GNT7 // UDP‐GlcNAc:betaGal beta‐1,3‐N‐acetylglucosaminyltransfera  B3GNT7  8.71E‐13  0.000548577 ‐1.68415  8.02E‐13  ‐5.66427 
3970307  NM_004726 // REPS2 // RALBP1 associated Eps domain containing 2 // Xp22.2 // 918  REPS2  8.71E‐13  1.39E‐09  1.6782  2.06E‐09  1.85488 
4012511  NM_021963 // NAP1L2 // nucleosome assembly protein 1‐like 2 // Xq13 // 4674 ///   NAP1L2  9.16E‐13  2.52E‐07  ‐1.73804  3.34E‐11  ‐2.65778 
2417016  NM_024763 // WDR78 // WD repeat domain 78 // 1p31.3 // 79819 /// NM_207014 // WD  WDR78  9.47E‐13  1.04E‐10  ‐1.92727  5.11E‐08  ‐1.84898 
3557614  NM_080545 // AP1G2 // adaptor‐related protein complex 1, gamma 2 subunit // 14q1  AP1G2  9.59E‐13  4.91E‐08  1.20753  1.09E‐10  1.34307 
2840393  NM_014211 // GABRP // gamma‐aminobutyric acid (GABA) A receptor, pi // 5q33‐q34   GABRP  9.61E‐13  2.17E‐11  2.83205  5.63E‐07  2.26596 
3462816  NM_007350 // PHLDA1 // pleckstrin homology‐like domain, family A, member 1 // 12  PHLDA1  9.66E‐13  3.12E‐08  1.69163  1.55E‐10  2.21346 
4006594  AK098783 // FLJ25917 // hypothetical gene supported by AK098783 // Xp11.3 // 401  FLJ25917  9.78E‐13  6.38E‐11  1.94934  1.08E‐07  1.8087 
3453252  NM_015270 // ADCY6 // adenylate cyclase 6 // 12q12‐q13 // 112 /// NM_020983 // A  ADCY6  1.03E‐12  3.69E‐10  ‐1.32424  1.19E‐08  ‐1.34316 
3226661  NM_006336 // ZER1 // zer‐1 homolog (C. elegans) // 9q34.11 // 10444 /// ENST0000  ZER1  1.04E‐12  7.15E‐08  ‐1.25111  9.25E‐11  ‐1.43165 
3601955  NM_002435 // MPI // mannose phosphate isomerase // 15q22‐qter // 4351 /// ENST00  MPI  1.05E‐12  4.97E‐12  ‐1.47774  1.10E‐05  ‐1.27866 
2749560  NM_004453 // ETFDH // electron‐transferring‐flavoprotein dehydrogenase // 4q32‐q  ETFDH  1.06E‐12  9.05E‐11  ‐2.02636  7.65E‐08  ‐1.90762 
3168309  NM_021111 // RECK // reversion‐inducing‐cysteine‐rich protein with kazal motifs   RECK  1.07E‐12  5.26E‐09  ‐1.3719  8.00E‐10  ‐1.51348 
3339382  NM_000803 // FOLR2 // folate receptor 2 (fetal) // 11q13.3‐q13.5 // 2350 /// NM_  FOLR2  1.08E‐12  1.21E‐09  ‐1.98388  3.38E‐09  ‐2.21744 
2835213  NM_133263 // PPARGC1B // peroxisome proliferator‐activated receptor gamma, coact  PPARGC1B  1.08E‐12  1.39E‐09  ‐1.28694  2.95E‐09  ‐1.34521 
3255220  NM_014394 // GHITM // growth hormone inducible transmembrane protein // 10q23.1   GHITM  1.10E‐12  8.56E‐12  ‐1.58852  4.10E‐06  ‐1.37067 
2987632  NM_025250 // TTYH3 // tweety homolog 3 (Drosophila) // 7p22 // 80727 /// ENST000  TTYH3  1.11E‐12  3.87E‐08  1.34514  1.60E‐10  1.57138 
3895381  NM_001009984 // C20orf194 // chromosome 20 open reading frame 194 // 20p13 // 25  C20orf194  1.16E‐12  3.73E‐09  ‐1.46747  1.24E‐09  ‐1.62709 
3861557  NM_006149 // LGALS4 // lectin, galactoside‐binding, soluble, 4 // 19q13.2 // 396  LGALS4  1.20E‐12  1.31E‐11  ‐1.31842  2.23E‐06  ‐1.21895 
3332334  NM_032597 // MS4A14 // membrane‐spanning 4‐domains, subfamily A, member 14 // 11  MS4A14  1.23E‐12  3.04E‐10  ‐1.62377  2.07E‐08  ‐1.63754 
2976448  AK299585 // NHSL1 // NHS‐like 1 // 6q23.3 // 57224 /// ENST00000343505 // NHSL1   NHSL1  1.26E‐12  8.10E‐07  ‐1.36694  2.47E‐11  ‐1.81018 
3090209  NM_014265 // ADAM28 // ADAM metallopeptidase domain 28 // 8p21.2 // 10863 /// NM  ADAM28  1.27E‐12  1.44E‐07  ‐1.76814  7.50E‐11  ‐2.58886 
3430552  NM_007062 // PWP1 // PWP1 homolog (S. cerevisiae) // 12q23.3 // 11137 /// ENST00  PWP1  1.27E‐12  1.28E‐07  1.27206  8.15E‐11  1.48903 
3191074  NM_014064 // METTL11A // methyltransferase like 11A // 9q34.11 // 28989 /// ENST  METTL11A  1.27E‐12  8.74E‐07  1.28255  2.40E‐11  1.60779 
3600212  NM_017691 // LRRC49 // leucine rich repeat containing 49 // 15q23 // 54839 /// E  LRRC49  1.27E‐12  2.69E‐10  1.56098  2.56E‐08  1.56305 




3258477  NM_016341 // PLCE1 // phospholipase C, epsilon 1 // 10q23 // 51196 /// ENST00000  PLCE1  1.30E‐12  1.91E‐08  ‐1.73698  3.50E‐10  ‐2.20548 
3375648  NM_002032 // FTH1 // ferritin, heavy polypeptide 1 // 11q13 // 2495 /// NM_00203  FTH1  1.30E‐12  6.65E‐09  ‐2.11467  8.68E‐10  ‐2.68644 
2337716  NM_006252 // PRKAA2 // protein kinase, AMP‐activated, alpha 2 catalytic subunit   PRKAA2  1.31E‐12  1.84E‐07  ‐1.84203  6.65E‐11  ‐2.81934 
2905391  ENST00000406939 // LOC646875 // similar to ribosomal protein L12 // 6p21.2 // 64  LOC646875  1.32E‐12  2.28E‐08  1.31577  3.10E‐10  1.489 
3929721  NM_000819 // GART // phosphoribosylglycinamide formyltransferase, phosphoribosyl  GART  1.33E‐12  1.14E‐07  1.43015  9.38E‐11  1.79616 
3648391  NM_001192 // TNFRSF17 // tumor necrosis factor receptor superfamily, member 17 /  TNFRSF17  1.33E‐12  6.97E‐10  ‐2.43944  8.89E‐09  ‐2.64562 
2334602  NM_005727 // TSPAN1 // tetraspanin 1 // 1p34.1 // 10103 /// ENST00000372003 // T  TSPAN1  1.38E‐12  2.51E‐08  ‐1.60142  3.06E‐10  ‐1.98674 
2354433  NM_000198 // HSD3B2 // hydroxy‐delta‐5‐steroid dehydrogenase, 3 beta‐ and steroi  HSD3B2  1.39E‐12  3.11E‐11  ‐5.95578  6.87E‐07  ‐4.08007 
3948640  NM_006486 // FBLN1 // fibulin 1 // 22q13.31 // 2192 /// NM_006485 // FBLN1 // fi  FBLN1  1.43E‐12  2.79E‐08  ‐1.68872  2.97E‐10  ‐2.15632 
4018080  NM_145234 // CHRDL1 // chordin‐like 1 // Xq22.3 // 91851 /// ENST00000372045 //   CHRDL1  1.43E‐12  1.50E‐07  ‐1.84919  8.61E‐11  ‐2.78127 
2779231  NM_000668 // ADH1B // alcohol dehydrogenase 1B (class I), beta polypeptide // 4q  ADH1B  1.47E‐12  6.07E‐05  ‐1.77628  3.40E‐12  ‐4.59149 
3834046  NM_021913 // AXL // AXL receptor tyrosine kinase // 19q13.1 // 558 /// NM_001699  AXL  1.47E‐12  9.44E‐09  ‐1.38526  7.67E‐10  ‐1.55073 
2880552  NM_001040172 // HTR4 // 5‐hydroxytryptamine (serotonin) receptor 4 // 5q31‐q33 /  HTR4  1.48E‐12  7.36E‐10  ‐1.7997  1.00E‐08  ‐1.8948 
3850725  NM_020812 // DOCK6 // dedicator of cytokinesis 6 // 19p13.2 // 57572 /// ENST000  DOCK6  1.49E‐12  2.57E‐09  1.26696  2.66E‐09  1.33177 
2544484  NM_004036 // ADCY3 // adenylate cyclase 3 // 2p23.3 // 109 /// ENST00000260600 /  ADCY3  1.50E‐12  3.33E‐08  1.29834  2.77E‐10  1.47259 
3025740  NM_018295 // TMEM140 // transmembrane protein 140 // 7q33 // 55281 /// ENST00000  TMEM140  1.50E‐12  3.01E‐06  ‐1.43955  1.48E‐11  ‐2.13302 
3753452  NM_001014445 // NLE1 // notchless homolog 1 (Drosophila) // 17q12 // 54475 /// N  NLE1  1.53E‐12  1.45E‐05  1.23399  6.80E‐12  1.63916 
3480885  NM_002010 // FGF9 // fibroblast growth factor 9 (glia‐activating factor) // 13q1  FGF9  1.60E‐12  1.39E‐08  ‐1.5496  6.26E‐10  ‐1.83054 
3687494  NM_001040056 // MAPK3 // mitogen‐activated protein kinase 3 // 16p11.2 // 5595 /  MAPK3  1.62E‐12  1.18E‐10  ‐1.55727  1.21E‐07  ‐1.49234 
3279313  NM_003638 // ITGA8 // integrin, alpha 8 // 10p13 // 8516 /// ENST00000378076 //   ITGA8  1.63E‐12  1.14E‐09  ‐1.78117  7.24E‐09  ‐1.91185 
3018309  NM_002649 // PIK3CG // phosphoinositide‐3‐kinase, catalytic, gamma polypeptide /  PIK3CG  1.65E‐12  1.18E‐06  ‐1.49362  2.81E‐11  ‐2.16695 
3802980  NM_004949 // DSC2 // desmocollin 2 // 18q12.1 // 1824 /// NM_024422 // DSC2 // d  DSC2  1.66E‐12  1.75E‐08  ‐1.4031  5.39E‐10  ‐1.6083 
2409507  NM_201649 // SLC6A9 // solute carrier family 6 (neurotransmitter transporter, gl  SLC6A9  1.66E‐12  1.13E‐11  ‐1.75541  6.29E‐06  ‐1.45873 
3026834  NM_024926 // TTC26 // tetratricopeptide repeat domain 26 // 7q34 // 79989 /// EN  TTC26  1.70E‐12  3.09E‐08  1.4192  3.53E‐10  1.66923 
3922793  NM_002606 // PDE9A // phosphodiesterase 9A // 21q22.3 // 5152 /// NM_001001582 /  PDE9A  1.77E‐12  5.53E‐10  ‐1.66045  1.92E‐08  ‐1.69871 
2534252  NM_024101 // MLPH // melanophilin // 2q37.3 // 79083 /// NM_001042467 // MLPH //  MLPH  1.81E‐12  2.60E‐11  1.66959  1.65E‐06  1.46639 
2387606  NM_000740 // CHRM3 // cholinergic receptor, muscarinic 3 // 1q43 // 1131 /// ENS  CHRM3  1.84E‐12  8.92E‐12  1.76856  1.31E‐05  1.43697 
3556924  NM_001039619 // PRMT5 // protein arginine methyltransferase 5 // 14q11.2‐q21 //   PRMT5  1.85E‐12  1.69E‐06  1.31031  2.64E‐11  1.70351 
2600689  NM_004438 // EPHA4 // EPH receptor A4 // 2q36.1 // 2043 /// ENST00000281821 // E  EPHA4  1.85E‐12  2.03E‐11  1.99601  2.70E‐06  1.64477 
3682028  NM_022844 // MYH11 // myosin, heavy chain 11, smooth muscle // 16p13.11 // 4629   MYH11  1.86E‐12  7.86E‐07  ‐1.69638  4.19E‐11  ‐2.67103 
3942502  NM_001001479 // SLC35E4 // solute carrier family 35, member E4 // 22q12.2 // 339  SLC35E4  1.90E‐12  6.07E‐06  1.32932  1.37E‐11  1.85596 
3426502  NM_005761 // PLXNC1 // plexin C1 // 12q23.3 // 10154 /// ENST00000258526 // PLXN  PLXNC1  1.92E‐12  1.53E‐06  ‐1.33473  2.93E‐11  ‐1.75719 
3203753  NM_018449 // UBAP2 // ubiquitin associated protein 2 // 9p13.3 // 55833 /// ENST  UBAP2  1.93E‐12  2.04E‐08  1.25773  5.97E‐10  1.38067 
3296386  NM_004747 // DLG5 // discs, large homolog 5 (Drosophila) // 10q23 // 9231 /// EN  DLG5  1.96E‐12  1.08E‐09  1.17909  1.05E‐08  1.19917 
3957486  NM_152511 // DUSP18 // dual specificity phosphatase 18 // 22q12.2 // 150290 ///   DUSP18  1.98E‐12  1.14E‐09  1.62129  1.01E‐08  1.70707 
2754073  NM_020225 // STOX2 // storkhead box 2 // 4q35.1 // 56977 /// ENST00000308497 //   STOX2  1.98E‐12  9.64E‐11  ‐1.38655  2.43E‐07  ‐1.32748 
3160658  NM_004170 // SLC1A1 // solute carrier family 1 (neuronal/epithelial high affinit  SLC1A1  2.00E‐12  3.76E‐08  ‐2.03619  3.82E‐10  ‐2.84802 
2546054  NM_022128 // RBKS // ribokinase // 2p23.3 // 64080 /// ENST00000302188 // RBKS /  RBKS  2.09E‐12  5.74E‐10  ‐1.62107  2.47E‐08  ‐1.64859 
3057514  NM_002991 // CCL24 // chemokine (C‐C motif) ligand 24 // 7q11.23 // 6369 /// ENS  CCL24  2.10E‐12  5.95E‐08  2.33765  2.87E‐10  3.63702 
3815143  BC052236 // C19orf21 // chromosome 19 open reading frame 21 // 19p13.3 // 126353  C19orf21  2.11E‐12  2.15E‐10  ‐1.5787  8.78E‐08  ‐1.53541 
3471300  NM_139283 // PPTC7 // PTC7 protein phosphatase homolog (S. cerevisiae) // 12q24.  PPTC7  2.14E‐12  3.72E‐11  ‐1.34745  1.29E‐06  ‐1.25696 




2842624  NM_017675 // PCDH24 // protocadherin 24 // 5q35.2 // 54825 /// ENST00000261944 /  PCDH24  2.15E‐12  1.02E‐09  ‐2.23769  1.31E‐08  ‐2.40431 
2635741  NM_198196 // CD96 // CD96 molecule // 3q13.13‐q13.2 // 10225 /// NM_005816 // CD  CD96  2.16E‐12  0.0049556  ‐1.22715  1.04E‐12  ‐2.34565 
3592401  NM_032413 // C15orf48 // chromosome 15 open reading frame 48 // 15q21.1 // 84419  C15orf48  2.17E‐12  4.77E‐08  ‐1.61925  3.55E‐10  ‐2.053 
3589857  BC061640 // LOC644844 // hypothetical LOC644844 // 15q15.1 // 644844  LOC644844  2.17E‐12  7.12E‐11  ‐2.61301  4.63E‐07  ‐2.21815 
2974935  NM_145176 // SLC2A12 // solute carrier family 2 (facilitated glucose transporter  SLC2A12  2.20E‐12  4.86E‐12  2.158  7.88E‐05  1.52756 
3465409  NM_001731 // BTG1 // B‐cell translocation gene 1, anti‐proliferative // 12q22 //  BTG1  2.22E‐12  2.38E‐07  ‐1.28871  1.14E‐10  ‐1.53287 
3655723  NM_017458 // MVP // major vault protein // 16p13.1‐p11.2 // 9961 /// NM_005115 /  MVP  2.27E‐12  7.15E‐12  ‐1.44229  3.59E‐05  ‐1.24139 
2528020  NM_014640 // TTLL4 // tubulin tyrosine ligase‐like family, member 4 // 2p24.3‐p2  TTLL4  2.31E‐12  2.61E‐08  1.27314  6.34E‐10  1.4087 
3185498  NM_001860 // SLC31A2 // solute carrier family 31 (copper transporters), member 2  SLC31A2  2.39E‐12  2.16E‐08  ‐1.46344  7.82E‐10  ‐1.7011 
2735459  NM_014606 // HERC3 // hect domain and RLD 3 // 4q21 // 8916 /// ENST00000402738   HERC3  2.44E‐12  7.65E‐07  ‐1.39402  6.05E‐11  ‐1.83729 
3746574  NM_000304 // PMP22 // peripheral myelin protein 22 // 17p12‐p11.2 // 5376 /// NM  PMP22  2.45E‐12  3.30E‐06  ‐1.56448  2.59E‐11  ‐2.50087 
2360506  NM_015872 // ZBTB7B // zinc finger and BTB domain containing 7B // 1q21.3 // 510  ZBTB7B  2.46E‐12  2.18E‐10  ‐1.42858  1.15E‐07  ‐1.39207 
3848540  NM_021155 // CD209 // CD209 molecule // 19p13 // 30835 /// ENST00000315599 // CD  CD209  2.48E‐12  1.76E‐09  ‐1.90824  9.13E‐09  ‐2.0773 
3442024  NM_001033714 // NOL1 // nucleolar protein 1, 120kDa // 12p13 // 4839 /// NM_0061  NOL1  2.49E‐12  7.68E‐05  1.25736  5.68E‐12  1.83478 
3762380  NM_001267 // CHAD // chondroadherin // 17q21.33 // 1101 /// ENST00000258969 // C  CHAD  2.49E‐12  2.04E‐07  ‐1.49322  1.48E‐10  ‐1.9415 
2505501  NM_033416 // IMP4 // IMP4, U3 small nucleolar ribonucleoprotein, homolog (yeast)  IMP4  2.53E‐12  0.000117894 1.13332  4.81E‐12  1.41128 
3127156  NM_001495 // GFRA2 // GDNF family receptor alpha 2 // 8p21.3 // 2675 /// ENST000  GFRA2  2.54E‐12  9.90E‐10  ‐1.51625  1.81E‐08  ‐1.56264 
2657250  NM_005578 // LPP // LIM domain containing preferred translocation partner in lip  LPP  2.57E‐12  1.86E‐05  ‐1.19733  1.13E‐11  ‐1.52576 
3665116  NM_001755 // CBFB // core‐binding factor, beta subunit // 16q22.1 // 865 /// NM_  CBFB  2.65E‐12  9.47E‐09  1.38595  1.89E‐09  1.52761 
3302360  NM_022362 // MMS19 // MMS19 nucleotide excision repair homolog (S. cerevisiae) /  MMS19  2.65E‐12  3.15E‐07  1.18974  1.20E‐10  1.34465 
3244488  NM_032023 // RASSF4 // Ras association (RalGDS/AF‐6) domain family member 4 // 1  RASSF4  2.67E‐12  1.13E‐08  ‐1.47425  1.63E‐09  ‐1.66658 
2773387  NM_002090 // CXCL3 // chemokine (C‐X‐C motif) ligand 3 // 4q21 // 2921 /// ENST0  CXCL3  2.70E‐12  5.71E‐09  1.63327  3.15E‐09  1.84056 
3921068  NM_005239 // ETS2 // v‐ets erythroblastosis virus E26 oncogene homolog 2 (avian)  ETS2  2.71E‐12  8.14E‐10  1.81267  2.55E‐08  1.86485 
3734966  NR_003587 // MYO15B // myosin XVB pseudogene // 17q25.1 // 80022 /// AF418286 //  MYO15B  2.73E‐12  1.41E‐08  ‐1.59763  1.38E‐09  ‐1.87176 
2656379  ‐‐‐    2.76E‐12  9.28E‐11  ‐2.91561  5.04E‐07  ‐2.44136 
3944826  NM_018957 // SH3BP1 // SH3‐domain binding protein 1 // 22q13.1 // 23616 /// ENST  SH3BP1  2.78E‐12  5.54E‐12  ‐1.48182  0.000109245 ‐1.23663 
3613725  NM_002487 // NDN // necdin homolog (mouse) // 15q11.2‐q12 // 4692 /// ENST000003  NDN  2.79E‐12  2.76E‐07  ‐1.51847  1.40E‐10  ‐2.0202 
3401259  NM_003213 // TEAD4 // TEA domain family member 4 // 12p13.3‐p13.2 // 7004 /// NM  TEAD4  2.85E‐12  6.89E‐07  1.36899  7.93E‐11  1.76154 
2423422  NM_003567 // BCAR3 // breast cancer anti‐estrogen resistance 3 // 1p22.1 // 8412  BCAR3  2.93E‐12  1.39E‐09  ‐1.35734  1.58E‐08  ‐1.39676 
2440354  NM_001778 // CD48 // CD48 molecule // 1q21.3‐q22 // 962 /// ENST00000368046 // C  CD48  2.94E‐12  1.83E‐05  ‐1.46423  1.33E‐11  ‐2.4306 
3425108  NM_001009894 // C12orf29 // chromosome 12 open reading frame 29 // 12q21.32 // 9  C12orf29  3.05E‐12  8.83E‐06  1.21173  2.00E‐11  1.52333 
2648305  NM_002563 // P2RY1 // purinergic receptor P2Y, G‐protein coupled, 1 // 3q25.2 //  P2RY1  3.06E‐12  4.79E‐08  ‐1.42991  5.82E‐10  ‐1.688 
2351854  BC017973 // C1orf162 // chromosome 1 open reading frame 162 // 1p13.2 // 128346   C1orf162  3.07E‐12  1.28E‐07  ‐1.60884  2.75E‐10  ‐2.11914 
3933039  NM_005656 // TMPRSS2 // transmembrane protease, serine 2 // 21q22.3 // 7113 ///   TMPRSS2  3.10E‐12  3.17E‐10  ‐1.63467  1.08E‐07  ‐1.59029 
2735598  NM_145715 // TIGD2 // tigger transposable element derived 2 // 4q22.1 // 166815   TIGD2  3.18E‐12  3.68E‐08  1.42184  7.65E‐10  1.65451 
2824089  NR_002922 // SNORA13 // small nucleolar RNA, H/ACA box 13 // 5q22.2 // 654322 //  SNORA13  3.23E‐12  6.06E‐11  1.44107  1.38E‐06  1.32879 
2479433  NM_172069 // PLEKHH2 // pleckstrin homology domain containing, family H (with My  PLEKHH2  3.28E‐12  4.01E‐10  ‐1.51731  8.77E‐08  ‐1.49362 
3653123  NM_002738 // PRKCB // protein kinase C, beta // 16p11.2 // 5579 /// NM_212535 //  PRKCB  3.29E‐12  2.62E‐08  ‐1.60434  1.07E‐09  ‐1.92913 
3263743  NM_004419 // DUSP5 // dual specificity phosphatase 5 // 10q25 // 1847 /// ENST00  DUSP5  3.29E‐12  3.70E‐10  ‐1.82043  9.81E‐08  ‐1.77102 
3864445  NM_006297 // XRCC1 // X‐ray repair complementing defective repair in Chinese ham  XRCC1  3.45E‐12  8.07E‐07  1.20073  9.21E‐11  1.3919 
3633148  NM_005697 // SCAMP2 // secretory carrier membrane protein 2 // 15q23‐q25 // 1006  SCAMP2  3.54E‐12  1.20E‐09  ‐1.27076  2.60E‐08  ‐1.2902 




3577612  NM_001002236 // SERPINA1 // serpin peptidase inhibitor, clade A (alpha‐1 antipro  SERPINA1  3.58E‐12  1.85E‐08  1.8123  1.64E‐09  2.22467 
2961177  NM_004370 // COL12A1 // collagen, type XII, alpha 1 // 6q12‐q13 // 1303 /// NM_0  COL12A1  3.65E‐12  1.58E‐10  1.97862  3.97E‐07  1.8003 
2514566  NM_003142 // SSB // Sjogren syndrome antigen B (autoantigen La) // 2q31.1 // 674  SSB  3.65E‐12  6.43E‐10  1.5326  5.83E‐08  1.53218 
2447877  NM_052966 // FAM129A // family with sequence similarity 129, member A // 1q25 //  FAM129A  3.69E‐12  1.33E‐07  ‐1.45401  3.47E‐10  ‐1.79849 
3132782  NM_003012 // SFRP1 // secreted frizzled‐related protein 1 // 8p12‐p11.1 // 6422   SFRP1  3.71E‐12  3.71E‐08  ‐1.52268  9.51E‐10  ‐1.81576 
3667281  NM_012426 // SF3B3 // splicing factor 3b, subunit 3, 130kDa // 16q22.1 // 23450   SF3B3  3.73E‐12  2.09E‐08  1.40506  1.56E‐09  1.5852 
3572443  BC001448 // FLVCR2 // feline leukemia virus subgroup C cellular receptor family,  FLVCR2  3.74E‐12  1.04E‐10  ‐2.23928  7.92E‐07  ‐1.93384 
4015709  NM_000061 // BTK // Bruton agammaglobulinemia tyrosine kinase // Xq21.33‐q22 //   BTK  3.76E‐12  1.14E‐07  ‐1.52942  3.98E‐10  ‐1.93058 
3050462  NM_001001555 // GRB10 // growth factor receptor‐bound protein 10 // 7p12‐p11.2 /  GRB10  3.80E‐12  4.92E‐10  1.49627  8.79E‐08  1.47819 
3795466  BC014195 // C18orf22 // chromosome 18 open reading frame 22 // 18q23 // 79863 //  C18orf22  3.83E‐12  7.73E‐08  1.26213  5.50E‐10  1.4181 
3391149  NM_138378 // hCG_2033039 // hypothetical protein BC006136 // 11q23.1 // 91893 //  hCG_2033039  3.87E‐12  1.37E‐08  ‐1.95959  2.42E‐09  ‐2.40716 
2338487  NM_001113411 // FGGY // FGGY carbohydrate kinase domain containing // 1p32.1 //   FGGY  3.88E‐12  8.01E‐09  1.57035  4.00E‐09  1.75718 
3118818  NM_032611 // PTP4A3 // protein tyrosine phosphatase type IVA, member 3 // 8q24.3  PTP4A3  3.88E‐12  4.62E‐07  1.6028  1.54E‐10  2.25278 
3599709  NM_015554 // GLCE // glucuronic acid epimerase // 15q23 // 26035 /// ENST0000026  GLCE  3.89E‐12  5.07E‐09  1.50472  6.32E‐09  1.63375 
2980516  NM_173515 // CNKSR3 // CNKSR family member 3 // 6q25.2 // 154043 /// ENST0000036  CNKSR3  3.90E‐12  3.51E‐06  ‐1.42117  4.48E‐11  ‐2.02992 
3680583  NM_015659 // RSL1D1 // ribosomal L1 domain containing 1 // 16p13.13 // 26156 ///  RSL1D1  3.91E‐12  5.63E‐08  1.44041  7.27E‐10  1.70492 
3824775  NM_015016 // MAST3 // microtubule associated serine/threonine kinase 3 // 19p13.  MAST3  3.93E‐12  1.40E‐08  ‐1.23256  2.42E‐09  ‐1.31429 
3554523  NM_174891 // C14orf79 // chromosome 14 open reading frame 79 // 14q32.33 // 1226  C14orf79  3.95E‐12  8.31E‐08  1.36864  5.44E‐10  1.60429 
3859622  NM_175872 // ZNF792 // zinc finger protein 792 // 19q13.11 // 126375 /// ENST000  ZNF792  4.04E‐12  1.53E‐09  1.43475  2.45E‐08  1.4751 
2673830  NM_001009996 // DALRD3 // DALR anticodon binding domain containing 3 // 3p21.31   DALRD3  4.05E‐12  4.58E‐07  1.12992  1.65E‐10  1.23327 
3753860  NM_002985 // CCL5 // chemokine (C‐C motif) ligand 5 // 17q11.2‐q12 // 6352 /// E  CCL5  4.11E‐12  7.25E‐06  ‐1.34684  3.21E‐11  ‐1.88473 
3761551  NM_173623 // TTLL6 // tubulin tyrosine ligase‐like family, member 6 // 17q21.32   TTLL6  4.12E‐12  1.76E‐07  ‐1.47774  3.29E‐10  ‐1.86285 
3970338  NM_198270 // NHS // Nance‐Horan syndrome (congenital cataracts and dental anomal  NHS  4.22E‐12  3.22E‐11  1.48924  7.67E‐06  1.31558 
3059667  NM_152754 // SEMA3D // sema domain, immunoglobulin domain (Ig), short basic doma  SEMA3D  4.26E‐12  0.000246605 ‐1.63608  6.42E‐12  ‐4.14544 
3658980  NM_133443 // GPT2 // glutamic pyruvate transaminase (alanine aminotransferase) 2  GPT2  4.26E‐12  0.00038987  1.27399  5.34E‐12  2.07883 
3775425  NM_001009905 // B3GNTL1 // UDP‐GlcNAc:betaGal beta‐1,3‐N‐acetylglucosaminyltrans  B3GNTL1  4.29E‐12  2.03E‐07  1.30743  3.12E‐10  1.53869 
3642815  NM_005009 // NME4 // non‐metastatic cells 4, protein expressed in // 16p13.3 //   NME4  4.47E‐12  1.52E‐05  1.22694  2.42E‐11  1.58499 
2363248  NM_002348 // LY9 // lymphocyte antigen 9 // 1q21.3‐q22 // 4063 /// NM_001033667   LY9  4.62E‐12  6.30E‐08  ‐1.43185  8.47E‐10  ‐1.68939 
3843180  NM_020657 // ZNF304 // zinc finger protein 304 // 19q13.4 // 57343 /// ENST00000  ZNF304  4.72E‐12  3.11E‐10  ‐1.59039  2.47E‐07  ‐1.52245 
2643901  NM_002718 // PPP2R3A // protein phosphatase 2 (formerly 2A), regulatory subunit   PPP2R3A  4.78E‐12  6.43E‐08  ‐1.56724  8.76E‐10  ‐1.92723 
3260895  NM_017893 // SEMA4G // sema domain, immunoglobulin domain (Ig), transmembrane do  SEMA4G  4.85E‐12  3.73E‐06  ‐1.27729  5.69E‐11  ‐1.63281 
3518455  NM_012158 // FBXL3 // F‐box and leucine‐rich repeat protein 3 // 13q22 // 26224   FBXL3  4.87E‐12  1.80E‐07  ‐1.34965  4.06E‐10  ‐1.60687 
2826343  NM_014035 // SNX24 // sorting nexin 24 // 5q23.2 // 28966 /// ENST00000261369 //  SNX24  4.92E‐12  4.84E‐09  ‐1.5658  9.70E‐09  ‐1.69515 
3210457  NM_018339 // RFK // riboflavin kinase // 9q21.13 // 55312 /// ENST00000257452 //  RFK  4.93E‐12  1.19E‐10  ‐1.31886  1.13E‐06  ‐1.25024 
3743906  NM_000546 // TP53 // tumor protein p53 // 17p13.1 // 7157 /// NM_001126112 // TP  TP53  5.01E‐12  3.55E‐08  1.48743  1.53E‐09  1.73565 
3293724  NM_022153 // C10orf54 // chromosome 10 open reading frame 54 // 10q22.1 // 64115  C10orf54  5.06E‐12  4.20E‐09  ‐1.41835  1.18E‐08  ‐1.50001 
3389330  NM_004347 // CASP5 // caspase 5, apoptosis‐related cysteine peptidase // 11q22.2  CASP5  5.06E‐12  1.06E‐11  ‐2.23137  0.000119562 ‐1.55364 
3103818  NM_004133 // HNF4G // hepatocyte nuclear factor 4, gamma // 8q21.11 // 3174 ///   HNF4G  5.07E‐12  2.48E‐08  ‐1.86288  2.13E‐09  ‐2.31307 
2955061  NM_178148 // SLC35B2 // solute carrier family 35, member B2 // 6p12.1‐p11.2 // 3  SLC35B2  5.07E‐12  1.67E‐05  1.20184  2.68E‐11  1.51445 
3891278  NM_198976 // TH1L // TH1‐like (Drosophila) // 20q13 // 51497 /// ENST00000344018  TH1L  5.08E‐12  4.44E‐06  1.219  5.47E‐11  1.49386 
2896545  NM_006877 // GMPR // guanosine monophosphate reductase // 6p23 // 2766 /// ENST0  GMPR  5.20E‐12  2.39E‐10  1.6642  4.34E‐07  1.55869 




2680046  NM_182920 // ADAMTS9 // ADAM metallopeptidase with thrombospondin type 1 motif,   ADAMTS9  5.33E‐12  4.62E‐09  1.44582  1.16E‐08  1.53685 
2786322  NM_014331 // SLC7A11 // solute carrier family 7, (cationic amino acid transporte  SLC7A11  5.38E‐12  1.24E‐08  1.95347  4.40E‐09  2.33744 
3543481  NM_000021 // PSEN1 // presenilin 1 // 14q24.3 // 5663 /// ENST00000324501 // PSE  PSEN1  5.46E‐12  1.10E‐09  ‐1.29908  6.11E‐08  ‐1.30556 
3286343  NM_001099282 // ZNF239 // zinc finger protein 239 // 10q11.22‐q11.23 // 8187 ///  ZNF239  5.46E‐12  7.20E‐09  1.43689  7.65E‐09  1.55027 
3168136  NM_001080496 // RGP1 // RGP1 retrograde golgi transport homolog (S. cerevisiae)   RGP1  5.47E‐12  4.71E‐11  ‐1.31344  6.86E‐06  ‐1.21133 
3624607  NM_000259 // MYO5A // myosin VA (heavy chain 12, myoxin) // 15q21 // 4644 /// EN  MYO5A  5.47E‐12  8.39E‐08  ‐1.50345  8.61E‐10  ‐1.82816 
3916527  NM_021219 // JAM2 // junctional adhesion molecule 2 // 21q21.2 // 58494 /// ENST  JAM2  5.62E‐12  8.08E‐05  ‐1.29739  1.43E‐11  ‐1.95456 
3521816  NM_080818 // OXGR1 // oxoglutarate (alpha‐ketoglutarate) receptor 1 // 13q32.1 /  OXGR1  5.66E‐12  5.19E‐07  1.60658  2.37E‐10  2.2427 
2364231  NM_001014796 // DDR2 // discoidin domain receptor tyrosine kinase 2 // 1q23.3 //  DDR2  5.71E‐12  6.86E‐08  ‐1.66955  1.07E‐09  ‐2.10541 
2864849  NM_012446 // SSBP2 // single‐stranded DNA binding protein 2 // 5q14.1 // 23635 /  SSBP2  5.75E‐12  1.28E‐07  ‐1.55308  6.64E‐10  ‐1.95727 
3178583  NM_001827 // CKS2 // CDC28 protein kinase regulatory subunit 2 // 9q22 // 1164 /  CKS2  5.78E‐12  0.000106336 1.36334  1.30E‐11  2.26343 
3357397  NM_138342 // GLB1L2 // galactosidase, beta 1‐like 2 // 11q25 // 89944 /// ENST00  GLB1L2  5.78E‐12  0.738773  ‐1.01318  8.57E‐13  1.62598 
3251023  NM_018344 // SLC29A3 // solute carrier family 29 (nucleoside transporters), memb  SLC29A3  5.81E‐12  2.32E‐06  1.24004  9.45E‐11  1.50911 
2448710  NM_199051 // FAM5C // family with sequence similarity 5, member C // 1q31.1 // 3  FAM5C  5.86E‐12  1.14E‐06  ‐1.99363  1.48E‐10  ‐3.48145 
3665857  NM_005796 // NUTF2 // nuclear transport factor 2 // 16q22.1 // 10204 /// ENST000  NUTF2  5.96E‐12  1.07E‐05  1.23719  4.13E‐11  1.58346 
2590582  NM_005019 // PDE1A // phosphodiesterase 1A, calmodulin‐dependent // 2q32.1 // 51  PDE1A  5.97E‐12  3.19E‐08  ‐1.38112  2.18E‐09  ‐1.55236 
3249533  BT006794 // AKR1B10 // aldo‐keto reductase family 1, member B10 (aldose reductas  AKR1B10  6.00E‐12  1.66E‐11  ‐3.07458  6.83E‐05  ‐1.92168 
2433232  NM_001461 // FMO5 // flavin containing monooxygenase 5 // 1q21.1 // 2330 /// ENS  FMO5  6.08E‐12  9.77E‐07  ‐1.49298  1.72E‐10  ‐2.04359 
3473436  NM_017899 // TESC // tescalcin // 12q24.22 // 54997 /// ENST00000392545 // TESC   TESC  6.13E‐12  3.99E‐10  1.98262  2.88E‐07  1.86136 
2414958  NM_002353 // TACSTD2 // tumor‐associated calcium signal transducer 2 // 1p32‐p31  TACSTD2  6.24E‐12  4.20E‐08  1.69744  1.84E‐09  2.08528 
2908474  NM_007355 // HSP90AB1 // heat shock protein 90kDa alpha (cytosolic), class B mem  HSP90AB1  6.28E‐12  7.54E‐08  1.46928  1.14E‐09  1.75075 
2418078  NM_173808 // NEGR1 // neuronal growth regulator 1 // 1p31.1 // 257194 /// ENST00  NEGR1  6.28E‐12  7.11E‐09  ‐1.50387  9.72E‐09  ‐1.62937 
2438125  NM_005998 // CCT3 // chaperonin containing TCP1, subunit 3 (gamma) // 1q23 // 72  CCT3  6.32E‐12  8.68E‐08  1.37001  1.03E‐09  1.58918 
2623922  NM_015136 // STAB1 // stabilin 1 // 3p21.1 // 23166 /// ENST00000321725 // STAB1  STAB1  6.33E‐12  1.62E‐09  ‐1.71604  4.99E‐08  ‐1.75816 
3472225  NM_001111322 // DDX54 // DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 54 // 12q24.13 /  DDX54  6.36E‐12  1.94E‐05  1.14454  3.27E‐11  1.35731 
2939298  NM_015482 // SLC22A23 // solute carrier family 22, member 23 // 6p25.2 // 63027   SLC22A23  6.44E‐12  3.20E‐07  ‐1.25773  3.95E‐10  ‐1.45301 
2516023  NM_031942 // CDCA7 // cell division cycle associated 7 // 2q31 // 83879 /// NM_1  CDCA7  6.47E‐12  2.10E‐08  1.54297  3.58E‐09  1.76451 
2807686  NM_032587 // CARD6 // caspase recruitment domain family, member 6 // 5p13.1 // 8  CARD6  6.53E‐12  1.59E‐09  1.62111  5.39E‐08  1.65303 
3598758  NM_005585 // SMAD6 // SMAD family member 6 // 15q21‐q22 // 4091 /// ENST00000288  SMAD6  6.59E‐12  3.27E‐08  1.26792  2.47E‐09  1.37992 
3741769  NM_002558 // P2RX1 // purinergic receptor P2X, ligand‐gated ion channel, 1 // 17  P2RX1  6.70E‐12  1.17E‐09  ‐1.46666  8.20E‐08  ‐1.47083 
3770390  NM_015654 // NAT9 // N‐acetyltransferase 9 // 17q25.1 // 26151 /// ENST000003578  NAT9  6.71E‐12  8.41E‐05  1.15813  1.72E‐11  1.457 
2734629  NM_080683 // PTPN13 // protein tyrosine phosphatase, non‐receptor type 13 (APO‐1  PTPN13  6.72E‐12  1.66E‐09  2.41171  5.39E‐08  2.50298 
2343823  NM_012302 // LPHN2 // latrophilin 2 // 1p31.1 // 23266 /// ENST00000359929 // LP  LPHN2  6.88E‐12  1.79E‐06  ‐1.64646  1.38E‐10  ‐2.52602 
3851651  NM_013433 // TNPO2 // transportin 2 (importin 3, karyopherin beta 2b) // 19p13.1  TNPO2  6.93E‐12  0.000462715 1.1272  8.62E‐12  1.43494 
2461891  NM_152490 // B3GALNT2 // beta‐1,3‐N‐acetylgalactosaminyltransferase 2 // 1q42.3   B3GALNT2  7.00E‐12  1.14E‐09  1.25322  9.20E‐08  1.25343 
2378662  NM_145759 // TRAF5 // TNF receptor‐associated factor 5 // 1q32 // 7188 /// NM_00  TRAF5  7.00E‐12  6.43E‐10  1.88003  1.92E‐07  1.81443 
3820921  NM_001128844 // SMARCA4 // SWI/SNF related, matrix associated, actin dependent r  SMARCA4  7.01E‐12  1.48E‐08  1.18357  5.63E‐09  1.23753 
2388794  NM_205768 // ZNF238 // zinc finger protein 238 // 1q44‐qter // 10472 /// NM_0063  ZNF238  7.02E‐12  3.32E‐11  1.35939  2.39E‐05  1.2177 
3405748  NM_001423 // EMP1 // epithelial membrane protein 1 // 12p12.3 // 2012 /// ENST00  EMP1  7.06E‐12  1.21E‐08  ‐2.12247  6.88E‐09  ‐2.54838 
2547114  NM_000379 // XDH // xanthine dehydrogenase // 2p23.1 // 7498 /// ENST00000379416  XDH  7.11E‐12  7.52E‐06  ‐1.50723  6.19E‐11  ‐2.34938 
2585972  NM_003742 // ABCB11 // ATP‐binding cassette, sub‐family B (MDR/TAP), member 11 /  ABCB11  7.20E‐12  1.30E‐11  ‐1.82513  0.000191323 ‐1.37806 




3995392  NM_007150 // ZNF185 // zinc finger protein 185 (LIM domain) // Xq28 // 7739 ///   ZNF185  7.34E‐12  8.20E‐08  1.37254  1.34E‐09  1.58372 
2778273  NM_014485 // PGDS // prostaglandin D2 synthase, hematopoietic // 4q22.3 // 27306  PGDS  7.35E‐12  1.28E‐08  ‐2.2895  6.97E‐09  ‐2.80459 
2371547  NM_030806 // C1orf21 // chromosome 1 open reading frame 21 // 1q25 // 81563 ///   C1orf21  7.50E‐12  1.53E‐05  ‐1.29939  4.52E‐11  ‐1.78013 
2815488  NM_001080479 // RGNEF // Rho‐guanine nucleotide exchange factor // 5q13.2 // 642  RGNEF  7.51E‐12  1.36E‐10  1.75074  2.18E‐06  1.54976 
2809810  NM_006144 // GZMA // granzyme A (granzyme 1, cytotoxic T‐lymphocyte‐associated s  GZMA  7.52E‐12  7.46E‐07  ‐1.65084  2.71E‐10  ‐2.37687 
3576749  NM_006329 // FBLN5 // fibulin 5 // 14q32.1 // 10516 /// ENST00000342058 // FBLN5  FBLN5  7.69E‐12  6.69E‐07  ‐1.44122  3.00E‐10  ‐1.86851 
2400518  NM_001113349 // ECE1 // endothelin converting enzyme 1 // 1p36.1 // 1889 /// NM_  ECE1  7.93E‐12  3.48E‐07  ‐1.3786  4.94E‐10  ‐1.68333 
3726406  NM_025149 // ACSF2 // acyl‐CoA synthetase family member 2 // 17q21.33 // 80221 /  ACSF2  7.95E‐12  1.07E‐09  ‐1.96431  1.25E‐07  ‐1.94258 
2778856  NM_005723 // TSPAN5 // tetraspanin 5 // 4q23 // 10098 /// ENST00000305798 // TSP  TSPAN5  7.98E‐12  2.41E‐09  1.76868  4.70E‐08  1.83547 
3239380  NM_024838 // THNSL1 // threonine synthase‐like 1 (S. cerevisiae) // 10p12.1 // 7  THNSL1  8.04E‐12  4.84E‐08  1.56033  2.37E‐09  1.85065 
3746040  NM_018127 // ELAC2 // elaC homolog 2 (E. coli) // 17p11.2 // 60528 /// ENST00000  ELAC2  8.06E‐12  6.44E‐06  1.17229  7.90E‐11  1.38383 
2320411  NM_001040196 // AGTRAP // angiotensin II receptor‐associated protein // 1p36.22   AGTRAP  8.19E‐12  2.29E‐06  1.21075  1.48E‐10  1.43255 
2599153  NM_022648 // TNS1 // tensin 1 // 2q35‐q36 // 7145 /// ENST00000171887 // TNS1 //  TNS1  8.22E‐12  6.52E‐08  ‐1.54795  1.90E‐09  ‐1.85626 
3317071  NM_002339 // LSP1 // lymphocyte‐specific protein 1 // 11p15.5 // 4046 /// NM_001  LSP1  8.49E‐12  2.81E‐06  ‐1.3929  1.37E‐10  ‐1.88104 
3381063  NM_030813 // CLPB // ClpB caseinolytic peptidase B homolog (E. coli) // 11q13.4   CLPB  8.60E‐12  0.0309109  1.06492  2.59E‐12  1.40146 
3182199  AY598327 // C9orf30 // chromosome 9 open reading frame 30 // 9q31.1 // 91283 ///  C9orf30  8.64E‐12  3.57E‐09  1.49087  3.42E‐08  1.55072 
3735151  NM_000213 // ITGB4 // integrin, beta 4 // 17q25 // 3691 /// NM_001005731 // ITGB  ITGB4  8.70E‐12  9.96E‐11  1.47401  5.06E‐06  1.3307 
2828716  NM_001039780 // CCNI2 // cyclin I family, member 2 // 5q31.1 // 645121 /// ENST0  CCNI2  8.71E‐12  4.88E‐07  1.58626  4.41E‐10  2.14843 
3041294  NM_032581 // FAM126A // family with sequence similarity 126, member A // 7p15.3   FAM126A  8.72E‐12  2.10E‐06  ‐1.45166  1.69E‐10  ‐2.00074 
3842675  NR_003127 // ZNF542 // zinc finger protein 542 // 19q13.43 // 147947 /// BC08941  ZNF542  8.74E‐12  1.20E‐07  ‐1.48519  1.27E‐09  ‐1.79704 
2645951  NM_003304 // TRPC1 // transient receptor potential cation channel, subfamily C,   TRPC1  8.77E‐12  8.76E‐09  ‐1.42496  1.34E‐08  ‐1.52428 
3329886  NM_175732 // PTPMT1 // protein tyrosine phosphatase, mitochondrial 1 // 11p11.2   PTPMT1  8.80E‐12  0.00662752  1.09859  4.26E‐12  1.47292 
3284302  NM_003873 // NRP1 // neuropilin 1 // 10p12 // 8829 /// NM_001024628 // NRP1 // n  NRP1  8.91E‐12  1.22E‐08  ‐1.4586  9.86E‐09  ‐1.58739 
3753500  NM_001104587 // SLFN11 // schlafen family member 11 // 17q12 // 91607 /// NM_001  SLFN11  9.12E‐12  4.47E‐07  ‐1.37408  5.00E‐10  ‐1.68504 
3940001  NM_015330 // SPECC1L // SPECC1‐like // 22q11.23 // 23384 /// ENST00000314328 //   SPECC1L  9.12E‐12  4.80E‐06  ‐1.29397  1.09E‐10  ‐1.66749 
2677723  NM_001128615 // ARHGEF3 // Rho guanine nucleotide exchange factor (GEF) 3 // 3p2  ARHGEF3  9.23E‐12  1.08E‐11  1.65925  0.000586828 1.27592 
3454576  NM_000617 // SLC11A2 // solute carrier family 11 (proton‐coupled divalent metal   SLC11A2  9.25E‐12  1.61E‐08  1.57834  7.98E‐09  1.7696 
3740664  NM_032895 // C17orf91 // chromosome 17 open reading frame 91 // 17p13.3 // 84981  C17orf91  9.26E‐12  4.49E‐10  ‐1.85172  5.37E‐07  ‐1.72337 
2622547  NM_004186 // SEMA3F // sema domain, immunoglobulin domain (Ig), short basic doma  SEMA3F  9.43E‐12  2.83E‐08  1.52732  4.85E‐09  1.74163 
3205659  NM_003028 // SHB // Src homology 2 domain containing adaptor protein B // 9p13.2  SHB  9.83E‐12  7.78E‐08  1.28521  2.13E‐09  1.42841 
2485406  NM_014181 // HSPC159 // galectin‐related protein // 2p14 // 29094 /// ENST000002  HSPC159  9.92E‐12  4.24E‐09  ‐1.5915  3.57E‐08  ‐1.67061 
2878437  NM_001040021 // CD14 // CD14 molecule // 5q22‐q32|5q31.1 // 929 /// NM_000591 //  CD14  9.97E‐12  4.75E‐08  ‐1.71331  3.31E‐09  ‐2.08346 
3226369  NM_012127 // CIZ1 // CDKN1A interacting zinc finger protein 1 // 9q34.1 // 25792  CIZ1  1.01E‐11  2.31E‐06  1.15702  1.92E‐10  1.3119 
3631964  NM_182470 // PKM2 // pyruvate kinase, muscle // 15q22 // 5315 /// NM_002654 // P  PKM2  1.01E‐11  4.61E‐06  1.23213  1.27E‐10  1.50793 
3101629  NM_144650 // ADHFE1 // alcohol dehydrogenase, iron containing, 1 // 8q13.1 // 13  ADHFE1  1.01E‐11  9.24E‐08  ‐1.56273  1.92E‐09  ‐1.90072 
2954678  NM_020750 // XPO5 // exportin 5 // 6p21.1 // 57510 /// ENST00000398799 // XPO5 /  XPO5  1.01E‐11  7.52E‐07  1.33815  4.02E‐10  1.64158 
3205506  NM_012166 // FBXO10 // F‐box protein 10 // 9p13.2 // 26267 /// NM_001001790 // T  FBXO10  1.02E‐11  0.00804936  1.09507  4.68E‐12  1.46637 
2518272  NM_000885 // ITGA4 // integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA‐4  ITGA4  1.04E‐11  2.35E‐05  ‐1.45038  5.38E‐11  ‐2.30827 
3701000  NM_001031804 // MAF // v‐maf musculoaponeurotic fibrosarcoma oncogene homolog (a  MAF  1.06E‐11  1.37E‐07  ‐1.42081  1.50E‐09  ‐1.68249 
3752258  NM_006495 // EVI2B // ecotropic viral integration site 2B // 17q11.2 // 2124 ///  EVI2B  1.07E‐11  1.22E‐06  ‐1.78451  3.11E‐10  ‐2.77751 
3706659  NM_000049 // ASPA // aspartoacylase (Canavan disease) // 17pter‐p13 // 443 /// N  ASPA  1.08E‐11  2.04E‐08  ‐2.2789  8.11E‐09  ‐2.82961 




2445643  NM_033127 // SEC16B // SEC16 homolog B (S. cerevisiae) // 1q25.2 // 89866 /// EN  SEC16B  1.13E‐11  7.65E‐10  1.65634  3.69E‐07  1.5907 
3821908  NM_006397 // RNASEH2A // ribonuclease H2, subunit A // 19p13.13 // 10535 /// ENS  RNASEH2A  1.14E‐11  0.0334334  1.11116  3.39E‐12  1.76651 
3332465  NM_031457 // MS4A8B // membrane‐spanning 4‐domains, subfamily A, member 8B // 11  MS4A8B  1.14E‐11  1.51E‐05  ‐1.74274  7.57E‐11  ‐3.31589 
2640855  NM_004526 // MCM2 // minichromosome maintenance complex component 2 // 3q21 // 4  MCM2  1.15E‐11  0.029654  1.08938  3.54E‐12  1.56944 
3346147  NM_032021 // TMEM133 // transmembrane protein 133 // 11q22.1 // 83935 /// ENST00  TMEM133  1.16E‐11  1.48E‐05  ‐1.40048  7.85E‐11  ‐2.06482 
3349293  NM_181351 // NCAM1 // neural cell adhesion molecule 1 // 11q23.1 // 4684 /// NM_  NCAM1  1.17E‐11  2.40E‐08  ‐1.42751  7.87E‐09  ‐1.57359 
4015440  NM_080737 // SYTL4 // synaptotagmin‐like 4 // Xq21.33 // 94121 /// NM_001129896   SYTL4  1.19E‐11  1.92E‐08  ‐1.35668  9.95E‐09  ‐1.46348 
3553389  NM_030943 // AMN // amnionless homolog (mouse) // 14q32.3 // 81693 /// ENST00000  AMN  1.20E‐11  2.26E‐09  ‐1.4822  1.03E‐07  ‐1.49606 
3063589  NM_001185 // AZGP1 // alpha‐2‐glycoprotein 1, zinc‐binding // 7q22.1 // 563 ///   AZGP1  1.21E‐11  1.22E‐08  2.2719  1.60E‐08  2.67357 
4021508  NM_017666 // ZNF280C // zinc finger protein 280C // Xq25 // 55609 /// ENST000003  ZNF280C  1.23E‐11  1.33E‐09  1.50499  2.08E‐07  1.48551 
3334025  NM_017490 // MARK2 // MAP/microtubule affinity‐regulating kinase 2 // 11q12‐q13   MARK2  1.24E‐11  6.89E‐10  ‐1.30859  5.15E‐07  ‐1.27405 
4055661  NM_000240 // MAOA // monoamine oxidase A // Xp11.3 // 4128 /// ENST00000338702 /  MAOA  1.25E‐11  9.34E‐09  ‐2.34764  2.23E‐08  ‐2.70742 
4011889  NM_201599 // ZMYM3 // zinc finger, MYM‐type 3 // Xq13.1 // 9203 /// NM_005096 //  ZMYM3  1.27E‐11  1.49E‐09  1.29775  1.91E‐07  1.28992 
3069082  NM_012252 // TFEC // transcription factor EC // 7q31.2 // 22797 /// NM_001018058  TFEC  1.28E‐11  1.22E‐08  ‐1.42619  1.76E‐08  ‐1.52746 
3071063  NM_001127323 // GRM8 // glutamate receptor, metabotropic 8 // 7q31.3‐q32.1 // 29  GRM8  1.30E‐11  2.56E‐09  2.71388  1.01E‐07  2.79653 
3918535  NM_000628 // IL10RB // interleukin 10 receptor, beta // 21q22.1‐q22.2|21q22.11 /  IL10RB  1.30E‐11  2.58E‐08  ‐1.33602  8.61E‐09  ‐1.44597 
2405152  NM_030786 // SYNC1 // syncoilin, intermediate filament 1 // 1p34.3‐p33 // 81493   SYNC1  1.33E‐11  2.24E‐08  ‐1.49628  1.03E‐08  ‐1.6583 
4022106  NM_018388 // MBNL3 // muscleblind‐like 3 (Drosophila) // Xq26.2 // 55796 /// NM_  MBNL3  1.37E‐11  2.31E‐07  ‐1.27573  1.42E‐09  ‐1.44899 
3272736  NM_145806 // ZNF511 // zinc finger protein 511 // 10q26.3 // 118472 /// ENST0000  ZNF511  1.37E‐11  1.10E‐05  1.28073  1.13E‐10  1.67426 
2339786  NM_002633 // PGM1 // phosphoglucomutase 1 // 1p31 // 5236 /// ENST00000371084 //  PGM1  1.37E‐11  1.70E‐09  ‐1.43242  1.85E‐07  ‐1.42393 
3704376  D87071 // FAM38A // family with sequence similarity 38, member A // 16q24.3 // 9  FAM38A  1.40E‐11  1.09E‐06  1.24618  4.79E‐10  1.46121 
2703902  NM_000055 // BCHE // butyrylcholinesterase // 3q26.1‐q26.2 // 590 /// ENST000002  BCHE  1.42E‐11  1.91E‐09  ‐1.7021  1.70E‐07  ‐1.69524 
3185593  NM_017688 // BSPRY // B‐box and SPRY domain containing // 9q32 // 54836 /// ENST  BSPRY  1.42E‐11  3.04E‐07  1.31409  1.22E‐09  1.52873 
3666189  NM_019023 // PRMT7 // protein arginine methyltransferase 7 // 16q22.1 // 54496 /  PRMT7  1.43E‐11  0.000168906 1.13238  3.02E‐11  1.3901 
3127775  NM_003844 // TNFRSF10A // tumor necrosis factor receptor superfamily, member 10a  TNFRSF10A  1.44E‐11  1.44E‐06  1.27335  4.12E‐10  1.5302 
2438207  NM_005920 // MEF2D // myocyte enhancer factor 2D // 1q12‐q23 // 4209 /// ENST000  MEF2D  1.44E‐11  2.38E‐08  ‐1.31716  1.10E‐08  ‐1.41305 
3656223  NM_002209 // ITGAL // integrin, alpha L (antigen CD11A (p180), lymphocyte functi  ITGAL  1.44E‐11  1.02E‐05  ‐1.32959  1.26E‐10  ‐1.80095 
3320819  NM_032867 // MICALCL // MICAL C‐terminal like // 11p15.3 // 84953 /// ENST000002  MICALCL  1.44E‐11  2.65E‐08  ‐1.5468  9.92E‐09  ‐1.73751 
3290649  NM_198215 // FAM13C1 // family with sequence similarity 13, member C1 // 10q21.1  FAM13C1  1.46E‐11  1.11E‐07  ‐1.34448  2.80E‐09  ‐1.52652 
3215245  NM_198841 // FAM120AOS // family with sequence similarity 120A opposite strand /  FAM120AOS  1.47E‐11  3.00E‐09  ‐1.33446  1.04E‐07  ‐1.34811 
4027769  NM_001289 // CLIC2 // chloride intracellular channel 2 // Xq28 // 1193 /// ENST0  CLIC2  1.50E‐11  6.54E‐08  ‐1.63545  4.61E‐09  ‐1.9567 
3351166  NM_001558 // IL10RA // interleukin 10 receptor, alpha // 11q23 // 3587 /// ENST0  IL10RA  1.52E‐11  2.04E‐07  ‐1.55278  1.83E‐09  ‐1.93334 
3909553  NM_012340 // NFATC2 // nuclear factor of activated T‐cells, cytoplasmic, calcine  NFATC2  1.53E‐11  0.000437861 ‐1.14968  2.16E‐11  ‐1.4993 
3804195  NM_012319 // SLC39A6 // solute carrier family 39 (zinc transporter), member 6 //  SLC39A6  1.53E‐11  1.07E‐07  1.39925  3.12E‐09  1.61135 
3718204  NM_005408 // CCL13 // chemokine (C‐C motif) ligand 13 // 17q11.2 // 6357 /// ENS  CCL13  1.55E‐11  1.76E‐09  ‐2.47036  2.21E‐07  ‐2.41778 
3276337  NM_030569 // ITIH5 // inter‐alpha (globulin) inhibitor H5 // 10p14 // 80760 ///   ITIH5  1.56E‐11  1.13E‐06  ‐1.43587  5.41E‐10  ‐1.86192 
3994795  NM_000252 // MTM1 // myotubularin 1 // Xq28 // 4534 /// ENST00000306167 // MTM1   MTM1  1.61E‐11  2.51E‐07  ‐1.51537  1.69E‐09  ‐1.87994 
3726298  NM_153229 // TMEM92 // transmembrane protein 92 // 17q21.33 // 162461 /// ENST00  TMEM92  1.62E‐11  2.22E‐10  1.99735  4.92E‐06  1.69247 
3250990  NM_170744 // UNC5B // unc‐5 homolog B (C. elegans) // 10q22.1 // 219699 /// ENST  UNC5B  1.63E‐11  5.64E‐11  ‐1.38946  6.22E‐05  ‐1.22316 
3221598  NM_001012361 // WDR31 // WD repeat domain 31 // 9q32 // 114987 /// NM_145241 //   WDR31  1.65E‐11  2.36E‐07  1.36245  1.83E‐09  1.59454 
2979246  NM_130900 // RAET1L // retinoic acid early transcript 1L // 6q25.1 // 154064 ///  RAET1L  1.72E‐11  1.67E‐07  2.64886  2.56E‐09  4.1582 




3169331  NM_000692 // ALDH1B1 // aldehyde dehydrogenase 1 family, member B1 // 9p11.1 //   ALDH1B1  1.75E‐11  2.27E‐06  1.49466  3.96E‐10  2.06826 
3507710  NM_003045 // SLC7A1 // solute carrier family 7 (cationic amino acid transporter,  SLC7A1  1.75E‐11  0.000235042 1.1934  3.30E‐11  1.61524 
2562271  NM_001747 // CAPG // capping protein (actin filament), gelsolin‐like // 2p11.2 /  CAPG  1.76E‐11  4.48E‐06  1.28747  2.61E‐10  1.62074 
3278813  BC064407 // FAM107B // family with sequence similarity 107, member B // 10p13 //  FAM107B  1.77E‐11  3.85E‐09  ‐1.60473  1.07E‐07  ‐1.6392 
2733498  NM_001201 // BMP3 // bone morphogenetic protein 3 // 4q21 // 651 /// ENST0000028  BMP3  1.79E‐11  5.67E‐08  ‐3.54516  6.79E‐09  ‐5.40599 
3017080  NM_031905 // ARMC10 // armadillo repeat containing 10 // 7q22.1 // 83787 /// ENS  ARMC10  1.81E‐11  3.15E‐08  1.2817  1.19E‐08  1.36931 
2434233  NM_020205 // OTUD7B // OTU domain containing 7B // 1q21.2 // 56957 /// ENST00000  OTUD7B  1.82E‐11  3.59E‐08  ‐1.27933  1.06E‐08  ‐1.37079 
3355733  NM_002017 // FLI1 // Friend leukemia virus integration 1 // 11q24.1‐q24.3 // 231  FLI1  1.83E‐11  4.23E‐07  ‐1.49279  1.35E‐09  ‐1.8784 
3469180  NM_032148 // SLC41A2 // solute carrier family 41, member 2 // 12q23.3 // 84102 /  SLC41A2  1.83E‐11  1.66E‐07  ‐1.65438  2.80E‐09  ‐2.08247 
3246888  NM_001098512 // PRKG1 // protein kinase, cGMP‐dependent, type I // 10q11.2 // 55  PRKG1  1.84E‐11  7.30E‐10  ‐1.51265  1.00E‐06  ‐1.43431 
3289445  NM_138933 // A1CF // APOBEC1 complementation factor // 10q11.23 // 29974 /// NM_  A1CF  1.88E‐11  1.06E‐08  ‐1.55359  3.77E‐08  ‐1.65671 
2324097  NM_032409 // PINK1 // PTEN induced putative kinase 1 // 1p36 // 65018 /// ENST00  PINK1  1.88E‐11  2.29E‐06  ‐1.2133  4.32E‐10  ‐1.41699 
3870692  NM_001081442 // LILRB5 // leukocyte immunoglobulin‐like receptor, subfamily B (w  LILRB5  1.91E‐11  2.98E‐10  ‐1.78145  4.28E‐06  ‐1.56501 
3388830  NM_002422 // MMP3 // matrix metallopeptidase 3 (stromelysin 1, progelatinase) //  MMP3  1.92E‐11  1.63E‐06  2.79735  5.56E‐10  6.06084 
2398287  NM_001102663 // NBPF16 // neuroblastoma breakpoint family, member 16 // 1q21.1 /  NBPF16  1.93E‐11  2.56E‐05  ‐1.27429  1.09E‐10  ‐1.70592 
3689880  NM_024745 // SHCBP1 // SHC SH2‐domain binding protein 1 // 16q11.2 // 79801 ///   SHCBP1  1.94E‐11  0.0095606  1.17049  8.79E‐12  1.94427 
3875108  AK292708 // C20orf196 // chromosome 20 open reading frame 196 // 20p12.3 // 1498  C20orf196  1.96E‐11  6.91E‐06  1.26045  2.30E‐10  1.57791 
2633256  NM_006100 // ST3GAL6 // ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 6 // 3q  ST3GAL6  2.01E‐11  4.11E‐08  ‐1.37787  1.09E‐08  ‐1.51068 
3696666  NM_000903 // NQO1 // NAD(P)H dehydrogenase, quinone 1 // 16q22.1 // 1728 /// NM_  NQO1  2.02E‐11  7.69E‐05  1.46334  6.55E‐11  2.5171 
2555830  NM_198276 // TMEM17 // transmembrane protein 17 // 2p15 // 200728 /// ENST000003  TMEM17  2.02E‐11  6.77E‐08  1.39177  6.97E‐09  1.55887 
2558612  NM_003236 // TGFA // transforming growth factor, alpha // 2p13 // 7039 /// NM_00  TGFA  2.03E‐11  2.34E‐09  ‐1.48749  2.50E‐07  ‐1.47677 
3252534  NM_144660 // SAMD8 // sterile alpha motif domain containing 8 // 10q22.2 // 1428  SAMD8  2.06E‐11  8.10E‐08  ‐1.32334  6.10E‐09  ‐1.46464 
2431886  NM_014644 // PDE4DIP // phosphodiesterase 4D interacting protein // 1q12 // 9659  PDE4DIP  2.06E‐11  2.51E‐08  ‐1.264  1.82E‐08  ‐1.33409 
2940202  NM_000129 // F13A1 // coagulation factor XIII, A1 polypeptide // 6p25.3‐p24.3 //  F13A1  2.07E‐11  9.60E‐07  ‐2.61462  8.82E‐10  ‐4.98177 
2673181  NM_002673 // PLXNB1 // plexin B1 // 3p21.31 // 5364 /// ENST00000296440 // PLXNB  PLXNB1  2.07E‐11  3.44E‐09  1.23596  1.61E‐07  1.24111 
3709327  NM_001037144 // CNTROB // centrobin, centrosomal BRCA2 interacting protein // 17  CNTROB  2.08E‐11  3.35E‐06  1.11892  3.87E‐10  1.23108 
2840036  NM_004946 // DOCK2 // dedicator of cytokinesis 2 // 5q35.1 // 1794 /// ENST00000  DOCK2  2.11E‐11  1.92E‐05  ‐1.41552  1.41E‐10  ‐2.10397 
2934521  NM_021977 // SLC22A3 // solute carrier family 22 (extraneuronal monoamine transp  SLC22A3  2.12E‐11  1.10E‐08  2.16672  4.41E‐08  2.41343 
2708066  NM_130446 // KLHL6 // kelch‐like 6 (Drosophila) // ‐‐‐ // 89857 /// ENST00000341  KLHL6  2.13E‐11  3.40E‐08  ‐1.58562  1.42E‐08  ‐1.78843 
2777564  NM_014883 // FAM13A1 // family with sequence similarity 13, member A1 // 4q22.1   FAM13A1  2.15E‐11  8.61E‐08  1.33142  6.15E‐09  1.4783 
3435980  NM_024809 // TCTN2 // tectonic family member 2 // 12q24.31 // 79867 /// ENST0000  TCTN2  2.15E‐11  2.70E‐08  1.32827  1.80E‐08  1.41986 
3014159  NM_014916 // LMTK2 // lemur tyrosine kinase 2 // 7q21.3 // 22853 /// ENST0000029  LMTK2  2.17E‐11  4.21E‐08  ‐1.31184  1.20E‐08  ‐1.41663 
2405284  NM_033504 // TMEM54 // transmembrane protein 54 // 1p35‐p34 // 113452 /// ENST00  TMEM54  2.18E‐11  1.34E‐11  ‐1.70131  0.00403508  ‐1.23438 
4010461  NM_001012968 // SPIN4 // spindlin family, member 4 // Xq11.1 // 139886 /// ENST0  SPIN4  2.18E‐11  6.79E‐08  1.34704  7.77E‐09  1.48925 
3817464  NM_032868 // MPND // MPN domain containing // 19p13.3 // 84954 /// ENST000002629  MPND  2.24E‐11  4.40E‐10  ‐1.29925  3.17E‐06  ‐1.23341 
2396781  NM_001127325 // MAD2L2 // MAD2 mitotic arrest deficient‐like 2 (yeast) // 1p36 /  MAD2L2  2.27E‐11  1.38E‐06  1.28735  7.79E‐10  1.54104 
2953139  NM_005943 // MOCS1 // molybdenum cofactor synthesis 1 // 6p21.3 // 4337 /// NM_0  MOCS1  2.28E‐11  1.10E‐10  ‐1.54585  3.63E‐05  ‐1.32856 
2955673  NM_021572 // ENPP5 // ectonucleotide pyrophosphatase/phosphodiesterase 5 (putati  ENPP5  2.35E‐11  6.81E‐10  1.83948  1.79E‐06  1.67066 
2645387  NM_152282 // ACPL2 // acid phosphatase‐like 2 // 3q23 // 92370 /// NM_001037172   ACPL2  2.36E‐11  2.68E‐06  1.20086  5.25E‐10  1.39152 
3992408  NM_001449 // FHL1 // four and a half LIM domains 1 // Xq26 // 2273 /// ENST00000  FHL1  2.38E‐11  2.84E‐08  ‐1.76117  2.01E‐08  ‐2.0078 
2922215  NM_002356 // MARCKS // myristoylated alanine‐rich protein kinase C substrate //   MARCKS  2.43E‐11  1.48E‐05  ‐1.28108  1.94E‐10  ‐1.67386 




2460296  NM_000029 // AGT // angiotensinogen (serpin peptidase inhibitor, clade A, member  AGT  2.44E‐11  5.49E‐09  1.57894  1.22E‐07  1.61837 
3839920  NM_002030 // FPR3 // formyl peptide receptor 3 // 19q13.3‐q13.4 // 2359 /// ENST  FPR3  2.45E‐11  1.67E‐08  ‐1.89131  3.62E‐08  ‐2.10917 
3129731  NM_057158 // DUSP4 // dual specificity phosphatase 4 // 8p12‐p11 // 1846 /// NM_  DUSP4  2.47E‐11  8.76E‐10  1.85954  1.36E‐06  1.70853 
2519480  NM_016315 // GULP1 // GULP, engulfment adaptor PTB domain containing 1 // 2q32.3  GULP1  2.47E‐11  4.05E‐05  ‐1.47939  1.15E‐10  ‐2.43094 
3744965  NM_201433 // GAS7 // growth arrest‐specific 7 // 17p13.1 // 8522 /// NM_201432 /  GAS7  2.50E‐11  5.57E‐08  ‐1.44566  1.14E‐08  ‐1.6163 
3651509  NM_030941 // LOC81691 // exonuclease NEF‐sp // 16p12.2 // 81691 /// ENST00000261  LOC81691  2.53E‐11  0.0775343  1.06066  6.14E‐12  1.46012 
3590498  NM_006293 // TYRO3 // TYRO3 protein tyrosine kinase // 15q15.1‐q21.1 // 7301 ///  TYRO3  2.54E‐11  6.60E‐08  1.44978  1.00E‐08  1.63306 
2777070  NM_016245 // HSD17B11 // hydroxysteroid (17‐beta) dehydrogenase 11 // 4q22.1 //   HSD17B11  2.57E‐11  1.23E‐06  ‐1.51956  9.93E‐10  ‐2.02374 
3388631  NM_052932 // TMEM123 // transmembrane protein 123 // 11q22.1 // 114908 /// ENST0  TMEM123  2.58E‐11  5.74E‐09  1.57831  1.27E‐07  1.61763 
3031466  NM_175571 // GIMAP8 // GTPase, IMAP family member 8 // 7q36.1 // 155038 /// ENST  GIMAP8  2.60E‐11  1.67E‐05  ‐1.27919  1.97E‐10  ‐1.67495 
3191352  NM_014286 // FREQ // frequenin homolog (Drosophila) // 9q34 // 23413 /// NM_0011  FREQ  2.61E‐11  0.000875934 1.20889  2.95E‐11  1.78668 
2360206  NM_020452 // ATP8B2 // ATPase, class I, type 8B, member 2 // 1q21.3 // 57198 ///  ATP8B2  2.61E‐11  9.79E‐08  ‐1.40334  7.35E‐09  ‐1.58727 
2607568  NM_006614 // CHL1 // cell adhesion molecule with homology to L1CAM (close homolo  CHL1  2.62E‐11  2.75E‐06  ‐1.4859  5.91E‐10  ‐2.03892 
3957160  NM_002309 // LIF // leukemia inhibitory factor (cholinergic differentiation fact  LIF  2.68E‐11  1.10E‐09  1.74348  1.14E‐06  1.63093 
3833093  NM_001001563 // TIMM50 // translocase of inner mitochondrial membrane 50 homolog  TIMM50  2.71E‐11  0.00483033  1.1301  1.59E‐11  1.5861 
3418007  NM_005412 // SHMT2 // serine hydroxymethyltransferase 2 (mitochondrial) // 12q12  SHMT2  2.72E‐11  0.00145339  1.20812  2.51E‐11  1.84379 
3435902  NM_020936 // DDX55 // DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 55 // 12q24.31 // 5  DDX55  2.73E‐11  5.59E‐07  1.24334  1.90E‐09  1.40885 
2798915  NM_004237 // TRIP13 // thyroid hormone receptor interactor 13 // 5p15.33 // 9319  TRIP13  2.73E‐11  5.39E‐05  1.43345  1.12E‐10  2.30281 
2700365  NM_014220 // TM4SF1 // transmembrane 4 L six family member 1 // 3q21‐q25 // 4071  TM4SF1  2.74E‐11  1.07E‐07  1.75999  7.26E‐09  2.16947 
3956342  BC016465 // TTC28 // tetratricopeptide repeat domain 28 // 22q12.1 // 23331 ///   TTC28  2.74E‐11  4.46E‐07  ‐1.26288  2.27E‐09  ‐1.43396 
3706992  NM_001124758 // SPNS2 // spinster homolog 2 (Drosophila) // 17p13.2 // 124976 //  SPNS2  2.74E‐11  1.88E‐06  1.38057  8.08E‐10  1.75232 
3167187  NM_007343 // PRSS3 // protease, serine, 3 // 9p11.2 // 5646 /// NM_002771 // PRS  PRSS3  2.75E‐11  2.48E‐08  ‐1.48573  2.90E‐08  ‐1.61083 
3722304  NM_000988 // RPL27 // ribosomal protein L27 // 17q21.1‐q21.2 // 6155 /// ENST000  RPL27  2.76E‐11  0.00041076  1.18712  4.33E‐11  1.6205 
2353988  NM_017709 // FAM46C // family with sequence similarity 46, member C // 1p12 // 5  FAM46C  2.77E‐11  1.86E‐08  ‐1.69235  3.92E‐08  ‐1.85299 
3997780  NM_000047 // ARSE // arylsulfatase E (chondrodysplasia punctata 1) // Xp22.3 //   ARSE  2.79E‐11  1.28E‐07  1.45666  6.41E‐09  1.68648 
2997272  NM_030636 // EEPD1 // endonuclease/exonuclease/phosphatase family domain contain  EEPD1  2.80E‐11  4.75E‐09  1.33671  1.83E‐07  1.34721 
3381925  NM_173582 // PGM2L1 // phosphoglucomutase 2‐like 1 // 11q13.4 // 283209 /// ENST  PGM2L1  2.83E‐11  2.71E‐09  1.81677  3.77E‐07  1.78194 
2797393  NM_005245 // FAT // FAT tumor suppressor homolog 1 (Drosophila) // 4q35 // 2195   FAT  2.84E‐11  5.84E‐10  1.48046  3.30E‐06  1.3733 
2987441  NM_001037283 // EIF3B // eukaryotic translation initiation factor 3, subunit B /  EIF3B  2.85E‐11  3.99E‐06  1.27379  5.19E‐10  1.56379 
3061805  NM_001099401 // SGCE // sarcoglycan, epsilon // 7q21‐q22 // 8910 /// NM_003919 /  SGCE  2.87E‐11  1.99E‐07  ‐1.48569  4.58E‐09  ‐1.76843 
2378180  NM_014388 // C1orf107 // chromosome 1 open reading frame 107 // 1q32.2 // 27042   C1orf107  2.87E‐11  5.27E‐08  1.43443  1.48E‐08  1.58945 
3680434  NM_004862 // LITAF // lipopolysaccharide‐induced TNF factor // 16p13.13 // 9516   LITAF  2.88E‐11  3.03E‐09  ‐1.35468  3.36E‐07  ‐1.3456 
2812359  NM_020726 // NLN // neurolysin (metallopeptidase M3 family) // 5q12.3 // 57486 /  NLN  2.88E‐11  3.00E‐05  1.27842  1.62E‐10  1.71367 
3667811  NM_001361 // DHODH // dihydroorotate dehydrogenase // 16q22 // 1723 /// ENST0000  DHODH  2.89E‐11  5.20E‐05  1.16284  1.22E‐10  1.41544 
3323748  NM_213599 // ANO5 // anoctamin 5 // 11p14.3 // 203859 /// ENST00000324559 // ANO  ANO5  2.90E‐11  0.000264379 ‐1.66409  5.57E‐11  ‐3.92653 
3258444  NM_018131 // CEP55 // centrosomal protein 55kDa // 10q23.33 // 55165 /// NM_0011  CEP55  2.93E‐11  1.22E‐05  1.52243  2.74E‐10  2.3439 
2426676  NM_144584 // C1orf59 // chromosome 1 open reading frame 59 // 1p13.3 // 113802 /  C1orf59  2.94E‐11  5.17E‐07  1.44682  2.23E‐09  1.77745 
3709540  NM_012393 // PFAS // phosphoribosylformylglycinamidine synthase // 17p13.1 // 51  PFAS  2.98E‐11  8.09E‐06  1.18064  3.56E‐10  1.38376 
3867223  NM_000979 // RPL18 // ribosomal protein L18 // 19q13 // 6141 /// ENST00000084795  RPL18  3.03E‐11  1.59E‐07  1.21373  6.01E‐09  1.31349 
3962023  CR456458 // FAM152B // family with sequence similarity 152, member B // 22q13.2   FAM152B  3.07E‐11  0.000448009 1.14264  4.69E‐11  1.45794 
3998247  NM_020742 // NLGN4X // neuroligin 4, X‐linked // Xp22.32‐p22.31 // 57502 /// NM_  NLGN4X  3.10E‐11  1.09E‐07  ‐1.4684  8.62E‐09  ‐1.68678 




3047660  NM_000168 // GLI3 // GLI‐Kruppel family member GLI3 // 7p13 // 2737 /// ENST0000  GLI3  3.14E‐11  6.98E‐08  ‐1.43982  1.31E‐08  ‐1.61129 
3340410  NM_006656 // NEU3 // sialidase 3 (membrane sialidase) // 11q13.5 // 10825 /// EN  NEU3  3.15E‐11  3.26E‐07  1.19937  3.52E‐09  1.3117 
3031573  NM_018384 // GIMAP5 // GTPase, IMAP family member 5 // 7q36.1 // 55340 /// ENST0  GIMAP5  3.18E‐11  0.000550518 ‐1.28587  4.47E‐11  ‐2.0656 
2373336  NM_000186 // CFH // complement factor H // 1q32 // 3075 /// NM_001014975 // CFH   CFH  3.23E‐11  0.000157794 ‐1.57428  8.02E‐11  ‐3.16825 
3438027  NM_006325 // RAN // RAN, member RAS oncogene family // 12q24.3 // 5901 /// ENST0  RAN  3.32E‐11  3.15E‐06  1.18228  7.38E‐10  1.35112 
2601414  NM_006216 // SERPINE2 // serpin peptidase inhibitor, clade E (nexin, plasminogen  SERPINE2  3.41E‐11  5.95E‐10  2.51339  4.63E‐06  2.07755 
2356818  NM_004326 // BCL9 // B‐cell CLL/lymphoma 9 // 1q21 // 607 /// ENST00000234739 //  BCL9  3.41E‐11  5.77E‐10  1.28112  4.87E‐06  1.2162 
3888263  NR_003605 // C20orf199 // chromosome 20 open reading frame 199 // 20q13.13 // 44  C20orf199  3.42E‐11  3.15E‐08  1.50244  3.20E‐08  1.63776 
3193339  NM_002957 // RXRA // retinoid X receptor, alpha // 9q34.3 // 6256 /// ENST000003  RXRA  3.45E‐11  3.63E‐10  ‐1.36285  1.06E‐05  ‐1.25744 
3317352  NM_000218 // KCNQ1 // potassium voltage‐gated channel, KQT‐like subfamily, membe  KCNQ1  3.45E‐11  3.54E‐07  1.27167  3.75E‐09  1.43215 
3692033  NM_015272 // RPGRIP1L // RPGRIP1‐like // 16q12.2 // 23322 /// NM_001127897 // RP  RPGRIP1L  3.50E‐11  7.72E‐07  1.3978  2.10E‐09  1.70557 
3955483  NM_001001663 // TMEM211 // transmembrane protein 211 // 22q11.23 // 255349 /// E  TMEM211  3.50E‐11  3.80E‐08  2.58707  2.76E‐08  3.22031 
3402398  NM_018173 // PLEKHG6 // pleckstrin homology domain containing, family G (with Rh  PLEKHG6  3.51E‐11  2.38E‐10  ‐1.31498  2.30E‐05  ‐1.20885 
3299467  NM_144590 // ANKRD22 // ankyrin repeat domain 22 // 10q23.31 // 118932 /// ENST0  ANKRD22  3.52E‐11  2.16E‐06  1.9542  1.02E‐09  3.20006 
2868904  NM_005668 // ST8SIA4 // ST8 alpha‐N‐acetyl‐neuraminide alpha‐2,8‐sialyltransfera  ST8SIA4  3.55E‐11  3.28E‐06  ‐1.39596  7.84E‐10  ‐1.82114 
2476671  NM_170672 // RASGRP3 // RAS guanyl releasing protein 3 (calcium and DAG‐regulate  RASGRP3  3.56E‐11  3.04E‐08  ‐1.65292  3.52E‐08  ‐1.83197 
2893392  NM_004271 // LY86 // lymphocyte antigen 86 // 6p25.1 // 9450 /// ENST00000379953  LY86  3.63E‐11  7.33E‐06  ‐1.37187  4.84E‐10  ‐1.83556 
3374874  NM_005142 // GIF // gastric intrinsic factor (vitamin B synthesis) // 11q13 // 2  GIF  3.68E‐11  7.64E‐09  2.14699  1.67E‐07  2.23525 
3625052  NM_182758 // WDR72 // WD repeat domain 72 // 15q21.3 // 256764 /// ENST000003963  WDR72  3.69E‐11  1.30E‐07  1.36569  9.53E‐09  1.53103 
2728056  NM_020722 // KIAA1211 // KIAA1211 protein // 4q12 // 57482 /// ENST00000264229 /  KIAA1211  3.70E‐11  4.84E‐06  ‐1.36047  6.42E‐10  ‐1.7689 
3021158  NM_024913 // C7orf58 // chromosome 7 open reading frame 58 // 7q31.31 // 79974 /  C7orf58  3.74E‐11  4.48E‐06  ‐1.48656  6.84E‐10  ‐2.07387 
2844888  NM_197975 // BTNL3 // butyrophilin‐like 3 // 5q35.3 // 10917 /// ENST00000342868  BTNL3  3.76E‐11  1.09E‐06  ‐2.32208  1.81E‐09  ‐3.95989 
3064638  NM_022777 // RABL5 // RAB, member RAS oncogene family‐like 5 // 7q22.1 // 64792   RABL5  3.79E‐11  1.28E‐07  1.53422  1.01E‐08  1.79168 
3261859  NM_178858 // SFXN2 // sideroflexin 2 // 10q24.32 // 118980 /// ENST00000369893 /  SFXN2  3.79E‐11  0.000482706 1.16244  5.78E‐11  1.52975 
3747812  NM_148172 // PEMT // phosphatidylethanolamine N‐methyltransferase // 17p11.2 //   PEMT  3.85E‐11  6.39E‐05  1.21288  1.54E‐10  1.56366 
3358950  NM_001909 // CTSD // cathepsin D // 11p15.5 // 1509 /// ENST00000236671 // CTSD   CTSD  3.90E‐11  2.82E‐08  ‐1.39195  4.41E‐08  ‐1.48137 
2728189  NM_001079525 // PAICS // phosphoribosylaminoimidazole carboxylase, phosphoribosy  PAICS  3.97E‐11  1.84E‐05  1.3205  3.15E‐10  1.77771 
2562605  NM_015425 // POLR1A // polymerase (RNA) I polypeptide A, 194kDa // 2p11.2 // 258  POLR1A  3.98E‐11  3.25E‐07  1.24867  4.90E‐09  1.38648 
2431066  NM_032044 // REG4 // regenerating islet‐derived family, member 4 // 1p13.1‐p12 /  REG4  4.01E‐11  9.56E‐09  3.5859  1.49E‐07  3.91654 
3969081  NM_016562 // TLR7 // toll‐like receptor 7 // Xp22.3 // 51284 /// ENST00000380659  TLR7  4.01E‐11  1.02E‐07  ‐1.60261  1.34E‐08  ‐1.87304 
2973232  NM_014702 // KIAA0408 // KIAA0408 // 6q22.33 // 9729 /// NM_001012279 // C6orf17  KIAA0408  4.03E‐11  3.16E‐08  ‐1.57974  4.13E‐08  ‐1.72942 
3229529  NM_015447 // CAMSAP1 // calmodulin regulated spectrin‐associated protein 1 // 9q  CAMSAP1  4.04E‐11  3.92E‐09  1.32512  4.44E‐07  1.31559 
2976360  NM_022121 // PERP // PERP, TP53 apoptosis effector // 6q24 // 64065 /// ENST0000  PERP  4.09E‐11  3.10E‐09  1.54899  6.13E‐07  1.51475 
3923218  NM_015056 // RRP1B // ribosomal RNA processing 1 homolog B (S. cerevisiae) // 21  RRP1B  4.11E‐11  5.25E‐06  1.25913  7.00E‐10  1.53344 
2351004  NM_000851 // GSTM5 // glutathione S‐transferase M5 // 1p13.3 // 2949 /// ENST000  GSTM5  4.12E‐11  2.18E‐08  ‐1.87039  6.27E‐08  ‐2.06159 
3820727  NM_031209 // QTRT1 // queuine tRNA‐ribosyltransferase 1 // 19p13.3 // 81890 ///   QTRT1  4.12E‐11  1.83E‐05  1.18733  3.30E‐10  1.42563 
2775214  NM_006259 // PRKG2 // protein kinase, cGMP‐dependent, type II // 4q13.1‐q21.1 //  PRKG2  4.14E‐11  2.35E‐08  ‐2.2074  5.86E‐08  ‐2.51142 
3946351  NM_000026 // ADSL // adenylosuccinate lyase // 22q13.1|22q13.2 // 158 /// NM_001  ADSL  4.16E‐11  5.38E‐05  1.20653  1.85E‐10  1.53201 
2807716  NM_000587 // C7 // complement component 7 // 5p13 // 730 /// ENST00000313164 //   C7  4.23E‐11  2.26E‐07  ‐2.13613  7.23E‐09  ‐2.9406 
2705164  NM_020390 // EIF5A2 // eukaryotic translation initiation factor 5A2 // 3q26.2 //  EIF5A2  4.28E‐11  1.64E‐07  1.38807  9.70E‐09  1.5728 
2645906  NM_002670 // PLS1 // plastin 1 (I isoform) // 3q23 // 5357 /// ENST00000337777 /  PLS1  4.33E‐11  6.84E‐08  ‐1.67758  2.17E‐08  ‐1.9374 




2620410  NR_023353 // EXOSC7 // exosome component 7 // 3p21.31 // 23016 /// NM_015004 //   EXOSC7  4.45E‐11  3.66E‐07  1.25634  5.23E‐09  1.4006 
3601387  NM_033240 // PML // promyelocytic leukemia // 15q22 // 5371 /// NM_033244 // PML  PML  4.45E‐11  2.83E‐08  1.26764  5.41E‐08  1.32205 
3226844  NM_000755 // CRAT // carnitine acetyltransferase // 9q34.1 // 1384 /// NM_004003  CRAT  4.47E‐11  6.07E‐10  ‐1.45291  7.81E‐06  ‐1.33307 
2621917  NM_018031 // WDR6 // WD repeat domain 6 // 3p21.31 // 11180 /// ENST00000395474   WDR6  4.48E‐11  2.99E‐07  1.22653  6.21E‐09  1.3447 
2325479  NM_013441 // RCAN3 // RCAN family member 3 // 1p35.3‐p33 // 11123 /// ENST000003  RCAN3  4.48E‐11  5.34E‐10  1.43247  9.69E‐06  1.31198 
3390542  NM_002906 // RDX // radixin // 11q23 // 5962 /// ENST00000343115 // RDX // radix  RDX  4.49E‐11  2.00E‐07  ‐1.77916  8.74E‐09  ‐2.24168 
2872848  NM_002317 // LOX // lysyl oxidase // 5q23.2 // 4015 /// ENST00000231004 // LOX /  LOX  4.50E‐11  1.74E‐09  ‐1.857  1.60E‐06  ‐1.7241 
2908100  NM_006502 // POLH // polymerase (DNA directed), eta // 6p21.1 // 5429 /// ENST00  POLH  4.52E‐11  1.67E‐08  1.46296  9.70E‐08  1.53049 
2324873  NM_001114101 // C1QC // complement component 1, q subcomponent, C chain // 1p36.  C1QC  4.57E‐11  5.33E‐09  ‐1.85118  3.75E‐07  ‐1.84628 
2407314  NM_001099439 // EPHA10 // EPH receptor A10 // 1p34.3 // 284656 /// ENST000003730  EPHA10  4.85E‐11  2.21E‐06  ‐1.2151  1.54E‐09  ‐1.39534 
2770039  NM_006681 // NMU // neuromedin U // 4q12 // 10874 /// ENST00000264218 // NMU //   NMU  4.92E‐11  2.75E‐09  1.60566  1.01E‐06  1.54565 
3148545  NM_178565 // RSPO2 // R‐spondin 2 homolog (Xenopus laevis) // 8q23.1 // 340419 /  RSPO2  4.97E‐11  1.02E‐07  ‐1.55934  1.85E‐08  ‐1.79122 
3107342  NM_018444 // PPM2C // protein phosphatase 2C, magnesium‐dependent, catalytic sub  PPM2C  5.07E‐11  3.49E‐10  1.56069  2.60E‐05  1.36407 
3645901  NM_024845 // FLJ14154 // hypothetical protein FLJ14154 // 16p13.3 // 79903 /// N  FLJ14154  5.26E‐11  7.17E‐09  ‐1.25851  3.32E‐07  ‐1.26276 
2903401  NM_002121 // HLA‐DPB1 // major histocompatibility complex, class II, DP beta 1 /  HLA‐DPB1  5.26E‐11  4.30E‐05  ‐1.48538  2.76E‐10  ‐2.38987 
3417371  NM_015292 // FAM62A // family with sequence similarity 62 (C2 domain containing)  FAM62A  5.27E‐11  2.77E‐06  1.28206  1.47E‐09  1.53897 
2949380  NM_006295 // VARS // valyl‐tRNA synthetase // 6p21.3 // 7407 /// ENST00000211402  VARS  5.31E‐11  5.35E‐05  1.17645  2.48E‐10  1.44031 
3474104  NM_007174 // CIT // citron (rho‐interacting, serine/threonine kinase 21) // 12q2  CIT  5.35E‐11  1.37E‐05  1.32395  5.41E‐10  1.74684 
2994981  NM_175887 // PRR15 // proline rich 15 // 7p15.1 // 222171 /// ENST00000319694 //  PRR15  5.36E‐11  4.17E‐10  ‐1.28407  2.14E‐05  ‐1.19469 
3860137  NM_003332 // TYROBP // TYRO protein tyrosine kinase binding protein // 19q13.1 /  TYROBP  5.40E‐11  1.15E‐08  ‐1.58654  1.99E‐07  ‐1.63301 
3319840  NM_006391 // IPO7 // importin 7 // 11p15.4 // 10527 /// NR_002962 // SNORA23 //   IPO7  5.41E‐11  7.40E‐08  1.59808  2.83E‐08  1.81182 
3939183  NM_004327 // BCR // breakpoint cluster region // 22q11|22q11.23 // 613 /// NM_02  BCR  5.44E‐11  6.42E‐08  1.18481  3.26E‐08  1.23636 
3601741  NM_003992 // CLK3 // CDC‐like kinase 3 // 15q24 // 1198 /// ENST00000345005 // C  CLK3  5.50E‐11  3.71E‐08  ‐1.18891  5.72E‐08  ‐1.22837 
3527493  NM_001641 // APEX1 // APEX nuclease (multifunctional DNA repair enzyme) 1 // 14q  APEX1  5.61E‐11  9.08E‐09  1.42048  2.80E‐07  1.43751 
2322004  NM_207348 // SLC25A34 // solute carrier family 25, member 34 // 1p36.21 // 28472  SLC25A34  5.66E‐11  7.12E‐09  ‐1.57788  3.80E‐07  ‐1.58326 
2328713  NM_175852 // TXLNA // taxilin alpha // 1p35.1 // 200081 /// ENST00000373610 // T  TXLNA  5.67E‐11  2.29E‐06  1.14277  1.85E‐09  1.25477 
3936913  NM_003504 // CDC45L // CDC45 cell division cycle 45‐like (S. cerevisiae) // 22q1  CDC45L  5.70E‐11  0.0720972  1.10364  1.46E‐11  1.82696 
3630668  NM_033429 // CALML4 // calmodulin‐like 4 // 15q23 // 91860 /// NM_001031733 // C  CALML4  5.76E‐11  1.69E‐08  ‐1.28853  1.43E‐07  ‐1.32113 
3303870  NM_013274 // POLL // polymerase (DNA directed), lambda // 10q23 // 27343 /// ENS  POLL  5.98E‐11  1.85E‐07  1.19814  1.42E‐08  1.28023 
2577700  NM_032143 // ZRANB3 // zinc finger, RAN‐binding domain containing 3 // 2q21.3 //  ZRANB3  5.99E‐11  5.59E‐07  1.24086  5.66E‐09  1.38332 
2910352  AK091117 // LOC730101 // hypothetical LOC730101 // 6p12.1 // 730101 /// BC003416  LOC730101  6.06E‐11  6.40E‐08  1.57143  3.87E‐08  1.75248 
3579501  NM_001039355 // SLC25A29 // solute carrier family 25, member 29 // 14q32.2 // 12  SLC25A29  6.08E‐11  8.36E‐09  1.35014  3.55E‐07  1.35747 
3939545  NM_002415 // MIF // macrophage migration inhibitory factor (glycosylation‐inhibi  MIF  6.11E‐11  0.000876893 1.23071  7.64E‐11  1.84607 
2964231  NM_021244 // RRAGD // Ras‐related GTP binding D // 6q15‐q16 // 58528 /// ENST000  RRAGD  6.13E‐11  2.82E‐08  ‐1.59295  9.06E‐08  ‐1.70718 
3345427  NM_015036 // ENDOD1 // endonuclease domain containing 1 // 11q21 // 23052 /// EN  ENDOD1  6.18E‐11  6.88E‐06  ‐1.26882  9.91E‐10  ‐1.55696 
2588487  BC030713 // LOC401022 // hypothetical LOC401022 // 2q31.2 // 401022  LOC401022  6.19E‐11  0.000185751 ‐1.27897  1.58E‐10  ‐1.85393 
3548346  NM_006888 // CALM1 // calmodulin 1 (phosphorylase kinase, delta) // 14q24‐q31 //  CALM1  6.20E‐11  6.24E‐08  ‐1.27724  4.11E‐08  ‐1.35328 
2679917  NM_198859 // PRICKLE2 // prickle homolog 2 (Drosophila) // 3p14.1 // 166336 ///   PRICKLE2  6.25E‐11  2.79E‐08  ‐1.31361  9.44E‐08  ‐1.367 
3674249  NM_004413 // DPEP1 // dipeptidase 1 (renal) // 16q24.3 // 1800 /// NM_001128141   DPEP1  6.36E‐11  4.66E‐08  2.61399  5.71E‐08  3.17179 
3192117  NM_013318 // KIAA0515 // KIAA0515 // 9q34.13 // 84726 /// NR_002914 // SNORD62A   KIAA0515  6.40E‐11  9.60E‐08  1.24505  2.85E‐08  1.32474 
3250055  NM_004728 // DDX21 // DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 21 // 10q21 // 9188  DDX21  6.41E‐11  1.82E‐06  1.5052  2.55E‐09  1.96886 




2324884  NM_000491 // C1QB // complement component 1, q subcomponent, B chain // 1p36.12   C1QB  6.44E‐11  7.13E‐09  ‐1.71157  4.75E‐07  ‐1.70799 
4010860  NM_031206 // LAS1L // LAS1‐like (S. cerevisiae) // Xq12‐q13 // 81887 /// ENST000  LAS1L  6.47E‐11  0.000102022 1.13426  2.24E‐10  1.34674 
3231774  NM_012341 // GTPBP4 // GTP binding protein 4 // 10p15‐p14 // 23560 /// ENST00000  GTPBP4  6.50E‐11  4.84E‐06  1.29638  1.33E‐09  1.59529 
2845973  NM_024830 // LPCAT1 // lysophosphatidylcholine acyltransferase 1 // 5p15.33 // 7  LPCAT1  6.53E‐11  8.91E‐07  1.27347  4.44E‐09  1.45699 
3920003  NM_005441 // CHAF1B // chromatin assembly factor 1, subunit B (p60) // 21q22.13   CHAF1B  6.54E‐11  0.00229698  1.14388  5.52E‐11  1.55847 
2686458  NM_015429 // ABI3BP // ABI gene family, member 3 (NESH) binding protein // 3q12   ABI3BP  6.59E‐11  4.37E‐05  ‐1.57814  3.60E‐10  ‐2.706 
2715634  NM_176801 // ADD1 // adducin 1 (alpha) // 4p16.3 // 118 /// NM_014189 // ADD1 //  ADD1  6.63E‐11  0.00108599  ‐1.08295  7.64E‐11  ‐1.27161 
3185558  NM_004697 // PRPF4 // PRP4 pre‐mRNA processing factor 4 homolog (yeast) // 9q31‐  PRPF4  6.64E‐11  5.48E‐05  1.23775  3.21E‐10  1.60801 
3482888  NM_002097 // GTF3A // general transcription factor IIIA // 13q12.3‐q13.1 // 2971  GTF3A  6.65E‐11  3.77E‐07  1.43601  9.02E‐09  1.68651 
2792800  NM_017631 // DDX60 // DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 60 // 4q32.3 // 556  DDX60  6.74E‐11  5.53E‐07  ‐1.80139  6.74E‐09  ‐2.40591 
3403299  NM_000319 // PEX5 // peroxisomal biogenesis factor 5 // 12p13.31 // 5830 /// ENS  PEX5  6.84E‐11  1.58E‐06  1.25812  3.09E‐09  1.45406 
3163982  NM_001040272 // ADAMTSL1 // ADAMTS‐like 1 // 9p22.2‐p22.1 // 92949 /// NM_052866  ADAMTSL1  6.85E‐11  8.09E‐09  ‐1.48243  4.54E‐07  ‐1.4847 
2828757  NM_175873 // ANKRD43 // ankyrin repeat domain 43 // 5q31.1 // 134548 /// ENST000  ANKRD43  7.04E‐11  6.71E‐08  ‐1.31118  4.65E‐08  ‐1.39681 
3392871  NM_003904 // ZNF259 // zinc finger protein 259 // 11q23.3 // 8882 /// ENST000002  ZNF259  7.08E‐11  1.67E‐06  1.18303  3.10E‐09  1.31641 
3308619  NM_173791 // PDZD8 // PDZ domain containing 8 // 10q25.3‐q26.11 // 118987 /// EN  PDZD8  7.15E‐11  6.34E‐09  1.47302  6.61E‐07  1.45839 
2783493  NM_000134 // FABP2 // fatty acid binding protein 2, intestinal // 4q28‐q31 // 21  FABP2  7.31E‐11  3.56E‐09  ‐2.66621  1.47E‐06  ‐2.44332 
3663228  NM_001126129 // GINS3 // GINS complex subunit 3 (Psf3 homolog) // 16q21 // 64785  GINS3  7.35E‐11  0.572164  1.02493  1.16E‐11  1.63593 
3164601  NM_017794 // KIAA1797 // KIAA1797 // 9p21 // 54914 /// ENST00000380249 // KIAA17  KIAA1797  7.38E‐11  2.30E‐07  1.48685  1.59E‐08  1.7248 
2950329  NM_033554 // HLA‐DPA1 // major histocompatibility complex, class II, DP alpha 1   HLA‐DPA1  7.39E‐11  3.51E‐05  ‐1.50672  4.67E‐10  ‐2.39187 
3865715  NM_004819 // SYMPK // symplekin // 19q13.3 // 8189 /// ENST00000245934 // SYMPK   SYMPK  7.49E‐11  4.16E‐07  1.19001  9.85E‐09  1.28603 
3452743  NM_015401 // HDAC7 // histone deacetylase 7 // 12q13.1 // 51564 /// NM_001098416  HDAC7  7.70E‐11  9.91E‐09  1.25406  4.33E‐07  1.25839 
3874498  NM_020746 // VISA // virus‐induced signaling adapter // 20p13 // 57506 /// ENST0  VISA  7.78E‐11  3.91E‐09  ‐1.31904  1.45E‐06  ‐1.28833 
3049025  NM_004749 // TBRG4 // transforming growth factor beta regulator 4 // 7p14‐p13 //  TBRG4  7.83E‐11  0.117648  1.06326  1.76E‐11  1.53741 
3197231  NM_001039395 // C9orf68 // chromosome 9 open reading frame 68 // 9p24.2‐p24.1 //  C9orf68  7.93E‐11  3.01E‐10  1.8071  9.22E‐05  1.45546 
3913926  NM_005975 // PTK6 // PTK6 protein tyrosine kinase 6 // 20q13.3 // 5753 /// ENST0  PTK6  7.96E‐11  3.52E‐10  ‐1.36549  6.91E‐05  ‐1.22514 
3279915  NM_001004470 // ST8SIA6 // ST8 alpha‐N‐acetyl‐neuraminide alpha‐2,8‐sialyltransf  ST8SIA6  8.04E‐11  7.71E‐08  ‐1.52123  4.99E‐08  ‐1.6807 
4000839  NM_175859 // CTPS2 // CTP synthase II // Xp22 // 56474 /// NM_019857 // CTPS2 //  CTPS2  8.46E‐11  9.38E‐08  1.31984  4.46E‐08  1.41692 
3985490  NM_001080425 // BEX4 // BEX family member 4 // Xq22.1‐q22.3 // 56271 /// NM_0011  BEX4  8.54E‐11  3.73E‐06  ‐1.76022  2.26E‐09  ‐2.66592 
2704763  NM_153353 // LRRC34 // leucine rich repeat containing 34 // 3q26.2 // 151827 ///  LRRC34  8.64E‐11  7.91E‐08  1.51041  5.42E‐08  1.66366 
3457824  NM_003920 // TIMELESS // timeless homolog (Drosophila) // 12q12‐q13 // 8914 ///   TIMELESS  8.69E‐11  0.0626845  1.09073  2.35E‐11  1.65407 
3043264  NM_175061 // JAZF1 // JAZF zinc finger 1 // 7p15.2‐p15.1 // 221895 /// ENST00000  JAZF1  8.71E‐11  0.000136454 ‐1.167  2.75E‐10  ‐1.448 
3649811  NM_017668 // NDE1 // nudE nuclear distribution gene E homolog 1 (A. nidulans) //  NDE1  8.89E‐11  2.19E‐07  1.33698  2.19E‐08  1.4806 
3845296  NM_203304 // MEX3D // mex‐3 homolog D (C. elegans) // 19p13.3 // 399664 /// ENST  MEX3D  8.89E‐11  3.00E‐08  1.28727  1.55E‐07  1.3278 
2783207  NM_003619 // PRSS12 // protease, serine, 12 (neurotrypsin, motopsin) // 4q28.1 /  PRSS12  8.97E‐11  1.05E‐06  ‐1.48404  6.05E‐09  ‐1.84412 
2939892  NM_020408 // LYRM4 // LYR motif containing 4 // 6p25.1 // 57128 /// ENST00000330  LYRM4  9.04E‐11  1.03E‐07  1.46391  4.51E‐08  1.61674 
3821263  NM_001299 // CNN1 // calponin 1, basic, smooth muscle // 19p13.2‐p13.1 // 1264 /  CNN1  9.12E‐11  1.09E‐07  ‐1.64871  4.34E‐08  ‐1.88331 
3261544  NM_004193 // GBF1 // golgi‐specific brefeldin A resistance factor 1 // 10q24 //   GBF1  9.28E‐11  1.17E‐07  ‐1.19155  4.15E‐08  ‐1.25002 
3468743  NM_016575 // NT5DC3 // 5'‐nucleotidase domain containing 3 // 12q22‐q23.1 // 515  NT5DC3  9.29E‐11  1.03E‐10  1.81817  0.00130799  1.33564 
3970214  NM_004726 // REPS2 // RALBP1 associated Eps domain containing 2 // Xp22.2 // 918  REPS2  9.32E‐11  5.47E‐08  1.5181  8.84E‐08  1.64041 
2796790  NM_020827 // KIAA1430 // KIAA1430 // 4q35.1 // 57587 /// BC030535 // KIAA1430 //  KIAA1430  9.41E‐11  2.07E‐08  1.44632  2.56E‐07  1.48797 
3443348  NM_000014 // A2M // alpha‐2‐macroglobulin // 12p13.3‐p12.3 // 2 /// ENST00000404  A2M  9.42E‐11  0.00085229  ‐1.31179  1.26E‐10  ‐2.19097 




2471364  NM_001105569 // MSGN1 // mesogenin 1 // 2p24.2 // 343930 /// ENST00000281047 //   MSGN1  9.56E‐11  1.77E‐09  3.23428  6.69E‐06  2.59086 
3536706  NR_003225 // LGALS3 // lectin, galactoside‐binding, soluble, 3 // 14q21‐q22 // 3  LGALS3  9.63E‐11  1.24E‐07  ‐1.38881  4.15E‐08  ‐1.52097 
3351300  NM_000073 // CD3G // CD3g molecule, gamma (CD3‐TCR complex) // 11q23 // 917 ///   CD3G  9.70E‐11  0.0116957  ‐1.23559  4.58E‐11  ‐2.37921 
2447124  NM_021133 // RNASEL // ribonuclease L (2',5'‐oligoisoadenylate synthetase‐depend  RNASEL  9.74E‐11  4.64E‐07  ‐1.43935  1.31E‐08  ‐1.68707 
2738378  NM_001033047 // NPNT // nephronectin // 4q24 // 255743 /// ENST00000379987 // NP  NPNT  1.01E‐10  2.71E‐08  1.45223  2.11E‐07  1.50787 
2677853  NM_017563 // IL17RD // interleukin 17 receptor D // 3p14.3 // 54756 /// ENST0000  IL17RD  1.01E‐10  7.95E‐08  1.5493  6.86E‐08  1.70677 
3504226  NM_015974 // CRYL1 // crystallin, lambda 1 // 13q12.11 // 51084 /// ENST00000298  CRYL1  1.01E‐10  1.06E‐10  ‐1.66682  0.00153839  ‐1.27569 
3747236  NM_001113567 // C17orf76 // chromosome 17 open reading frame 76 // 17p11.2 // 38  C17orf76  1.02E‐10  3.69E‐08  ‐1.33108  1.55E‐07  ‐1.38273 
4004853  NM_006307 // SRPX // sushi‐repeat‐containing protein, X‐linked // Xp21.1 // 8406  SRPX  1.02E‐10  2.45E‐09  ‐1.69811  4.70E‐06  ‐1.55969 
3181600  NM_024642 // GALNT12 // UDP‐N‐acetyl‐alpha‐D‐galactosamine:polypeptide N‐acetylg  GALNT12  1.03E‐10  9.84E‐07  ‐1.45088  7.74E‐09  ‐1.76622 
3319119  NM_198474 // OLFML1 // olfactomedin‐like 1 // 11p15.4 // 283298 /// ENST00000329  OLFML1  1.05E‐10  1.47E‐06  ‐1.57557  5.84E‐09  ‐2.05189 
3003193  NM_001762 // CCT6A // chaperonin containing TCP1, subunit 6A (zeta 1) // 7p11.2   CCT6A  1.06E‐10  2.59E‐06  1.40092  3.87E‐09  1.75022 
2613441  NM_003884 // KAT2B // K(lysine) acetyltransferase 2B // 3p24 // 8850 /// ENST000  KAT2B  1.06E‐10  0.000103946 ‐1.32029  4.00E‐10  ‐1.90186 
3175971  NM_058179 // PSAT1 // phosphoserine aminotransferase 1 // 9q21.2 // 29968 /// NM  PSAT1  1.06E‐10  0.000622496 1.64946  1.66E‐10  4.01335 
2363202  NM_021181 // SLAMF7 // SLAM family member 7 // 1q23.1‐q24.1 // 57823 /// ENST000  SLAMF7  1.06E‐10  3.58E‐07  ‐1.77102  1.84E‐08  ‐2.22067 
2427619  NM_002232 // KCNA3 // potassium voltage‐gated channel, shaker‐related subfamily,  KCNA3  1.07E‐10  4.17E‐07  ‐1.89101  1.63E‐08  ‐2.46287 
3190822  NM_015354 // NUP188 // nucleoporin 188kDa // 9q34.11 // 23511 /// ENST0000037257  NUP188  1.08E‐10  0.000716272 1.18185  1.59E‐10  1.60135 
3102096  NM_024870 // DEPDC2 // DEP domain containing 2 // 8q13.2 // 80243 /// NM_025170   DEPDC2  1.08E‐10  1.76E‐07  ‐1.39143  3.57E‐08  ‐1.54023 
2322036  NM_017556 // FBLIM1 // filamin binding LIM protein 1 // 1p36.21 // 54751 /// NM_  FBLIM1  1.09E‐10  3.32E‐08  ‐1.31081  1.94E‐07  ‐1.35242 
3072368  NM_016478 // ZC3HC1 // zinc finger, C3HC‐type containing 1 // 7q32.2 // 51530 //  ZC3HC1  1.11E‐10  0.00240649  1.08487  9.72E‐11  1.30288 
3031650  NM_001091 // ABP1 // amiloride binding protein 1 (amine oxidase (copper‐containi  ABP1  1.12E‐10  4.77E‐07  ‐1.46718  1.56E‐08  ‐1.72813 
3300597  NM_013451 // FER1L3 // fer‐1‐like 3, myoferlin (C. elegans) // 10q24 // 26509 //  FER1L3  1.13E‐10  2.15E‐10  2.13841  0.000420114 1.5237 
3850040  NM_003755 // EIF3G // eukaryotic translation initiation factor 3, subunit G // 1  EIF3G  1.14E‐10  3.85E‐07  1.25431  1.92E‐08  1.37283 
3822122  NM_002501 // NFIX // nuclear factor I/X (CCAAT‐binding transcription factor) //   NFIX  1.15E‐10  6.00E‐09  1.29444  1.65E‐06  1.26971 
2651711  NM_001080460 // LRRIQ4 // leucine‐rich repeats and IQ motif containing 4 // 3q26  LRRIQ4  1.15E‐10  2.70E‐06  1.3802  4.20E‐09  1.70654 
3372097  NM_001610 // ACP2 // acid phosphatase 2, lysosomal // 11p11.2‐p11.11|11p12‐p11 /  ACP2  1.15E‐10  2.19E‐08  ‐1.30491  3.35E‐07  ‐1.32776 
3333899  NM_004585 // RARRES3 // retinoic acid receptor responder (tazarotene induced) 3   RARRES3  1.15E‐10  0.0146815  ‐1.27434  5.08E‐11  ‐2.78705 
3402506  NM_001242 // CD27 // CD27 molecule // 12p13 // 939 /// ENST00000266557 // CD27 /  CD27  1.16E‐10  2.60E‐06  ‐1.48816  4.35E‐09  ‐1.92895 
3102372  NM_001128205 // SULF1 // sulfatase 1 // 8q13.2‐q13.3 // 23213 /// NM_015170 // S  SULF1  1.16E‐10  8.83E‐11  1.7134  0.0034332  1.26264 
2772167  NR_024010 // UGT2A3 // UDP glucuronosyltransferase 2 family, polypeptide A3 // 4  UGT2A3  1.17E‐10  1.52E‐07  ‐3.27454  4.59E‐08  ‐4.58248 
2491661  NM_003761 // VAMP8 // vesicle‐associated membrane protein 8 (endobrevin) // 2p12  VAMP8  1.18E‐10  3.08E‐07  ‐1.36476  2.44E‐08  ‐1.53028 
3136229  NM_138969 // RDHE2 // epidermal retinal dehydrogenase 2 // 8q12.1 // 195814 ///   RDHE2  1.19E‐10  2.35E‐09  2.16415  6.62E‐06  1.88503 
3774635  NM_004104 // FASN // fatty acid synthase // 17q25 // 2194 /// ENST00000306749 //  FASN  1.19E‐10  1.11E‐05  1.30862  1.70E‐09  1.65511 
2688955  NM_138806 // CD200R1 // CD200 receptor 1 // 3q13.2 // 131450 /// NM_170780 // CD  CD200R1  1.20E‐10  0.00015261  ‐1.26087  3.77E‐10  ‐1.73954 
2508611  NM_018460 // ARHGAP15 // Rho GTPase activating protein 15 // 2q22.2 // 55843 ///  ARHGAP15  1.20E‐10  0.000182698 ‐1.46204  3.45E‐10  ‐2.51761 
2427898  NM_002557 // OVGP1 // oviductal glycoprotein 1, 120kDa // 1p13 // 5016 /// ENST0  OVGP1  1.20E‐10  2.09E‐08  1.3812  3.79E‐07  1.40658 
2384401  NM_021205 // RHOU // ras homolog gene family, member U // 1q42.11‐q42.3 // 58480  RHOU  1.21E‐10  4.86E‐07  ‐1.29787  1.71E‐08  ‐1.44902 
2745547  NM_207123 // GAB1 // GRB2‐associated binding protein 1 // 4q31.21 // 2549 /// NM  GAB1  1.24E‐10  8.29E‐06  ‐1.32343  2.15E‐09  ‐1.66634 
2950561  NM_005452 // WDR46 // WD repeat domain 46 // 6p21.3 // 9277 /// ENST00000383074   WDR46  1.25E‐10  2.48E‐05  1.17579  1.09E‐09  1.38457 
3237282  NM_001098844 // FAM23A // family with sequence similarity 23, member A // 10p12.  FAM23A  1.25E‐10  3.23E‐05  ‐2.6037  9.33E‐10  ‐7.16439 
2336706  NM_000098 // CPT2 // carnitine palmitoyltransferase II // 1p32 // 1376 /// ENST0  CPT2  1.25E‐10  2.78E‐10  ‐1.46525  0.00031212  ‐1.24522 




3373724  NM_003146 // SSRP1 // structure specific recognition protein 1 // 11q12 // 6749   SSRP1  1.26E‐10  1.14E‐05  1.24429  1.79E‐09  1.50553 
2891341  NM_002460 // IRF4 // interferon regulatory factor 4 // 6p25‐p23 // 3662 /// ENST  IRF4  1.28E‐10  1.70E‐08  ‐1.78415  5.39E‐07  ‐1.81321 
3001479  NM_006060 // IKZF1 // IKAROS family zinc finger 1 (Ikaros) // 7p13‐p11.1 // 1032  IKZF1  1.29E‐10  0.000120276 ‐1.29127  4.68E‐10  ‐1.81177 
2410522  NM_017739 // POMGNT1 // protein O‐linked mannose beta1,2‐N‐acetylglucosaminyltra  POMGNT1  1.32E‐10  1.38E‐06  1.19497  8.31E‐09  1.31848 
3302495  NM_021732 // AVPI1 // arginine vasopressin‐induced 1 // 10q24.2 // 60370 /// ENS  AVPI1  1.33E‐10  1.48E‐09  ‐1.59052  1.71E‐05  ‐1.42247 
3764199  NM_017777 // MKS1 // Meckel syndrome, type 1 // 17q22 // 54903 /// ENST000003931  MKS1  1.34E‐10  8.31E‐07  1.18334  1.27E‐08  1.28348 
3736259  NM_001010982 // AFMID // arylformamidase // 17q25.3 // 125061 /// ENST0000032789  AFMID  1.34E‐10  3.26E‐07  1.2177  2.81E‐08  1.30801 
2935475  NM_206855 // QKI // quaking homolog, KH domain RNA binding (mouse) // 6q26|6q26‐  QKI  1.35E‐10  1.74E‐06  ‐1.46554  7.25E‐09  ‐1.82985 
3048413  NM_001127218 // POLD2 // polymerase (DNA directed), delta 2, regulatory subunit   POLD2  1.37E‐10  0.000200817 1.18351  3.85E‐10  1.50817 
3355956  NM_003658 // BARX2 // BARX homeobox 2 // 11q25 // 8538 /// ENST00000281437 // BA  BARX2  1.38E‐10  1.03E‐07  ‐1.43351  8.60E‐08  ‐1.55337 
3845944  NM_052847 // GNG7 // guanine nucleotide binding protein (G protein), gamma 7 //   GNG7  1.38E‐10  2.21E‐08  ‐1.50277  4.50E‐07  ‐1.53348 
3873629  NM_001040022 // SIRPA // signal‐regulatory protein alpha // 20p13 // 140885 ///   SIRPA  1.38E‐10  1.80E‐06  ‐1.39042  7.24E‐09  ‐1.68561 
3837866  NM_004605 // SULT2B1 // sulfotransferase family, cytosolic, 2B, member 1 // 19q1  SULT2B1  1.41E‐10  0.000221057 1.36418  3.77E‐10  2.14666 
3079103  NM_024711 // GIMAP6 // GTPase, IMAP family member 6 // ‐‐‐ // 474344 /// NM_0010  GIMAP6  1.43E‐10  3.18E‐05  ‐1.33494  1.11E‐09  ‐1.80313 
3646542  NM_019109 // ALG1 // asparagine‐linked glycosylation 1 homolog (S. cerevisiae, b  ALG1  1.46E‐10  5.74E‐06  1.19168  3.39E‐09  1.35891 
3288518  NM_001031746 // C10orf72 // chromosome 10 open reading frame 72 // 10q11.22 // 1  C10orf72  1.48E‐10  3.26E‐07  ‐1.44165  3.24E‐08  ‐1.64123 
3159040  NM_000973 // RPL8 // ribosomal protein L8 // 8q24.3 // 6132 /// NM_033301 // RPL  RPL8  1.49E‐10  0.000275078 1.17143  3.61E‐10  1.48733 
3555675  NM_198232 // RNASE1 // ribonuclease, RNase A family, 1 (pancreatic) // 14q11.2 /  RNASE1  1.53E‐10  1.61E‐09  ‐1.74084  1.97E‐05  ‐1.51978 
2384705  AK291013 // KIAA0133 // KIAA0133 // 1q42.13 // 9816 /// BC114559 // KIAA0133 //   KIAA0133  1.53E‐10  0.0001034  1.22067  6.21E‐10  1.57331 
3672059  NM_014732 // KIAA0513 // KIAA0513 // 16q24.1 // 9764 /// ENST00000258180 // KIAA  KIAA0513  1.54E‐10  2.94E‐08  ‐1.2705  3.90E‐07  ‐1.29233 
3261492  NM_004741 // NOLC1 // nucleolar and coiled‐body phosphoprotein 1 // 10q24.32 //   NOLC1  1.57E‐10  2.71E‐05  1.40318  1.38E‐09  1.97006 
3350908  NM_014956 // CEP164 // centrosomal protein 164kDa // 11q23.3 // 22897 /// ENST00  CEP164  1.58E‐10  3.27E‐09  1.19807  7.02E‐06  1.16173 
3394488  NM_002855 // PVRL1 // poliovirus receptor‐related 1 (herpesvirus entry mediator   PVRL1  1.60E‐10  0.000109923 1.22456  6.33E‐10  1.58758 
3217167  NM_003389 // CORO2A // coronin, actin binding protein, 2A // 9q22.3 // 7464 ///   CORO2A  1.62E‐10  3.75E‐10  ‐1.60113  0.000311219 ‐1.31454 
3715489  NM_014573 // TMEM97 // transmembrane protein 97 // 17q11.2 // 27346 /// ENST0000  TMEM97  1.62E‐10  0.000761523 1.22539  2.45E‐10  1.76213 
2599869  NM_144712 // SLC23A3 // solute carrier family 23 (nucleobase transporters), memb  SLC23A3  1.63E‐10  6.70E‐10  ‐2.14741  0.000102681 ‐1.64259 
2669533  NM_001607 // ACAA1 // acetyl‐Coenzyme A acyltransferase 1 // 3p23‐p22 // 30 ///   ACAA1  1.64E‐10  1.01E‐09  ‐1.37333  5.00E‐05  ‐1.24694 
3331730  NM_053023 // ZFP91 // zinc finger protein 91 homolog (mouse) // 11q12 // 80829 /  ZFP91  1.68E‐10  1.80E‐08  ‐1.24544  7.99E‐07  ‐1.24802 
3837001  NM_004491 // GRLF1 // glucocorticoid receptor DNA binding factor 1 // 19q13.3 //  GRLF1  1.68E‐10  2.35E‐06  ‐1.20473  7.72E‐09  ‐1.34809 
3960440  NM_012264 // TMEM184B // transmembrane protein 184B // 22q12 // 25829 /// ENST00  TMEM184B  1.69E‐10  2.70E‐07  1.2968  4.66E‐08  1.40909 
3756546  NM_000223 // KRT12 // keratin 12 // 17q12 // 3859 /// ENST00000251643 // KRT12 /  KRT12  1.71E‐10  1.63E‐10  ‐1.773  0.0021738  ‐1.30659 
2401849  BC063891 // C1orf201 // chromosome 1 open reading frame 201 // 1p36.11 // 90529   C1orf201  1.71E‐10  2.14E‐08  ‐1.59613  6.72E‐07  ‐1.6161 
3018375  NM_002736 // PRKAR2B // protein kinase, cAMP‐dependent, regulatory, type II, bet  PRKAR2B  1.71E‐10  2.58E‐07  ‐1.77009  4.97E‐08  ‐2.11591 
3338293  NM_018043 // ANO1 // anoctamin 1, calcium activated chloride channel // 11q13.3   ANO1  1.72E‐10  5.57E‐08  1.42617  2.30E‐07  1.49503 
3846538  NM_001961 // EEF2 // eukaryotic translation elongation factor 2 // 19pter‐q12 //  EEF2  1.73E‐10  3.31E‐06  1.24969  6.25E‐09  1.44448 
2354082  NM_006784 // WDR3 // WD repeat domain 3 // 1p13‐p12 // 10885 /// ENST00000349139  WDR3  1.74E‐10  3.34E‐07  1.46226  4.01E‐08  1.66587 
2877028  NM_017415 // KLHL3 // kelch‐like 3 (Drosophila) // 5q31 // 26249 /// ENST0000030  KLHL3  1.75E‐10  1.70E‐08  1.42234  9.21E‐07  1.422 
3838118  NM_006666 // RUVBL2 // RuvB‐like 2 (E. coli) // 19q13.3 // 10856 /// ENST0000022  RUVBL2  1.76E‐10  0.00262127  1.14014  1.56E‐10  1.52571 
3512449  NM_012345 // NUFIP1 // nuclear fragile X mental retardation protein interacting   NUFIP1  1.76E‐10  5.35E‐06  1.31241  4.54E‐09  1.59619 
3778772  NM_153000 // APCDD1 // adenomatosis polyposis coli down‐regulated 1 // 18p11.22   APCDD1  1.78E‐10  1.90E‐06  1.76006  9.83E‐09  2.42667 
2501835  NM_020868 // DPP10 // dipeptidyl‐peptidase 10 // 2q14.1 // 57628 /// NM_00100436  DPP10  1.80E‐10  9.10E‐07  ‐2.0955  1.78E‐08  ‐2.96139 




2511820  NM_003628 // PKP4 // plakophilin 4 // 2q23‐q31 // 8502 /// NM_001005476 // PKP4   PKP4  1.82E‐10  1.13E‐08  1.51786  1.64E‐06  1.48732 
3000984  NM_152701 // ABCA13 // ATP‐binding cassette, sub‐family A (ABC1), member 13 // 7  ABCA13  1.84E‐10  2.28E‐09  1.45603  1.65E‐05  1.33793 
3389077  NM_025208 // PDGFD // platelet derived growth factor D // 11q22.3 // 80310 /// N  PDGFD  1.86E‐10  3.76E‐07  ‐1.47647  3.97E‐08  ‐1.6934 
3204692  NM_032818 // C9orf100 // chromosome 9 open reading frame 100 // 9p13.3 // 84904   C9orf100  1.86E‐10  0.0425766  1.09193  5.86E‐11  1.56893 
3877892  NM_002594 // PCSK2 // proprotein convertase subtilisin/kexin type 2 // 20p11.2 /  PCSK2  1.86E‐10  6.29E‐09  ‐1.48323  3.75E‐06  ‐1.41759 
2713095  NM_025163 // PIGZ // phosphatidylinositol glycan anchor biosynthesis, class Z //  PIGZ  1.88E‐10  1.71E‐07  ‐1.37814  8.40E‐08  ‐1.49547 
3726211  NM_002611 // PDK2 // pyruvate dehydrogenase kinase, isozyme 2 // 17q21.33 // 516  PDK2  1.89E‐10  1.27E‐06  ‐1.34713  1.45E‐08  ‐1.56719 
3774593  NM_022156 // DUS1L // dihydrouridine synthase 1‐like (S. cerevisiae) // 17q25.3   DUS1L  1.90E‐10  0.00272776  1.10526  1.67E‐10  1.38124 
3831620  NM_198539 // ZNF568 // zinc finger protein 568 // 19q13.12 // 374900 /// ENST000  ZNF568  1.90E‐10  5.93E‐07  ‐1.51302  2.77E‐08  ‐1.79054 
2530713  NM_004591 // CCL20 // chemokine (C‐C motif) ligand 20 // 2q33‐q37 // 6364 /// EN  CCL20  1.91E‐10  7.60E‐06  1.94848  3.96E‐09  3.25005 
3852034  NM_017722 // TRMT1 // TRM1 tRNA methyltransferase 1 homolog (S. cerevisiae) // 1  TRMT1  1.92E‐10  2.23E‐05  1.22942  1.98E‐09  1.495 
2706938  NM_021629 // GNB4 // guanine nucleotide binding protein (G protein), beta polype  GNB4  1.93E‐10  2.94E‐07  ‐1.4055  5.26E‐08  ‐1.56605 
2593159  NM_004226 // STK17B // serine/threonine kinase 17b // 2q32.3 // 9262 /// ENST000  STK17B  1.94E‐10  2.17E‐06  ‐1.58949  1.00E‐08  ‐2.07806 
2925237  NM_000426 // LAMA2 // laminin, alpha 2 // 6q22‐q23 // 3908 /// NM_001079823 // L  LAMA2  1.95E‐10  8.92E‐08  ‐1.51159  1.70E‐07  ‐1.62527 
2477598  NM_144713 // FAM82A1 // family with sequence similarity 82, member A1 // 2p22.2   FAM82A1  1.96E‐10  7.70E‐08  ‐1.62662  2.00E‐07  ‐1.75653 
2545478  NM_006569 // CGREF1 // cell growth regulator with EF‐hand domain 1 // 2p23.3 //   CGREF1  1.97E‐10  2.12E‐07  1.57137  7.33E‐08  1.78052 
3008376  NM_032999 // GTF2I // general transcription factor II, i // 7q11.23 // 2969 ///   GTF2I  1.97E‐10  1.28E‐09  1.39662  4.93E‐05  1.2647 
3434413  NM_014868 // RNF10 // ring finger protein 10 // 12q24.31 // 9921 /// ENST0000032  RNF10  1.99E‐10  2.63E‐08  ‐1.20433  6.74E‐07  ‐1.21244 
2402942  NM_003047 // SLC9A1 // solute carrier family 9 (sodium/hydrogen exchanger), memb  SLC9A1  2.01E‐10  4.93E‐08  ‐1.45948  3.37E‐07  ‐1.51856 
3902764  NM_080616 // C20orf112 // chromosome 20 open reading frame 112 // 20q11.1‐q11.23  C20orf112  2.02E‐10  4.55E‐07  ‐1.20501  3.79E‐08  ‐1.29056 
3108226  NM_016134 // PGCP // plasma glutamate carboxypeptidase // 8q22.2 // 10404 /// EN  PGCP  2.02E‐10  9.75E‐07  ‐1.40028  1.98E‐08  ‐1.63814 
3150455  NM_002546 // TNFRSF11B // tumor necrosis factor receptor superfamily, member 11b  TNFRSF11B  2.03E‐10  1.78E‐07  1.66432  9.06E‐08  1.89304 
3333169  NM_001127392 // C11orf9 // chromosome 11 open reading frame 9 // 11q12‐q13.1 //   C11orf9  2.04E‐10  7.15E‐09  1.42097  3.73E‐06  1.36723 
2848265  NM_138809 // CMBL // carboxymethylenebutenolidase homolog (Pseudomonas) // 5p15.  CMBL  2.05E‐10  2.08E‐07  ‐1.80103  7.93E‐08  ‐2.11172 
3731142  NM_001085423 // C17orf60 // chromosome 17 open reading frame 60 // 17q23.3 // 28  C17orf60  2.05E‐10  1.19E‐06  ‐1.24302  1.73E‐08  ‐1.38308 
3227159  NM_015033 // FNBP1 // formin binding protein 1 // 9q34 // 23048 /// ENST00000372  FNBP1  2.06E‐10  3.86E‐06  ‐1.3988  7.04E‐09  ‐1.74342 
3757970  NM_013290 // PSMC3IP // PSMC3 interacting protein // 17q12‐q21 // 29893 /// NM_0  PSMC3IP  2.08E‐10  0.151765  1.0697  4.49E‐11  1.64803 
2403793  NM_001024732 // MECR // mitochondrial trans‐2‐enoyl‐CoA reductase // 1p36.1‐p35.  MECR  2.13E‐10  3.38E‐05  1.17905  1.75E‐09  1.39289 
2464005  NM_181690 // AKT3 // v‐akt murine thymoma viral oncogene homolog 3 (protein kina  AKT3  2.15E‐10  1.14E‐05  ‐1.58609  3.51E‐09  ‐2.31621 
3987996  NM_005032 // PLS3 // plastin 3 (T isoform) // Xq23 // 5358 /// ENST00000289290 /  PLS3  2.16E‐10  1.58E‐08  1.88305  1.45E‐06  1.84996 
2466039  NM_017865 // ZNF692 // zinc finger protein 692 // 1q44 // 55657 /// ENST00000306  ZNF692  2.19E‐10  2.79E‐07  1.26013  6.65E‐08  1.35063 
2881187  NM_005211 // CSF1R // colony stimulating factor 1 receptor // 5q33‐q35 // 1436 /  CSF1R  2.20E‐10  2.42E‐07  ‐1.50321  7.62E‐08  ‐1.68674 
3243708  NM_014753 // BMS1 // BMS1 homolog, ribosome assembly protein (yeast) // 10q11.21  BMS1  2.21E‐10  1.78E‐08  1.36721  1.30E‐06  1.36002 
3272205  NM_005539 // INPP5A // inositol polyphosphate‐5‐phosphatase, 40kDa // 10q26.3 //  INPP5A  2.24E‐10  2.58E‐09  ‐1.25783  2.00E‐05  ‐1.19296 
3204463  NM_004629 // FANCG // Fanconi anemia, complementation group G // 9p13 // 2189 //  FANCG  2.24E‐10  0.0377917  1.07727  7.42E‐11  1.44539 
3125571  NM_002445 // MSR1 // macrophage scavenger receptor 1 // 8p22 // 4481 /// NM_1387  MSR1  2.25E‐10  9.40E‐08  ‐1.65704  2.02E‐07  ‐1.80436 
2633460  BC006512 // C3orf26 // chromosome 3 open reading frame 26 // 3q12.1 // 84319 ///  C3orf26  2.28E‐10  2.57E‐06  1.26818  1.09E‐08  1.45809 
3687803  NM_012248 // SEPHS2 // selenophosphate synthetase 2 // 16p11.2 // 22928 /// ENST  SEPHS2  2.29E‐10  1.52E‐09  ‐1.28821  4.99E‐05  ‐1.1962 
3374606  NM_001039396 // MPEG1 // macrophage expressed gene 1 // 11q12.1 // 219972 /// EN  MPEG1  2.29E‐10  2.43E‐06  ‐1.7636  1.15E‐08  ‐2.4498 
3408505  NM_006152 // LRMP // lymphoid‐restricted membrane protein // 12p12.1 // 4033 ///  LRMP  2.30E‐10  4.91E‐07  ‐1.59659  4.29E‐08  ‐1.89426 
3824963  NM_017712 // PGPEP1 // pyroglutamyl‐peptidase I // 19p13.11 // 54858 /// ENST000  PGPEP1  2.33E‐10  4.76E‐08  ‐1.25926  4.46E‐07  ‐1.28494 




3761441  NM_024016 // HOXB8 // homeobox B8 // 17q21.3 // 3218 /// ENST00000239144 // HOXB HOXB8  2.34E‐10  2.67E‐06  1.58422  1.10E‐08  2.07892 
3703885  NM_003486 // SLC7A5 // solute carrier family 7 (cationic amino acid transporter,  SLC7A5  2.36E‐10  0.000407404 1.46557  5.09E‐10  2.66004 
3548152  NM_018319 // TDP1 // tyrosyl‐DNA phosphodiesterase 1 // 14q32.11 // 55775 /// NM  TDP1  2.36E‐10  5.20E‐06  1.22589  6.83E‐09  1.41021 
2632225  NM_005233 // EPHA3 // EPH receptor A3 // 3p11.2 // 2042 /// NM_182644 // EPHA3 /  EPHA3  2.37E‐10  0.0529195  ‐1.14087  7.06E‐11  ‐2.02141 
3755976  NM_014815 // MED24 // mediator complex subunit 24 // 17q21.1 // 9862 /// NM_0010  MED24  2.38E‐10  0.00257539  1.07898  2.20E‐10  1.27273 
2615808  NM_015141 // GPD1L // glycerol‐3‐phosphate dehydrogenase 1‐like // 3p22.3 // 231  GPD1L  2.41E‐10  2.67E‐09  ‐1.55227  2.20E‐05  ‐1.40019 
3456049  NM_000889 // ITGB7 // integrin, beta 7 // 12q13.13 // 3695 /// ENST00000267082 /  ITGB7  2.43E‐10  4.15E‐06  ‐1.32594  8.34E‐09  ‐1.59327 
2855614  BC036867 // C5orf34 // chromosome 5 open reading frame 34 // 5p12 // 375444 ///   C5orf34  2.43E‐10  0.0153848  1.12227  1.11E‐10  1.61159 
3638566  NM_003847 // PEX11A // peroxisomal biogenesis factor 11 alpha // 15q26.1 // 8800  PEX11A  2.44E‐10  6.08E‐10  ‐1.37328  0.000306533 ‐1.20693 
2882897  NM_015465 // GEMIN5 // gem (nuclear organelle) associated protein 5 // 5q33.2 //  GEMIN5  2.46E‐10  5.51E‐07  1.35839  4.27E‐08  1.52323 
2610241  NM_033084 // FANCD2 // Fanconi anemia, complementation group D2 // 3p26 // 2177   FANCD2  2.47E‐10  0.00253891  1.1381  2.31E‐10  1.50528 
3771642  NM_134268 // CYGB // cytoglobin // 17q25.3 // 114757 /// ENST00000293230 // CYGB  CYGB  2.48E‐10  3.71E‐09  ‐1.66143  1.38E‐05  ‐1.50077 
3621194  NM_005657 // TP53BP1 // tumor protein p53 binding protein 1 // 15q15‐q21 // 7158  TP53BP1  2.49E‐10  1.31E‐09  1.39534  7.73E‐05  1.25476 
2413203  NM_004631 // LRP8 // low density lipoprotein receptor‐related protein 8, apolipo  LRP8  2.51E‐10  2.10E‐06  1.52337  1.45E‐08  1.92038 
2896958  NM_016255 // FAM8A1 // family with sequence similarity 8, member A1 // 6p22‐p23   FAM8A1  2.53E‐10  5.37E‐05  ‐1.15737  1.64E‐09  ‐1.35586 
3404567  NM_207345 // CLEC9A // C‐type lectin domain family 9, member A // 12p13.2 // 283  CLEC9A  2.54E‐10  4.39E‐07  ‐1.36723  5.46E‐08  ‐1.52181 
3581386  NM_017955 // CDCA4 // cell division cycle associated 4 // 14q32.33 // 55038 ///   CDCA4  2.58E‐10  0.0255613  1.1086  9.85E‐11  1.59614 
2955691  NM_005822 // RCAN2 // regulator of calcineurin 2 // 6p12.3 // 10231 /// ENST0000  RCAN2  2.60E‐10  6.23E‐07  ‐1.49093  4.13E‐08  ‐1.73856 
3332276  NM_000139 // MS4A2 // membrane‐spanning 4‐domains, subfamily A, member 2 (Fc fra  MS4A2  2.63E‐10  8.80E‐05  ‐1.27329  1.30E‐09  ‐1.69326 
3261447  NM_015062 // PPRC1 // peroxisome proliferator‐activated receptor gamma, coactiva  PPRC1  2.64E‐10  0.000138747 1.18211  1.01E‐09  1.46428 
3443891  NM_005127 // CLEC2B // C‐type lectin domain family 2, member B // 12p13‐p12 // 9  CLEC2B  2.65E‐10  1.55E‐05  ‐1.40199  3.77E‐09  ‐1.86912 
3861738  NM_017827 // SARS2 // seryl‐tRNA synthetase 2, mitochondrial // 19q13.2 // 54938  SARS2  2.66E‐10  0.000438906 1.14306  5.61E‐10  1.40934 
3815328  NM_024100 // WDR18 // WD repeat domain 18 // 19p13.3 // 57418 /// ENST0000025128  WDR18  2.66E‐10  0.130547  1.05499  6.04E‐11  1.45003 
3442706  NM_004244 // CD163 // CD163 molecule // 12p13.3 // 9332 /// NM_203416 // CD163 /  CD163  2.66E‐10  1.26E‐08  ‐1.79715  2.79E‐06  ‐1.7229 
3703665  NM_015144 // ZCCHC14 // zinc finger, CCHC domain containing 14 // 16q24.2 // 231  ZCCHC14  2.70E‐10  1.39E‐06  ‐1.16993  2.22E‐08  ‐1.26285 
3416577  NM_005337 // NCKAP1L // NCK‐associated protein 1‐like // 12q13.1 // 3071 /// ENS  NCKAP1L  2.71E‐10  3.61E‐06  ‐1.53042  1.07E‐08  ‐1.99277 
3850576  NM_024029 // YIPF2 // Yip1 domain family, member 2 // 19p13.2 // 78992 /// ENST0  YIPF2  2.76E‐10  0.00066292  1.11656  4.79E‐10  1.3438 
2332144  NM_001905 // CTPS // CTP synthase // 1p34.1 // 1503 /// ENST00000372621 // CTPS   CTPS  2.77E‐10  0.000444485 1.34403  5.86E‐10  2.13465 
3601229  NM_001024736 // CD276 // CD276 molecule // 15q23‐q24 // 80381 /// NM_025240 // C  CD276  2.78E‐10  8.64E‐07  1.23572  3.44E‐08  1.35082 
3223967  NR_003191 // GGTA1 // glycoprotein, alpha‐galactosyltransferase 1 // 9q33.2‐q34.  GGTA1  2.79E‐10  8.54E‐07  ‐1.82263  3.50E‐08  ‐2.34361 
3046020  NM_001100425 // KIAA0895 // KIAA0895 protein // 7p14.2 // 23366 /// NM_015314 //  KIAA0895  2.80E‐10  4.65E‐07  1.29318  5.99E‐08  1.41155 
3628498  NM_001218 // CA12 // carbonic anhydrase XII // 15q22 // 771 /// NM_206925 // CA1  CA12  2.81E‐10  5.93E‐07  ‐1.65171  4.83E‐08  ‐1.99004 
3459956  NM_152440 // C12orf66 // chromosome 12 open reading frame 66 // 12q14.2 // 14457  C12orf66  2.82E‐10  4.01E‐06  1.25727  1.04E‐08  1.453 
2532894  NM_152879 // DGKD // diacylglycerol kinase, delta 130kDa // 2q37.1 // 8527 /// N  DGKD  2.83E‐10  2.63E‐07  ‐1.16173  1.03E‐07  ‐1.20965 
3349453  NM_017868 // TTC12 // tetratricopeptide repeat domain 12 // 11q23.1 // 54970 ///  TTC12  2.90E‐10  6.38E‐08  1.23423  4.59E‐07  1.26072 
3538555  NM_021003 // PPM1A // protein phosphatase 1A (formerly 2C), magnesium‐dependent,  PPM1A  2.91E‐10  7.26E‐07  ‐1.33373  4.26E‐08  ‐1.49395 
3652424  NM_013302 // EEF2K // eukaryotic elongation factor‐2 kinase // 16p12.1 // 29904   EEF2K  2.92E‐10  6.85E‐07  ‐1.21321  4.50E‐08  ‐1.30725 
3742627  AY358809 // C17orf87 // chromosome 17 open reading frame 87 // 17p13.2 // 388325  C17orf87  2.92E‐10  2.63E‐05  ‐1.52122  3.02E‐09  ‐2.25116 
3378433  NM_006946 // SPTBN2 // spectrin, beta, non‐erythrocytic 2 // 11q13 // 6712 /// E  SPTBN2  2.92E‐10  2.51E‐07  1.38359  1.13E‐07  1.50593 
3342426  ENST00000329143 // C11orf82 // chromosome 11 open reading frame 82 // 11q14.1 //  C11orf82  2.97E‐10  0.00435394  1.22189  2.25E‐10  1.96554 
2953408  NM_173561 // UNC5CL // unc‐5 homolog C (C. elegans)‐like // 6p21.1 // 222643 ///  UNC5CL  2.99E‐10  1.49E‐07  1.68391  1.95E‐07  1.86573 




3590460  NM_002220 // ITPKA // inositol 1,4,5‐trisphosphate 3‐kinase A // 15q14‐q21 // 37  ITPKA  3.01E‐10  3.93E‐09  ‐1.49763  1.86E‐05  ‐1.37395 
2622912  NM_004635 // MAPKAPK3 // mitogen‐activated protein kinase‐activated protein kina  MAPKAPK3  3.01E‐10  1.24E‐05  1.14478  5.11E‐09  1.27593 
3379597  NM_004923 // MTL5 // metallothionein‐like 5, testis‐specific (tesmin) // 11q13.2  MTL5  3.04E‐10  2.00E‐07  1.25646  1.50E‐07  1.32411 
2525182  NM_152523 // CCNYL1 // cyclin Y‐like 1 // 2q33.3 // 151195 /// ENST00000295414 /  CCNYL1  3.06E‐10  4.59E‐08  ‐1.38445  7.26E‐07  ‐1.4111 
2902844  NM_001710 // CFB // complement factor B // 6p21.3 // 629 /// ENST00000375443 //   CFB  3.08E‐10  2.25E‐07  1.89548  1.36E‐07  2.21386 
3665949  NM_006742 // PSKH1 // protein serine kinase H1 // 16q22.1 // 5681 /// ENST000002  PSKH1  3.08E‐10  1.92E‐10  ‐1.30844  0.00714346  ‐1.11549 
2955282  NM_181356 // SUPT3H // suppressor of Ty 3 homolog (S. cerevisiae) // 6p21.1‐p21.  SUPT3H  3.14E‐10  3.98E‐09  1.38339  1.98E‐05  1.28962 
3095002  NM_003816 // ADAM9 // ADAM metallopeptidase domain 9 (meltrin gamma) // 8p11.23   ADAM9  3.17E‐10  8.20E‐09  1.36392  6.91E‐06  1.30734 
3712675  NM_030665 // RAI1 // retinoic acid induced 1 // 17p11.2 // 10743 /// ENST0000035  RAI1  3.19E‐10  3.75E‐07  1.23649  8.80E‐08  1.31841 
2541699  NM_030797 // FAM49A // family with sequence similarity 49, member A // 2p24.3 //  FAM49A  3.20E‐10  3.60E‐07  ‐1.45976  9.19E‐08  ‐1.63323 
3140478  BC042877 // RPESP // RPE‐spondin // 8q21.11 // 157869 /// AK292970 // RPESP // R  RPESP  3.20E‐10  1.70E‐07  2.24785  1.90E‐07  2.65606 
2528308  NM_138802 // ZFAND2B // zinc finger, AN1‐type domain 2B // 2q35 // 130617 /// EN  ZFAND2B  3.22E‐10  1.90E‐09  ‐1.28511  6.93E‐05  ‐1.19114 
3577256  NM_032490 // C14orf142 // chromosome 14 open reading frame 142 // 14q32.12 // 84  C14orf142  3.23E‐10  4.99E‐10  ‐1.84832  0.00088465  ‐1.38893 
3098756  NM_052898 // XKR4 // XK, Kell blood group complex subunit‐related family, member  XKR4  3.23E‐10  2.41E‐09  ‐1.4563  4.68E‐05  ‐1.31282 
2627390  NM_001128149 // ATXN7 // ataxin 7 // 3p21.1‐p12 // 6314 /// NM_000333 // ATXN7 /  ATXN7  3.23E‐10  0.000660507 ‐1.12348  5.75E‐10  ‐1.363 
3815278  NM_005224 // ARID3A // AT rich interactive domain 3A (BRIGHT‐like) // 19p13.3 //  ARID3A  3.26E‐10  1.24E‐06  1.25807  3.18E‐08  1.39625 
3219788  NM_019114 // EPB41L4B // erythrocyte membrane protein band 4.1 like 4B // 9q31‐q  EPB41L4B  3.30E‐10  3.25E‐08  ‐1.19399  1.23E‐06  ‐1.19675 
3719980  NM_006148 // LASP1 // LIM and SH3 protein 1 // 17q11‐q21.3 // 3927 /// ENST00000  LASP1  3.30E‐10  4.45E‐07  ‐1.24074  7.93E‐08  ‐1.32945 
2906333  NM_015345 // DAAM2 // dishevelled associated activator of morphogenesis 2 // 6p2  DAAM2  3.32E‐10  2.36E‐09  ‐1.45681  5.13E‐05  ‐1.31054 
2931569  NM_005100 // AKAP12 // A kinase (PRKA) anchor protein 12 // 6q24‐q25 // 9590 ///  AKAP12  3.33E‐10  1.85E‐06  ‐1.27151  2.36E‐08  ‐1.43589 
3952825  NM_024627 // C22orf29 // chromosome 22 open reading frame 29 // 22q11.21 // 7968  C22orf29  3.34E‐10  2.79E‐06  1.20941  1.72E‐08  1.34608 
3671935  NM_031476 // CRISPLD2 // cysteine‐rich secretory protein LCCL domain containing   CRISPLD2  3.36E‐10  1.38E‐08  ‐1.34931  3.76E‐06  ‐1.3157 
3320717  NM_014632 // MICAL2 // microtubule associated monoxygenase, calponin and LIM dom  MICAL2  3.43E‐10  4.29E‐07  ‐1.32825  8.66E‐08  ‐1.45129 
3652489  NM_018119 // POLR3E // polymerase (RNA) III (DNA directed) polypeptide E (80kD)   POLR3E  3.44E‐10  2.25E‐05  1.12766  4.11E‐09  1.2549 
2374501  DQ983818 // C1orf81 // chromosome 1 open reading frame 81 // 1q32.1 // 647215  C1orf81  3.45E‐10  2.74E‐08  ‐1.55904  1.64E‐06  ‐1.55171 
2593407  NM_024989 // PGAP1 // post‐GPI attachment to proteins 1 // 2q33.1 // 80055 /// E  PGAP1  3.53E‐10  1.35E‐09  2.45645  0.000154116 1.78942 
2962683  NM_198920 // UBE2CBP // ubiquitin‐conjugating enzyme E2C binding protein // 6q14  UBE2CBP  3.57E‐10  4.96E‐07  1.26487  8.04E‐08  1.36575 
3839142  NM_015428 // ZNF473 // zinc finger protein 473 // 19q13.33 // 25888 /// NM_00100  ZNF473  3.59E‐10  0.000146369 1.16083  1.42E‐09  1.40033 
3572782  NM_015305 // ANGEL1 // angel homolog 1 (Drosophila) // 14q24.3 // 23357 /// ENST  ANGEL1  3.60E‐10  0.000861019 1.15397  5.73E‐10  1.4779 
3217123  NM_014788 // TRIM14 // tripartite motif‐containing 14 // 9q22.33 // 9830 /// NM_  TRIM14  3.60E‐10  8.61E‐10  ‐1.26995  0.000377909 ‐1.15158 
2759582  NM_198595 // AFAP1 // actin filament associated protein 1 // 4p16 // 60312 /// N  AFAP1  3.61E‐10  1.18E‐07  1.29225  3.34E‐07  1.34359 
3465274  NM_001920 // DCN // decorin // 12q21.33 // 1634 /// NM_133503 // DCN // decorin   DCN  3.62E‐10  1.63E‐05  ‐1.74497  5.41E‐09  ‐2.76802 
3986672  NM_052936 // ATG4A // ATG4 autophagy related 4 homolog A (S. cerevisiae) // Xq22  ATG4A  3.64E‐10  3.12E‐08  ‐1.55472  1.53E‐06  ‐1.55424 
2340845  NM_020948 // MIER1 // mesoderm induction early response 1 homolog (Xenopus laevi  MIER1  3.65E‐10  7.71E‐07  ‐1.51177  5.59E‐08  ‐1.7695 
3189932  NM_003165 // STXBP1 // syntaxin binding protein 1 // 9q34.1 // 6812 /// NM_00103  STXBP1  3.65E‐10  3.36E‐09  1.77122  3.48E‐05  1.53491 
3050609  NM_015198 // COBL // cordon‐bleu homolog (mouse) // 7p12.1 // 23242 /// ENST0000  COBL  3.66E‐10  1.16E‐07  ‐1.32615  3.46E‐07  ‐1.38316 
3185063  NM_003358 // UGCG // UDP‐glucose ceramide glucosyltransferase // 9q31 // 7357 //  UGCG  3.70E‐10  5.67E‐08  ‐1.56037  7.77E‐07  ‐1.60633 
3006572  NM_015570 // AUTS2 // autism susceptibility candidate 2 // 7q11.22 // 26053 ///   AUTS2  3.71E‐10  8.49E‐09  1.28679  8.80E‐06  1.23969 
3377423  NM_080668 // CDCA5 // cell division cycle associated 5 // 11q12.1 // 113130 ///   CDCA5  3.73E‐10  0.139335  1.08754  8.40E‐11  1.80186 
3457667  NM_014255 // CNPY2 // canopy 2 homolog (zebrafish) // 12q15 // 10330 /// ENST000  CNPY2  3.73E‐10  1.85E‐05  1.16863  5.17E‐09  1.33368 
3260338  NM_145285 // NKX2‐3 // NK2 transcription factor related, locus 3 (Drosophila) //  NKX2‐3  3.75E‐10  2.99E‐07  ‐1.3204  1.39E‐07  ‐1.41919 




3599873  BC029061 // LOC145837 // hypothetical protein LOC145837 // 15q23 // 145837 /// B  LOC145837  3.77E‐10  8.15E‐09  ‐1.88452  9.65E‐06  ‐1.70912 
3148871  NM_001099744 // GOLSYN // Golgi‐localized protein // 8q23.2 // 55638 /// NM_0010  GOLSYN  3.80E‐10  2.06E‐08  1.42367  2.78E‐06  1.39796 
3962338  NM_005650 // TCF20 // transcription factor 20 (AR1) // 22q13.3|22q13.3 // 6942 /  TCF20  3.81E‐10  7.60E‐08  1.25944  5.86E‐07  1.28764 
3781980  NM_153211 // TTC39C // tetratricopeptide repeat domain 39C // 18q11.2 // 125488   TTC39C  3.82E‐10  3.13E‐09  1.54469  4.27E‐05  1.37763 
2887633  NM_138369 // FAM44B // family with sequence similarity 44, member B // 5q35.2 //  FAM44B  3.83E‐10  9.40E‐07  1.21342  5.04E‐08  1.31161 
2536625  NM_032515 // BOK // BCL2‐related ovarian killer // 2q37.3 // 666 /// ENST0000031  BOK  3.86E‐10  1.72E‐07  1.35289  2.50E‐07  1.43312 
3286921  NM_001002265 // MARCH8 // membrane‐associated ring finger (C3HC4) 8 // 10q11.21   MARCH8  3.88E‐10  6.95E‐07  ‐1.37485  6.70E‐08  ‐1.54268 
2766492  BC008502 // C4orf34 // chromosome 4 open reading frame 34 // 4p14 // 201895 ///   C4orf34  3.88E‐10  3.85E‐06  ‐1.36854  1.65E‐08  ‐1.64979 
2746693  NM_024605 // ARHGAP10 // Rho GTPase activating protein 10 // 4q31.23 // 79658 //  ARHGAP10  3.92E‐10  6.15E‐06  ‐1.36639  1.18E‐08  ‐1.68149 
2611779  NM_024334 // TMEM43 // transmembrane protein 43 // 3p25.1 // 79188 /// ENST00000  TMEM43  3.95E‐10  3.65E‐09  1.31052  3.57E‐05  1.22507 
3073013  NM_001018111 // PODXL // podocalyxin‐like // 7q32‐q33 // 5420 /// NM_005397 // P  PODXL  3.96E‐10  1.20E‐09  1.44009  0.000248561 1.25372 
3962781  NM_173467 // MCAT // malonyl CoA:ACP acyltransferase (mitochondrial) // 22q13.31  MCAT  3.98E‐10  0.014987  1.07169  1.90E‐10  1.32238 
3792656  NM_024781 // CCDC102B // coiled‐coil domain containing 102B // 18q22.1 // 79839   CCDC102B  4.01E‐10  8.32E‐08  ‐1.52252  5.77E‐07  ‐1.58901 
2527971  NM_015690 // STK36 // serine/threonine kinase 36, fused homolog (Drosophila) //   STK36  4.10E‐10  1.29E‐07  1.20498  3.72E‐07  1.23927 
3022465  NM_014390 // SND1 // staphylococcal nuclease and tudor domain containing 1 // 7q  SND1  4.11E‐10  6.26E‐07  1.35553  7.99E‐08  1.50469 
3381965  NM_005472 // KCNE3 // potassium voltage‐gated channel, Isk‐related family, membe  KCNE3  4.13E‐10  1.24E‐08  1.82813  6.32E‐06  1.70446 
2997376  NM_018685 // ANLN // anillin, actin binding protein // 7p15‐p14 // 54443 /// ENS  ANLN  4.20E‐10  0.000154859 1.50767  1.66E‐09  2.52234 
2766456  NM_003359 // UGDH // UDP‐glucose dehydrogenase // 4p15.1 // 7358 /// ENST0000031  UGDH  4.27E‐10  2.08E‐08  ‐2.05747  3.36E‐06  ‐1.96841 
2835576  NM_007286 // SYNPO // synaptopodin // 5q33.1 // 11346 /// NM_001109974 // SYNPO   SYNPO  4.34E‐10  8.13E‐08  ‐1.32402  6.71E‐07  ‐1.35857 
3942681  NM_134269 // SMTN // smoothelin // 22q12.2 // 6525 /// NM_134270 // SMTN // smoo  SMTN  4.35E‐10  2.97E‐06  1.20183  2.35E‐08  1.3291 
2625907  NM_001457 // FLNB // filamin B, beta (actin binding protein 278) // 3p14.3 // 23  FLNB  4.38E‐10  8.33E‐08  ‐1.36922  6.64E‐07  ‐1.41014 
3915936  NM_004540 // NCAM2 // neural cell adhesion molecule 2 // 21q21.1 // 4685 /// ENS  NCAM2  4.39E‐10  5.55E‐08  ‐1.31647  1.05E‐06  ‐1.33359 
3931112  NM_000411 // HLCS // holocarboxylase synthetase (biotin‐(proprionyl‐Coenzyme A‐c  HLCS  4.40E‐10  3.23E‐07  1.30895  1.64E‐07  1.40166 
3139580  NM_030958 // SLCO5A1 // solute carrier organic anion transporter family, member   SLCO5A1  4.42E‐10  1.08E‐09  1.47548  0.000387872 1.26022 
3458133  NM_000946 // PRIM1 // primase, DNA, polypeptide 1 (49kDa) // 12q13 // 5557 /// E  PRIM1  4.42E‐10  0.0632723  1.10365  1.28E‐10  1.7122 
2770242  NM_002703 // PPAT // phosphoribosyl pyrophosphate amidotransferase // 4q12 // 54  PPAT  4.49E‐10  1.61E‐06  1.53193  4.02E‐08  1.86294 
2981912  NM_003379 // EZR // ezrin // 6q25.2‐q26 // 7430 /// NM_001111077 // EZR // ezrin  EZR  4.52E‐10  4.68E‐07  ‐1.38697  1.20E‐07  ‐1.52887 
3521372  NM_198968 // DZIP1 // DAZ interacting protein 1 // 13q32.1 // 22873 /// NM_01493  DZIP1  4.52E‐10  1.10E‐07  ‐1.25031  5.15E‐07  ‐1.28511 
2903703  NM_006772 // SYNGAP1 // synaptic Ras GTPase activating protein 1 homolog (rat) /  SYNGAP1  4.53E‐10  0.00261894  1.10835  4.45E‐10  1.3745 
3509473  NM_004734 // DCLK1 // doublecortin‐like kinase 1 // 13q13 // 9201 /// ENST000002  DCLK1  4.53E‐10  1.90E‐07  ‐1.36379  2.90E‐07  ‐1.44548 
3063685  NM_005916 // MCM7 // minichromosome maintenance complex component 7 // 7q21.3‐q2  MCM7  4.54E‐10  0.000909113 1.21689  7.26E‐10  1.70434 
3201120  NM_001010915 // PTPLAD2 // protein tyrosine phosphatase‐like A domain containing  PTPLAD2  4.58E‐10  3.21E‐05  ‐1.41827  4.69E‐09  ‐1.95893 
3643703  NM_194259 // UBE2I // ubiquitin‐conjugating enzyme E2I (UBC9 homolog, yeast) //   UBE2I  4.58E‐10  1.90E‐05  1.10603  6.59E‐09  1.20269 
2365119  NM_004528 // MGST3 // microsomal glutathione S‐transferase 3 // 1q23 // 4259 ///  MGST3  4.58E‐10  1.74E‐07  ‐1.52012  3.23E‐07  ‐1.63632 
2901879  NM_001109938 // C6orf136 // chromosome 6 open reading frame 136 // 6p21.33 // 22  C6orf136  4.59E‐10  3.09E‐08  ‐1.29639  2.30E‐06  ‐1.28842 
3541073  NM_022474 // MPP5 // membrane protein, palmitoylated 5 (MAGUK p55 subfamily memb  MPP5  4.59E‐10  2.26E‐07  ‐1.44798  2.48E‐07  ‐1.56332 
3442941  NM_004054 // C3AR1 // complement component 3a receptor 1 // 12p13.31 // 719 ///   C3AR1  4.69E‐10  6.91E‐08  ‐1.68393  9.14E‐07  ‐1.74279 
3421630  NM_006431 // CCT2 // chaperonin containing TCP1, subunit 2 (beta) // 12q15 // 10  CCT2  4.75E‐10  4.74E‐05  1.36967  3.84E‐09  1.87213 
3989448  NM_007325 // GRIA3 // glutamate receptor, ionotrophic, AMPA 3 // Xq25‐q26 // 289  GRIA3  4.78E‐10  4.05E‐09  ‐1.44959  4.40E‐05  ‐1.3178 
3923312  NM_003683 // RRP1 // ribosomal RNA processing 1 homolog (S. cerevisiae) // 21q22  RRP1  4.85E‐10  4.06E‐06  1.18818  2.13E‐08  1.31367 
3181193  NM_014290 // TDRD7 // tudor domain containing 7 // 9q22.33 // 23424 /// ENST0000  TDRD7  4.88E‐10  1.63E‐07  ‐1.32081  3.82E‐07  ‐1.38176 




3040518  NM_182762 // 7A5 // putative binding protein 7a5 // 7p15.3 // 346389 /// ENST000  7A5  4.90E‐10  3.16E‐07  1.73634  1.97E‐07  1.98401 
3190893  BC009114 // FAM73B // family with sequence similarity 73, member B // 9q34.11 //  FAM73B  4.93E‐10  6.71E‐10  ‐1.36642  0.00130901  ‐1.17648 
3404660  NM_002262 // KLRD1 // killer cell lectin‐like receptor subfamily D, member 1 //   KLRD1  4.94E‐10  0.000181059 ‐1.31833  1.84E‐09  ‐1.8734 
2881860  NM_015621 // CCDC69 // coiled‐coil domain containing 69 // 5q33.1 // 26112 /// E  CCDC69  5.04E‐10  4.02E‐05  ‐1.35226  4.59E‐09  ‐1.80448 
3025433  NM_020299 // AKR1B10 // aldo‐keto reductase family 1, member B10 (aldose reducta  AKR1B10  5.10E‐10  9.20E‐09  ‐3.05691  1.42E‐05  ‐2.52775 
2779199  NM_000667 // ADH1A // alcohol dehydrogenase 1A (class I), alpha polypeptide // 4  ADH1A  5.12E‐10  4.92E‐05  ‐1.67448  4.12E‐09  ‐2.79334 
3445820  NM_032918 // RERG // RAS‐like, estrogen‐regulated, growth inhibitor // 12p12.3 /  RERG  5.12E‐10  1.44E‐06  ‐1.38059  5.31E‐08  ‐1.58659 
2695295  NM_014065 // ASTE1 // asteroid homolog 1 (Drosophila) // 3q22.1 // 28990 /// ENS  ASTE1  5.14E‐10  4.96E‐08  ‐1.39263  1.57E‐06  ‐1.40158 
3015911  NM_003302 // TRIP6 // thyroid hormone receptor interactor 6 // 7q22 // 7205 ///   TRIP6  5.16E‐10  1.52E‐06  1.38155  5.10E‐08  1.592 
4026263  NM_004344 // CETN2 // centrin, EF‐hand protein, 2 // Xq28 // 1069 /// ENST000003  CETN2  5.29E‐10  1.16E‐05  1.29702  1.11E‐08  1.57035 
3428447  NM_014503 // UTP20 // UTP20, small subunit (SSU) processome component, homolog (  UTP20  5.30E‐10  3.76E‐07  1.51619  1.87E‐07  1.68645 
4011683  NM_001003811 // TEX11 // testis expressed 11 // Xq13.1 // 56159 /// NM_031276 //  TEX11  5.38E‐10  2.93E‐08  ‐1.23256  3.24E‐06  ‐1.22104 
4015481  NM_007052 // NOX1 // NADPH oxidase 1 // Xq22 // 27035 /// NM_013955 // NOX1 // N  NOX1  5.39E‐10  1.53E‐07  2.14458  4.76E‐07  2.39674 
3486096  NM_207361 // FREM2 // FRAS1 related extracellular matrix protein 2 // 13q13.3 //  FREM2  5.41E‐10  6.13E‐06  1.67309  1.81E‐08  2.31765 
3697015  NM_001605 // AARS // alanyl‐tRNA synthetase // 16q22 // 16 /// ENST00000261772 /  AARS  5.42E‐10  0.0119614  1.13685  2.88E‐10  1.63513 
2505957  NM_017958 // PLEKHB2 // pleckstrin homology domain containing, family B (evectin  PLEKHB2  5.44E‐10  6.53E‐09  ‐1.35552  2.68E‐05  ‐1.26956 
3725572  NM_153446 // B4GALNT2 // beta‐1,4‐N‐acetyl‐galactosaminyl transferase 2 // 17q21  B4GALNT2  5.46E‐10  8.42E‐10  ‐2.69086  0.00103713  ‐1.70278 
2726542  NM_025087 // FLJ21511 // hypothetical protein FLJ21511 // 4p12‐p11 // 80157 ///   FLJ21511  5.50E‐10  1.16E‐08  ‐3.38716  1.18E‐05  ‐2.81481 
3895795  NM_007219 // RNF24 // ring finger protein 24 // 20p13‐p12.1 // 11237 /// ENST000  RNF24  5.51E‐10  4.09E‐06  1.19764  2.52E‐08  1.32761 
3704980  NM_000135 // FANCA // Fanconi anemia, complementation group A // 16q24.3 // 2175  FANCA  5.52E‐10  0.217764  1.05877  1.11E‐10  1.61207 
3396003  NM_170601 // SIAE // sialic acid acetylesterase // 11q24 // 54414 /// ENST000002  SIAE  5.59E‐10  1.04E‐07  ‐1.32275  7.65E‐07  ‐1.35921 
3942766  NM_001002837 // PIB5PA // phosphatidylinositol (4,5) bisphosphate 5‐phosphatase,  PIB5PA  5.66E‐10  1.62E‐09  ‐1.52468  0.000308539 ‐1.29698 
3417500  NM_173596 // SLC39A5 // solute carrier family 39 (metal ion transporter), member  SLC39A5  5.67E‐10  6.17E‐09  ‐1.86391  3.17E‐05  ‐1.61915 
3474831  NM_003733 // OASL // 2'‐5'‐oligoadenylate synthetase‐like // 12q24.2 // 8638 ///  OASL  5.70E‐10  5.21E‐10  ‐2.2169  0.00326292  ‐1.44987 
2351572  NM_000560 // CD53 // CD53 molecule // 1p13 // 963 /// NM_001040033 // CD53 // CD  CD53  5.76E‐10  9.27E‐05  ‐1.49915  3.25E‐09  ‐2.34718 
3719515  NM_007026 // DUSP14 // dual specificity phosphatase 14 // 17q12 // 11072 /// ENS  DUSP14  5.80E‐10  6.23E‐06  1.38202  1.96E‐08  1.69393 
3451375  NM_153026 // PRICKLE1 // prickle homolog 1 (Drosophila) // 12q12 // 144165 /// E  PRICKLE1  5.92E‐10  9.63E‐07  ‐1.30361  9.22E‐08  ‐1.43599 
2669184  NM_006309 // LRRFIP2 // leucine rich repeat (in FLII) interacting protein 2 // 3  LRRFIP2  5.94E‐10  1.00E‐05  ‐1.32716  1.43E‐08  ‐1.61801 
2672857  NM_003074 // SMARCC1 // SWI/SNF related, matrix associated, actin dependent regu  SMARCC1  5.99E‐10  3.62E‐08  1.47091  2.99E‐06  1.45335 
3413212  AK294075 // FLJ20489 // hypothetical protein FLJ20489 // 12q13.11 // 55652 /// B  FLJ20489  6.01E‐10  0.0100911  1.08129  3.44E‐10  1.33657 
2352609  NM_152900 // MAGI3 // membrane associated guanylate kinase, WW and PDZ domain co  MAGI3  6.03E‐10  0.000149244 ‐1.19776  2.61E‐09  ‐1.48875 
3990566  NM_006649 // UTP14A // UTP14, U3 small nucleolar ribonucleoprotein, homolog A (y  UTP14A  6.04E‐10  1.38E‐05  1.31682  1.17E‐08  1.61895 
3928415  NM_199328 // CLDN8 // claudin 8 // 21q22.11 // 9073 /// ENST00000399899 // CLDN8  CLDN8  6.18E‐10  0.000177156 ‐2.50043  2.44E‐09  ‐7.80063 
3444117  NM_007333 // KLRC3 // killer cell lectin‐like receptor subfamily C, member 3 //   KLRC3  6.18E‐10  1.06E‐06  ‐1.37524  9.03E‐08  ‐1.54878 
3362124  NM_020644 // TMEM9B // TMEM9 domain family, member B // 11p15.3 // 56674 /// ENS  TMEM9B  6.29E‐10  2.25E‐06  ‐1.26273  4.86E‐08  ‐1.41015 
3944147  NM_006739 // MCM5 // minichromosome maintenance complex component 5 // 22q13.1 /  MCM5  6.30E‐10  0.0652635  1.08454  1.83E‐10  1.55253 
3752271  NM_001003927 // EVI2A // ecotropic viral integration site 2A // 17q11.2 // 2123   EVI2A  6.31E‐10  3.03E‐07  ‐1.53171  3.01E‐07  ‐1.67738 
3644764  NM_001761 // CCNF // cyclin F // 16p13.3 // 899 /// NR_003574 // ABCA17P // ATP‐  CCNF  6.40E‐10  0.02706  1.12012  2.53E‐10  1.65125 
3419471  ENST00000338970 // RPL14 // ribosomal protein L14 // 3p22‐p21.2 // 9045 /// U167  RPL14  6.41E‐10  2.02E‐05  1.31359  9.71E‐09  1.63776 
3740479  NM_006445 // PRPF8 // PRP8 pre‐mRNA processing factor 8 homolog (S. cerevisiae)   PRPF8  6.48E‐10  1.76E‐07  1.17811  5.49E‐07  1.20643 
3662150  NM_176870 // MT1M // metallothionein 1M // 16q13 // 4499 /// ENST00000379818 //   MT1M  6.51E‐10  1.31E‐05  ‐2.99125  1.34E‐08  ‐6.68863 




3395416  NM_006597 // HSPA8 // heat shock 70kDa protein 8 // 11q24.1 // 3312 /// NM_15320  HSPA8  6.58E‐10  0.00111548  1.13942  1.01E‐09  1.42901 
3830216  NM_144779 // FXYD5 // FXYD domain containing ion transport regulator 5 // 19q12‐  FXYD5  6.59E‐10  5.25E‐07  1.43553  1.88E‐07  1.58692 
3837796  NM_031485 // GRWD1 // glutamate‐rich WD repeat containing 1 // 19q13.32 // 83743  GRWD1  6.61E‐10  0.00429141  1.11144  5.45E‐10  1.4099 
3321361  NM_006108 // SPON1 // spondin 1, extracellular matrix protein // 11p15.2 // 1041  SPON1  6.61E‐10  0.000364056 ‐1.64226  1.78E‐09  ‐3.30508 
3578069  BC008299 // C14orf139 // chromosome 14 open reading frame 139 // 14q32.13 // 796  C14orf139  6.64E‐10  2.04E‐05  ‐1.40181  1.01E‐08  ‐1.84104 
3000953  NM_003364 // UPP1 // uridine phosphorylase 1 // 7p12.3 // 7378 /// NM_181597 //   UPP1  6.72E‐10  3.78E‐09  ‐1.51818  9.86E‐05  ‐1.33895 
2347732  NM_152487 // TMEM56 // transmembrane protein 56 // 1p21.3 // 148534 /// ENST0000  TMEM56  6.76E‐10  1.15E‐09  ‐1.5978  0.000902464 ‐1.29517 
3335952  NM_018026 // PACS1 // phosphofurin acidic cluster sorting protein 1 // 11q13.1 /  PACS1  6.76E‐10  5.51E‐09  1.29232  5.36E‐05  1.20976 
3844567  NM_012435 // SHC2 // SHC (Src homology 2 domain containing) transforming protein  SHC2  6.79E‐10  2.22E‐06  1.26865  5.45E‐08  1.41695 
3685329  NM_024675 // PALB2 // partner and localizer of BRCA2 // 16p12.1 // 79728 /// ENS  PALB2  6.80E‐10  6.78E‐05  1.23624  4.80E‐09  1.53666 
2701018  NM_013308 // GPR171 // G protein‐coupled receptor 171 // 3q25.1 // 29909 /// ENS  GPR171  6.87E‐10  0.000163223 ‐1.30262  2.90E‐09  ‐1.79415 
2599955  NM_001077198 // ATG9A // ATG9 autophagy related 9 homolog A (S. cerevisiae) // 2  ATG9A  6.95E‐10  4.73E‐08  ‐1.14809  2.75E‐06  ‐1.14581 
4004575  NM_031442 // TMEM47 // transmembrane protein 47 // Xp11.4 // 83604 /// ENST00000  TMEM47  6.97E‐10  7.15E‐06  ‐1.4729  2.26E‐08  ‐1.88138 
2533019  NM_021027 // UGT1A9 // UDP glucuronosyltransferase 1 family, polypeptide A9 // 2  UGT1A9  7.02E‐10  8.12E‐09  ‐1.59704  3.15E‐05  ‐1.44307 
2841699  NM_030627 // CPEB4 // cytoplasmic polyadenylation element binding protein 4 // 5  CPEB4  7.08E‐10  6.45E‐08  ‐1.44495  1.95E‐06  ‐1.45528 
2741139  NM_001128933 // SYNPO2 // synaptopodin 2 // 4q26 // 171024 /// NM_133477 // SYNP  SYNPO2  7.09E‐10  2.23E‐06  ‐1.80701  5.78E‐08  ‐2.37363 
3662265  NM_014669 // NUP93 // nucleoporin 93kDa // 16q13 // 9688 /// ENST00000308159 //   NUP93  7.09E‐10  0.00942113  1.1321  4.24E‐10  1.57194 
3216319  NM_153695 // ZNF367 // zinc finger protein 367 // 9q22|9q22.32 // 195828 /// ENS  ZNF367  7.11E‐10  0.22244  1.04212  1.43E‐10  1.41232 
2468351  NM_080657 // RSAD2 // radical S‐adenosyl methionine domain containing 2 // 2p25.  RSAD2  7.18E‐10  2.60E‐08  ‐1.98716  6.25E‐06  ‐1.87342 
3369442  NM_015430 // DKFZP586H2123 // regeneration associated muscle protease // 11p13 /  DKFZP586H2123  7.26E‐10  1.00E‐09  ‐1.55916  0.00141235  ‐1.26259 
2738244  BC105695 // FLJ20184 // hypothetical protein FLJ20184 // 4q24 // 54848 /// NM_01  FLJ20184  7.33E‐10  3.73E‐09  1.79885  0.000120417 1.49798 
3638819  NM_006384 // CIB1 // calcium and integrin binding 1 (calmyrin) // 15q25.3‐q26 //  CIB1  7.39E‐10  2.85E‐08  ‐1.32735  5.85E‐06  ‐1.29817 
2952065  NM_016059 // PPIL1 // peptidylprolyl isomerase (cyclophilin)‐like 1 // 6p21.1 //  PPIL1  7.40E‐10  0.000842754 1.19773  1.32E‐09  1.60795 
3577938  AB007969 // CLMN // calmin (calponin‐like, transmembrane) // 14q32.13 // 79789  CLMN  7.49E‐10  0.000236296 ‐1.29566  2.61E‐09  ‐1.80858 
2644702  NM_001033030 // FAIM // Fas apoptotic inhibitory molecule // 3q22.3 // 55179 ///  FAIM  7.52E‐10  2.39E‐06  1.39088  5.94E‐08  1.62129 
3590164  NM_181642 // SPINT1 // serine peptidase inhibitor, Kunitz type 1 // 15q15.1 // 6  SPINT1  7.57E‐10  3.98E‐06  ‐1.22011  3.96E‐08  ‐1.3576 
3838809  NM_198319 // PRMT1 // protein arginine methyltransferase 1 // 19q13.3 // 3276 //  PRMT1  7.60E‐10  3.20E‐05  1.23979  8.86E‐09  1.49547 
2329041  NM_020888 // KIAA1522 // KIAA1522 // 1p35.1 // 57648 /// ENST00000401073 // KIAA  KIAA1522  7.63E‐10  8.88E‐07  ‐1.18725  1.43E‐07  ‐1.25659 
3258966  NM_000772 // CYP2C18 // cytochrome P450, family 2, subfamily C, polypeptide 18 /  CYP2C18  7.64E‐10  1.06E‐09  ‐2.99916  0.00141015  ‐1.78258 
3619690  NM_017726 // PPP1R14D // protein phosphatase 1, regulatory (inhibitor) subunit 1  PPP1R14D  7.69E‐10  1.61E‐08  ‐1.55713  1.37E‐05  ‐1.45873 
2495758  BC021264 // C2orf15 // chromosome 2 open reading frame 15 // 2q11.2 // 150590 //  C2orf15  7.77E‐10  1.26E‐07  1.56131  1.05E‐06  1.62402 
2902633  NM_025259 // MSH5 // mutS homolog 5 (E. coli) // 6p21.3 // 4439 /// NM_002441 //  MSH5  7.80E‐10  1.12E‐06  1.24721  1.20E‐07  1.35014 
3136129  NM_001023 // RPS20 // ribosomal protein S20 // 8q12 // 6224 /// NR_002437 // SNO  RPS20  7.83E‐10  2.35E‐06  1.23439  6.36E‐08  1.35953 
2714644  NM_052861 // C4orf42 // chromosome 4 open reading frame 42 // 4p16.3 // 92070 //  C4orf42  7.83E‐10  0.00164418  1.10852  1.02E‐09  1.34049 
2867443  NM_024717 // MCTP1 // multiple C2 domains, transmembrane 1 // 5q15 // 79772 ///   MCTP1  7.88E‐10  0.000136744 ‐1.23168  3.78E‐09  ‐1.56733 
3549517  NM_023112 // OTUB2 // OTU domain, ubiquitin aldehyde binding 2 // 14q32.13 // 78  OTUB2  7.88E‐10  1.57E‐06  1.44399  9.02E‐08  1.67452 
3854297  NM_005234 // NR2F6 // nuclear receptor subfamily 2, group F, member 6 // 19p13.1  NR2F6  7.97E‐10  1.86E‐09  ‐1.31896  0.000509022 ‐1.1786 
3497790  NM_002271 // IPO5 // importin 5 // 13q32.2 // 3843 /// ENST00000357602 // IPO5 /  IPO5  8.00E‐10  1.99E‐05  1.30602  1.30E‐08  1.60995 
3408018  NM_018638 // ETNK1 // ethanolamine kinase 1 // 12p12.1 // 55500 /// NM_001039481  ETNK1  8.00E‐10  1.10E‐09  ‐2.19041  0.0014701  ‐1.50899 
3485074  NM_002915 // RFC3 // replication factor C (activator 1) 3, 38kDa // 13q12.3‐q13   RFC3  8.07E‐10  0.0628008  1.13956  2.41E‐10  2.00161 
3351841  NM_000190 // HMBS // hydroxymethylbilane synthase // 11q23.3 // 3145 /// NM_0010  HMBS  8.25E‐10  0.541537  1.02326  1.36E‐10  1.47419 




3356115  NM_001642 // APLP2 // amyloid beta (A4) precursor‐like protein 2 // 11q23‐q25|11  APLP2  8.42E‐10  7.69E‐08  ‐1.33558  2.12E‐06  ‐1.34461 
2545549  NM_021095 // SLC5A6 // solute carrier family 5 (sodium‐dependent vitamin transpo  SLC5A6  8.45E‐10  0.038091  1.11854  3.00E‐10  1.69296 
2451043  NM_012134 // LMOD1 // leiomodin 1 (smooth muscle) // 1q32 // 25802 /// ENST00000  LMOD1  8.48E‐10  1.88E‐06  ‐1.48191  8.56E‐08  ‐1.74855 
3726960  NM_001018137 // NME2 // non‐metastatic cells 2, protein (NM23B) expressed in //   NME2  8.51E‐10  4.37E‐05  1.28137  8.34E‐09  1.60877 
3734575  NM_001545 // ICT1 // immature colon carcinoma transcript 1 // 17q25.1 // 3396 //  ICT1  8.55E‐10  0.00422401  1.12187  7.29E‐10  1.44608 
2925953  NM_006208 // ENPP1 // ectonucleotide pyrophosphatase/phosphodiesterase 1 // 6q22  ENPP1  8.59E‐10  3.27E‐06  ‐1.55971  5.51E‐08  ‐1.94473 
2442493  NM_005814 // GPA33 // glycoprotein A33 (transmembrane) // 1q24.1 // 10223 /// EN  GPA33  8.64E‐10  1.52E‐07  ‐1.33724  1.01E‐06  ‐1.37701 
3058991  NM_000722 // CACNA2D1 // calcium channel, voltage‐dependent, alpha 2/delta subun  CACNA2D1  8.71E‐10  0.000117449 ‐1.26313  4.66E‐09  ‐1.63804 
3634071  NM_005724 // TSPAN3 // tetraspanin 3 // 15q24.3 // 10099 /// NM_198902 // TSPAN3  TSPAN3  8.82E‐10  7.82E‐06  ‐1.24226  2.89E‐08  ‐1.42198 
3973839  NM_000397 // CYBB // cytochrome b‐245, beta polypeptide // Xp21.1 // 1536 /// EN  CYBB  8.83E‐10  1.93E‐05  ‐1.38055  1.51E‐08  ‐1.76879 
3367036  NM_030771 // CCDC34 // coiled‐coil domain containing 34 // 11p14.1 // 91057 ///   CCDC34  8.88E‐10  0.0291207  1.07775  3.48E‐10  1.39312 
2554018  NM_004105 // EFEMP1 // EGF‐containing fibulin‐like extracellular matrix protein   EFEMP1  8.90E‐10  0.0297377  ‐1.20763  3.47E‐10  ‐2.31382 
2324084  NM_001785 // CDA // cytidine deaminase // 1p36.2‐p35 // 978 /// ENST00000375071   CDA  8.95E‐10  1.84E‐06  ‐2.24611  9.42E‐08  ‐3.13584 
3554728  NM_004689 // MTA1 // metastasis associated 1 // 14q32.3 // 9112 /// ENST00000331  MTA1  9.05E‐10  8.18E‐07  1.17867  1.98E‐07  1.23906 
3470193  NM_004072 // CMKLR1 // chemokine‐like receptor 1 // 12q24.1 // 1240 /// ENST0000  CMKLR1  9.12E‐10  1.46E‐08  ‐1.61415  2.16E‐05  ‐1.4837 
3160773  NM_005772 // RCL1 // RNA terminal phosphate cyclase‐like 1 // 9p24.1‐p23 // 1017  RCL1  9.19E‐10  2.80E‐06  1.34302  6.85E‐08  1.54187 
2526759  NM_004044 // ATIC // 5‐aminoimidazole‐4‐carboxamide ribonucleotide formyltransfe  ATIC  9.22E‐10  2.26E‐05  1.37031  1.43E‐08  1.75818 
2326749  NM_032283 // ZDHHC18 // zinc finger, DHHC‐type containing 18 // 1p36.11 // 84243  ZDHHC18  9.24E‐10  1.14E‐07  ‐1.1976  1.56E‐06  ‐1.2107 
2691668  NM_005335 // HCLS1 // hematopoietic cell‐specific Lyn substrate 1 // 3q13 // 305  HCLS1  9.26E‐10  0.000177483 ‐1.27034  3.94E‐09  ‐1.6917 
2641083  NM_021937 // EEFSEC // eukaryotic elongation factor, selenocysteine‐tRNA‐specifi  EEFSEC  9.27E‐10  0.00180971  1.09487  1.17E‐09  1.29552 
3803120  NM_004775 // B4GALT6 // UDP‐Gal:betaGlcNAc beta 1,4‐ galactosyltransferase, poly  B4GALT6  9.36E‐10  9.53E‐08  1.37884  1.96E‐06  1.3959 
3525538  NM_024537 // CARS2 // cysteinyl‐tRNA synthetase 2, mitochondrial (putative) // 1  CARS2  9.41E‐10  0.00562892  1.11415  7.16E‐10  1.433 
2621881  NM_177938 // PH‐4 // hypoxia‐inducible factor prolyl 4‐hydroxylase // 3p21.31 //  PH‐4  9.46E‐10  3.60E‐06  1.14477  5.83E‐08  1.22494 
2828146  NM_020240 // CDC42SE2 // CDC42 small effector 2 // 5q31.1 // 56990 /// NM_001038  CDC42SE2  9.53E‐10  2.52E‐06  ‐1.30263  7.89E‐08  ‐1.46706 
3942531  NM_030758 // OSBP2 // oxysterol binding protein 2 // 22q12.2 // 23762 /// ENST00  OSBP2  9.62E‐10  6.69E‐07  1.26439  2.61E‐07  1.34785 
2395564  NM_003039 // SLC2A5 // solute carrier family 2 (facilitated glucose/fructose tra  SLC2A5  9.73E‐10  2.74E‐07  ‐1.51877  6.48E‐07  ‐1.62405 
3974948  NM_001097579 // GPR34 // G protein‐coupled receptor 34 // Xp11.4‐p11.3 // 2857 /  GPR34  9.79E‐10  3.80E‐06  ‐1.54431  5.84E‐08  ‐1.92345 
2938636  NM_001500 // GMDS // GDP‐mannose 4,6‐dehydratase // 6p25 // 2762 /// ENST0000038  GMDS  9.83E‐10  4.09E‐05  1.30064  1.04E‐08  1.64351 
3944129  NM_002133 // HMOX1 // heme oxygenase (decycling) 1 // 22q12|22q13.1 // 3162 ///   HMOX1  9.84E‐10  3.91E‐10  ‐2.06767  0.0285507  ‐1.27543 
3095815  NM_178819 // AGPAT6 // 1‐acylglycerol‐3‐phosphate O‐acyltransferase 6 (lysophosp  AGPAT6  9.85E‐10  3.51E‐05  1.14842  1.16E‐08  1.29399 
2461531  NM_182972 // IRF2BP2 // interferon regulatory factor 2 binding protein 2 // 1q42  IRF2BP2  9.85E‐10  1.06E‐08  1.28888  4.02E‐05  1.21867 
3293537  NM_000281 // PCBD1 // pterin‐4 alpha‐carbinolamine dehydratase/dimerization cofa  PCBD1  9.89E‐10  4.78E‐06  1.21973  4.93E‐08  1.35717 
4012142  NM_017669 // ERCC6L // excision repair cross‐complementing rodent repair deficie  ERCC6L  9.91E‐10  0.0126461  1.168  5.40E‐10  1.79641 
3526325  BC080517 // hCG_1774568 // similar to hCG1774568 // 13q34 // 100134018  hCG_1774568  9.91E‐10  9.70E‐07  1.22458  1.93E‐07  1.30592 
4054639  NM_015658 // NOC2L // nucleolar complex associated 2 homolog (S. cerevisiae) //   NOC2L  1.01E‐09  0.0209019  1.10413  4.51E‐10  1.50474 
2363579  NM_032174 // TOMM40L // translocase of outer mitochondrial membrane 40 homolog (  TOMM40L  1.01E‐09  5.22E‐08  ‐1.28407  4.64E‐06  ‐1.2715 
2951567  NM_004117 // FKBP5 // FK506 binding protein 5 // 6p21.3‐p21.2 // 2289 /// ENST00  FKBP5  1.02E‐09  3.89E‐07  ‐1.54493  4.88E‐07  ‐1.68435 
2596763  NM_003468 // FZD5 // frizzled homolog 5 (Drosophila) // 2q33‐q34 // 7855 /// ENS  FZD5  1.03E‐09  3.24E‐06  ‐1.41222  7.10E‐08  ‐1.6654 
3636522  NM_016073 // HDGFRP3 // hepatoma‐derived growth factor, related protein 3 // 15q  HDGFRP3  1.04E‐09  1.17E‐06  ‐1.41478  1.74E‐07  ‐1.59072 
2435195  NM_031420 // MRPL9 // mitochondrial ribosomal protein L9 // 1q21 // 65005 /// EN  MRPL9  1.04E‐09  8.74E‐07  1.22576  2.29E‐07  1.3027 
3861948  NM_004877 // GMFG // glia maturation factor, gamma // 19q13.2 // 9535 /// ENST00  GMFG  1.04E‐09  0.000247196 ‐1.32848  3.77E‐09  ‐1.90065 




3678147  NM_020677 // NMRAL1 // NmrA‐like family domain containing 1 // 16p13.3 // 57407   NMRAL1  1.05E‐09  0.0257937  1.06368  4.37E‐10  1.30318 
3896370  NM_019593 // RP5‐1022P6.2 // hypothetical protein KIAA1434 // 20p12.3 // 56261 /  RP5‐1022P6.2  1.06E‐09  2.87E‐08  1.66281  1.09E‐05  1.57053 
3645555  NM_016639 // TNFRSF12A // tumor necrosis factor receptor superfamily, member 12A  TNFRSF12A  1.06E‐09  2.15E‐05  1.3853  1.77E‐08  1.77946 
3844470  NM_003712 // PPAP2C // phosphatidic acid phosphatase type 2C // 19p13 // 8612 //  PPAP2C  1.07E‐09  0.000292634 1.15112  3.52E‐09  1.38216 
2836518  NM_198321 // GALNT10 // UDP‐N‐acetyl‐alpha‐D‐galactosamine:polypeptide N‐acetylg  GALNT10  1.08E‐09  5.07E‐08  1.2727  5.37E‐06  1.25778 
3157660  NM_003313 // TSTA3 // tissue specific transplantation antigen P35B // 8q24.3 //   TSTA3  1.09E‐09  1.30E‐05  1.42676  2.64E‐08  1.81796 
3773241  AL512709 // TBC1D16 // TBC1 domain family, member 16 // 17q25.3 // 125058  TBC1D16  1.10E‐09  7.47E‐07  1.55819  2.86E‐07  1.75968 
3279108  NM_004808 // NMT2 // N‐myristoyltransferase 2 // 10p13 // 9397 /// ENST000003781  NMT2  1.12E‐09  8.33E‐06  ‐1.33789  3.80E‐08  ‐1.59738 
3850261  NM_002162 // ICAM3 // intercellular adhesion molecule 3 // 19p13.3‐p13.2 // 3385  ICAM3  1.13E‐09  6.20E‐07  ‐1.39001  3.57E‐07  ‐1.50812 
3244061  NM_145312 // ZNF485 // zinc finger protein 485 // 10q11.21 // 220992 /// ENST000  ZNF485  1.14E‐09  2.87E‐06  1.38756  9.08E‐08  1.60827 
4023467  NM_004840 // ARHGEF6 // Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 //   ARHGEF6  1.15E‐09  0.00106077  ‐1.29596  1.94E‐09  ‐1.98758 
3160175  NM_003383 // VLDLR // very low density lipoprotein receptor // 9p24 // 7436 ///   VLDLR  1.15E‐09  3.96E‐08  ‐1.6087  8.25E‐06  ‐1.54594 
2954207  NM_003192 // TBCC // tubulin folding cofactor C // 6pter‐p12.1 // 6903 /// ENST0  TBCC  1.16E‐09  5.99E‐10  ‐1.28518  0.0148263  ‐1.10053 
2957126  NM_002388 // MCM3 // minichromosome maintenance complex component 3 // 6p12 // 4  MCM3  1.16E‐09  0.000727083 1.25247  2.38E‐09  1.76896 
3859668  NM_139284 // LGI4 // leucine‐rich repeat LGI family, member 4 // 19q13.12|19q13.  LGI4  1.17E‐09  2.98E‐08  ‐1.46138  1.24E‐05  ‐1.39734 
3434048  NM_178499 // CCDC60 // coiled‐coil domain containing 60 // 12q24.23 // 160777 //  CCDC60  1.17E‐09  1.33E‐06  1.47766  1.84E‐07  1.68958 
2524602  NM_020923 // ZDBF2 // zinc finger, DBF‐type containing 2 // 2q33.3 // 57683 ///   ZDBF2  1.17E‐09  1.39E‐06  ‐1.46095  1.77E‐07  ‐1.66748 
3830530  NM_032635 // TMEM147 // transmembrane protein 147 // 19q13.1 // 10430 /// ENST00  TMEM147  1.18E‐09  0.0166593  1.13983  5.84E‐10  1.67239 
3214845  NM_017680 // ASPN // asporin // 9q22 // 54829 /// ENST00000375544 // ASPN // asp  ASPN  1.19E‐09  6.62E‐06  ‐1.82568  4.88E‐08  ‐2.57055 
2346625  NM_173567 // ABHD7 // abhydrolase domain containing 7 // 1p22.1 // 253152 /// EN  ABHD7  1.20E‐09  5.20E‐09  1.88445  0.000186785 1.5332 
3880827  BC012542 // GINS1 // GINS complex subunit 1 (Psf1 homolog) // 20p11.21 // 9837 /  GINS1  1.20E‐09  0.490395  1.04399  2.02E‐10  1.88336 
3698919  NM_012201 // GLG1 // golgi apparatus protein 1 // 16q22‐q23 // 2734 /// ENST0000  GLG1  1.21E‐09  7.72E‐09  1.38306  9.93E‐05  1.26314 
3149528  NM_014112 // TRPS1 // trichorhinophalangeal syndrome I // 8q24.12 // 7227 /// EN  TRPS1  1.21E‐09  4.92E‐05  ‐1.27922  1.21E‐08  ‐1.5977 
3956433  NM_001005735 // CHEK2 // CHK2 checkpoint homolog (S. pombe) // 22q11|22q12.1 //   CHEK2  1.21E‐09  0.00642022  1.10141  8.94E‐10  1.38288 
2909167  NM_001010870 // TDRD6 // tudor domain containing 6 // 6p12.3 // 221400 /// NM_00  TDRD6  1.23E‐09  4.78E‐09  1.67967  0.000229485 1.40883 
2407729  NM_022157 // RRAGC // Ras‐related GTP binding C // 1p34 // 64121 /// ENST0000037  RRAGC  1.23E‐09  1.10E‐06  ‐1.24352  2.36E‐07  ‐1.33133 
3415937  NM_021640 // C12orf10 // chromosome 12 open reading frame 10 // 12q13 // 60314 /  C12orf10  1.24E‐09  0.000333864 1.11341  3.90E‐09  1.28239 
2886174  NM_003062 // SLIT3 // slit homolog 3 (Drosophila) // 5q35 // 6586 /// ENST000003  SLIT3  1.24E‐09  4.80E‐07  ‐1.36512  5.28E‐07  ‐1.45583 
3923436  NM_003274 // TRAPPC10 // trafficking protein particle complex 10 // 21q22.3 // 7  TRAPPC10  1.24E‐09  1.98E‐07  ‐1.24026  1.35E‐06  ‐1.26677 
2496962  NM_000877 // IL1R1 // interleukin 1 receptor, type I // 2q12 // 3554 /// ENST000  IL1R1  1.25E‐09  4.76E‐06  ‐1.42716  6.81E‐08  ‐1.71362 
3660213  NM_015247 // CYLD // cylindromatosis (turban tumor syndrome) // 16q12.1 // 1540   CYLD  1.26E‐09  0.00443524  ‐1.17471  1.10E‐09  ‐1.66717 
3696317  NM_018667 // SMPD3 // sphingomyelin phosphodiesterase 3, neutral membrane (neutr  SMPD3  1.27E‐09  4.42E‐06  ‐1.4077  7.34E‐08  ‐1.67155 
3984907  NM_016608 // ARMCX1 // armadillo repeat containing, X‐linked 1 // Xq21.33‐q22.2   ARMCX1  1.27E‐09  5.47E‐08  ‐1.41848  6.44E‐06  ‐1.39102 
3748957  NM_000691 // ALDH3A1 // aldehyde dehydrogenase 3 family, memberA1 // 17p11.2 //   ALDH3A1  1.28E‐09  0.0189773  1.14234  6.07E‐10  1.70507 
2731332  NM_000584 // IL8 // interleukin 8 // 4q13‐q21 // 3576 /// ENST00000307407 // IL8  IL8  1.30E‐09  2.68E‐06  2.38543  1.16E‐07  3.46199 
2636626  NM_017577 // GRAMD1C // GRAM domain containing 1C // 3q13.31 // 54762 /// NM_015  GRAMD1C  1.31E‐09  5.89E‐06  ‐1.35455  6.08E‐08  ‐1.59658 
4017212  NM_024657 // MORC4 // MORC family CW‐type zinc finger 4 // Xq22.3 // 79710 /// N  MORC4  1.31E‐09  4.13E‐07  1.84215  6.66E‐07  2.06022 
3362191  NM_020974 // SCUBE2 // signal peptide, CUB domain, EGF‐like 2 // 11p15.3 // 5775  SCUBE2  1.33E‐09  6.80E‐08  ‐1.64308  5.31E‐06  ‐1.61462 
3743306  NM_182906 // CLEC10A // C‐type lectin domain family 10, member A // 17p13.1 // 1  CLEC10A  1.34E‐09  9.80E‐07  ‐1.46521  2.97E‐07  ‐1.63694 
2633631  NM_020202 // NIT2 // nitrilase family, member 2 // 3q12.2 // 56954 /// ENST00000  NIT2  1.35E‐09  1.28E‐05  1.28549  3.51E‐08  1.5167 
3960827  NM_015374 // UNC84B // unc‐84 homolog B (C. elegans) // 22q13.1 // 25777 /// ENS  UNC84B  1.36E‐09  6.50E‐07  ‐1.17655  4.50E‐07  ‐1.22258 




2720584  NM_004787 // SLIT2 // slit homolog 2 (Drosophila) // 4p15.2 // 9353 /// ENST0000  SLIT2  1.39E‐09  2.64E‐06  ‐1.58089  1.28E‐07  ‐1.91652 
3838067  NM_138764 // BAX // BCL2‐associated X protein // 19q13.3‐q13.4 // 581 /// NM_138  BAX  1.40E‐09  0.00351377  1.13895  1.36E‐09  1.48885 
3858794  NM_032816 // CCDC123 // coiled‐coil domain containing 123 // 19q13.11 // 84902 /  CCDC123  1.40E‐09  2.25E‐05  1.13891  2.44E‐08  1.25538 
3676300  NM_002952 // RPS2 // ribosomal protein S2 // 16p13.3 // 6187 /// NR_002327 // SN  RPS2  1.40E‐09  4.16E‐05  1.28527  1.62E‐08  1.59346 
3296981  NM_153367 // ZCCHC24 // zinc finger, CCHC domain containing 24 // 10q22.3 // 219  ZCCHC24  1.43E‐09  1.27E‐07  ‐1.31144  2.78E‐06  ‐1.3229 
3848118  NM_001080452 // GPR108 // G protein‐coupled receptor 108 // 19p13.3 // 56927 ///  GPR108  1.45E‐09  2.19E‐08  ‐1.24772  2.85E‐05  ‐1.20002 
2454378  NM_021194 // SLC30A1 // solute carrier family 30 (zinc transporter), member 1 //  SLC30A1  1.45E‐09  2.39E‐08  ‐1.24243  2.51E‐05  ‐1.1985 
2726910  NM_145263 // SPATA18 // spermatogenesis associated 18 homolog (rat) // 4q12 // 1  SPATA18  1.46E‐09  1.11E‐06  1.58542  2.99E‐07  1.81891 
2835290  BX648997 // LOC153346 // hypothetical protein LOC153346 // 5q33.1 // 153346  LOC153346  1.46E‐09  2.39E‐07  ‐1.60449  1.41E‐06  ‐1.68648 
2473149  NM_147223 // NCOA1 // nuclear receptor coactivator 1 // 2p23 // 8648 /// NM_0037  NCOA1  1.46E‐09  0.0142241  ‐1.14044  7.83E‐10  ‐1.64464 
2404209  NM_014654 // SDC3 // syndecan 3 // 1pter‐p22.3 // 9672 /// ENST00000339394 // SD  SDC3  1.47E‐09  2.06E‐06  1.29162  1.72E‐07  1.42382 
3978518  NM_014599 // MAGED2 // melanoma antigen family D, 2 // Xp11.2 // 10916 /// NM_17  MAGED2  1.48E‐09  2.04E‐06  1.25253  1.76E‐07  1.36391 
2369680  NM_173533 // TDRD5 // tudor domain containing 5 // 1q25.2 // 163589 /// ENST0000  TDRD5  1.49E‐09  6.59E‐06  1.36019  6.65E‐08  1.60876 
2814756  NM_005909 // MAP1B // microtubule‐associated protein 1B // 5q13 // 4131 /// ENST  MAP1B  1.50E‐09  3.39E‐07  ‐1.40863  1.01E‐06  ‐1.48066 
3188697  NM_014397 // NEK6 // NIMA (never in mitosis gene a)‐related kinase 6 // 9q33.3‐q  NEK6  1.52E‐09  0.000289673 1.13373  5.38E‐09  1.32745 
2350952  NM_000848 // GSTM2 // glutathione S‐transferase M2 (muscle) // 1p13.3 // 2946 //  GSTM2  1.52E‐09  8.11E‐06  ‐1.47328  5.83E‐08  ‐1.84092 
3473750  BC034471 // FLJ20674 // hypothetical protein FLJ20674 // 12q24.23 // 54621 /// B  FLJ20674  1.54E‐09  0.000245644 ‐1.14989  6.00E‐09  ‐1.36272 
3957507  ENST00000377087 // DUSP18 // dual specificity phosphatase 18 // 22q12.2 // 15029  DUSP18  1.54E‐09  8.50E‐07  1.23218  4.16E‐07  1.30056 
2906824  NM_001012426 // FOXP4 // forkhead box P4 // 6p21.1 // 116113 /// NM_001012427 //  FOXP4  1.54E‐09  5.84E‐09  1.29046  0.000258651 1.18332 
3868857  NM_145894 // KLK12 // kallikrein‐related peptidase 12 // 19q13.3‐q13.4 // 43849   KLK12  1.55E‐09  3.09E‐07  1.84643  1.17E‐06  2.00121 
3305801  NM_052918 // SORCS1 // sortilin‐related VPS10 domain containing receptor 1 // 10  SORCS1  1.55E‐09  2.82E‐08  ‐1.32098  2.23E‐05  ‐1.26598 
2460817  NM_020808 // SIPA1L2 // signal‐induced proliferation‐associated 1 like 2 // 1q42  SIPA1L2  1.55E‐09  1.84E‐06  ‐1.38849  2.06E‐07  ‐1.5624 
2745899  NM_022475 // HHIP // hedgehog interacting protein // 4q28‐q32 // 64399 /// ENST0  HHIP  1.56E‐09  4.00E‐05  ‐1.43205  1.90E‐08  ‐1.93504 
2406735  NM_145047 // C1orf102 // chromosome 1 open reading frame 102 // 1p34.3 // 127700  C1orf102  1.56E‐09  3.07E‐05  1.16349  2.27E‐08  1.31154 
2592356  NM_003151 // STAT4 // signal transducer and activator of transcription 4 // 2q32  STAT4  1.57E‐09  0.000958412 ‐1.16873  2.92E‐09  ‐1.49506 
2777113  NM_001128310 // SPARCL1 // SPARC‐like 1 (hevin) // 4q22.1 // 8404 /// NM_004684   SPARCL1  1.57E‐09  1.54E‐05  ‐1.74502  3.75E‐08  ‐2.53807 
2780999  NM_005443 // PAPSS1 // 3'‐phosphoadenosine 5'‐phosphosulfate synthase 1 // 4q24   PAPSS1  1.57E‐09  8.99E‐09  1.45149  0.000130241 1.30298 
2783596  NM_001083 // PDE5A // phosphodiesterase 5A, cGMP‐specific // 4q25‐q27 // 8654 //  PDE5A  1.59E‐09  0.000227965 ‐1.35555  6.50E‐09  ‐1.94965 
2457261  NM_007207 // DUSP10 // dual specificity phosphatase 10 // 1q41 // 11221 /// NM_1  DUSP10  1.59E‐09  5.00E‐08  1.45238  1.06E‐05  1.40532 
3475838  NM_024667 // VPS37B // vacuolar protein sorting 37 homolog B (S. cerevisiae) //   VPS37B  1.59E‐09  8.98E‐07  ‐1.20534  4.16E‐07  ‐1.26589 
3778601  NM_003574 // VAPA // VAMP (vesicle‐associated membrane protein)‐associated prote  VAPA  1.60E‐09  8.00E‐07  ‐1.2935  4.68E‐07  ‐1.3784 
3400730  NM_199460 // CACNA1C // calcium channel, voltage‐dependent, L type, alpha 1C sub  CACNA1C  1.61E‐09  6.48E‐06  1.24714  7.48E‐08  1.40372 
2485688  NM_015147 // CEP68 // centrosomal protein 68kDa // 2p14 // 23177 /// ENST0000037  CEP68  1.62E‐09  2.33E‐07  1.28581  1.71E‐06  1.31613 
3290368  NM_152230 // IPMK // inositol polyphosphate multikinase // 10q21.1 // 253430 ///  IPMK  1.62E‐09  3.83E‐07  ‐1.33061  1.00E‐06  ‐1.3902 
4025339  NM_000202 // IDS // iduronate 2‐sulfatase // Xq28 // 3423 /// NM_006123 // IDS /  IDS  1.62E‐09  0.278682  ‐1.04384  3.14E‐10  ‐1.48155 
2417095  NM_015139 // SLC35D1 // solute carrier family 35 (UDP‐glucuronic acid/UDP‐N‐acet  SLC35D1  1.63E‐09  5.26E‐07  ‐1.62185  7.29E‐07  ‐1.77981 
3567556  NM_001017970 // TMEM30B // transmembrane protein 30B // 14q23.1 // 161291 /// EN  TMEM30B  1.66E‐09  2.14E‐08  ‐1.27679  3.76E‐05  ‐1.21816 
3642137  NM_203472 // SELS // selenoprotein S // 15q26.3 // 55829 /// NM_018445 // SELS /  SELS  1.68E‐09  2.19E‐05  ‐1.28773  3.17E‐08  ‐1.54675 
2495121  NM_001862 // COX5B // cytochrome c oxidase subunit Vb // 2cen‐q13 // 1329 /// EN  COX5B  1.70E‐09  2.48E‐09  ‐1.35716  0.00159919  ‐1.17851 
2561955  NM_003849 // SUCLG1 // succinate‐CoA ligase, alpha subunit // 2p11.2 // 8802 ///  SUCLG1  1.74E‐09  8.27E‐09  ‐1.52914  0.000182837 ‐1.34004 
3742236  NM_014389 // PELP1 // proline, glutamate and leucine rich protein 1 // 17p13.2 /  PELP1  1.74E‐09  0.00132839  1.11059  2.80E‐09  1.32311 




3816699  NM_173480 // ZNF57 // zinc finger protein 57 // 19p13.3 // 126295 /// ENST000003  ZNF57  1.75E‐09  1.66E‐08  ‐1.48063  6.05E‐05  ‐1.35416 
2701033  NM_001081455 // P2RY14 // purinergic receptor P2Y, G‐protein coupled, 14 // 3q24  P2RY14  1.75E‐09  8.30E‐07  ‐1.58481  5.16E‐07  ‐1.77265 
2479693  XR_038049 // LOC100129982 // similar to ribosomal protein L12 // 2p21 // 1001299  LOC100129982  1.76E‐09  6.23E‐06  1.38675  8.73E‐08  1.64414 
3558745  NM_002515 // NOVA1 // neuro‐oncological ventral antigen 1 // 14q // 4857 /// NM_  NOVA1  1.77E‐09  1.06E‐05  ‐1.28469  5.81E‐08  ‐1.49353 
3598430  NM_004727 // SLC24A1 // solute carrier family 24 (sodium/potassium/calcium excha  SLC24A1  1.78E‐09  1.38E‐06  1.2618  3.26E‐07  1.35543 
3887479  NM_172111 // EYA2 // eyes absent homolog 2 (Drosophila) // 20q13.1 // 2139 /// N  EYA2  1.78E‐09  1.80E‐08  ‐1.8239  5.55E‐05  ‐1.59795 
3899111  NM_001195 // BFSP1 // beaded filament structural protein 1, filensin // 20p11.23  BFSP1  1.81E‐09  7.02E‐06  1.37584  8.22E‐08  1.6325 
3340449  NM_007256 // SLCO2B1 // solute carrier organic anion transporter family, member   SLCO2B1  1.81E‐09  3.93E‐08  ‐1.47979  1.86E‐05  ‐1.40646 
3949017  NM_017931 // TTC38 // tetratricopeptide repeat domain 38 // 22q13 // 55020 /// E  TTC38  1.81E‐09  1.92E‐09  ‐1.34486  0.00314468  ‐1.1576 
2904597  NM_006238 // PPARD // peroxisome proliferator‐activated receptor delta // 6p21.2  PPARD  1.82E‐09  3.57E‐08  ‐1.39101  2.14E‐05  ‐1.32758 
3352404  NM_178507 // OAF // OAF homolog (Drosophila) // 11q23.3 // 220323 /// ENST000003  OAF  1.83E‐09  4.08E‐07  ‐1.33282  1.14E‐06  ‐1.39115 
2363389  NM_005600 // NIT1 // nitrilase 1 // 1q21‐q22 // 4817 /// ENST00000368009 // NIT1  NIT1  1.86E‐09  1.51E‐07  ‐1.31867  3.51E‐06  ‐1.32851 
3825201  NM_001033930 // UBA52 // ubiquitin A‐52 residue ribosomal protein fusion product  UBA52  1.86E‐09  7.18E‐05  1.18688  1.61E‐08  1.39199 
3336640  AK026328 // C11orf86 // chromosome 11 open reading frame 86 // 11q13.1 // 254439  C11orf86  1.87E‐09  3.22E‐07  ‐1.72604  1.50E‐06  ‐1.8414 
2815331  NM_001037637 // BTF3 // basic transcription factor 3 // 5q13.2 // 689 /// NM_001  BTF3  1.87E‐09  2.64E‐06  1.27954  1.95E‐07  1.40913 
2677850  NM_017563 // IL17RD // interleukin 17 receptor D // 3p14.3 // 54756 /// ENST0000  IL17RD  1.95E‐09  1.89E‐07  2.1531  2.91E‐06  2.23641 
2544781  NM_021907 // DTNB // dystrobrevin, beta // 2p24 // 1838 /// NM_033147 // DTNB //  DTNB  1.95E‐09  7.66E‐06  1.19559  8.49E‐08  1.31711 
3732885  NM_212472 // PRKAR1A // protein kinase, cAMP‐dependent, regulatory, type I, alph  PRKAR1A  1.96E‐09  2.67E‐07  1.25667  1.99E‐06  1.28303 
2475407  NM_024692 // CLIP4 // CAP‐GLY domain containing linker protein family, member 4   CLIP4  1.98E‐09  6.27E‐06  ‐1.34918  1.01E‐07  ‐1.57208 
3417075  NM_201444 // DGKA // diacylglycerol kinase, alpha 80kDa // 12q13.3 // 1606 /// N  DGKA  1.98E‐09  2.43E‐06  ‐1.33052  2.28E‐07  ‐1.48065 
3718682  NM_001030006 // AP2B1 // adaptor‐related protein complex 2, beta 1 subunit // 17  AP2B1  2.02E‐09  1.03E‐06  1.32023  5.19E‐07  1.41795 
3068097  NM_014705 // DOCK4 // dedicator of cytokinesis 4 // 7q31.1 // 9732 /// ENST00000  DOCK4  2.02E‐09  1.50E‐06  ‐1.37461  3.62E‐07  ‐1.51573 
3401197  NM_031465 // C12orf32 // chromosome 12 open reading frame 32 // 12p13.33 // 8369  C12orf32  2.02E‐09  0.00192048  1.11131  2.75E‐09  1.34037 
3955327  NM_031444 // C22orf13 // chromosome 22 open reading frame 13 // 22q11.2 // 83606  C22orf13  2.02E‐09  1.32E‐08  ‐1.30435  0.000115137 ‐1.21377 
3335029  NM_002689 // POLA2 // polymerase (DNA directed), alpha 2 (70kD subunit) // 11q13  POLA2  2.03E‐09  0.452612  1.03526  3.51E‐10  1.58053 
3708798  NM_015670 // SENP3 // SUMO1/sentrin/SMT3 specific peptidase 3 // 17p13 // 26168   SENP3  2.04E‐09  0.137154  1.04585  4.89E‐10  1.33943 
2887164  NM_001017995 // SH3PXD2B // SH3 and PX domains 2B // 5q35.1 // 285590 /// ENST00  SH3PXD2B  2.05E‐09  4.26E‐06  1.38183  1.47E‐07  1.59841 
2550175  NM_133329 // KCNG3 // potassium voltage‐gated channel, subfamily G, member 3 //   KCNG3  2.07E‐09  1.62E‐09  ‐1.51699  0.00630103  ‐1.20626 
3421523  NM_006530 // YEATS4 // YEATS domain containing 4 // 12q13‐q15 // 8089 /// ENST00  YEATS4  2.08E‐09  4.28E‐06  1.38467  1.49E‐07  1.60289 
2327391  NM_031459 // SESN2 // sestrin 2 // 1p35.3 // 83667 /// ENST00000253063 // SESN2   SESN2  2.08E‐09  1.46E‐07  ‐1.19587  4.37E‐06  ‐1.19853 
3812074  NM_032160 // DSEL // dermatan sulfate epimerase‐like // 18q22.1 // 92126 /// ENS  DSEL  2.08E‐09  3.16E‐07  ‐1.37623  1.82E‐06  ‐1.42346 
3666146  NM_003983 // SLC7A6 // solute carrier family 7 (cationic amino acid transporter,  SLC7A6  2.09E‐09  5.72E‐05  1.28457  2.16E‐08  1.59897 
3105749  NM_152565 // ATP6V0D2 // ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2  ATP6V0D2  2.12E‐09  4.01E‐07  ‐1.70727  1.44E‐06  ‐1.83346 
3984468  NM_014467 // SRPX2 // sushi‐repeat‐containing protein, X‐linked 2 // Xq21.33‐q23  SRPX2  2.13E‐09  6.96E‐05  1.61165  1.93E‐08  2.48842 
3067302  NM_002291 // LAMB1 // laminin, beta 1 // 7q22 // 3912 /// ENST00000222399 // LAM  LAMB1  2.15E‐09  1.05E‐08  1.46325  0.000187637 1.30279 
3204301  NM_002989 // CCL21 // chemokine (C‐C motif) ligand 21 // 9p13 // 6366 /// ENST00  CCL21  2.20E‐09  0.00154791  ‐1.75467  3.37E‐09  ‐4.53913 
3362826  NM_006691 // LYVE1 // lymphatic vessel endothelial hyaluronan receptor 1 // 11p1  LYVE1  2.23E‐09  8.28E‐06  ‐1.70255  9.56E‐08  ‐2.26988 
3944404  NM_145343 // APOL1 // apolipoprotein L, 1 // 22q13.1 // 8542 /// NM_003661 // AP  APOL1  2.26E‐09  3.21E‐07  1.62858  2.03E‐06  1.70972 
2545869  NM_015662 // IFT172 // intraflagellar transport 172 homolog (Chlamydomonas) // 2  IFT172  2.27E‐09  4.79E‐08  1.23115  2.12E‐05  1.19849 
3216671  NM_001333 // CTSL2 // cathepsin L2 // 9q22.2 // 1515 /// ENST00000259470 // CTSL  CTSL2  2.27E‐09  0.0157635  1.19793  1.21E‐09  1.97968 
3970642  NM_001037343 // CDKL5 // cyclin‐dependent kinase‐like 5 // Xp22 // 6792 /// NM_0  CDKL5  2.29E‐09  0.000119206 1.17329  1.50E‐08  1.37905 




3592511  NM_021199 // SQRDL // sulfide quinone reductase‐like (yeast) // 15q15 // 58472 /  SQRDL  2.32E‐09  2.59E‐08  ‐1.51763  5.28E‐05  ‐1.39362 
3755820  NM_033419 // PERLD1 // per1‐like domain containing 1 // 17q12 // 93210 /// ENST0  PERLD1  2.33E‐09  5.41E‐09  ‐1.23655  0.000709171 ‐1.13639 
3214668  NM_013417 // IARS // isoleucyl‐tRNA synthetase // 9q21 // 3376 /// NM_002161 //   IARS  2.35E‐09  9.62E‐05  1.4012  1.77E‐08  1.93959 
2348992  NM_001078 // VCAM1 // vascular cell adhesion molecule 1 // 1p32‐p31 // 7412 ///   VCAM1  2.35E‐09  0.000249763 ‐1.45789  9.87E‐09  ‐2.26758 
2855542  NM_148672 // CCL28 // chemokine (C‐C motif) ligand 28 // 5p12 // 56477 /// ENST0  CCL28  2.36E‐09  8.72E‐06  ‐1.50432  9.88E‐08  ‐1.87776 
2334098  NM_006845 // KIF2C // kinesin family member 2C // 1p34.1 // 11004 /// ENST000003  KIF2C  2.36E‐09  0.00150433  1.23374  3.71E‐09  1.75272 
2458338  NM_001008493 // ENAH // enabled homolog (Drosophila) // 1q42.12 // 55740 /// NM_  ENAH  2.37E‐09  2.99E‐07  1.53861  2.38E‐06  1.59671 
2334706  NM_199044 // NSUN4 // NOL1/NOP2/Sun domain family, member 4 // 1p34 // 387338 //  NSUN4  2.38E‐09  0.000118923 1.18283  1.58E‐08  1.40051 
2793137  NM_020870 // SH3RF1 // SH3 domain containing ring finger 1 // 4q32.3‐q33 // 5763  SH3RF1  2.39E‐09  1.27E‐05  ‐1.18825  7.50E‐08  ‐1.31791 
3590086  NM_002875 // RAD51 // RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) // 1  RAD51  2.39E‐09  0.979804  1.00124  3.73E‐10  1.62563 
3110789  NM_012082 // ZFPM2 // zinc finger protein, multitype 2 // 8q23 // 23414 /// ENST  ZFPM2  2.40E‐09  1.14E‐06  ‐1.42505  6.03E‐07  ‐1.55936 
2404158  NM_006762 // LAPTM5 // lysosomal multispanning membrane protein 5 // 1p34 // 780  LAPTM5  2.42E‐09  1.63E‐05  ‐1.48294  6.31E‐08  ‐1.90791 
3851868  NM_004461 // FARSA // phenylalanyl‐tRNA synthetase, alpha subunit // 19p13.2 //   FARSA  2.43E‐09  0.0672742  1.05882  7.45E‐10  1.34376 
3866898  NM_000234 // LIG1 // ligase I, DNA, ATP‐dependent // 19q13.2‐q13.3 // 3978 /// E  LIG1  2.45E‐09  0.00167815  1.11279  3.65E‐09  1.33507 
3962054  NM_005008 // NHP2L1 // NHP2 non‐histone chromosome protein 2‐like 1 (S. cerevisi  NHP2L1  2.51E‐09  0.00873935  1.12809  1.73E‐09  1.50801 
3420854  NM_006482 // DYRK2 // dual‐specificity tyrosine‐(Y)‐phosphorylation regulated ki  DYRK2  2.55E‐09  9.91E‐07  ‐1.25602  7.58E‐07  ‐1.32365 
3712949  NM_001388 // DRG2 // developmentally regulated GTP binding protein 2 // 17p11.2   DRG2  2.61E‐09  0.0171114  1.07287  1.36E‐09  1.30777 
3736290  NM_001168 // BIRC5 // baculoviral IAP repeat‐containing 5 // 17q25 // 332 /// NM  BIRC5  2.62E‐09  0.0310736  1.1429  1.07E‐09  1.7731 
3509719  NM_015087 // SPG20 // spastic paraplegia 20 (Troyer syndrome) // 13q13.3 // 2311  SPG20  2.62E‐09  7.67E‐06  ‐1.42117  1.26E‐07  ‐1.70192 
2500803  NM_153712 // TTL // tubulin tyrosine ligase // 2q13 // 150465 /// ENST0000023333  TTL  2.62E‐09  5.56E‐06  1.24637  1.65E‐07  1.38073 
3969047  NM_001039091 // PRPS2 // phosphoribosyl pyrophosphate synthetase 2 // Xp22.3‐p22  PRPS2  2.64E‐09  0.00237871  1.1568  3.35E‐09  1.50762 
2723605  NM_001104629 // C4orf19 // chromosome 4 open reading frame 19 // 4p14 // 55286 /  C4orf19  2.64E‐09  8.39E‐07  ‐1.37466  9.42E‐07  ‐1.46743 
2796951  NM_014476 // PDLIM3 // PDZ and LIM domain 3 // 4q35 // 27295 /// NM_001114107 //  PDLIM3  2.64E‐09  6.56E‐05  ‐1.32937  2.64E‐08  ‐1.70578 
2877861  NM_005847 // SLC23A1 // solute carrier family 23 (nucleobase transporters), memb  SLC23A1  2.66E‐09  7.71E‐08  ‐1.74266  1.48E‐05  ‐1.65901 
2721633  NM_003102 // SOD3 // superoxide dismutase 3, extracellular // 4p15.3‐p15.1 // 66  SOD3  2.66E‐09  1.00E‐08  1.62395  0.000313112 1.38044 
3066436  NM_019042 // PUS7 // pseudouridylate synthase 7 homolog (S. cerevisiae) // 7q22.  PUS7  2.67E‐09  1.17E‐05  1.56744  9.27E‐08  2.03049 
3568616  NM_198686 // RAB15 // RAB15, member RAS onocogene family // 14q23.3 // 376267 //  RAB15  2.67E‐09  3.30E‐06  1.41058  2.65E‐07  1.61198 
2359817  NM_023015 // INTS3 // integrator complex subunit 3 // 1q21.3 // 65123 /// ENST00  INTS3  2.70E‐09  7.22E‐08  1.24395  1.65E‐05  1.21764 
3340589  NM_001235 // SERPINH1 // serpin peptidase inhibitor, clade H (heat shock protein  SERPINH1  2.70E‐09  0.000610401 1.16355  6.98E‐09  1.43457 
2617433  NM_015873 // VILL // villin‐like // 3p21.3 // 50853 /// ENST00000283713 // VILL   VILL  2.73E‐09  3.99E‐05  ‐1.29131  3.85E‐08  ‐1.57632 
2656146  NM_004721 // MAP3K13 // mitogen‐activated protein kinase kinase kinase 13 // 3q2  MAP3K13  2.76E‐09  0.000239168 ‐1.26402  1.23E‐08  ‐1.65244 
4026956  NM_005334 // HCFC1 // host cell factor C1 (VP16‐accessory protein) // Xq28 // 30  HCFC1  2.76E‐09  0.000291908 1.0906  1.09E‐08  1.20922 
2474977  NM_005253 // FOSL2 // FOS‐like antigen 2 // 2p23.3 // 2355 /// ENST00000264716 /  FOSL2  2.79E‐09  6.47E‐07  ‐1.28126  1.33E‐06  ‐1.33532 
3986585  NM_012216 // MID2 // midline 2 // Xq22 // 11043 /// NM_052817 // MID2 // midline  MID2  2.79E‐09  2.44E‐06  1.30012  3.69E‐07  1.42211 
2615892  NM_178868 // CMTM8 // CKLF‐like MARVEL transmembrane domain containing 8 // 3p22  CMTM8  2.84E‐09  1.18E‐07  1.34698  9.52E‐06  1.32953 
3064574  NM_014343 // CLDN15 // claudin 15 // 7q11.22 // 24146 /// ENST00000401528 // CLD  CLDN15  2.85E‐09  2.86E‐07  ‐1.45736  3.36E‐06  ‐1.49201 
3886223  NM_002466 // MYBL2 // v‐myb myeloblastosis viral oncogene homolog (avian)‐like 2  MYBL2  2.86E‐09  0.0304954  1.16167  1.19E‐09  1.89198 
3738224  NM_012140 // SLC25A10 // solute carrier family 25 (mitochondrial carrier; dicarb  SLC25A10  2.90E‐09  0.00864059  ‐1.10451  2.04E‐09  1.39936 
2675315  NM_001005505 // CACNA2D2 // calcium channel, voltage‐dependent, alpha 2/delta su  CACNA2D2  2.91E‐09  2.65E‐06  1.58458  3.63E‐07  1.8607 
2383356  NM_020247 // CABC1 // chaperone, ABC1 activity of bc1 complex homolog (S. pombe)  CABC1  2.93E‐09  1.99E‐06  1.20341  4.76E‐07  1.27433 
2555174  NM_144709 // PUS10 // pseudouridylate synthase 10 // 2p16.1 // 150962 /// ENST00  PUS10  2.95E‐09  2.81E‐06  ‐1.37141  3.50E‐07  ‐1.53474 




3032446  NM_020445 // ACTR3B // ARP3 actin‐related protein 3 homolog B (yeast) // 7q36.1   ACTR3B  2.97E‐09  9.45E‐05  1.26783  2.40E‐08  1.58272 
3007894  NM_017528 // WBSCR22 // Williams Beuren syndrome chromosome region 22 // ‐‐‐ //   WBSCR22  2.98E‐09  8.18E‐05  1.21035  2.64E‐08  1.43889 
2456805  NM_006085 // BPNT1 // 3'(2'), 5'‐bisphosphate nucleotidase 1 // 1q41 // 10380 //  BPNT1  2.98E‐09  1.20E‐06  ‐1.36135  7.91E‐07  ‐1.46598 
3108526  NM_002380 // MATN2 // matrilin 2 // 8q22 // 4147 /// NM_030583 // MATN2 // matri  MATN2  3.01E‐09  0.000211645 ‐1.40164  1.47E‐08  ‐2.03587 
3736232  NM_004710 // SYNGR2 // synaptogyrin 2 // 17q25.3 // 9144 /// ENST00000225777 //   SYNGR2  3.02E‐09  4.58E‐05  1.23499  3.99E‐08  1.46047 
3870824  NM_002287 // LAIR1 // leukocyte‐associated immunoglobulin‐like receptor 1 // 19q  LAIR1  3.04E‐09  5.60E‐06  ‐1.35544  2.01E‐07  ‐1.55486 
2408111  NM_017646 // TRIT1 // tRNA isopentenyltransferase 1 // 1p35.3‐p34.1 // 54802 ///  TRIT1  3.06E‐09  6.05E‐07  1.37452  1.65E‐06  1.44138 
3589697  NM_001211 // BUB1B // BUB1 budding uninhibited by benzimidazoles 1 homolog beta   BUB1B  3.09E‐09  0.00436792  1.21895  2.98E‐09  1.82587 
3192062  NM_013318 // KIAA0515 // KIAA0515 // 9q34.13 // 84726 /// ENST00000357304 // KIA  KIAA0515  3.10E‐09  3.18E‐07  1.24653  3.40E‐06  1.2652 
2770427  NM_032313 // C4orf14 // chromosome 4 open reading frame 14 // 4q12 // 84273 ///   C4orf14  3.13E‐09  1.22E‐06  1.235  8.38E‐07  1.2984 
4053550  NM_198576 // AGRN // agrin // 1p36.33 // 375790 /// ENST00000379370 // AGRN // a  AGRN  3.14E‐09  4.02E‐07  1.23427  2.67E‐06  1.25926 
3572235  NM_001040108 // MLH3 // mutL homolog 3 (E. coli) // 14q24.3 // 27030 /// NM_0143  MLH3  3.15E‐09  1.55E‐07  1.32217  8.12E‐06  1.31417 
2870964  NM_022140 // EPB41L4A // erythrocyte membrane protein band 4.1 like 4A // 5q22.2  EPB41L4A  3.17E‐09  0.0256553  ‐1.23019  1.42E‐09  ‐2.33236 
2605735  NM_018645 // HES6 // hairy and enhancer of split 6 (Drosophila) // 2q37.3 // 555  HES6  3.17E‐09  0.000170818 1.33435  1.78E‐08  1.80747 
3881786  NM_015352 // POFUT1 // protein O‐fucosyltransferase 1 // 20q11 // 23509 /// NM_1  POFUT1  3.18E‐09  6.42E‐07  1.30537  1.65E‐06  1.35965 
3864597  NM_019108 // C19orf61 // chromosome 19 open reading frame 61 // 19q13.31 // 5600  C19orf61  3.22E‐09  0.000569222 1.11559  8.90E‐09  1.29207 
3469844  NM_001033050 // MTERFD3 // MTERF domain containing 3 // 12q24.1 // 80298 /// NM_  MTERFD3  3.27E‐09  0.00027764  1.24117  1.37E‐08  1.5945 
4000269  NM_017856 // GEMIN8 // gem (nuclear organelle) associated protein 8 // Xp22.2 //  GEMIN8  3.27E‐09  1.17E‐06  1.26249  9.30E‐07  1.33128 
3884830  NM_015568 // PPP1R16B // protein phosphatase 1, regulatory (inhibitor) subunit 1  PPP1R16B  3.28E‐09  6.86E‐06  ‐1.27195  1.88E‐07  ‐1.42558 
3982612  NM_032553 // GPR174 // G protein‐coupled receptor 174 // Xq21.1 // 84636 /// ENS  GPR174  3.33E‐09  0.0409329  ‐1.29605  1.25E‐09  ‐3.21942 
2883349  NM_032782 // HAVCR2 // hepatitis A virus cellular receptor 2 // 5q33.3 // 84868   HAVCR2  3.41E‐09  1.73E‐06  ‐1.28289  6.77E‐07  ‐1.37403 
3401704  NM_001759 // CCND2 // cyclin D2 // 12p13 // 894 /// ENST00000261254 // CCND2 //   CCND2  3.42E‐09  5.25E‐06  1.4979  2.50E‐07  1.78233 
3561952  NM_006364 // SEC23A // Sec23 homolog A (S. cerevisiae) // 14q21.1 // 10484 /// E  SEC23A  3.42E‐09  2.79E‐08  ‐1.50993  9.80E‐05  ‐1.36953 
3150715  NM_024094 // DSCC1 // defective in sister chromatid cohesion 1 homolog (S. cerev  DSCC1  3.43E‐09  0.0126088  1.19091  2.08E‐09  1.8662 
3302990  NM_002079 // GOT1 // glutamic‐oxaloacetic transaminase 1, soluble (aspartate ami  GOT1  3.47E‐09  3.00E‐09  ‐1.62732  0.00566399  ‐1.25599 
2420642  NM_153259 // MCOLN2 // mucolipin 2 // 1p22 // 255231 /// ENST00000370608 // MCOL  MCOLN2  3.48E‐09  8.37E‐06  ‐1.88582  1.73E‐07  ‐2.58641 
2420511  BC137361 // C1orf180 // chromosome 1 open reading frame 180 // 1p22.3 // 439927   C1orf180  3.51E‐09  2.89E‐08  2.05528  9.75E‐05  1.7347 
2918037  NM_052904 // KLHL32 // kelch‐like 32 (Drosophila) // 6q16.1 // 114792 /// ENST00  KLHL32  3.59E‐09  6.16E‐07  1.695  2.07E‐06  1.82105 
4002741  NM_001037171 // ACOT9 // acyl‐CoA thioesterase 9 // Xp22.11 // 23597 /// NM_0010  ACOT9  3.60E‐09  4.54E‐05  1.19229  5.01E‐08  1.36627 
2362469  NM_021189 // CADM3 // cell adhesion molecule 3 // 1q21.2‐q22 // 57863 /// NM_001  CADM3  3.62E‐09  1.04E‐06  ‐1.36949  1.22E‐06  ‐1.4592 
3430868  NM_001917 // DAO // D‐amino‐acid oxidase // 12q24 // 1610 /// ENST00000228476 //  DAO  3.64E‐09  3.28E‐08  ‐1.83225  8.60E‐05  ‐1.60008 
3454223  NM_013277 // RACGAP1 // Rac GTPase activating protein 1 // 12q13.13 // 29127 ///  RACGAP1  3.69E‐09  0.00953745  1.16806  2.54E‐09  1.69507 
3089535  NM_176871 // PDLIM2 // PDZ and LIM domain 2 (mystique) // 8p21.2 // 64236 /// NM  PDLIM2  3.70E‐09  4.30E‐07  ‐1.40974  3.21E‐06  ‐1.45285 
2432714  NM_007053 // CD160 // CD160 molecule // 1q21.1 // 11126 /// ENST00000369288 // C  CD160  3.72E‐09  1.32E‐05  ‐1.33301  1.31E‐07  ‐1.56682 
3705539  NM_018146 // RNMTL1 // RNA methyltransferase like 1 // 17p13.3 // 55178 /// ENST  RNMTL1  3.73E‐09  0.0491639  1.06927  1.31E‐09  1.36856 
3862273  NM_018457 // PRR13 // proline rich 13 // 12q12 // 54458 /// ENST00000379786 // P  PRR13  3.75E‐09  1.17E‐07  ‐1.58864  1.55E‐05  ‐1.53586 
3878533  NM_080820 // DTD1 // D‐tyrosyl‐tRNA deacylase 1 homolog (S. cerevisiae) // 20p11  DTD1  3.77E‐09  1.36E‐05  1.23242  1.30E‐07  1.38698 
3409211  NM_003622 // PPFIBP1 // PTPRF interacting protein, binding protein 1 (liprin bet  PPFIBP1  3.77E‐09  5.49E‐07  1.28785  2.53E‐06  1.32638 
3323443  NM_005788 // PRMT3 // protein arginine methyltransferase 3 // 11p15.1 // 10196 /  PRMT3  3.79E‐09  0.00011664  1.31939  2.82E‐08  1.71756 
3974098  NM_021242 // MID1IP1 // MID1 interacting protein 1 (gastrulation specific G12 ho  MID1IP1  3.83E‐09  2.93E‐06  1.24859  4.89E‐07  1.34536 
2888284  AF151875 // HSPC111 // hypothetical protein HSPC111 // 5q35.2 // 51491 /// AK300  HSPC111  3.85E‐09  7.65E‐05  1.22152  3.81E‐08  1.45243 




3150060  NM_000127 // EXT1 // exostoses (multiple) 1 // 8q24.11‐q24.13 // 2131 /// ENST00  EXT1  3.86E‐09  1.56E‐06  ‐1.34286  8.95E‐07  ‐1.44548 
3428225  NM_005123 // NR1H4 // nuclear receptor subfamily 1, group H, member 4 // 12q23.1  NR1H4  3.89E‐09  2.04E‐08  ‐2.68101  0.000205684 ‐2.01469 
2971801  NM_005907 // MAN1A1 // mannosidase, alpha, class 1A, member 1 // 6q22 // 4121 //  MAN1A1  3.89E‐09  5.77E‐08  ‐1.47485  4.28E‐05  ‐1.38467 
3921490  NM_033171 // B3GALT5 // UDP‐Gal:betaGlcNAc beta 1,3‐galactosyltransferase, polyp  B3GALT5  3.90E‐09  0.00232302  ‐1.66679  5.26E‐09  ‐4.09176 
3067890  NM_032549 // IMMP2L // IMP2 inner mitochondrial membrane peptidase‐like (S. cere  IMMP2L  3.93E‐09  4.28E‐06  1.32198  3.62E‐07  1.47274 
3938384  BC071804 // IGL@ // immunoglobulin lambda locus // 22q11.1‐q11.2 // 3535 /// BC0  IGL@  3.94E‐09  7.62E‐07  ‐1.68346  1.91E‐06  ‐1.82386 
3985218  NM_022838 // ARMCX5 // armadillo repeat containing, X‐linked 5 // Xq22.1‐q22.3 /  ARMCX5  3.97E‐09  0.000191579 1.10631  2.18E‐08  1.2304 
3607232  NM_022767 // AEN // apoptosis enhancing nuclease // 15q26.1 // 64782 /// ENST000  AEN  3.98E‐09  3.44E‐05  1.34323  6.95E‐08  1.65843 
2989112  NM_018106 // ZDHHC4 // zinc finger, DHHC‐type containing 4 // 7p22.1 // 55146 //  ZDHHC4  3.98E‐09  0.000178201 1.14209  2.29E‐08  1.31064 
3107242  NM_153704 // TMEM67 // transmembrane protein 67 // 8q22.1 // 91147 /// ENST00000  TMEM67  4.02E‐09  5.47E‐07  1.43798  2.81E‐06  1.49641 
2950263  NM_002118 // HLA‐DMB // major histocompatibility complex, class II, DM beta // 6  HLA‐DMB  4.03E‐09  2.84E‐05  ‐1.59051  8.13E‐08  ‐2.18048 
3591704  NM_024908 // WDR76 // WD repeat domain 76 // 15q15.3 // 79968 /// ENST0000026379  WDR76  4.05E‐09  0.00263253  1.15601  5.15E‐09  1.50054 
2787266  NM_020724 // RNF150 // ring finger protein 150 // 4q31.21 // 57484 /// ENST00000  RNF150  4.08E‐09  2.71E‐07  ‐1.26827  6.36E‐06  ‐1.27449 
3543714  NM_152331 // ACOT4 // acyl‐CoA thioesterase 4 // 14q24.3 // 122970 /// ENST00000  ACOT4  4.11E‐09  1.04E‐09  ‐1.40046  0.127052  ‐1.08376 
3352040  NM_024791 // PDZD3 // PDZ domain containing 3 // 11q23.3 // 79849 /// ENST000003  PDZD3  4.12E‐09  2.67E‐05  ‐1.43575  8.75E‐08  ‐1.82763 
2443120  NM_001937 // DPT // dermatopontin // 1q12‐q23 // 1805 /// ENST00000367817 // DPT  DPT  4.12E‐09  3.98E‐06  ‐1.78258  4.13E‐07  ‐2.21009 
3763390  NM_001099640 // TMEM100 // transmembrane protein 100 // 17q22 // 55273 /// NM_01  TMEM100  4.13E‐09  7.95E‐08  ‐1.81552  3.05E‐05  ‐1.6803 
2904683  NM_007104 // RPL10A // ribosomal protein L10a // 6p21.3‐p21.2 // 4736 /// ENST00  RPL10A  4.14E‐09  2.12E‐05  1.22587  1.05E‐07  1.39315 
3413344  NM_000289 // PFKM // phosphofructokinase, muscle // 12q13.3 // 5213 /// ENST0000  PFKM  4.16E‐09  0.00140284  1.20003  7.34E‐09  1.59974 
3711700  NM_020652 // ZNF286A // zinc finger protein 286A // 17p11.2 // 57335 /// ENST000  ZNF286A  4.25E‐09  2.59E‐07  1.31292  7.15E‐06  1.31691 
3855633  NM_001001524 // TM6SF2 // transmembrane 6 superfamily member 2 // 19p13.3‐p12 //  TM6SF2  4.27E‐09  2.76E‐07  ‐1.95335  6.69E‐06  ‐1.97764 
2464909  NM_022743 // SMYD3 // SET and MYND domain containing 3 // 1q44 // 64754 /// ENST  SMYD3  4.29E‐09  3.42E‐06  1.20485  5.00E‐07  1.28523 
3947036  NM_152513 // MEI1 // meiosis inhibitor 1 // 22q13.2 // 150365 /// BC070111 // ME  MEI1  4.30E‐09  3.03E‐07  ‐1.46608  6.06E‐06  ‐1.48268 
3625234  NM_016304 // C15orf15 // chromosome 15 open reading frame 15 // 15q21 // 51187 /  C15orf15  4.31E‐09  6.38E‐07  1.38864  2.64E‐06  1.44564 
3513794  NM_018191 // RCBTB1 // regulator of chromosome condensation (RCC1) and BTB (POZ)  RCBTB1  4.33E‐09  3.48E‐06  1.3193  4.99E‐07  1.45294 
3833793  NM_016154 // RAB4B // RAB4B, member RAS oncogene family // 19q13.2 // 53916 ///   RAB4B  4.34E‐09  9.37E‐07  ‐1.25526  1.78E‐06  ‐1.30509 
2905327  NM_173558 // FGD2 // FYVE, RhoGEF and PH domain containing 2 // 6p21.2 // 221472  FGD2  4.34E‐09  1.33E‐06  ‐1.2926  1.25E‐06  ‐1.36655 
3217807  NM_017746 // TEX10 // testis expressed 10 // 9q31.1 // 54881 /// ENST00000374902  TEX10  4.38E‐09  1.80E‐06  1.40917  9.36E‐07  1.5389 
3168066  NM_001216 // CA9 // carbonic anhydrase IX // 9p13‐p12 // 768 /// ENST00000378357  CA9  4.38E‐09  9.04E‐08  2.0515  2.84E‐05  1.88169 
3644375  NM_000548 // TSC2 // tuberous sclerosis 2 // 16p13.3 // 7249 /// NM_001114382 //  TSC2  4.41E‐09  5.51E‐07  1.15133  3.20E‐06  1.16795 
3326183  NM_005898 // CAPRIN1 // cell cycle associated protein 1 // 11p13 // 4076 /// NM_  CAPRIN1  4.42E‐09  1.35E‐06  1.27416  1.26E‐06  1.34315 
2887309  NM_004417 // DUSP1 // dual specificity phosphatase 1 // 5q34 // 1843 /// ENST000  DUSP1  4.43E‐09  0.000263071 ‐1.70319  2.04E‐08  ‐3.07935 
2920803  AK094715 // FLJ37396 // hypothetical protein FLJ37396 // 6q21 // 285754  FLJ37396  4.46E‐09  2.36E‐08  1.60644  0.000212053 1.40223 
2884578  NM_024565 // CCNJL // cyclin J‐like // 5q33.3 // 79616 /// ENST00000393977 // CC  CCNJL  4.46E‐09  6.47E‐09  ‐1.38911  0.00208889  ‐1.19588 
3835879  NM_000041 // APOE // apolipoprotein E // 19q13.2 // 348 /// ENST00000252486 // A  APOE  4.47E‐09  3.80E‐08  ‐1.62718  0.000101074 ‐1.45635 
3031517  NM_153236 // GIMAP7 // GTPase, IMAP family member 7 // 7q36.1 // 168537 /// ENST  GIMAP7  4.47E‐09  0.0103102  ‐1.31369  3.02E‐09  ‐2.53632 
2468376  NM_014746 // RNF144A // ring finger protein 144A // 2p25.2‐p25.1 // 9781 /// ENS  RNF144A  4.51E‐09  0.000220255 ‐1.17489  2.33E‐08  ‐1.39589 
3951927  NM_197966 // BID // BH3 interacting domain death agonist // 22q11.1 // 637 /// N  BID  4.52E‐09  8.13E‐05  1.12989  4.46E‐08  1.25504 
3607510  NM_001113378 // FANCI // Fanconi anemia, complementation group I // 15q26.1 // 5  FANCI  4.54E‐09  0.0729553  1.15204  1.40E‐09  2.07226 
3768880  NM_080282 // ABCA10 // ATP‐binding cassette, sub‐family A (ABC1), member 10 // 1  ABCA10  4.57E‐09  0.000103917 ‐1.2888  3.84E‐08  ‐1.62253 
3862167  NM_001436 // FBL // fibrillarin // 19q13.1 // 2091 /// ENST00000221801 // FBL //  FBL  4.57E‐09  2.94E‐06  1.30786  6.29E‐07  1.42485 




3214800  NM_033014 // OGN // osteoglycin // 9q22 // 4969 /// NM_014057 // OGN // osteogly  OGN  4.66E‐09  6.25E‐05  ‐1.66535  5.55E‐08  ‐2.51276 
3354443  NM_198277 // SLC37A2 // solute carrier family 37 (glycerol‐3‐phosphate transport  SLC37A2  4.72E‐09  1.36E‐07  ‐4.01585  1.88E‐05  ‐3.60268 
3834502  NM_001783 // CD79A // CD79a molecule, immunoglobulin‐associated alpha // 19q13.2  CD79A  4.74E‐09  9.04E‐06  ‐1.63788  2.47E‐07  ‐2.07426 
2532699  NM_001017915 // INPP5D // inositol polyphosphate‐5‐phosphatase, 145kDa // 2q37.1  INPP5D  4.79E‐09  9.49E‐08  1.48582  3.11E‐05  1.41488 
3264059  NM_000681 // ADRA2A // adrenergic, alpha‐2A‐, receptor // 10q24‐q26 // 150 /// E  ADRA2A  4.80E‐09  9.68E‐09  ‐1.64135  0.00113514  ‐1.33964 
3684486  NM_005849 // IGSF6 // immunoglobulin superfamily, member 6 // 16p12‐p13 // 10261  IGSF6  4.83E‐09  1.96E‐07  ‐1.44415  1.24E‐05  ‐1.42519 
2568687  NM_201555 // FHL2 // four and a half LIM domains 2 // 2q12‐q14 // 2274 /// NM_00  FHL2  4.83E‐09  1.26E‐05  1.24645  1.93E‐07  1.40029 
3166815  NM_014471 // SPINK4 // serine peptidase inhibitor, Kazal type 4 // 9p13.3 // 272  SPINK4  4.89E‐09  3.74E‐05  2.60301  8.50E‐08  5.12492 
3846667  NM_016539 // SIRT6 // sirtuin (silent mating type information regulation 2 homol  SIRT6  4.89E‐09  2.47E‐08  ‐1.35734  0.000234549 ‐1.24183 
3724969  NM_018129 // PNPO // pyridoxamine 5'‐phosphate oxidase // 17q21.32 // 55163 ///   PNPO  4.91E‐09  0.25439  1.05231  1.00E‐09  1.52757 
3508898  NM_178006 // STARD13 // StAR‐related lipid transfer (START) domain containing 13  STARD13  4.92E‐09  1.68E‐07  ‐1.23518  1.55E‐05  ‐1.22047 
2333635  NM_001384 // DPH2 // DPH2 homolog (S. cerevisiae) // 1p34 // 1802 /// NM_0010395  DPH2  4.94E‐09  0.0325123  1.08898  2.07E‐09  1.43192 
3307680  NM_014881 // DCLRE1A // DNA cross‐link repair 1A (PSO2 homolog, S. cerevisiae) /  DCLRE1A  4.95E‐09  2.03E‐05  1.26773  1.37E‐07  1.4624 
3532935  NM_138731 // MIPOL1 // mirror‐image polydactyly 1 // 14q13.3‐q21.1 // 145282 ///  MIPOL1  4.96E‐09  3.33E‐07  1.6092  6.82E‐06  1.62998 
3189080  NM_005833 // RABEPK // Rab9 effector protein with kelch motifs // 9q33.3 // 1024  RABEPK  5.00E‐09  0.00818551  1.10991  3.79E‐09  1.40621 
2871801  NM_020177 // FEM1C // fem‐1 homolog c (C. elegans) // 5q22 // 56929 /// ENST0000  FEM1C  5.04E‐09  5.69E‐07  ‐1.22717  3.81E‐06  ‐1.25063 
2544201  NM_004881 // TP53I3 // tumor protein p53 inducible protein 3 // 2p23.3 // 9540 /  TP53I3  5.07E‐09  4.11E‐07  ‐1.33235  5.55E‐06  ‐1.35197 
2650357  NM_025047 // ARL14 // ADP‐ribosylation factor‐like 14 // 3q26.1 // 80117 /// ENS  ARL14  5.10E‐09  3.45E‐06  ‐1.86757  6.33E‐07  ‐2.29644 
2952497  NM_052893 // BTBD9 // BTB (POZ) domain containing 9 // 6p21 // 114781 /// NM_001  BTBD9  5.15E‐09  1.26E‐05  ‐1.24992  2.11E‐07  ‐1.40414 
3031533  NM_018326 // GIMAP4 // GTPase, IMAP family member 4 // 7q36.1 // 55303 /// ENST0  GIMAP4  5.20E‐09  0.00118739  ‐1.32452  1.04E‐08  ‐2.01666 
3676395  NM_002528 // NTHL1 // nth endonuclease III‐like 1 (E. coli) // 16p13.3 // 4913 /  NTHL1  5.21E‐09  0.000516602 1.16826  1.66E‐08  1.42102 
3890109  NM_080821 // C20orf108 // chromosome 20 open reading frame 108 // 20q13.2 // 116  C20orf108  5.22E‐09  1.37E‐06  1.18869  1.59E‐06  1.23106 
3708201  BC040148 // RNASEK // ribonuclease, RNase K // 17p13.1 // 440400 /// AK295795 //  RNASEK  5.25E‐09  0.000155583 1.18653  3.50E‐08  1.40208 
3894047  NM_018257 // PCMTD2 // protein‐L‐isoaspartate (D‐aspartate) O‐methyltransferase   PCMTD2  5.28E‐09  3.56E‐08  1.41468  0.000152905 1.29527 
3016380  NM_181552 // CUX1 // cut‐like homeobox 1 // 7q22.1 // 1523 /// NM_001913 // CUX1  CUX1  5.29E‐09  2.88E‐05  1.14124  1.15E‐07  1.24426 
3301914  NM_152309 // PIK3AP1 // phosphoinositide‐3‐kinase adaptor protein 1 // 10q24.1 /  PIK3AP1  5.32E‐09  0.000162736 ‐1.17599  3.45E‐08  ‐1.37942 
3838385  NM_001774 // CD37 // CD37 molecule // 19q13.3 // 951 /// NM_001040031 // CD37 //  CD37  5.38E‐09  0.000241142 ‐1.51771  2.73E‐08  ‐2.37175 
3071636  NM_018077 // RBM28 // RNA binding motif protein 28 // 7q32.1 // 55131 /// ENST00  RBM28  5.39E‐09  1.15E‐06  1.24323  1.99E‐06  1.29203 
3382061  NM_182969 // XRRA1 // X‐ray radiation resistance associated 1 // 11q13.4 // 1435  XRRA1  5.40E‐09  5.17E‐05  1.08951  7.67E‐08  1.1624 
2795819  NM_001012732 // DCTD // dCMP deaminase // 4q35.1 // 1635 /// NM_001921 // DCTD /  DCTD  5.43E‐09  6.79E‐06  1.34445  3.79E‐07  1.52348 
3645947  NM_015041 // CLUAP1 // clusterin associated protein 1 // 16p13.3 // 23059 /// NM  CLUAP1  5.44E‐09  7.97E‐07  1.40988  2.98E‐06  1.47319 
3699044  NM_018124 // RFWD3 // ring finger and WD repeat domain 3 // 16q22.3 // 55159 ///  RFWD3  5.45E‐09  0.00602897  1.15355  4.81E‐09  1.55822 
2780388  NM_025212 // CXXC4 // CXXC finger 4 // 4q22‐q24 // 80319 /// ENST00000394767 //   CXXC4  5.45E‐09  1.56E‐07  1.77727  2.02E‐05  1.70123 
2537171  NM_001002919 // FAM150B // family with sequence similarity 150, member B // 2p25  FAM150B  5.47E‐09  3.47E‐08  ‐1.78776  0.000170067 ‐1.53602 
3850832  NM_198536 // TMEM205 // transmembrane protein 205 // 19p13.2 // 374882 /// ENST0  TMEM205  5.47E‐09  9.85E‐06  1.23147  2.80E‐07  1.36015 
3755862  NM_012481 // IKZF3 // IKAROS family zinc finger 3 (Aiolos) // 17q21 // 22806 ///  IKZF3  5.48E‐09  0.00105283  ‐1.3146  1.18E‐08  ‐1.95598 
3888217  NM_017895 // DDX27 // DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 27 // 20q13.13 // 5  DDX27  5.49E‐09  8.29E‐05  1.17401  5.62E‐08  1.34401 
3301011  NM_022451 // NOC3L // nucleolar complex associated 3 homolog (S. cerevisiae) //   NOC3L  5.53E‐09  5.61E‐05  1.39496  7.45E‐08  1.80129 
3479438  NM_018223 // CHFR // checkpoint with forkhead and ring finger domains // 12q24.3  CHFR  5.59E‐09  1.72E‐07  ‐1.40647  1.86E‐05  ‐1.37478 
3390852  NM_207429 // FLJ45803 // FLJ45803 protein // 11q23.1 // 399948 /// ENST000003554  FLJ45803  5.62E‐09  7.83E‐08  2.26903  5.38E‐05  1.98397 
2328465  NM_006559 // KHDRBS1 // KH domain containing, RNA binding, signal transduction a  KHDRBS1  5.65E‐09  1.90E‐06  1.2134  1.30E‐06  1.27066 




2766289  NM_024943 // TMEM156 // transmembrane protein 156 // 4p14 // 80008 /// ENST00000  TMEM156  5.69E‐09  2.49E‐05  ‐1.54369  1.41E‐07  ‐2.02224 
2768273  NM_152995 // NFXL1 // nuclear transcription factor, X‐box binding‐like 1 // 4p12  NFXL1  5.71E‐09  4.81E‐07  1.34355  5.61E‐06  1.36705 
2863885  NM_005779 // LHFPL2 // lipoma HMGIC fusion partner‐like 2 // 5q14.1 // 10184 ///  LHFPL2  5.79E‐09  1.63E‐07  ‐1.32418  2.13E‐05  ‐1.29572 
2429556  NM_001232 // CASQ2 // calsequestrin 2 (cardiac muscle) // 1p13.3‐p11 // 845 ///   CASQ2  5.83E‐09  3.57E‐06  ‐1.41373  7.42E‐07  ‐1.58069 
3046520  NM_001003799 // TARP // TCR gamma alternate reading frame protein // 7p15‐p14 //  TARP  5.84E‐09  0.00182973  ‐1.19871  9.40E‐09  ‐1.6081 
3662041  NM_018233 // OGFOD1 // 2‐oxoglutarate and iron‐dependent oxygenase domain contai  OGFOD1  6.02E‐09  0.000193451 1.16236  3.59E‐08  1.35271 
3473727  NM_018639 // WSB2 // WD repeat and SOCS box‐containing 2 // 12q24.23 // 55884 //  WSB2  6.02E‐09  4.35E‐09  ‐1.34557  0.00944822  ‐1.14066 
3758317  NM_007296 // BRCA1 // breast cancer 1, early onset // 17q21 // 672 /// NM_007294  BRCA1  6.02E‐09  0.143348  1.09496  1.48E‐09  1.77675 
2589929  NM_178123 // SESTD1 // SEC14 and spectrin domains 1 // 2q31.2 // 91404 /// ENST0  SESTD1  6.08E‐09  7.41E‐09  1.6254  0.00317668  1.28874 
3514348  NR_003923 // GUCY1B2 // guanylate cyclase 1, soluble, beta 2 // 13q14.2‐q14.3 //  GUCY1B2  6.11E‐09  3.17E‐08  1.42846  0.000243162 1.2903 
3854877  NM_005354 // JUND // jun D proto‐oncogene // 19p13.2 // 3727 /// ENST00000252818  JUND  6.17E‐09  2.99E‐07  ‐1.28242  1.11E‐05  ‐1.27966 
2503200  NM_002881 // RALB // v‐ral simian leukemia viral oncogene homolog B (ras related  RALB  6.18E‐09  4.48E‐08  ‐1.42316  0.000144388 ‐1.30627 
3035135  NM_182491 // ZFAND2A // zinc finger, AN1‐type domain 2A // 7p22.3 // 90637 /// E  ZFAND2A  6.19E‐09  9.03E‐07  ‐1.42175  3.18E‐06  ‐1.48896 
3304355  NM_024040 // CUEDC2 // CUE domain containing 2 // 10q24.32 // 79004 /// ENST0000  CUEDC2  6.20E‐09  0.000117464 1.19048  5.17E‐08  1.39253 
3741715  NM_032294 // CAMKK1 // calcium/calmodulin‐dependent protein kinase kinase 1, alp  CAMKK1  6.31E‐09  6.42E‐05  1.19726  8.00E‐08  1.37758 
3945014  NM_014291 // GCAT // glycine C‐acetyltransferase (2‐amino‐3‐ketobutyrate coenzym  GCAT  6.31E‐09  0.000958518 1.17302  1.46E‐08  1.46838 
2531522  NM_016289 // CAB39 // calcium binding protein 39 // 2q37.1 // 51719 /// ENST0000  CAB39  6.32E‐09  1.99E‐05  ‐1.28763  1.92E‐07  ‐1.48865 
3040454  NM_001002926 // TWISTNB // TWIST neighbor // 7p15.3 // 221830 /// ENST0000022256 TWISTNB  6.37E‐09  1.13E‐05  1.26204  3.05E‐07  1.41251 
2843283  NM_007255 // B4GALT7 // xylosylprotein beta 1,4‐galactosyltransferase, polypepti  B4GALT7  6.40E‐09  0.000960306 1.0951  1.48E‐08  1.24432 
2714955  NM_006342 // TACC3 // transforming, acidic coiled‐coil containing protein 3 // 4  TACC3  6.40E‐09  0.00361576  1.16076  7.36E‐09  1.53173 
2401643  NM_000147 // FUCA1 // fucosidase, alpha‐L‐ 1, tissue // 1p34 // 2517 /// ENST000  FUCA1  6.53E‐09  5.06E‐07  ‐1.81278  6.55E‐06  ‐1.86934 
2333678  NM_003780 // B4GALT2 // UDP‐Gal:betaGlcNAc beta 1,4‐ galactosyltransferase, poly  B4GALT2  6.59E‐09  0.000313458 1.12671  2.96E‐08  1.28592 
3833992  NM_030622 // CYP2S1 // cytochrome P450, family 2, subfamily S, polypeptide 1 //   CYP2S1  6.59E‐09  3.47E‐08  1.52596  0.000243461 1.35431 
3417485  NM_024068 // OBFC2B // oligonucleotide/oligosaccharide‐binding fold containing 2  OBFC2B  6.63E‐09  0.00814764  1.12203  5.18E‐09  1.44951 
3944873  NM_020315 // PDXP // pyridoxal (pyridoxine, vitamin B6) phosphatase // 22cen‐q12  PDXP  6.66E‐09  1.63E‐07  ‐1.33642  2.69E‐05  ‐1.30141 
3418534  NM_206914 // FAM119B // family with sequence similarity 119, member B // 12q14.1  FAM119B  6.67E‐09  3.75E‐06  1.20346  8.60E‐07  1.27598 
2462456  NM_018072 // HEATR1 // HEAT repeat containing 1 // 1q43 // 55127 /// ENST0000036  HEATR1  6.68E‐09  2.63E‐07  1.46651  1.47E‐05  1.44845 
3417146  NM_001798 // CDK2 // cyclin‐dependent kinase 2 // 12q13 // 1017 /// NM_052827 //  CDK2  6.69E‐09  0.0896569  1.09406  1.94E‐09  1.6216 
3744229  NM_032354 // TMEM107 // transmembrane protein 107 // 17p13.1 // 84314 /// NM_183  TMEM107  6.81E‐09  0.480013  1.02314  1.19E‐09  1.35829 
2779271  NM_000669 // ADH1C // alcohol dehydrogenase 1C (class I), gamma polypeptide // 4  ADH1C  6.82E‐09  0.000201084 ‐1.9574  4.09E‐08  ‐3.83767 
3378732  NM_021173 // POLD4 // polymerase (DNA‐directed), delta 4 // 11q13 // 57804 /// E  POLD4  6.83E‐09  2.62E‐07  ‐1.33406  1.54E‐05  ‐1.32054 
3012064  NM_012395 // PFTK1 // PFTAIRE protein kinase 1 // 7q21‐q22 // 5218 /// ENST00000  PFTK1  6.85E‐09  8.13E‐06  ‐1.322  4.47E‐07  ‐1.48885 
3730784  NM_016360 // CCDC44 // coiled‐coil domain containing 44 // 17q23.3 // 51204 ///   CCDC44  6.86E‐09  4.15E‐09  ‐1.29468  0.0144605  ‐1.11311 
3695107  NM_004614 // TK2 // thymidine kinase 2, mitochondrial // 16q22‐q23.1 // 7084 ///  TK2  6.87E‐09  0.000236066 1.12095  3.72E‐08  1.2619 
3456130  NM_015665 // AAAS // achalasia, adrenocortical insufficiency, alacrimia (Allgrov  AAAS  6.97E‐09  0.0406141  1.06988  2.74E‐09  1.34227 
3869097  NM_001245 // SIGLEC6 // sialic acid binding Ig‐like lectin 6 // 19q13.3 // 946 /  SIGLEC6  7.02E‐09  1.41E‐05  ‐1.25293  2.91E‐07  ‐1.4051 
3235789  NM_182751 // MCM10 // minichromosome maintenance complex component 10 // 10p13 /  MCM10  7.02E‐09  0.224494  1.06464  1.51E‐09  1.61584 
3226331  AL833509 // LOC286208 // hypothetical protein LOC286208 // 9q34.11 // 286208 ///  LOC286208  7.05E‐09  2.07E‐08  ‐1.3029  0.000652869 ‐1.18558 
3210497  NM_015225 // PRUNE2 // prune homolog 2 (Drosophila) // 9q21.13 // 158471 /// AB0  PRUNE2  7.07E‐09  2.24E‐06  1.71405  1.53E‐06  1.94905 
3985665  NM_004780 // TCEAL1 // transcription elongation factor A (SII)‐like 1 // Xq22.1   TCEAL1  7.13E‐09  8.34E‐07  1.31328  4.30E‐06  1.35209 
2914444  NM_001010844 // IRAK1BP1 // interleukin‐1 receptor‐associated kinase 1 binding p  IRAK1BP1  7.13E‐09  1.31E‐06  1.21441  2.67E‐06  1.25405 




2481379  NM_172311 // STON1‐GTF2A1L // STON1‐GTF2A1L // 2p16.3 // 286749 /// NM_006872 // STON1‐GTF2A1L  7.23E‐09  2.89E‐05  ‐1.25651  1.72E‐07  ‐1.44837 
3960174  NM_006498 // LGALS2 // lectin, galactoside‐binding, soluble, 2 // 22q12‐q13|22q1  LGALS2  7.28E‐09  0.000878199 ‐1.71903  1.81E‐08  ‐3.59992 
2470838  NM_005378 // MYCN // v‐myc myelocytomatosis viral related oncogene, neuroblastom  MYCN  7.36E‐09  1.74E‐06  1.40183  2.08E‐06  1.50013 
3878836  NM_018993 // RIN2 // Ras and Rab interactor 2 // 20p11.22 // 54453 /// ENST00000  RIN2  7.39E‐09  0.00172831  ‐1.16352  1.27E‐08  ‐1.47613 
3335327  NM_006396 // SSSCA1 // Sjogren syndrome/scleroderma autoantigen 1 // 11q13.1 //   SSSCA1  7.39E‐09  0.0330416  1.10121  3.17E‐09  1.49214 
2587790  NM_001033045 // GPR155 // G protein‐coupled receptor 155 // 2q31.1 // 151556 ///  GPR155  7.41E‐09  2.01E‐05  ‐1.43527  2.35E‐07  ‐1.75703 
2880422  NM_003122 // SPINK1 // serine peptidase inhibitor, Kazal type 1 // 5q32 // 6690   SPINK1  7.42E‐09  1.26E‐06  2.10226  2.94E‐06  2.36212 
3709107  NM_020877 // DNAH2 // dynein, axonemal, heavy chain 2 // 17p13.1 // 146754 /// E  DNAH2  7.42E‐09  1.66E‐06  1.36422  2.22E‐06  1.44864 
3995804  NM_005629 // SLC6A8 // solute carrier family 6 (neurotransmitter transporter, cr  SLC6A8  7.46E‐09  9.05E‐07  ‐1.41292  4.22E‐06  ‐1.46913 
2528476  NM_001927 // DES // desmin // 2q35 // 1674 /// ENST00000373960 // DES // desmin   DES  7.48E‐09  8.76E‐06  ‐1.39884  4.74E‐07  ‐1.61497 
2620842  NM_000648 // CCR2 // chemokine (C‐C motif) receptor 2 // 3p21.31 // 1231 /// NM_  CCR2  7.50E‐09  2.63E‐05  ‐1.7851  1.94E‐07  ‐2.53099 
3751541  NM_001085454 // GIT1 // G protein‐coupled receptor kinase interactor 1 // 17p11.  GIT1  7.53E‐09  0.000253799 1.10184  3.97E‐08  1.2192 
3304004  NM_006993 // NPM3 // nucleophosmin/nucleoplasmin, 3 // 10q24.31 // 10360 /// ENS  NPM3  7.57E‐09  0.00479983  1.13679  7.73E‐09  1.46062 
3661940  NM_020988 // GNAO1 // guanine nucleotide binding protein (G protein), alpha acti  GNAO1  7.64E‐09  2.93E‐05  ‐1.3147  1.83E‐07  ‐1.55725 
2977471  NM_182503 // ADAT2 // adenosine deaminase, tRNA‐specific 2, TAD2 homolog (S. cer  ADAT2  7.72E‐09  9.16E‐06  1.33608  4.76E‐07  1.5141 
3630099  NM_017858 // TIPIN // TIMELESS interacting protein // 15q22.31 // 54962 /// NR_0  TIPIN  7.79E‐09  0.00567049  1.17581  7.35E‐09  1.63219 
3817698  NM_001048201 // UHRF1 // ubiquitin‐like with PHD and ring finger domains 1 // 19  UHRF1  7.79E‐09  0.000613429 1.25591  2.41E‐08  1.6724 
3720921  NM_000964 // RARA // retinoic acid receptor, alpha // 17q21 // 5914 /// NM_00102  RARA  7.80E‐09  2.38E‐07  ‐1.2384  2.16E‐05  ‐1.22243 
3294142  NM_032562 // PLA2G12B // phospholipase A2, group XIIB // 10q22.1 // 84647 /// EN  PLA2G12B  7.82E‐09  1.84E‐06  ‐2.09258  2.16E‐06  ‐2.42932 
3636956  NM_032856 // WDR73 // WD repeat domain 73 // 15q25.2 // 84942 /// ENST0000039852  WDR73  7.85E‐09  0.000674173 1.12157  2.30E‐08  1.29918 
3302886  NM_021828 // HPSE2 // heparanase 2 // 10q23‐q24 // 60495 /// ENST00000370552 //   HPSE2  7.86E‐09  3.18E‐08  ‐1.506  0.000393549 ‐1.32453 
2587841  NM_003387 // WIPF1 // WAS/WASL interacting protein family, member 1 // 2q31.1 //  WIPF1  7.90E‐09  0.00128648  ‐1.3211  1.61E‐08  ‐1.98823 
3038065  NM_004968 // ICA1 // islet cell autoantigen 1, 69kDa // 7p22 // 3382 /// NM_0223  ICA1  7.91E‐09  1.62E‐07  1.63111  3.63E‐05  1.54569 
2827709  NM_016048 // ISOC1 // isochorismatase domain containing 1 // 5q22.1‐q33.3 // 510  ISOC1  8.07E‐09  2.22E‐08  ‐1.30371  0.000759482 ‐1.18386 
2608725  NM_003670 // BHLHB2 // basic helix‐loop‐helix domain containing, class B, 2 // 3  BHLHB2  8.08E‐09  7.38E‐09  1.55586  0.00610406  1.23722 
3424218  NM_024560 // ACSS3 // acyl‐CoA synthetase short‐chain family member 3 // 12q21.3  ACSS3  8.17E‐09  1.59E‐05  ‐1.27644  3.24E‐07  ‐1.4461 
3458837  NM_005371 // METTL1 // methyltransferase like 1 // 12q13 // 4234 /// NM_023033 /  METTL1  8.28E‐09  0.0320382  1.0921  3.62E‐09  1.43542 
3639031  NM_003981 // PRC1 // protein regulator of cytokinesis 1 // 15q26.1 // 9055 /// N  PRC1  8.30E‐09  0.00458266  1.25541  8.75E‐09  1.9439 
3510858  NM_002015 // FOXO1 // forkhead box O1 // 13q14.1 // 2308 /// ENST00000379561 //   FOXO1  8.31E‐09  0.000557793 ‐1.14081  2.76E‐08  ‐1.34045 
3630701  NM_017882 // CLN6 // ceroid‐lipofuscinosis, neuronal 6, late infantile, variant   CLN6  8.32E‐09  0.934554  ‐1.00308  1.32E‐09  1.42487 
2324856  NM_015991 // C1QA // complement component 1, q subcomponent, A chain // 1p36.12   C1QA  8.45E‐09  1.69E‐07  ‐1.84641  3.84E‐05  ‐1.7244 
2513827  ‐‐‐    8.49E‐09  0.00154805  ‐1.1614  1.58E‐08  ‐1.4574 
3908631  NM_020820 // PREX1 // phosphatidylinositol 3,4,5‐trisphosphate‐dependent RAC exc  PREX1  8.53E‐09  5.79E‐05  ‐1.23832  1.27E‐07  ‐1.44677 
3208995  NM_001206 // KLF9 // Kruppel‐like factor 9 // 9q13 // 687 /// ENST00000377126 //  KLF9  8.55E‐09  4.35E‐07  ‐1.30086  1.20E‐05  ‐1.30272 
3971877  NM_001415 // EIF2S3 // eukaryotic translation initiation factor 2, subunit 3 gam  EIF2S3  8.58E‐09  2.42E‐06  1.33181  1.88E‐06  1.42249 
2949488  NM_025257 // SLC44A4 // solute carrier family 44, member 4 // 6p21.3 // 80736 //  SLC44A4  8.60E‐09  2.73E‐06  ‐1.23456  1.68E‐06  ‐1.30022 
3735623  NM_024311 // MFSD11 // major facilitator superfamily domain containing 11 // 17q  MFSD11  8.61E‐09  7.63E‐07  ‐1.25163  6.36E‐06  ‐1.27327 
3946817  NM_003216 // TEF // thyrotrophic embryonic factor // 22q13|22q13.2 // 7008 /// E  TEF  8.71E‐09  3.46E‐06  ‐1.21556  1.36E‐06  ‐1.28326 
2453365  NM_025179 // PLXNA2 // plexin A2 // 1q32.2 // 5362 /// ENST00000367033 // PLXNA2  PLXNA2  8.73E‐09  4.14E‐06  ‐1.44753  1.15E‐06  ‐1.61924 
3634811  NM_004390 // CTSH // cathepsin H // 15q24‐q25 // 1512 /// NM_148979 // CTSH // c  CTSH  8.82E‐09  3.07E‐07  1.62072  1.92E‐05  1.58854 
3589822  NM_033510 // DISP2 // dispatched homolog 2 (Drosophila) // 15q15.1 // 85455 ///   DISP2  8.91E‐09  7.44E‐08  ‐1.58038  0.000133175 ‐1.42908 




3802602  NM_001792 // CDH2 // cadherin 2, type 1, N‐cadherin (neuronal) // 18q11.2 // 100  CDH2  8.91E‐09  4.68E‐06  ‐1.24336  1.06E‐06  ‐1.33262 
2640579  NM_032242 // PLXNA1 // plexin A1 // 3q21.3 // 5361 /// ENST00000251772 // PLXNA1  PLXNA1  8.92E‐09  5.94E‐05  1.19018  1.31E‐07  1.35099 
3474815  BC014661 // C12orf43 // chromosome 12 open reading frame 43 // 12q // 64897 ///   C12orf43  8.93E‐09  0.00760393  1.07826  7.43E‐09  1.26735 
3448428  NM_018164 // C12orf11 // chromosome 12 open reading frame 11 // 12p11.23 // 5572  C12orf11  9.01E‐09  3.20E‐05  1.40513  2.12E‐07  1.73322 
3434907  NM_001080825 // TMEM120B // transmembrane protein 120B // 12q24.31 // 144404 ///  TMEM120B  9.03E‐09  0.00209994  1.14747  1.44E‐08  1.43219 
3424442  NM_152588 // TMTC2 // transmembrane and tetratricopeptide repeat containing 2 //  TMTC2  9.05E‐09  3.33E‐07  1.46269  1.82E‐05  1.44381 
3828112  NM_001238 // CCNE1 // cyclin E1 // 19q12 // 898 /// NM_057182 // CCNE1 // cyclin  CCNE1  9.05E‐09  0.152541  1.07763  2.22E‐09  1.6111 
2604254  NM_018410 // HJURP // Holliday junction recognition protein // 2q37.1 // 55355 /  HJURP  9.06E‐09  0.00407937  1.17983  1.02E‐08  1.60503 
3518418  NM_138444 // KCTD12 // potassium channel tetramerisation domain containing 12 //  KCTD12  9.09E‐09  0.00034447  ‐1.2424  4.11E‐08  ‐1.5751 
3674199  NM_014427 // CPNE7 // copine VII // 16q24.3 // 27132 /// NM_153636 // CPNE7 // c  CPNE7  9.10E‐09  5.29E‐07  1.41021  1.06E‐05  1.4218 
2772088  NM_001077 // UGT2B17 // UDP glucuronosyltransferase 2 family, polypeptide B17 //  UGT2B17  9.12E‐09  0.000112483 ‐2.21135  8.60E‐08  ‐4.33515 
3811949  NM_021153 // CDH19 // cadherin 19, type 2 // 18q22‐q23 // 28513 /// ENST00000262  CDH19  9.13E‐09  8.54E‐07  ‐1.37396  6.15E‐06  ‐1.4116 
3603687  NM_007364 // TMED3 // transmembrane emp24 protein transport domain containing 3   TMED3  9.13E‐09  2.35E‐06  1.29725  2.12E‐06  1.37358 
3768703  NM_080283 // ABCA9 // ATP‐binding cassette, sub‐family A (ABC1), member 9 // 17q  ABCA9  9.15E‐09  2.34E‐07  ‐1.46383  2.88E‐05  ‐1.42027 
2369110  NM_170692 // RASAL2 // RAS protein activator like 2 // 1q24 // 9462 /// NM_00484  RASAL2  9.21E‐09  2.64E‐07  1.33005  2.50E‐05  1.30561 
3725392  NM_005831 // CALCOCO2 // calcium binding and coiled‐coil domain 2 // 17q21.32 //  CALCOCO2  9.32E‐09  2.25E‐06  ‐1.39105  2.29E‐06  ‐1.49164 
3633109  NM_001099436 // ULK3 // unc‐51‐like kinase 3 (C. elegans) // 15q24.1 // 25989 //  ULK3  9.38E‐09  1.93E‐06  ‐1.21174  2.69E‐06  ‐1.25683 
2633191  NM_005290 // GPR15 // G protein‐coupled receptor 15 // 3q11.2‐q13.1 // 2838 ///   GPR15  9.40E‐09  4.11E‐05  ‐1.91344  1.85E‐07  ‐2.92872 
3658925  NM_014321 // ORC6L // origin recognition complex, subunit 6 like (yeast) // 16q1  ORC6L  9.46E‐09  0.502204  1.03308  1.65E‐09  1.57233 
3384321  NM_014488 // RAB30 // RAB30, member RAS oncogene family // 11q12‐q14 // 27314 //  RAB30  9.48E‐09  1.98E‐07  ‐1.57486  3.80E‐05  ‐1.50223 
3148796  NM_001128211 // NUDCD1 // NudC domain containing 1 // 8q23 // 84955 /// NM_03286  NUDCD1  9.62E‐09  6.31E‐05  1.25102  1.39E‐07  1.47346 
3275042  NM_024701 // ASB13 // ankyrin repeat and SOCS box‐containing 13 // 10p15.1 // 79  ASB13  9.64E‐09  7.56E‐08  ‐1.2765  0.000150387 ‐1.2078 
3442054  NM_001273 // CHD4 // chromodomain helicase DNA binding protein 4 // 12p13 // 110  CHD4  9.68E‐09  5.40E‐07  1.31847  1.14E‐05  1.32585 
3896034  NM_014737 // RASSF2 // Ras association (RalGDS/AF‐6) domain family member 2 // 2  RASSF2  9.74E‐09  2.78E‐05  ‐1.33907  2.62E‐07  ‐1.58841 
2326463  NM_001803 // CD52 // CD52 molecule // 1p36 // 1043 /// ENST00000374213 // CD52 /  CD52  9.78E‐09  0.00674393  ‐1.29987  8.70E‐09  ‐2.23856 
3347831  NM_004398 // DDX10 // DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 10 // 11q22‐q23 //   DDX10  9.78E‐09  1.74E‐06  1.48008  3.20E‐06  1.58314 
2886595  NM_005565 // LCP2 // lymphocyte cytosolic protein 2 (SH2 domain containing leuko  LCP2  9.88E‐09  0.00315604  ‐1.20435  1.29E‐08  ‐1.66672 
3587015  NM_015995 // KLF13 // Kruppel‐like factor 13 // 15q12 // 51621 /// ENST000003071  KLF13  1.00E‐08  7.63E‐07  ‐1.16656  8.09E‐06  ‐1.17754 
3056131  NM_012453 // TBL2 // transducin (beta)‐like 2 // 7q11.23 // 26608 /// ENST000003  TBL2  1.01E‐08  7.97E‐05  1.13185  1.25E‐07  1.24499 
3089285  NM_001722 // POLR3D // polymerase (RNA) III (DNA directed) polypeptide D, 44kDa   POLR3D  1.01E‐08  1.56E‐05  1.13524  4.39E‐07  1.20754 
2571075  NM_022662 // ANAPC1 // anaphase promoting complex subunit 1 // 2q12.1 // 64682 /  ANAPC1  1.03E‐08  0.000662278 1.16589  3.19E‐08  1.41127 
2652675  NM_018098 // ECT2 // epithelial cell transforming sequence 2 oncogene // 3q26.1‐  ECT2  1.03E‐08  1.05E‐05  1.74525  6.25E‐07  2.21007 
3183364  NM_018112 // TMEM38B // transmembrane protein 38B // 9q31.2 // 55151 /// ENST000  TMEM38B  1.03E‐08  2.17E‐09  ‐1.68527  0.25195  ‐1.10055 
3942161  NM_001003684 // UCRC // ubiquinol‐cytochrome c reductase complex (7.2 kD) // 22c  UCRC  1.04E‐08  1.27E‐08  ‐1.35237  0.00358531  ‐1.17245 
2325002  NM_015013 // AOF2 // amine oxidase (flavin containing) domain 2 // 1p36.12 // 23  AOF2  1.06E‐08  1.82E‐06  1.44406  3.42E‐06  1.53727 
3842768  NM_020813 // ZNF471 // zinc finger protein 471 // 19q13.43 // 57573 /// ENST0000  ZNF471  1.06E‐08  1.17E‐06  ‐1.29387  5.48E‐06  ‐1.3315 
3778504  NM_006868 // RAB31 // RAB31, member RAS oncogene family // 18p11.3 // 11031 ///   RAB31  1.06E‐08  5.31E‐07  ‐1.39754  1.35E‐05  ‐1.40141 
3329904  NM_004551 // NDUFS3 // NADH dehydrogenase (ubiquinone) Fe‐S protein 3, 30kDa (NA  NDUFS3  1.07E‐08  2.25E‐08  ‐1.31954  0.00133271  ‐1.18187 
4013460  NM_006639 // CYSLTR1 // cysteinyl leukotriene receptor 1 // Xq13.2‐q21.1 // 1080  CYSLTR1  1.08E‐08  8.19E‐05  ‐1.49877  1.32E‐07  ‐2.04491 
3168255  NM_001039792 // UNQ338 // hypothetical protein LOC646962 // 9p13.3 // 646962 ///  UNQ338  1.09E‐08  5.16E‐06  ‐1.87198  1.28E‐06  ‐2.27694 
3818515  NM_004240 // TRIP10 // thyroid hormone receptor interactor 10 // 19p13.3 // 9322  TRIP10  1.09E‐08  3.90E‐09  ‐1.37846  0.0548293  ‐1.10823 




3753760  NM_024302 // MMP28 // matrix metallopeptidase 28 // 17q11‐q21.1 // 79148 /// NM_  MMP28  1.09E‐08  0.000425067 ‐1.32747  4.50E‐08  ‐1.82455 
3290210  NM_032997 // ZWINT // ZW10 interactor // 10q21‐q22 // 11130 /// NM_007057 // ZWI  ZWINT  1.09E‐08  0.370992  1.05054  2.06E‐09  1.66284 
3833757  NM_004596 // SNRPA // small nuclear ribonucleoprotein polypeptide A // 19q13.1 /  SNRPA  1.11E‐08  0.0294115  1.08944  5.14E‐09  1.40577 
3850069  NM_001379 // DNMT1 // DNA (cytosine‐5‐)‐methyltransferase 1 // 19p13.2 // 1786 /  DNMT1  1.11E‐08  0.0346989  1.07608  4.81E‐09  1.35258 
3190366  NM_005094 // SLC27A4 // solute carrier family 27 (fatty acid transporter), membe  SLC27A4  1.13E‐08  2.20E‐09  ‐1.47657  0.326135  ‐1.06313 
2327283  NM_001105556 // C1orf38 // chromosome 1 open reading frame 38 // 1p35.3 // 9473   C1orf38  1.13E‐08  1.78E‐07  ‐1.34411  5.91E‐05  ‐1.29123 
3808854  NM_001083962 // TCF4 // transcription factor 4 // 18q21.1 // 6925 /// NM_003199   TCF4  1.13E‐08  2.56E‐05  ‐1.41719  3.40E‐07  ‐1.72021 
2835614  ENST00000394243 // SYNPO // synaptopodin // 5q33.1 // 11346 /// AK095279 // SYNP  SYNPO  1.13E‐08  2.56E‐07  ‐1.41658  3.69E‐05  ‐1.37249 
3061319  NM_001259 // CDK6 // cyclin‐dependent kinase 6 // 7q21‐q22 // 1021 /// ENST00000  CDK6  1.14E‐08  8.58E‐08  1.70267  0.000168924 1.50724 
3192525  NM_012204 // GTF3C4 // general transcription factor IIIC, polypeptide 4, 90kDa /  GTF3C4  1.14E‐08  5.42E‐05  1.23058  1.93E‐07  1.41837 
2326561  NM_002953 // RPS6KA1 // ribosomal protein S6 kinase, 90kDa, polypeptide 1 // 1p   RPS6KA1  1.15E‐08  3.32E‐07  ‐1.24996  2.70E‐05  ‐1.23358 
2420521  NM_014021 // SSX2IP // synovial sarcoma, X breakpoint 2 interacting protein // 1  SSX2IP  1.15E‐08  2.29E‐06  1.35944  3.07E‐06  1.44232 
3734413  NM_175738 // RAB37 // RAB37, member RAS oncogene family // 17q25.1 // 326624 ///  RAB37  1.16E‐08  8.86E‐05  ‐1.25786  1.37E‐07  ‐1.50264 
3022814  NM_013332 // HIG2 // hypoxia‐inducible protein 2 // 7q32.1 // 29923 /// NM_00109  HIG2  1.17E‐08  6.57E‐05  1.31722  1.73E‐07  1.60505 
2730281  NM_017855 // ODAM // odontogenic, ameloblast asssociated // 4q13.3 // 54959 ///   ODAM  1.17E‐08  5.09E‐08  2.17764  0.000400767 1.72462 
3687752  NM_052838 // SEPT1 // septin 1 // 16p11.1 // 1731 /// ENST00000321367 // SEPT1 /  SEPT1  1.18E‐08  0.00328264  ‐1.2034  1.54E‐08  ‐1.66028 
3918779  NM_003024 // ITSN1 // intersectin 1 (SH3 domain protein) // 21q22.1‐q22.2 // 645  ITSN1  1.18E‐08  9.16E‐05  ‐1.17396  1.37E‐07  ‐1.33029 
3080283  NM_005431 // XRCC2 // X‐ray repair complementing defective repair in Chinese ham  XRCC2  1.18E‐08  0.172543  1.07007  2.81E‐09  1.56694 
3874249  NM_033453 // ITPA // inosine triphosphatase (nucleoside triphosphate pyrophospha  ITPA  1.19E‐08  0.000164708 1.16269  9.22E‐08  1.33106 
3881874  NM_015338 // ASXL1 // additional sex combs like 1 (Drosophila) // 20q11.1 // 171  ASXL1  1.19E‐08  4.13E‐08  1.22955  0.00057871  1.14881 
2491788  NM_032827 // ATOH8 // atonal homolog 8 (Drosophila) // 2p11.2 // 84913 /// ENST0  ATOH8  1.20E‐08  0.000667084 1.2509  3.84E‐08  1.64634 
2363852  NM_032738 // FCRLA // Fc receptor‐like A // 1q23.3 // 84824 /// ENST00000236938   FCRLA  1.21E‐08  0.000125457 ‐1.38322  1.13E‐07  ‐1.81626 
2819779  NM_032119 // GPR98 // G protein‐coupled receptor 98 // 5q13 // 84059 /// NR_0031  GPR98  1.21E‐08  7.74E‐07  ‐1.31947  1.06E‐05  ‐1.33568 
2500838  NM_019014 // POLR1B // polymerase (RNA) I polypeptide B, 128kDa // 2q13 // 84172  POLR1B  1.21E‐08  7.35E‐06  1.35349  1.07E‐06  1.50632 
3320944  NM_021961 // TEAD1 // TEA domain family member 1 (SV40 transcriptional enhancer   TEAD1  1.21E‐08  4.40E‐07  1.45672  2.08E‐05  1.44094 
3471819  NM_024953 // C12orf30 // chromosome 12 open reading frame 30 // 12q24.13 // 8001  C12orf30  1.22E‐08  6.14E‐06  1.39281  1.29E‐06  1.55144 
2620937  NM_003212 // TDGF1 // teratocarcinoma‐derived growth factor 1 // 3p21.31 // 6997  TDGF1  1.23E‐08  8.14E‐07  4.65759  1.03E‐05  5.02208 
2542651  NM_001006657 // WDR35 // WD repeat domain 35 // 2p24.1 // 57539 /// NM_020779 //  WDR35  1.23E‐08  2.26E‐07  1.46081  4.95E‐05  1.39875 
2911903  NM_003463 // PTP4A1 // protein tyrosine phosphatase type IVA, member 1 // 6q12 /  PTP4A1  1.23E‐08  1.20E‐05  ‐1.58626  7.14E‐07  ‐1.9305 
3925473  NM_022136 // SAMSN1 // SAM domain, SH3 domain and nuclear localization signals 1  SAMSN1  1.24E‐08  5.88E‐05  ‐1.31313  2.03E‐07  ‐1.58484 
2489172  NM_001040409 // MTHFD2 // methylenetetrahydrofolate dehydrogenase (NADP+ depende  MTHFD2  1.26E‐08  0.000377945 1.29742  5.72E‐08  1.7178 
3012213  NM_003505 // FZD1 // frizzled homolog 1 (Drosophila) // 7q21 // 8321 /// ENST000  FZD1  1.26E‐08  1.37E‐06  ‐1.21205  6.03E‐06  ‐1.23895 
2488732  NM_006429 // CCT7 // chaperonin containing TCP1, subunit 7 (eta) // 2p13.2 // 10  CCT7  1.26E‐08  0.00213193  1.19793  2.09E‐08  1.59136 
3896200  NM_002592 // PCNA // proliferating cell nuclear antigen // 20pter‐p12 // 5111 //  PCNA  1.26E‐08  0.112639  1.09332  3.48E‐09  1.65223 
2352804  NM_020190 // OLFML3 // olfactomedin‐like 3 // 1p13.2 // 56944 /// ENST0000032033  OLFML3  1.27E‐08  4.05E‐06  ‐1.37471  2.02E‐06  ‐1.4941 
3743701  NM_020360 // PLSCR3 // phospholipid scramblase 3 // 17p13.1 // 57048 /// ENST000  PLSCR3  1.27E‐08  6.02E‐06  1.24745  1.39E‐06  1.33845 
3723264  NM_021079 // NMT1 // N‐myristoyltransferase 1 // 17q21.31 // 4836 /// ENST000002  NMT1  1.27E‐08  1.11E‐06  1.19181  7.73E‐06  1.20975 
3931250  NM_153681 // PIGP // phosphatidylinositol glycan anchor biosynthesis, class P //  PIGP  1.28E‐08  1.92E‐05  1.25174  5.06E‐07  1.39904 
3845365  NM_003200 // TCF3 // transcription factor 3 (E2A immunoglobulin enhancer binding  TCF3  1.29E‐08  0.000258259 1.1175  7.56E‐08  1.24686 
2612175  NM_003298 // NR2C2 // nuclear receptor subfamily 2, group C, member 2 // 3p25 //  NR2C2  1.30E‐08  0.313098  1.02281  2.57E‐09  ‐1.22649 
2678526  BC132815 // C3orf67 // chromosome 3 open reading frame 67 // 3p14.2 // 200844 //  C3orf67  1.31E‐08  1.52E‐05  1.36329  6.36E‐07  1.57024 




3872928  NM_003433 // ZNF132 // zinc finger protein 132 // 19q13.4 // 7691 /// ENST000002  ZNF132  1.31E‐08  3.34E‐07  ‐1.44764  3.36E‐05  ‐1.40937 
3830993  NM_014266 // HCST // hematopoietic cell signal transducer // 19q13.1 // 10870 //  HCST  1.32E‐08  2.00E‐05  ‐1.43632  5.09E‐07  ‐1.72097 
2352743  NM_022836 // DCLRE1B // DNA cross‐link repair 1B (PSO2 homolog, S. cerevisiae) /  DCLRE1B  1.32E‐08  0.42155  1.03561  2.42E‐09  1.49088 
4017281  NM_017681 // NUP62CL // nucleoporin 62kDa C‐terminal like // Xq22.3 // 54830 ///  NUP62CL  1.33E‐08  0.000431905 1.21715  5.64E‐08  1.51192 
2854327  NM_001465 // FYB // FYN binding protein (FYB‐120/130) // 5p13.1 // 2533 /// NM_1  FYB  1.34E‐08  0.0108379  ‐1.27484  9.83E‐09  ‐2.2111 
2420229  NM_024686 // TTLL7 // tubulin tyrosine ligase‐like family, member 7 // 1p31.1 //  TTLL7  1.34E‐08  6.17E‐07  ‐1.36048  1.64E‐05  ‐1.36199 
3075932  NM_022750 // PARP12 // poly (ADP‐ribose) polymerase family, member 12 // 7q34 //  PARP12  1.35E‐08  1.89E‐05  ‐1.22705  5.52E‐07  ‐1.35573 
3665029  NM_024922 // CES3 // carboxylesterase 3 // 16q22.1 // 23491 /// ENST00000303334   CES3  1.36E‐08  1.92E‐06  ‐1.40889  4.71E‐06  ‐1.48422 
3696454  NM_001039690 // CTF8 // chromosome transmission fidelity factor 8 homolog (S. ce  CTF8  1.36E‐08  0.00174797  1.11746  2.55E‐08  1.3194 
2434746  NM_018379 // FAM63A // family with sequence similarity 63, member A // 1q21.2 //  FAM63A  1.36E‐08  8.08E‐05  ‐1.14999  1.81E‐07  ‐1.27522 
3821869  NM_017682 // BEST2 // bestrophin 2 // 19p13.13 // 54831 /// ENST00000042931 // B  BEST2  1.37E‐08  4.43E‐06  ‐1.79987  2.06E‐06  ‐2.10572 
3602497  NM_173469 // UBE2Q2 // ubiquitin‐conjugating enzyme E2Q family member 2 // 15q24  UBE2Q2  1.37E‐08  7.92E‐06  1.32649  1.20E‐06  1.46496 
3094286  NM_007198 // PROSC // proline synthetase co‐transcribed homolog (bacterial) // 8  PROSC  1.38E‐08  9.18E‐06  ‐1.1937  1.06E‐06  ‐1.2752 
3274173  NM_014889 // PITRM1 // pitrilysin metallopeptidase 1 // 10p15.2 // 10531 /// ENS  PITRM1  1.38E‐08  1.44E‐06  1.24169  6.54E‐06  1.27212 
3759356  NM_004247 // EFTUD2 // elongation factor Tu GTP binding domain containing 2 // 1  EFTUD2  1.38E‐08  0.00523607  1.1445  1.45E‐08  1.48044 
3727583  NM_002126 // HLF // hepatic leukemia factor // 17q22 // 3131 /// ENST00000226067  HLF  1.39E‐08  1.91E‐07  ‐1.46162  7.72E‐05  ‐1.381 
2573232  NR_000034 // TMEM185B // transmembrane protein 185B (pseudogene) // 2q14.2 // 79  TMEM185B  1.39E‐08  0.0029044  1.12758  1.98E‐08  1.37787 
3433591  NM_153348 // FBXW8 // F‐box and WD repeat domain containing 8 // 12q24.22|tdb993  FBXW8  1.39E‐08  0.000443485 1.10276  5.87E‐08  1.22858 
2816459  NM_001992 // F2R // coagulation factor II (thrombin) receptor // 5q13 // 2149 //  F2R  1.40E‐08  2.05E‐07  1.41189  7.05E‐05  1.34496 
3607537  NM_001113378 // FANCI // Fanconi anemia, complementation group I // 15q26.1 // 5  FANCI  1.40E‐08  0.00514714  1.28501  1.48E‐08  2.06818 
2531233  NM_007237 // SP140 // SP140 nuclear body protein // 2q37.1 // 11262 /// NM_00100  SP140  1.41E‐08  0.000274291 ‐1.26052  8.06E‐08  ‐1.58522 
3502710  NM_007111 // TFDP1 // transcription factor Dp‐1 // 13q34 // 7027 /// ENST0000037  TFDP1  1.41E‐08  0.0143163  1.09511  9.13E‐09  1.36457 
2678448  NM_007177 // FAM107A // family with sequence similarity 107, member A // 3p21.1   FAM107A  1.43E‐08  1.44E‐06  ‐1.40846  6.93E‐06  ‐1.46147 
2593464  NM_153697 // ANKRD44 // ankyrin repeat domain 44 // 2q33.1 // 91526 /// ENST0000  ANKRD44  1.43E‐08  0.000865498 ‐1.26029  4.04E‐08  ‐1.69341 
3055999  NM_018044 // NSUN5 // NOL1/NOP2/Sun domain family, member 5 // 7q11.23 // 55695   NSUN5  1.45E‐08  0.0376287  1.09801  6.14E‐09  1.47334 
3399545  NM_015261 // NCAPD3 // non‐SMC condensin II complex, subunit D3 // 11q25 // 2331  NCAPD3  1.45E‐08  0.0116788  1.14673  1.03E‐08  1.57062 
3722195  NM_003734 // AOC3 // amine oxidase, copper containing 3 (vascular adhesion prote  AOC3  1.45E‐08  2.59E‐05  ‐1.46822  4.68E‐07  ‐1.80073 
3159483  NM_153186 // KANK1 // KN motif and ankyrin repeat domains 1 // 9p24.3 // 23189 /  KANK1  1.46E‐08  3.57E‐07  1.32687  3.68E‐05  1.29892 
3939707  NM_012295 // CABIN1 // calcineurin binding protein 1 // 22q11.23 // 23523 /// EN  CABIN1  1.46E‐08  0.000883265 1.07841  4.09E‐08  1.18783 
3173831  NM_000144 // FXN // frataxin // 9q13‐q21.1 // 2395 /// NM_181425 // FXN // frata  FXN  1.47E‐08  0.0425424  1.0963  5.92E‐09  1.47953 
3856594  NM_003423 // ZNF43 // zinc finger protein 43 // 19p13.1‐p12 // 7594 /// ENST0000  ZNF43  1.48E‐08  4.35E‐05  ‐1.7358  3.18E‐07  ‐2.44093 
2768954  NM_001024611 // LRRC66 // leucine rich repeat containing 66 // 4q12 // 339977 //  LRRC66  1.48E‐08  1.70E‐06  ‐1.91639  6.09E‐06  ‐2.08143 
2870397  NM_014819 // PJA2 // praja 2, RING‐H2 motif containing // 5q21.3 // 9867 /// ENS  PJA2  1.48E‐08  0.000198818 ‐1.356  1.07E‐07  ‐1.79039 
2451593  NM_001276 // CHI3L1 // chitinase 3‐like 1 (cartilage glycoprotein‐39) // 1q32.1   CHI3L1  1.49E‐08  0.000126102 1.73482  1.46E‐07  2.72178 
2613880  NM_152653 // UBE2E2 // ubiquitin‐conjugating enzyme E2E 2 (UBC4/5 homolog, yeast  UBE2E2  1.49E‐08  9.63E‐06  ‐1.34889  1.13E‐06  ‐1.50792 
2681278  NM_015123 // FRMD4B // FERM domain containing 4B // 3p14.1 // 23150 /// ENST0000  FRMD4B  1.49E‐08  1.08E‐05  ‐1.33089  1.02E‐06  ‐1.48751 
3145564  NM_006294 // UQCRB // ubiquinol‐cytochrome c reductase binding protein // 8q22 /  UQCRB  1.49E‐08  3.60E‐07  ‐1.49887  3.77E‐05  ‐1.45327 
3051868  NM_004577 // PSPH // phosphoserine phosphatase // 7p15.2‐p15.1 // 5723 /// ENST0  PSPH  1.50E‐08  0.00113731  1.18177  3.63E‐08  1.48066 
2748163  NM_032117 // MND1 // meiotic nuclear divisions 1 homolog (S. cerevisiae) // 4q31  MND1  1.52E‐08  0.000941681 1.26155  4.11E‐08  1.7039 
3320169  NM_001025390 // AMPD3 // adenosine monophosphate deaminase (isoform E) // 11p15   AMPD3  1.52E‐08  5.07E‐07  1.15464  2.54E‐05  1.14892 
3526761  XM_001721602 // LOC100134226 // hypothetical protein LOC100134226 // ‐‐‐ // 1001  LOC100134226  1.54E‐08  1.75E‐07  1.47316  0.000103771 1.37844 




2905069  NM_173562 // KCTD20 // potassium channel tetramerisation domain containing 20 //  KCTD20  1.54E‐08  3.07E‐05  1.25026  4.43E‐07  1.41478 
3845681  NM_130807 // MOBKL2A // MOB1, Mps One Binder kinase activator‐like 2A (yeast) //  MOBKL2A  1.55E‐08  3.18E‐06  ‐1.21806  3.41E‐06  ‐1.26902 
3129234  NM_001010906 // C8orf80 // chromosome 8 open reading frame 80 // 8p21.1 // 38964  C8orf80  1.56E‐08  7.06E‐07  ‐1.3176  1.77E‐05  ‐1.31966 
3394192  NM_001382 // DPAGT1 // dolichyl‐phosphate (UDP‐N‐acetylglucosamine) N‐acetylgluc  DPAGT1  1.56E‐08  0.152952  1.06394  3.91E‐09  1.47182 
3864893  NM_014518 // ZNF229 // zinc finger protein 229 // 19q13.31 // 7772 /// ENST00000  ZNF229  1.57E‐08  4.98E‐06  ‐1.27287  2.24E‐06  ‐1.3585 
3699080  NM_152649 // MLKL // mixed lineage kinase domain‐like // 16q22.3 // 197259 /// E  MLKL  1.57E‐08  5.00E‐06  1.3051  2.24E‐06  1.40244 
3845782  NM_018049 // PLEKHJ1 // pleckstrin homology domain containing, family J member 1  PLEKHJ1  1.57E‐08  2.02E‐08  ‐1.26958  0.00365088  ‐1.13668 
3129588  NM_015254 // KIF13B // kinesin family member 13B // 8p21.1 // 23303 /// ENST0000  KIF13B  1.58E‐08  0.0237987  ‐1.10035  8.20E‐09  ‐1.43078 
3023483  AK290165 // FAM40B // family with sequence similarity 40, member B // 7q32.1 //   FAM40B  1.58E‐08  0.00042245  1.31901  7.02E‐08  1.77788 
3901361  NM_001898 // CST1 // cystatin SN // 20p11.21 // 1469 /// NM_001899 // CST4 // cy  CST1  1.60E‐08  1.10E‐05  2.06305  1.11E‐06  2.72613 
3815710  NM_001405 // EFNA2 // ephrin‐A2 // 19p13.3 // 1943 /// ENST00000215368 // EFNA2   EFNA2  1.60E‐08  2.53E‐06  ‐1.53286  4.53E‐06  ‐1.65015 
2970532  NM_001527 // HDAC2 // histone deacetylase 2 // 6q21 // 3066 /// ENST00000398283   HDAC2  1.60E‐08  1.61E‐06  1.46474  7.32E‐06  1.52818 
3395464  NM_024769 // ASAM // adipocyte‐specific adhesion molecule // 11q24.1 // 79827 //  ASAM  1.61E‐08  1.25E‐05  ‐1.36952  9.96E‐07  ‐1.55519 
2438282  NM_178229 // IQGAP3 // IQ motif containing GTPase activating protein 3 // 1q22‐q  IQGAP3  1.63E‐08  0.000407778 1.25398  7.47E‐08  1.59601 
3728037  NM_021626 // SCPEP1 // serine carboxypeptidase 1 // 17q22 // 59342 /// ENST00000  SCPEP1  1.65E‐08  2.17E‐06  ‐1.34877  5.54E‐06  ‐1.41019 
3719702  NM_032351 // MRPL45 // mitochondrial ribosomal protein L45 // 17q21.2 // 84311 /  MRPL45  1.65E‐08  4.44E‐05  1.25643  3.62E‐07  1.44412 
3450861  NM_005164 // ABCD2 // ATP‐binding cassette, sub‐family D (ALD), member 2 // 12q1  ABCD2  1.66E‐08  2.72E‐05  ‐1.26102  5.38E‐07  ‐1.42444 
3281068  NM_005028 // PIP4K2A // phosphatidylinositol‐5‐phosphate 4‐kinase, type II, alph  PIP4K2A  1.66E‐08  0.0166544  ‐1.11276  1.02E‐08  ‐1.45181 
2513925  NM_020981 // B3GALT1 // UDP‐Gal:betaGlcNAc beta 1,3‐galactosyltransferase, polyp  B3GALT1  1.67E‐08  0.000366959 ‐1.5696  8.22E‐08  ‐2.5059 
3354799  NM_001114122 // CHEK1 // CHK1 checkpoint homolog (S. pombe) // 11q24‐q24 // 1111  CHEK1  1.67E‐08  0.00313032  1.2926  2.34E‐08  1.98563 
3037839  NM_001037763 // COL28A1 // collagen, type XXVIII, alpha 1 // 7p21.3 // 340267 //  COL28A1  1.68E‐08  1.96E‐06  ‐1.35527  6.37E‐06  ‐1.41105 
3154136  NM_012472 // LRRC6 // leucine rich repeat containing 6 // 8q24.22 // 23639 /// E  LRRC6  1.72E‐08  1.11E‐05  1.733  1.21E‐06  2.13507 
4000704  NM_003916 // AP1S2 // adaptor‐related protein complex 1, sigma 2 subunit // Xp22  AP1S2  1.72E‐08  4.91E‐05  ‐1.2195  3.52E‐07  ‐1.38013 
3721886  NM_170607 // MLX // MAX‐like protein X // 17q21.1 // 6945 /// NM_198204 // MLX /  MLX  1.72E‐08  1.11E‐06  ‐1.26601  1.24E‐05  ‐1.28226 
2569649  NM_022336 // EDAR // ectodysplasin A receptor // 2q11‐q13 // 10913 /// ENST00000  EDAR  1.72E‐08  7.01E‐08  1.61887  0.000501435 1.39896 
3191391  AL834139 // HMCN2 // hemicentin 2 // 9q34.11 // 256158 /// AK093583 // HMCN2 //   HMCN2  1.73E‐08  9.79E‐08  ‐1.32218  0.000299081 ‐1.22974 
3542145  BC064697 // KIAA0247 // KIAA0247 // 14q24.1 // 9766 /// ENST00000342745 // KIAA0  KIAA0247  1.73E‐08  4.26E‐05  ‐1.19757  3.99E‐07  ‐1.33377 
3438617  NM_015409 // EP400 // E1A binding protein p400 // 12q24.33 // 57634 /// NR_00297  EP400  1.76E‐08  7.68E‐08  1.1555  0.00045098  1.10752 
3129361  NM_172366 // FBXO16 // F‐box protein 16 // 8p21.1 // 157574 /// ENST00000380254   FBXO16  1.76E‐08  2.69E‐05  1.39447  5.90E‐07  1.65605 
2835021  NM_024028 // PCYOX1L // prenylcysteine oxidase 1 like // 5q33.1 // 78991 /// ENS  PCYOX1L  1.76E‐08  2.48E‐05  1.19092  6.30E‐07  1.30053 
3442579  NM_031491 // RBP5 // retinol binding protein 5, cellular // 12p13.31 // 83758 //  RBP5  1.77E‐08  0.000560059 ‐1.25  6.74E‐08  ‐1.61032 
3402899  NM_001098536 // USP5 // ubiquitin specific peptidase 5 (isopeptidase T) // 12p13  USP5  1.78E‐08  0.290743  1.04118  3.63E‐09  1.40985 
2621451  NM_138615 // DHX30 // DEAH (Asp‐Glu‐Ala‐His) box polypeptide 30 // 3p21.31 // 22  DHX30  1.78E‐08  9.17E‐05  1.10772  2.31E‐07  1.19421 
3046062  NM_001637 // AOAH // acyloxyacyl hydrolase (neutrophil) // 7p14‐p12 // 313 /// E  AOAH  1.79E‐08  3.00E‐06  ‐1.58924  4.48E‐06  ‐1.73129 
3539499  NM_020663 // RHOJ // ras homolog gene family, member J // 14q23.2 // 57381 /// E  RHOJ  1.79E‐08  9.28E‐06  ‐1.38795  1.51E‐06  ‐1.55547 
3607503  NM_007011 // ABHD2 // abhydrolase domain containing 2 // 15q26.1 // 11057 /// NM  ABHD2  1.79E‐08  1.06E‐06  1.34447  1.39E‐05  1.36203 
3142381  NM_001442 // FABP4 // fatty acid binding protein 4, adipocyte // 8q21 // 2167 //  FABP4  1.80E‐08  1.36E‐05  ‐1.70019  1.08E‐06  ‐2.10881 
2484520  BC014578 // C2orf74 // chromosome 2 open reading frame 74 // 2p15 // 339804  C2orf74  1.81E‐08  7.85E‐05  ‐1.2915  2.64E‐07  ‐1.54622 
3468261  NM_024057 // NUP37 // nucleoporin 37kDa // 12q23.2 // 79023 /// ENST00000251074   NUP37  1.81E‐08  0.000111354 1.31793  2.04E‐07  1.63057 
2732508  NM_006419 // CXCL13 // chemokine (C‐X‐C motif) ligand 13 // 4q21 // 10563 /// EN  CXCL13  1.81E‐08  0.00348723  ‐1.81405  2.43E‐08  ‐5.00003 
2881672  NM_006058 // TNIP1 // TNFAIP3 interacting protein 1 // 5q32‐q33.1 // 10318 /// E  TNIP1  1.82E‐08  6.56E‐06  ‐1.17567  2.13E‐06  ‐1.23305 




3569257  NM_016445 // PLEK2 // pleckstrin 2 // 14q23.3 // 26499 /// ENST00000216446 // PL  PLEK2  1.85E‐08  0.00480452  1.23722  2.10E‐08  1.82585 
3212848  NM_016548 // GOLM1 // golgi membrane protein 1 // 9q21.33 // 51280 /// NM_177937  GOLM1  1.87E‐08  8.77E‐05  ‐1.37315  2.53E‐07  ‐1.72598 
2522094  NM_001100422 // LOC26010 // viral DNA polymerase‐transactivated protein 6 // 2q3  LOC26010  1.87E‐08  2.42E‐06  ‐1.34201  6.00E‐06  ‐1.40265 
3947123  NM_004599 // SREBF2 // sterol regulatory element binding transcription factor 2   SREBF2  1.89E‐08  7.84E‐08  ‐1.26303  0.000499286 ‐1.17782 
3033531  AK124321 // tcag7.1275 // hypothetical LOC389602 // 7q36.3 // 389602 /// ENST000  tcag7.1275  1.89E‐08  0.000119929 1.88783  2.05E‐07  3.10033 
2995254  NM_152793 // C7orf41 // chromosome 7 open reading frame 41 // 7p15.1 // 222166 /  C7orf41  1.89E‐08  1.40E‐07  1.57681  0.000206407 1.42443 
3902743  NM_080616 // C20orf112 // chromosome 20 open reading frame 112 // 20q11.1‐q11.23  C20orf112  1.90E‐08  4.82E‐06  ‐1.58356  3.04E‐06  ‐1.77268 
3824540  NM_015122 // FCHO1 // FCH domain only 1 // 19p13.11 // 23149 /// ENST00000252771  FCHO1  1.92E‐08  9.03E‐07  1.46024  1.85E‐05  1.46916 
2863363  NM_004101 // F2RL2 // coagulation factor II (thrombin) receptor‐like 2 // 5q13 /  F2RL2  1.92E‐08  5.62E‐05  1.44347  3.67E‐07  1.82278 
3943101  NM_014662 // DEPDC5 // DEP domain containing 5 // 22q12.3 // 9681 /// NM_0010071  DEPDC5  1.93E‐08  3.79E‐07  ‐1.19894  5.42E‐05  ‐1.178 
3333226  NM_004111 // FEN1 // flap structure‐specific endonuclease 1 // 11q12 // 2237 ///  FEN1  1.94E‐08  0.325489  1.05063  3.84E‐09  1.57007 
2449711  NM_144977 // DENND1B // DENN/MADD domain containing 1B // 1q31.3 // 163486 /// E  DENND1B  1.95E‐08  0.000329757 ‐1.26884  1.07E‐07  ‐1.60774 
3775157  NM_019613 // WDR45L // WDR45‐like // 17q25.3 // 56270 /// ENST00000392325 // WDR WDR45L  1.96E‐08  0.00623852  1.09867  1.96E‐08  1.31801 
2676854  NM_018397 // CHDH // choline dehydrogenase // 3p21.1 // 55349 /// ENST0000031525  CHDH  1.97E‐08  3.88E‐06  1.24989  3.99E‐06  1.31004 
2327219  NM_177424 // STX12 // syntaxin 12 // 1p35‐p34.1 // 23673 /// ENST00000373943 //   STX12  1.98E‐08  7.38E‐07  ‐1.43564  2.46E‐05  ‐1.42872 
2855578  BC013351 // C5orf28 // chromosome 5 open reading frame 28 // 5p12 // 64417 /// B  C5orf28  1.98E‐08  9.50E‐06  1.29034  1.70E‐06  1.4075 
2493858  NM_002371 // MAL // mal, T‐cell differentiation protein // 2cen‐q13 // 4118 ///   MAL  1.98E‐08  5.56E‐06  ‐1.38531  2.80E‐06  ‐1.5088 
3255491  AK056561 // LOC170425 // hypothetical protein LOC170425 // 10q23.1 // 170425  LOC170425  1.98E‐08  6.21E‐07  2.27441  3.05E‐05  2.20772 
2869096  NM_180991 // SLCO4C1 // solute carrier organic anion transporter family, member   SLCO4C1  1.99E‐08  0.00560576  ‐1.21577  2.10E‐08  ‐1.75687 
3693214  NM_018110 // DOK4 // docking protein 4 // 16q13 // 55715 /// ENST00000340099 //   DOK4  2.00E‐08  4.55E‐07  ‐1.3226  4.58E‐05  ‐1.29419 
3662387  NM_014685 // HERPUD1 // homocysteine‐inducible, endoplasmic reticulum stress‐ind  HERPUD1  2.01E‐08  1.19E‐06  ‐1.4439  1.44E‐05  ‐1.4697 
3420151  NM_001031679 // MSRB3 // methionine sulfoxide reductase B3 // 12q14.3 // 253827   MSRB3  2.01E‐08  1.89E‐06  ‐1.34926  8.65E‐06  ‐1.3944 
3315607  NM_025092 // ATHL1 // ATH1, acid trehalase‐like 1 (yeast) // 11p15.5 // 80162 //  ATHL1  2.02E‐08  1.74E‐06  1.52604  9.56E‐06  1.59047 
3423002  AK074510 // LOC652993 // hypothetical LOC652993 // 12q21 // 652993  LOC652993  2.03E‐08  0.000208525 1.28001  1.52E‐07  1.59342 
3415668  NM_170754 // TENC1 // tensin like C1 domain containing phosphatase (tensin 2) //  TENC1  2.04E‐08  5.49E‐06  ‐1.18858  2.97E‐06  ‐1.24252 
2481142  NM_000179 // MSH6 // mutS homolog 6 (E. coli) // 2p16 // 2956 /// ENST0000023442  MSH6  2.04E‐08  0.00063424  1.16455  7.39E‐08  1.38756 
2358360  NM_004425 // ECM1 // extracellular matrix protein 1 // 1q21 // 1893 /// NM_02266  ECM1  2.06E‐08  5.38E‐05  1.50249  4.15E‐07  1.9342 
3831143  NM_001281 // TBCB // tubulin folding cofactor B // 19q13.11‐q13.12 // 1155 /// E  TBCB  2.07E‐08  0.00209848  1.12189  3.72E‐08  1.33343 
2379754  NM_020197 // SMYD2 // SET and MYND domain containing 2 // 1q41 // 56950 /// ENST  SMYD2  2.08E‐08  5.15E‐06  1.35295  3.26E‐06  1.45721 
2438344  NM_182679 // GPATCH4 // G patch domain containing 4 // 1q22 // 54865 /// NM_0155  GPATCH4  2.09E‐08  5.07E‐06  1.22725  3.32E‐06  1.28984 
3042012  NM_138811 // C7orf31 // chromosome 7 open reading frame 31 // 7p15.2 // 136895 /  C7orf31  2.09E‐08  1.92E‐06  ‐1.42706  9.06E‐06  ‐1.4827 
3683018  NM_001019 // RPS15A // ribosomal protein S15a // 16p // 6210 /// NM_001030009 //  RPS15A  2.10E‐08  0.00270744  1.22875  3.29E‐08  1.70434 
3874751  NM_000311 // PRNP // prion protein // 20p13 // 5621 /// NM_183079 // PRNP // pri  PRNP  2.11E‐08  0.000404658 ‐1.36127  1.03E‐07  ‐1.87228 
3373893  NM_003627 // SLC43A1 // solute carrier family 43, member 1 // 11p11.2‐p11.1 // 8  SLC43A1  2.11E‐08  1.58E‐05  1.25557  1.18E‐06  1.37892 
3734379  NM_007261 // CD300A // CD300a molecule // 17q25.1 // 11314 /// ENST00000360141 /  CD300A  2.17E‐08  6.34E‐07  ‐1.40174  3.44E‐05  ‐1.3815 
2742935  NM_014278 // HSPA4L // heat shock 70kDa protein 4‐like // 4q28 // 22824 /// ENST  HSPA4L  2.17E‐08  3.83E‐06  1.82275  4.64E‐06  2.05423 
3294576  NM_152586 // USP54 // ubiquitin specific peptidase 54 // 10q22.2 // 159195 /// E  USP54  2.18E‐08  2.86E‐07  1.40516  9.77E‐05  1.3365 
3933817  NM_018669 // WDR4 // WD repeat domain 4 // 21q22.3 // 10785 /// NM_033661 // WDR  WDR4  2.20E‐08  0.080062  1.07872  7.08E‐09  1.4532 
2407439  NM_006802 // SF3A3 // splicing factor 3a, subunit 3, 60kDa // 1p34.3 // 10946 //  SF3A3  2.22E‐08  7.73E‐07  1.30119  2.81E‐05  1.29443 
2832459  NM_018934 // PCDHB14 // protocadherin beta 14 // 5q31 // 56122 /// ENST000002394  PCDHB14  2.23E‐08  8.86E‐08  1.81087  0.00056118  1.51323 
3329029  NM_021117 // CRY2 // cryptochrome 2 (photolyase‐like) // 11p11.2 // 1408 /// NM_  CRY2  2.24E‐08  4.55E‐06  ‐1.14863  4.08E‐06  ‐1.18427 




3076882  NM_176817 // TAS2R38 // taste receptor, type 2, member 38 // 7q34 // 5726 /// EN  TAS2R38  2.26E‐08  3.09E‐06  1.72665  6.13E‐06  1.8895 
3355021  NM_024556 // FAM118B // family with sequence similarity 118, member B // 11q24.2  FAM118B  2.26E‐08  6.83E‐07  ‐1.30989  3.36E‐05  ‐1.2966 
3556816  NM_003982 // SLC7A7 // solute carrier family 7 (cationic amino acid transporter,  SLC7A7  2.29E‐08  9.75E‐07  ‐1.59676  2.24E‐05  ‐1.60247 
3402522  NM_018009 // TAPBPL // TAP binding protein‐like // 12p13.31 // 55080 /// ENST000  TAPBPL  2.31E‐08  9.22E‐08  ‐1.27683  0.000563195 ‐1.18619 
3203524  NM_001170 // AQP7 // aquaporin 7 // 9p13 // 364 /// NR_002817 // AQP7P1 // aquap  AQP7  2.33E‐08  6.57E‐07  ‐1.62919  3.71E‐05  ‐1.59294 
3300115  NM_005398 // PPP1R3C // protein phosphatase 1, regulatory (inhibitor) subunit 3C  PPP1R3C  2.34E‐08  3.43E‐07  ‐1.64606  8.58E‐05  ‐1.54196 
3329099  NM_152312 // GYLTL1B // glycosyltransferase‐like 1B // 11p11.2 // 120071 /// ENS  GYLTL1B  2.34E‐08  1.07E‐06  1.41198  2.07E‐05  1.42069 
3204243  NM_005866 // OPRS1 // opioid receptor, sigma 1 // 9p13.3 // 10280 /// NM_147157   OPRS1  2.34E‐08  0.163236  1.05657  5.81E‐09  1.41354 
3504617  NM_145061 // C13orf3 // chromosome 13 open reading frame 3 // 13q12.11 // 221150  C13orf3  2.34E‐08  0.0340147  1.16937  1.07E‐08  1.8591 
2967769  BC131628 // KIAA1553 // KIAA1553 // 6q21 // 57673 /// NM_001080450 // KIAA1553 /  KIAA1553  2.37E‐08  2.65E‐05  1.17822  8.83E‐07  1.2755 
2486927  NM_014882 // ARHGAP25 // Rho GTPase activating protein 25 // 2p14 // 9938 /// NM  ARHGAP25  2.39E‐08  0.000915009 ‐1.21081  7.12E‐08  ‐1.53191 
2328320  NM_022164 // TINAGL1 // tubulointerstitial nephritis antigen‐like 1 // 1p35.2 //  TINAGL1  2.39E‐08  3.28E‐07  1.29147  9.44E‐05  1.24632 
2452977  NM_005449 // FAIM3 // Fas apoptotic inhibitory molecule 3 // 1q32.1 // 9214 ///   FAIM3  2.41E‐08  0.000252045 ‐1.46841  1.65E‐07  ‐2.08222 
3944690  NM_013385 // CYTH4 // cytohesin 4 // 22q12.3‐q13.1 // 27128 /// ENST00000248901   CYTH4  2.46E‐08  1.49E‐05  ‐1.32609  1.53E‐06  ‐1.4793 
2829171  NM_003202 // TCF7 // transcription factor 7 (T‐cell specific, HMG‐box) // 5q31.1  TCF7  2.46E‐08  2.87E‐07  1.42145  0.000119504 1.34364 
3726569  NM_022827 // SPATA20 // spermatogenesis associated 20 // 17q21.33 // 64847 /// E  SPATA20  2.46E‐08  0.0029783  1.11753  3.74E‐08  1.33519 
2862274  BC043557 // LOC340090 // hypothetical protein LOC340090 // 5q13.3 // 340090  LOC340090  2.48E‐08  9.66E‐07  ‐1.47398  2.58E‐05  ‐1.47269 
3842301  NM_016535 // ZNF581 // zinc finger protein 581 // 19q13.42 // 51545 /// ENST0000  ZNF581  2.53E‐08  3.64E‐05  1.20511  7.42E‐07  1.33039 
3301512  NM_002860 // ALDH18A1 // aldehyde dehydrogenase 18 family, member A1 // 10q24.3   ALDH18A1  2.54E‐08  4.32E‐08  ‐1.27981  0.00243711  ‐1.15446 
3435154  NM_020993 // BCL7A // B‐cell CLL/lymphoma 7A // 12q24.13 // 605 /// NM_001024808  BCL7A  2.55E‐08  0.0415193  1.0529  1.08E‐08  1.23729 
3624145  NM_015263 // DMXL2 // Dmx‐like 2 // 15q21.2 // 23312 /// ENST00000251076 // DMXL  DMXL2  2.55E‐08  0.00147149  ‐1.26161  5.79E‐08  ‐1.73081 
3230282  NM_006412 // AGPAT2 // 1‐acylglycerol‐3‐phosphate O‐acyltransferase 2 (lysophosp  AGPAT2  2.60E‐08  1.60E‐08  ‐1.45777  0.0179082  ‐1.17364 
2407191  NM_013285 // GNL2 // guanine nucleotide binding protein‐like 2 (nucleolar) // 1p  GNL2  2.60E‐08  8.86E‐05  1.25643  3.84E‐07  1.46965 
2747961  NM_033393 // FHDC1 // FH2 domain containing 1 // 4q31.3 // 85462 /// ENST0000026  FHDC1  2.63E‐08  7.11E‐06  1.28774  3.34E‐06  1.37806 
2426385  NM_006113 // VAV3 // vav 3 guanine nucleotide exchange factor // 1p13.3 // 10451  VAV3  2.66E‐08  0.00337997  ‐1.17507  3.80E‐08  ‐1.53047 
2693217  NM_022776 // OSBPL11 // oxysterol binding protein‐like 11 // 3q21 // 114885 ///   OSBPL11  2.67E‐08  2.24E‐07  ‐1.52067  0.000194715 ‐1.39756 
3325680  NM_006360 // EIF3M // eukaryotic translation initiation factor 3, subunit M // 1  EIF3M  2.70E‐08  1.06E‐05  1.4035  2.36E‐06  1.56726 
4017381  NM_198057 // TSC22D3 // TSC22 domain family, member 3 // Xq22.3 // 1831 /// NM_0  TSC22D3  2.70E‐08  2.11E‐05  ‐1.36617  1.28E‐06  ‐1.56366 
3464912  NM_172240 // WDR51B // WD repeat domain 51B // 12q21.33 // 282809 /// ENST000003  WDR51B  2.72E‐08  4.10E‐06  1.69711  6.02E‐06  1.87207 
3565571  NM_007086 // WDHD1 // WD repeat and HMG‐box DNA binding protein 1 // 14q22.3 //   WDHD1  2.72E‐08  0.0389983  1.15496  1.19E‐08  1.79434 
3212008  NM_174938 // FRMD3 // FERM domain containing 3 // 9q21.32 // 257019 /// ENST0000  FRMD3  2.75E‐08  4.10E‐06  ‐1.51357  6.12E‐06  ‐1.6337 
3598721  NR_003105 // ZWILCH // Zwilch, kinetochore associated, homolog (Drosophila) // 1  ZWILCH  2.75E‐08  0.247113  1.06829  5.97E‐09  1.65185 
3339971  NM_021200 // PLEKHB1 // pleckstrin homology domain containing, family B (evectin  PLEKHB1  2.76E‐08  1.08E‐05  1.41408  2.40E‐06  1.5829 
2428501  NM_003051 // SLC16A1 // solute carrier family 16, member 1 (monocarboxylic acid   SLC16A1  2.79E‐08  1.94E‐07  ‐1.99823  0.000258512 ‐1.70987 
4001850  NM_031892 // SH3KBP1 // SH3‐domain kinase binding protein 1 // Xp22.1‐p21.3 // 3  SH3KBP1  2.80E‐08  1.79E‐05  ‐1.24261  1.55E‐06  ‐1.35618 
3360772  NM_032127 // FAM160A2 // family with sequence similarity 160, member A2 // 11p15  FAM160A2  2.80E‐08  4.80E‐06  ‐1.22382  5.37E‐06  ‐1.27545 
2859195  NM_014473 // DIMT1L // DIM1 dimethyladenosine transferase 1‐like (S. cerevisiae)  DIMT1L  2.82E‐08  1.75E‐05  1.30875  1.60E‐06  1.45679 
2774365  NM_006835 // CCNI // cyclin I // 4q21.1 // 10983 /// ENST00000237654 // CCNI //   CCNI  2.82E‐08  6.88E‐08  1.27198  0.00133907  1.1648 
3476796  NM_032656 // DHX37 // DEAH (Asp‐Glu‐Ala‐His) box polypeptide 37 // 12q24.31 // 5  DHX37  2.83E‐08  0.000694074 1.12458  1.03E‐07  1.28471 
2409220  NM_006824 // EBNA1BP2 // EBNA1 binding protein 2 // 1p35‐p33 // 10969 /// ENST00  EBNA1BP2  2.84E‐08  0.000181477 1.25255  2.54E‐07  1.50646 
3721926  NM_001070 // TUBG1 // tubulin, gamma 1 // 17q21 // 7283 /// ENST00000251413 // T  TUBG1  2.86E‐08  0.786106  1.01671  4.70E‐09  1.72796 




3235726  NM_001008211 // OPTN // optineurin // 10p13 // 10133 /// NM_001008213 // OPTN //  OPTN  2.88E‐08  0.00136603  ‐1.22776  6.97E‐08  ‐1.61049 
3009399  NM_001540 // HSPB1 // heat shock 27kDa protein 1 // 7q11.23 // 3315 /// ENST0000  HSPB1  2.89E‐08  1.98E‐08  ‐1.45952  0.014572  ‐1.18256 
2462329  NM_019891 // ERO1LB // ERO1‐like beta (S. cerevisiae) // 1q42.2‐q43 // 56605 ///  ERO1LB  2.89E‐08  0.000796961 ‐1.20679  9.72E‐08  ‐1.50311 
3638760  NM_002168 // IDH2 // isocitrate dehydrogenase 2 (NADP+), mitochondrial // 15q26.  IDH2  2.90E‐08  0.00691406  1.15728  2.87E‐08  1.53283 
3645359  NM_145252 // LOC124220 // similar to common salivary protein 1 // 16p13.3 // 124  LOC124220  2.90E‐08  2.98E‐05  1.34067  1.05E‐06  1.54386 
2700404  NM_015472 // WWTR1 // WW domain containing transcription regulator 1 // 3q23‐q24  WWTR1  2.92E‐08  0.000106537 ‐1.27584  3.87E‐07  ‐1.51655 
3031544  NM_130759 // GIMAP1 // GTPase, IMAP family member 1 // 7q36.1 // 170575 /// ENST  GIMAP1  2.92E‐08  0.000689697 ‐1.16122  1.08E‐07  ‐1.37456 
3310041  NM_000141 // FGFR2 // fibroblast growth factor receptor 2 // 10q26 // 2263 /// N  FGFR2  2.93E‐08  1.05E‐06  ‐1.54969  3.04E‐05  ‐1.54357 
2688717  NM_181780 // BTLA // B and T lymphocyte associated // 3q13.2 // 151888 /// NM_00  BTLA  2.94E‐08  0.000492696 ‐1.42702  1.34E‐07  ‐2.0673 
3815243  NM_001928 // CFD // complement factor D (adipsin) // 19p13.3 // 1675 /// ENST000  CFD  2.94E‐08  4.77E‐08  ‐1.61957  0.00276102  ‐1.32054 
3072546  NM_018718 // TSGA14 // testis specific, 14 // 7q32 // 95681 /// ENST00000223208   TSGA14  2.95E‐08  0.000340291 1.11314  1.72E‐07  1.23293 
3262535  NM_183239 // GSTO2 // glutathione S‐transferase omega 2 // 10q25.1 // 119391 ///  GSTO2  2.95E‐08  2.08E‐05  1.22367  1.47E‐06  1.33202 
3331903  AY457926 // FAM111B // family with sequence similarity 111, member B // 11q12.1   FAM111B  2.99E‐08  0.0124532  1.28604  2.22E‐08  2.24745 
3627422  NM_134260 // RORA // RAR‐related orphan receptor A // 15q21‐q22 // 6095 /// NM_0  RORA  3.00E‐08  0.0147288  ‐1.13619  2.05E‐08  ‐1.52722 
2891052  NM_006098 // GNB2L1 // guanine nucleotide binding protein (G protein), beta poly  GNB2L1  3.00E‐08  1.47E‐05  1.2402  2.04E‐06  1.34136 
3155489  NM_015912 // FAM135B // family with sequence similarity 135, member B // 8q24.23  FAM135B  3.02E‐08  2.35E‐07  ‐1.45071  0.000225679 ‐1.34215 
2326993  NM_032872 // SYTL1 // synaptotagmin‐like 1 // 1p36.11 // 84958 /// ENST000003180  SYTL1  3.02E‐08  3.01E‐06  1.38461  9.74E‐06  1.44485 
3307939  NM_002313 // ABLIM1 // actin binding LIM protein 1 // 10q25 // 3983 /// NM_00100  ABLIM1  3.04E‐08  3.88E‐06  1.24217  7.55E‐06  1.28759 
2343289  NM_007034 // DNAJB4 // DnaJ (Hsp40) homolog, subfamily B, member 4 // 1p31.1 //   DNAJB4  3.05E‐08  2.00E‐05  ‐1.61677  1.58E‐06  ‐1.96985 
2995589  NM_198098 // AQP1 // aquaporin 1 (Colton blood group) // 7p14 // 358 /// ENST000  AQP1  3.05E‐08  0.00136151  ‐1.30749  7.48E‐08  ‐1.85968 
3707214  NM_002663 // PLD2 // phospholipase D2 // 17p13.1 // 5338 /// ENST00000263088 //   PLD2  3.05E‐08  5.89E‐07  1.19891  6.63E‐05  1.17958 
2672016  NM_024513 // FYCO1 // FYVE and coiled‐coil domain containing 1 // 3p21.31 // 794  FYCO1  3.07E‐08  1.01E‐07  1.21688  0.0008331  1.14207 
3940185  NM_004175 // SNRPD3 // small nuclear ribonucleoprotein D3 polypeptide 18kDa // 2  SNRPD3  3.10E‐08  0.000852662 1.12756  1.01E‐07  1.29884 
3772661  NM_003255 // TIMP2 // TIMP metallopeptidase inhibitor 2 // 17q25 // 7077 /// ENS  TIMP2  3.11E‐08  0.00394995  ‐1.29962  4.17E‐08  ‐2.01646 
2738314  NM_001031720 // GSTCD // glutathione S‐transferase, C‐terminal domain containing  GSTCD  3.13E‐08  0.000315568 1.17054  1.95E‐07  1.35501 
3048631  NM_015332 // NUDCD3 // NudC domain containing 3 // 7p13‐p12 // 23386 /// ENST000  NUDCD3  3.14E‐08  9.95E‐05  1.14922  4.47E‐07  1.26468 
3421985  NM_014505 // KCNMB4 // potassium large conductance calcium‐activated channel, su  KCNMB4  3.16E‐08  4.56E‐07  ‐1.32699  9.78E‐05  ‐1.2802 
3959613  NM_024955 // FOXRED2 // FAD‐dependent oxidoreductase domain containing 2 // 22q1  FOXRED2  3.17E‐08  0.0417177  1.07856  1.36E‐08  1.36273 
3822074  NM_005053 // RAD23A // RAD23 homolog A (S. cerevisiae) // 19p13.2 // 5886 /// EN  RAD23A  3.17E‐08  0.00315365  1.10149  4.83E‐08  1.28425 
3449910  NR_004854 // AMN1 // antagonist of mitotic exit network 1 homolog (S. cerevisiae  AMN1  3.18E‐08  0.000125817 1.23093  3.81E‐07  1.43331 
3532793  NM_006194 // PAX9 // paired box 9 // 14q12‐q13 // 5083 /// ENST00000402703 // PA  PAX9  3.20E‐08  2.30E‐06  1.57048  1.42E‐05  1.63381 
2621705  NM_130384 // ATRIP // ATR interacting protein // 3p21.31 // 84126 /// NM_032166   ATRIP  3.21E‐08  0.00150921  1.08776  7.47E‐08  1.21742 
3145953  NM_000989 // RPL30 // ribosomal protein L30 // 8q22 // 6156 /// NR_002581 // SNO  RPL30  3.22E‐08  3.55E‐05  1.23501  1.04E‐06  1.37248 
3905875  NM_005461 // MAFB // v‐maf musculoaponeurotic fibrosarcoma oncogene homolog B (a  MAFB  3.26E‐08  5.44E‐06  ‐1.25587  5.91E‐06  ‐1.31639 
3699757  NM_005548 // KARS // lysyl‐tRNA synthetase // 16q23‐q24 // 3735 /// ENST00000319  KARS  3.28E‐08  0.00013734  1.22514  3.72E‐07  1.42569 
3638660  NR_023361 // AP3S2 // adaptor‐related protein complex 3, sigma 2 subunit // 15q2  AP3S2  3.33E‐08  3.48E‐07  ‐1.48079  0.000154267 ‐1.38605 
2439052  NM_030764 // FCRL2 // Fc receptor‐like 2 // 1q21 // 79368 /// NM_138738 // FCRL2  FCRL2  3.36E‐08  3.09E‐05  ‐1.30936  1.24E‐06  ‐1.48697 
3771543  NM_022066 // UBE2O // ubiquitin‐conjugating enzyme E2O // 17q25.1 // 63893 /// E  UBE2O  3.37E‐08  5.26E‐05  1.13177  8.05E‐07  1.21346 
3845909  NM_032737 // LMNB2 // lamin B2 // 19p13.3 // 84823 /// ENST00000325327 // LMNB2   LMNB2  3.38E‐08  0.0771338  1.06905  1.13E‐08  1.37641 
2725013  NM_004181 // UCHL1 // ubiquitin carboxyl‐terminal esterase L1 (ubiquitin thioles  UCHL1  3.42E‐08  1.17E‐07  ‐1.46197  0.000810046 ‐1.29631 
4019784  NM_017938 // FAM70A // family with sequence similarity 70, member A // Xq24 // 5  FAM70A  3.42E‐08  1.36E‐05  ‐1.30038  2.63E‐06  ‐1.42101 




3565663  NM_014750 // DLGAP5 // discs, large (Drosophila) homolog‐associated protein 5 //  DLGAP5  3.44E‐08  0.00387267  1.33273  4.74E‐08  2.14335 
3824874  NM_006332 // IFI30 // interferon, gamma‐inducible protein 30 // 19p13.1 // 10437  IFI30  3.48E‐08  7.93E‐06  ‐1.42569  4.47E‐06  ‐1.56059 
2420808  NM_003921 // BCL10 // B‐cell CLL/lymphoma 10 // 1p22 // 8915 /// ENST00000394761  BCL10  3.48E‐08  7.18E‐06  ‐1.29621  4.93E‐06  ‐1.37955 
3513953  NM_020456 // C13orf1 // chromosome 13 open reading frame 1 // 13q14 // 57213 ///  C13orf1  3.52E‐08  3.59E‐08  ‐1.25555  0.00682424  ‐1.12279 
3992148  NM_182540 // DDX26B // DEAD/H (Asp‐Glu‐Ala‐Asp/His) box polypeptide 26B // Xq26.  DDX26B  3.53E‐08  0.00113413  ‐1.30377  9.89E‐08  ‐1.8124 
3395735  NM_003455 // ZNF202 // zinc finger protein 202 // 11q23.3 // 7753 /// ENST000003  ZNF202  3.54E‐08  2.44E‐05  1.20081  1.63E‐06  1.29845 
3227696  NM_198679 // RAPGEF1 // Rap guanine nucleotide exchange factor (GEF) 1 // 9q34.3  RAPGEF1  3.55E‐08  3.49E‐06  ‐1.17625  1.06E‐05  ‐1.20227 
3722084  NM_032387 // WNK4 // WNK lysine deficient protein kinase 4 // 17q21‐q22 // 65266  WNK4  3.57E‐08  1.41E‐06  1.40074  2.92E‐05  1.40538 
2792166  NM_017923 // MARCH1 // membrane‐associated ring finger (C3HC4) 1 // 4q32.3 // 55  MARCH1  3.59E‐08  0.000149191 ‐1.50333  3.93E‐07  ‐2.04346 
3595096  NM_207036 // TCF12 // transcription factor 12 // 15q21 // 6938 /// NM_207037 //   TCF12  3.62E‐08  4.81E‐06  1.46005  7.82E‐06  1.5617 
3687241  BC150579 // C16orf53 // chromosome 16 open reading frame 53 // 16p11.2 // 79447   C16orf53  3.63E‐08  4.24E‐07  ‐1.48717  0.00013683  ‐1.40009 
3129258  NM_001010906 // C8orf80 // chromosome 8 open reading frame 80 // 8p21.1 // 38964  C8orf80  3.64E‐08  8.38E‐07  ‐1.64117  5.68E‐05  ‐1.5914 
4047607  NM_024850 // BTNL8 // butyrophilin‐like 8 // 5q35.3 // 79908 /// NM_001040462 //  BTNL8  3.66E‐08  2.41E‐06  ‐1.92196  1.66E‐05  ‐2.02487 
2476510  NM_206943 // LTBP1 // latent transforming growth factor beta binding protein 1 /  LTBP1  3.67E‐08  2.32E‐07  1.31266  0.000324905 1.232 
3822593  BC011002 // LOC113230 // hypothetical protein LOC113230 // 19p13.12 // 113230  LOC113230  3.67E‐08  0.00181525  1.14126  7.81E‐08  1.36944 
3105033  NM_152284 // CHMP4C // chromatin modifying protein 4C // 8q21.13 // 92421 /// EN  CHMP4C  3.67E‐08  3.18E‐06  1.26258  1.23E‐05  1.29776 
2877990  NM_198282 // TMEM173 // transmembrane protein 173 // 5q31.2 // 340061 /// ENST00  TMEM173  3.72E‐08  4.12E‐07  1.27972  0.000148681 1.23056 
3032243  NM_022087 // GALNT11 // UDP‐N‐acetyl‐alpha‐D‐galactosamine:polypeptide N‐acetylg  GALNT11  3.72E‐08  0.00233619  1.13131  6.87E‐08  1.35468 
2993639  NM_016587 // CBX3 // chromobox homolog 3 (HP1 gamma homolog, Drosophila) // 7p15  CBX3  3.73E‐08  0.000591784 1.15455  1.59E‐07  1.3444 
3214749  NM_017948 // NOL8 // nucleolar protein 8 // 9q22.31 // 55035 /// ENST00000358855  NOL8  3.76E‐08  1.13E‐05  1.33023  3.56E‐06  1.44905 
3490892  NM_006418 // OLFM4 // olfactomedin 4 // 13q21.1 // 10562 /// ENST00000219022 //   OLFM4  3.77E‐08  0.000619204 2.22941  1.56E‐07  5.25604 
3226493  NM_015679 // TRUB2 // TruB pseudouridine (psi) synthase homolog 2 (E. coli) // 9  TRUB2  3.78E‐08  0.255664  1.05818  8.21E‐09  1.53975 
2830638  NM_005733 // KIF20A // kinesin family member 20A // 5q31 // 10112 /// ENST000003  KIF20A  3.80E‐08  0.000990759 1.38341  1.17E‐07  2.03841 
2638676  NM_018456 // EAF2 // ELL associated factor 2 // 3q13.33 // 55840 /// ENST0000027  EAF2  3.80E‐08  0.000300222 ‐1.35138  2.56E‐07  ‐1.76972 
2334314  NM_032756 // HPDL // 4‐hydroxyphenylpyruvate dioxygenase‐like // 1p34.1 // 84842  HPDL  3.83E‐08  9.60E‐05  1.33332  5.93E‐07  1.61177 
3121054  NR_003572 // FLJ45055 // 60S ribosomal pseudogene // 8p23.3 // 644128 /// NM_001  FLJ45055  3.84E‐08  0.000110806 1.25431  5.33E‐07  1.46546 
3241316  NM_030751 // ZEB1 // zinc finger E‐box binding homeobox 1 // 10p11.2 // 6935 ///  ZEB1  3.84E‐08  2.58E‐05  ‐1.31392  1.74E‐06  ‐1.47652 
3019793  NM_148898 // FOXP2 // forkhead box P2 // 7q31 // 93986 /// NM_148899 // FOXP2 //  FOXP2  3.87E‐08  5.25E‐05  ‐1.52011  9.65E‐07  ‐1.91206 
2628785  NM_006722 // MITF // microphthalmia‐associated transcription factor // 3p14.2‐p1  MITF  3.88E‐08  5.62E‐06  ‐1.24654  7.36E‐06  ‐1.30077 
3108146  NM_002998 // SDC2 // syndecan 2 // 8q22‐q23 // 6383 /// ENST00000302190 // SDC2   SDC2  3.89E‐08  5.89E‐06  ‐1.26976  7.05E‐06  ‐1.33179 
3061438  NM_017654 // SAMD9 // sterile alpha motif domain containing 9 // 7q21.2 // 54809  SAMD9  3.92E‐08  0.0294699  ‐1.26443  1.99E‐08  ‐2.41021 
3317868  NM_014489 // FRAG1 // FGF receptor activating protein 1 // 11p15.5 // 27315 ///   FRAG1  3.94E‐08  0.0425345  1.0773  1.70E‐08  1.35388 
2877257  NM_139199 // BRD8 // bromodomain containing 8 // 5q31 // 10902 /// NM_006696 //   BRD8  3.96E‐08  2.00E‐08  1.2307  0.0295987  1.08478 
3224650  NM_020946 // DENND1A // DENN/MADD domain containing 1A // 9q33.2 // 57706 /// NM DENND1A  3.96E‐08  4.43E‐06  ‐1.1957  9.69E‐06  ‐1.22972 
3064541  NM_001084 // PLOD3 // procollagen‐lysine, 2‐oxoglutarate 5‐dioxygenase 3 // 7q22  PLOD3  3.97E‐08  0.0196787  1.08954  2.43E‐08  1.34463 
2340186  NM_018211 // RAVER2 // ribonucleoprotein, PTB‐binding 2 // 1p31.3 // 55225 /// E  RAVER2  3.99E‐08  3.83E‐05  ‐1.2847  1.30E‐06  ‐1.45238 
3047581  NM_002192 // INHBA // inhibin, beta A // 7p15‐p13 // 3624 /// ENST00000242208 //  INHBA  4.00E‐08  1.58E‐06  1.51617  3.06E‐05  1.52449 
3230811  NM_013379 // DPP7 // dipeptidyl‐peptidase 7 // 9q34.3 // 29952 /// ENST000003715  DPP7  4.04E‐08  0.00110591  1.13023  1.18E‐07  1.31189 
3152558  NM_174911 // FAM84B // family with sequence similarity 84, member B // 8q24.21 /  FAM84B  4.06E‐08  0.0106863  1.08335  3.35E‐08  1.28046 
3134034  NM_006904 // PRKDC // protein kinase, DNA‐activated, catalytic polypeptide // 8q  PRKDC  4.08E‐08  8.27E‐06  1.45163  5.39E‐06  1.59006 
2726234  NM_207330 // NPAL1 // NIPA‐like domain containing 1 // 4p12 // 152519 /// ENST00  NPAL1  4.08E‐08  1.72E‐05  ‐1.17329  2.70E‐06  ‐1.24202 




3547696  NM_144596 // TTC8 // tetratricopeptide repeat domain 8 // 14q31.3 // 123016 ///   TTC8  4.15E‐08  1.09E‐05  1.25826  4.23E‐06  1.34311 
2430762  NM_201263 // WARS2 // tryptophanyl tRNA synthetase 2, mitochondrial // 1p13.3‐p1  WARS2  4.17E‐08  6.56E‐05  1.26693  8.92E‐07  1.45301 
3848871  NM_016579 // CD320 // CD320 molecule // 19p13.3‐p13.2 // 51293 /// ENST000003014  CD320  4.18E‐08  0.0562752  1.09693  1.61E‐08  1.49518 
2549007  NM_198963 // DHX57 // DEAH (Asp‐Glu‐Ala‐Asp/His) box polypeptide 57 // 2p22.1 //  DHX57  4.21E‐08  2.26E‐07  1.20538  0.000432442 1.1498 
2376849  NM_182663 // RASSF5 // Ras association (RalGDS/AF‐6) domain family member 5 // 1  RASSF5  4.22E‐08  0.00291875  ‐1.17623  6.99E‐08  ‐1.50563 
2417272  NM_018841 // GNG12 // guanine nucleotide binding protein (G protein), gamma 12 /  GNG12  4.22E‐08  0.000226038 ‐1.26957  3.56E‐07  ‐1.54444 
2862784  NM_015566 // FAM169A // family with sequence similarity 169, member A // 5q13.3   FAM169A  4.24E‐08  0.000200244 1.47966  3.90E‐07  2.02039 
3388785  NM_002425 // MMP10 // matrix metallopeptidase 10 (stromelysin 2) // 11q22.3 // 4  MMP10  4.29E‐08  0.00112255  1.64556  1.25E‐07  3.01298 
3185354  NM_001012994 // SNX30 // sorting nexin family member 30 // 9q32 // 401548 /// EN  SNX30  4.29E‐08  8.37E‐06  ‐1.24051  5.73E‐06  ‐1.30656 
3149754  NM_003756 // EIF3H // eukaryotic translation initiation factor 3, subunit H // 8  EIF3H  4.39E‐08  1.01E‐05  1.29498  4.93E‐06  1.38734 
3443804  NM_002258 // KLRB1 // killer cell lectin‐like receptor subfamily B, member 1 //   KLRB1  4.42E‐08  0.0666161  ‐1.13991  1.59E‐08  ‐1.81091 
3025545  NM_033138 // CALD1 // caldesmon 1 // 7q33 // 800 /// NM_033157 // CALD1 // calde  CALD1  4.46E‐08  0.00016618  ‐1.34111  4.77E‐07  ‐1.67152 
3947302  NM_001002034 // FAM109B // family with sequence similarity 109, member B // 22q1  FAM109B  4.46E‐08  0.000103119 1.19255  6.82E‐07  1.33857 
2724671  NM_004310 // RHOH // ras homolog gene family, member H // 4p13 // 399 /// ENST00  RHOH  4.47E‐08  0.00369113  ‐1.2798  6.54E‐08  ‐1.89902 
2626097  NM_020676 // ABHD6 // abhydrolase domain containing 6 // 3p14.3 // 57406 /// ENS  ABHD6  4.47E‐08  6.30E‐07  ‐1.36035  0.000114824 ‐1.30989 
2428796  NM_015967 // PTPN22 // protein tyrosine phosphatase, non‐receptor type 22 (lymph  PTPN22  4.54E‐08  0.00360665  ‐1.24275  6.74E‐08  ‐1.75522 
3085403  NM_012331 // MSRA // methionine sulfoxide reductase A // 8p23.1 // 4482 /// ENST  MSRA  4.55E‐08  1.99E‐06  ‐1.21738  2.87E‐05  ‐1.22471 
3293280  NM_021129 // PPA1 // pyrophosphatase (inorganic) 1 // 10q11.1‐q24 // 5464 /// EN  PPA1  4.59E‐08  1.93E‐05  1.66352  2.87E‐06  1.99952 
3488985  NM_021999 // ITM2B // integral membrane protein 2B // 13q14.3 // 9445 /// ENST00  ITM2B  4.60E‐08  0.0182475  ‐1.10577  2.95E‐08  ‐1.40459 
3393670  NM_001098526 // AMICA1 // adhesion molecule, interacts with CXADR antigen 1 // 1  AMICA1  4.64E‐08  0.00745096  ‐1.28336  4.67E‐08  ‐2.05596 
3695648  NM_013304 // ZDHHC1 // zinc finger, DHHC‐type containing 1 // 16q22.1 // 29800 /  ZDHHC1  4.65E‐08  1.60E‐05  1.25492  3.48E‐06  1.35271 
2329196  NM_052998 // ADC // arginine decarboxylase // 1p33‐p34.3 // 113451 /// ENST00000  ADC  4.67E‐08  2.57E‐08  ‐1.4244  0.0255865  ‐1.15503 
3631517  NM_020147 // THAP10 // THAP domain containing 10 // 15q23 // 56906 /// ENST00000  THAP10  4.72E‐08  0.000104594 1.19875  7.24E‐07  1.3493 
3261009  NM_030929 // KAZALD1 // Kazal‐type serine peptidase inhibitor domain 1 // 10q24.  KAZALD1  4.73E‐08  6.92E‐05  1.23241  1.01E‐06  1.38979 
3374538  AK091446 // LOC283194 // hypothetical protein LOC283194 // 11q12.2 // 283194  LOC283194  4.73E‐08  4.66E‐07  1.47071  0.000189755 1.37754 
2705706  NM_003810 // TNFSF10 // tumor necrosis factor (ligand) superfamily, member 10 //  TNFSF10  4.76E‐08  0.01517  ‐1.19337  3.35E‐08  ‐1.77912 
2619480  ENST00000396102 // CCBP2 // chemokine binding protein 2 // 3p21.3 // 1238 /// BC  CCBP2  4.76E‐08  1.05E‐05  ‐1.46328  5.32E‐06  ‐1.61804 
3035682  NM_013393 // FTSJ2 // FtsJ homolog 2 (E. coli) // 7p22 // 29960 /// ENST00000242  FTSJ2  4.76E‐08  0.172562  1.04568  1.19E‐08  1.32119 
3846594  NM_015898 // ZBTB7A // zinc finger and BTB domain containing 7A // 19p13.3 // 51  ZBTB7A  4.78E‐08  4.01E‐06  ‐1.16607  1.42E‐05  ‐1.18825 
3250699  NM_004096 // EIF4EBP2 // eukaryotic translation initiation factor 4E binding pro  EIF4EBP2  4.78E‐08  0.000706102 ‐1.16134  1.91E‐07  ‐1.36382 
3484641  NM_000059 // BRCA2 // breast cancer 2, early onset // 13q12.3 // 675 /// ENST000  BRCA2  4.82E‐08  0.050284  1.14539  1.96E‐08  1.76782 
3592214  NM_017434 // DUOX1 // dual oxidase 1 // 15q15.3 // 53905 /// NM_175940 // DUOX1   DUOX1  4.86E‐08  8.40E‐06  1.32512  6.83E‐06  1.413 
3402786  NM_000616 // CD4 // CD4 molecule // 12pter‐p12 // 920 /// ENST00000011653 // CD4  CD4  4.89E‐08  0.000240641 ‐1.37158  4.08E‐07  ‐1.77593 
3236958  NM_003380 // VIM // vimentin // 10p13 // 7431 /// ENST00000224237 // VIM // vime  VIM  4.89E‐08  4.75E‐05  ‐1.47453  1.43E‐06  ‐1.79381 
3043648  NM_019029 // CPVL // carboxypeptidase, vitellogenic‐like // 7p15‐p14 // 54504 //  CPVL  4.96E‐08  8.50E‐05  ‐1.35347  9.10E‐07  ‐1.62674 
3088213  NM_022071 // SH2D4A // SH2 domain containing 4A // 8p21.2 // 63898 /// ENST00000  SH2D4A  5.02E‐08  1.83E‐06  1.36403  3.69E‐05  1.36759 
3430926  NM_003362 // UNG // uracil‐DNA glycosylase // 12q23‐q24.1 // 7374 /// NM_080911   UNG  5.11E‐08  0.121605  1.05764  1.46E‐08  1.35548 
2947572  NM_006510 // TRIM27 // tripartite motif‐containing 27 // 6p22 // 5987 /// ENST00  TRIM27  5.11E‐08  1.62E‐05  1.23711  3.92E‐06  1.32495 
3948047  NM_022141 // PARVG // parvin, gamma // 22q13.2‐q13 // 64098 /// ENST00000356909   PARVG  5.14E‐08  0.000600498 ‐1.21811  2.31E‐07  ‐1.49097 





Supplementary table 4.   
GeneGo MetaCore pathways, process and metabolic networks  significantly 
overrepresented  in the set of genes differentially expressed in nonpolypoid (vs normal 
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 Based on cancer incidence rates estimated in the United States, colorectal cancer is 
the fourth most frequent cancer in humans (after prostate, breast, and lung) 1.  This estimation 
is very similar in most of the countries offering reliable cancer statistics.  In these countries, 
approximately one out of eighteen persons develop colorectal cancer (more than twice more 
frequently in the colon than in the rectum).  This ~5% lifetime probability of developing 
colorectal cancer increases to 10-15% in individuals with one first-degree relative affected by 
colorectal cancer 2(and references herein) .  The percentage increases considerably if more than one 
relative are affected by colorectal cancer or other cancers often diagnosed in familial 
aggregations of colorectal cancer.   The cumulative lifetime probability reaches 60-100% in 
carriers of a mutation in a highly-penetrant allele, such as in one of the DNA mismatch repair 
(MMR) genes 3 in hereditary non-polyposis colon cancer (HNPCC, also known as Lynch 
syndrome) or in the adenomatous polyposis coli (APC) gene in familial adenomatous 
polyposis  (FAP) 4.   MMR-defective HNPCC, which will be the main subject of this article, 
represents the most frequent colorectal cancer predisposition syndrome of known etiology, 
and adenocarcinomas of MMR(-) HNPCC account for ~3% of all cancers in the colon.   
FAP is responsible for ~0.5% of all colorectal cancers, and an additional ~0.5%  arise 
in the colorectum of individuals affected by one of the hamartomatous polyposis syndromes 
or by hyperplastic polyposis, whose underlying genetic alterations are the subject of intensive 
search.  The latter three conditions will be discussed solely in the light of some interesting 
aspects that emerged recently from basic and clinical research studies. 
A genetic susceptibility underlies an additional ~15% of all colorectal cancers 5, also 
referred to as familial or hereditary, but the underlying genetic disorder is unknown.  In this 
large portion of familial colon cancers, the cumulative lifetime risk is very variable, ranging 
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from very high in familial aggregations that are clinically indistinguishable from HNPCC, but 
not associated with MMR defects, to conditions with only a slightly higher predisposition to 
colorectal cancer as compared to the general population.  At this latter end of the spectrum 
lies a blurred border between familial and non-familial (hereafter called sporadic) colorectal 
cancers.  In this group lie many apparently sporadic cases that could be familial (i.e. in small 
families where only one case has been detected so far, in cases of poor diagnosis or where 
medical records are incomplete, in families where a de novo mutation arose for the first time, 
non-paternity, etc), or apparently familial that could be sporadic (i.e., two sporadic colorectal 
cancers in the same family).  Thus, the challenge for the years to come is to unravel novel 
high-penetrance predisposition alleles responsible for familial aggregations of colorectal 
cancer clinically similar to HNPCC but with intact MMR, and low-penetrance alleles 
responsible for the remainder of familial colorectal cancers.  Theoretically, all the remaining 
sporadic colorectal cancers might also be associated with very-low penetrance mutations or 
polymorphisms whose degree of penetrance may be modulated by environmental factors, 
mainly dietary ones. 
Importantly, the genetic alterations detected in rare inherited syndromes can have 
roles also in the initiation and progression of a large portion of sporadic cases when these 
alterations occur somatically, as for those in APC or the MMR gene MLH1.   
The discovery rate in the field of cancer genetics has dramatically increased due to the 
implementation of genomics, with which an enormous number of identified genetic variants 
and their combinations can be used in studies aimed at verifying their association with the 
predisposition to colorectal cancer.  Transcriptomics, another tool for molecular global 
screening of tumours, has been instrumental in the classification of tumours, and is helping to 
unravel the molecular mechanisms underlying their origin and to identify the genes 
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responsible for the epithelial cell transformation (an example of application of this approach 
is reported in the last section of this article).  A paradigm of this type of search was the 
discovery, in 1992, of the involvement of the MMR defect in HNPCC by using a molecular, 
yet pre-omics, screening technique, the arbitrarily-primed polymerase chain reaction, which 
helped identify a specific tumour phenotype, microasatellite instability 6.  Since this 
phenotype was already known to be caused by a defect of the MMR system in bacteria and 
yeast, the mutated MMR alleles were easily identified in members of HNPCC families 7. 
 
MMR(-) HNPCC (Lynch syndrome) 
The recent advancements in the MMR field have been propelled by the discovery in 
the early nineties of a causal link between inherited mutations in MMR genes and the colon 
cancer predisposition syndrome HNPCC 7.  As mentioned, this was possible only after the 
identification of microsatellite instability (MSI) in a subset of colorectal cancers by using 
arbitrarily-primed PCR 6.  Later on, about 10% of sporadic colon cancers were also found to 
be defective in MMR as a result of somatic transcriptional silencing of the MMR gene MLH1 
8 9.  Thus, there was an urgent need to identify tools that could be easily deployed in the 
diagnosis of this type of tumours, which would facilitate more effective clinical management.  
One tool was of course the analysis of tumour DNA for the presence of MSI. This test is 
today performed routinely by many molecular biology or genetic laboratories.  Later, when 
antibodies able to reliably recognize MMR proteins in tissue samples became available, 
immunohistochemistry started to be used extensively in research laboratories and in 
pathology departments.  In order to appreciate the prowess of these diagnostic procedures, it 
is essential to understand the basics of MMR.  The brief excursion into MMR biochemistry 
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that follows will also help the reader to understand some of the phenotypic differences 
underlying defects in different MMR genes. 
MMR is often referred to as post-replicative MMR, as its primary function is the 
correction of errors occurring during DNA replication.  This editing function is necessary, 
since the fidelity of replicating DNA polymerases is insufficient to generate an error-free 
copy of genomic DNA.  Single-base substitutions arise once in every 104-106 nucleotides 
incorporated.  The intrinsic exonucleolytic proofreading activity of the replicative 
polymerases increases the fidelity of DNA synthesis by a further two orders of magnitude, 
i.e. to one error in 107 to 108  ref.10.  MMR reduces the error rate to a range of 10-9 to 10-10, 
which ensures that the human genome of 6.6 x 109 nucleotides can be duplicated without 
mutations.  When MMR is defective, the mutation rate increases considerably and mutations 
are accumulated in the genome (i.e. a mutator phenotype  arises). 
In addition to base-base mismatches, slippage of the newly synthesized strand with 
respect to the template can give rise to misalignments, often referred to as insertion/deletion 
loops (IDLs) (FIGURE 1).  These structures arise more often in repetitive DNA sequences, 
such as mono- and di-nucleotide repeats, also called microsatellites, where replicative DNA 
polymerases are more prone to “slippage” than on non-repetitive templates.  The frequency 
of IDLs rises substantially with increasing length of the repeat.  When not repaired by the 
MMR, extrahelical nucleotides in the primer strand give rise to insertions in the progeny 
DNA, while their presence in the template strand leads to deletions (Figure 1).  The term MSI 
refers to the length variation of these sequences in the tumour DNA, when compared with 
their normal length in the DNA from normal tissue.  Interestingly, deletions predominate over 
insertions in microsatellites of MMR(-) tumours, which suggests either that the formation of 
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extrahelical loops in the template strand is more frequent than in the newly-synthesized 
strand,  and/or that the latter lesions are repaired by a system distinct from MMR. 
The process of mismatch correction is initiated by the binding of one of two mismatch 
recognition complexes, MSH2/MSH6 (also termed MutSα) or MSH2/MSH3 (MutSβ), to 
base/base mismatches or strand misalignments (IDLs) that were generated by the replicating 
DNA polymerase, but that escaped its proofreading activity (FIGURE 2) (refer to 11 for a 
detailed description of the MMR reaction).  The mismatch-bound MutS heterodimer then 
undergoes an ATP-driven conformational change that enables its interaction with the 
MLH1/PMS2 heterodimer (MutLα).  This interaction stimulates an endonucleolytic function 
of MutLα, which nicks the newly synthesized strand both on the 3’ and the 5’ side of the 
mismatch 12.  The nick 5’ from the mismatch is then utilized by exonuclease 1 (EXO1) to  
degrade the newly synthesized strand up to and a short distance beyond the mispaired 
nucleotide, which is thus removed.  Finally, the degraded tract is filled-in by the replicating 
DNA polymerase δ.  
In vitro MMR repair assays showed that MutSα supports the correction of G/T, A/C, 
G/G and A/A mispairs, and of IDLs of 1 to 4 extrahelical nucleotides with high efficiency.  
The remaining mismatches were repaired with intermediate efficiency, while C/C and larger 
IDLs were poor substrates for the MMR system (reviewed in 13).   In vivo, MSH6 and MSH3 
compete for MSH2.  The MSH2/MSH3 heterodimer, termed MutSβ, has been shown to 
address IDLs of 1-8 extrahelical nucleotides, but not mismatches.  It has been suggested that 
MutSα might have a prominent role in the repair of IDLs in vivo, given that MutSα is around 
10 times more abundant than MutSβ in cultured human cells 14-16.  The reverse is true in cells 
overexpressing MSH3 as a result of amplification of the DHFR/MSH3 locus through 
exposure to methotrexate.  These cells have extremely low levels of MutSα, because the 
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abundant MSH3 sequesters all available MSH2, and the partnerless MSH6 is degraded 14 17.  
As anticipated, these cells are proficient in IDL repair, but deficient in the repair of base-base 
mismatches, thus they would display no MSI, in spite of having a mutator phenotype.  
Indeed, MSI is in general not detectable in MMR(-) tumours in which the mutated MMR gene 
is MSH6, and MutSβ is normally expressed.  As we will see later, the clinical phenotype of 
MSH6-defective HNPCC families also differs from that of MSH2-defective ones.   
At this point it is important to introduce another biochemical feature of the MMR 
MutS heterodimers that has also implication in diagnostics.  MSH3 and MSH6 compete for 
the same region of MSH2 18,  and several studies showed that molecules of the former 
polypeptides that fail to form heterodimers with MSH2 are destabilized.  Thus, when MSH2 
is mutated and its protein product is not expressed (germline mutation in one allele and 
somatic second-hit in the wild type allele, see below), MSH6 and MSH3 are degraded and 
both MutSα and MutSβ are absent.  The cells are consequently unable to repair mismatches 
and IDL, and MSI is clearly evident.  This should be taken into consideration during 
immunohistochemical analysis of tumours for MMR protein expression.  MSH2-defective 
tumours lack MSH2, MSH6 and MSH3, whereas MSH6- or MSH3-defective tumours 
normally express MSH2, since this latter protein is stabilized by its interaction with MSH3 or 
MSH6, respectively.   As in the case of the MutS homologs, the stabilities of the MLH1 and 
PMS2 polypeptides are also different.  Thus, when MLH1 is not expressed, or when it is 
mutated such that it is either destabilized or that it cannot interact with PMS2, the latter 
protein is degraded.  In contrast, MLH1 remains stable in the absence of PMS2 15 19 through 
interactions with other MutL homologs such as PMS1 or MLH3, whose involvement in 
MMR however appears to be marginal 19 20.  Translating this biochemical knowledge to 
clinical pathology,  a MLH1-defective tumour lacks both MLH1 and PMS2, whereas a 
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tumour with a primary alteration in the PMS2 gene lacks only PMS2, but contains normal 
levels of MLH1. 
The role of the MLH1/PMS2 heterodimer in MMR is only partially known.  Its most 
probable role is to link the mismatch- or IDL-recognition event by one of the two MutS 
heterodimers to the excision function of EXO1 (FIGURE 2).  The endonucleolytic activity 
of MutLα that has been only recently described 12 and that is essential for the 5’ to 3’ 
exonucleolytic activity of EXO1, relies on an endonuclease active site localized in PMS2 12.   
Both of these proteins are thus essential for MMR and an alteration of either MLH1 or PMS2 
leads to MSI. 
The biochemical mechanism of MMR discussed above implies that inactivating 
mutations in the MMR genes MSH2, MLH1 and PMS2 should have the most severe 
phenotypes, whereas those in MSH6 would have reduced MSI and thus also a weaker MMR 
defect. Indeed, analysis of HNPCC families shows that germline mutations in MSH2 and 
MLH1 are substantially more often associated with this syndrome than mutations in the other 
two genes (HNPCC mutation database at http://www.insight-group.org/).  Germline 
mutations in MSH3 have not been reported yet, and it makes little sense to search for them in 
tumours with classical MSI, because of the redundant function of the two MutS heterodimers 
in the repair of short IDLs.  The role of missense EXO1 variants in predisposition to 
colorectal cancer is still under investigation 21(and references herein), however these variants might 
represent low-penetrance alleles due to the possible redundancy of EXO1 with other, as yet 
unidentified, exonucleases during MMR. 
Today,  MSI analysis and immunohistochemistry are the most common tools used in 
the diagnosis of MMR(-) tumours.   Immunohistochemistry for the four most frequently 
involved MMR proteins (MSH2, MSH6, MLH1 and PMS2) has the advantage that it is rapid 
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and economical, and it allows to compare tumour with normal tissue in the same histological 
section.  It also identifies the defective MMR gene, and should thus be carried out prior to 
DNA sequence analysis in search for germline mutations.  In contrast, MSI analysis only 
detects a defect in the MMR, not in a specific MMR gene.   However, there are occasions 
when MMR(-) tumours will not be identified by these methods: i) in MSH6-defective cases, 
the level of MSI is often low, such that it is not detected with the standard panel of 
microsatellite primers, and ii) in cases of missense germline mutations that do not affect the 
stability of the protein but only its function.   However, most of the genetic changes in MMR 
genes, including missense mutations, lead to decay or degradation of the corresponding RNA 
or protein.   This situation is very different from that resulting from alterations in the APC 
gene (see below).   Since only ~3% of colorectal cancers are associated with an inherited 
mutation in one of the MMR genes, today only cases fulfilling the Bethesda guidelines 22  are 
included in the diagnostic screening using MSI analysis and immunohistochemistry.   These 
guidelines consider the age of the patient (younger than the average age of onset of sporadic 
colorectal cancers), the presence of synchronous or metachronous HNPCC-related 
carcinomas (MMR defects predispose individuals to colorectal and endometrial cancers, but 
to a lesser extent also to carcinoma of the small bowel, transitional cell carcinoma of the 
upper urinary tract, stomach cancer and ovarian cancer), cases carrying tumours with 
pathological features more often found in MMR-deficient tumours (conspicuous, 
peritumoural and intratumoural, lymphocytic infiltration, and mucinous differentiation), and 
the presence in the family of first or second-degree relatives with HNPCC-related tumours.    
It has been often the case that genes whose alterations were found to cause inherited 
forms of cancer were also found somatically altered in a portion of sporadic tumours.  Thus, a 
few years ago, we initiated an immunohistochemical screening of consecutive, unselected 
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colorectal cancers (not selected for family history or other parameters) for the four main 
MMR proteins. Using this approach, we identified aberrant patterns of MMR protein 
expression in 13.2% of 1048 colorectal cancers in Switzerland.  Loss of expression of MSH2, 
MSH6, MLH1 and PMS2 was found in 1.4%, 0.5%, 9.8% and 1.5%, respectively 9.  Most of 
the MLH1-defective cases were sporadic, and the expression of this gene was silenced by 
somatic, bi-allelic methylation of its promoter.  Thus, sporadic, MLH1-defective tumours are 
the most frequent MMR(-) colorectal cancers; they occur more often in old persons (even 
older than in the rest of the sporadic cases), slightly more frequently in women, and almost 
exclusively in the proximal colon. Several other studies have reported that ~10% of all 
colorectal cancers are MLH1-defective, sporadic tumours.  This large subset of colorectal 
cancers could be detected by routinely applying immunohistochemistry for MLH1 in all 
sporadic cancers of the proximal colon (~ 25% of the tumours in this tract). 
A considerable proportion of inherited forms of MMR(-) colorectal cancers fulfill the 
Amsterdam criteria for diagnosis of HNPCC 23: 1) at least 3 colon or endometrial cancers in a 
family; 2) one case should be a first-degree relative of the other two, and 3) at least one of 
them should be diagnosed before the age of 50.  Most persons carrying germline mutations in 
MSH2 or MLH1 do belong to classical HNPCC families, but germline mutations in MMR 
genes have been found also in families with a lower burden of cancers and even in 
individuals without a family history of colorectal cancers.  Germline mutations in MSH6 for 
example, result in an attenuated phenotype, the families often not fulfilling the above-
mentioned criteria 24(and references herein).  The risk of colorectal cancer is lower in women and, in 
both genders, the mean age of diagnosis of colorectal cancer is around 12 years later than in 
those with MSH2 or MLH1 mutations.  However, by the age of 70, men with MSH6 
mutations have the same risk of colorectal cancer as those with MSH2 or MLH1 mutations.  
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In addition, the risk of endometrial cancer, although delayed in onset, is significantly greater 
than in women carriers of MSH2 or MLH1 mutations.  These phenotypic differences can be 
explained by the biochemical role of MSH6 in MMR, in particular its partial functional 
redundancy with MSH3.  Correspondingly, the MSI phenotype in MSH6-negative tumours is 
attenuated, as the MSH2/MSH3 heterodimer partially compensates for the absence of 
MSH2/MSH6 in the IDL repair, but the mutator phenotype due to uncorrected base/base 
mismatches remains extremely high.  
 Since the discovery of the etiologic association between MMR deficiency and 
hereditary colorectal cancer, only a few cases with germline mutations in PMS2 have been 
described 25-30.  The mutation carriers did not belong to classical HNPCC families, rather, 
they presented with colorectal cancers and brain tumours in their first two decades of life, a 
condition also called Turcot’s syndrome (reviewed in 31 and 29).  In most of these cases, both 
PMS2 alleles were mutated in the germline, and MSI was detectable even in non-neoplastic 
tissues, suggesting a recessive way of inheritance.  These findings resemble the childhood 
cancer syndromes characterized by gastrointestinal, haematological and brain cancers in 
subjects with compound heterozygous germline mutations in MLH1 32(and references herein).   The 
severity of this syndrome is attributed to the fact that both alleles of a MMR gene are affected 
in the germline.   Besides the rare cases of a PMS2-associated childhood cancer syndrome, 
the absence of involvement of PMS2 in HNPCC was unexpected.   Despite the existence of 
PMS1 and MLH3, both of which have been shown to interact with MLH1, the participation 
of the former proteins in MMR appears to be only marginal 19 20 33.  These two polypeptides 
are therefore unlikely to compensate for the lack of PMS2 to a substantial extent.  
Correspondingly, cell lines lacking PMS2 display MSI and their extracts are MMR deficient 
to an extent similar to that observed in cells mutated in MLH1 or MSH2.  It might therefore 
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be anticipated that, similarly to MSH2 and MLH1, germline mutations in a single PMS2 allele 
would predispose to colorectal cancer.  Indeed, loss of expression of PMS2 has been recently 
identified 9 34-39.  In our immunohistochemical study 9, tumours lacking PMS2 expression 
were identified with a frequency similar to that of MSH2-defective colorectal cancers.  As the 
1048 tumours were collected consecutively and without any selection bias, this frequency 
represents the true occurrence of PMS2 deficiency.  Individuals carrying PMS2-deficient 
colon cancers did not belong to HNPCC families as defined by Amsterdam criteria, however, 
a closer examination of the clinical and pathological data showed several features of 
inheritance.  Indeed, we identified heterozygous germline mutations in PMS2 in many of 
these subjects.  Thus, the inheritance pattern of PMS2 mutations apparently differs from the 
autosomal dominant trait characteristic of MSH2 and MLH1 mutations in HNPCC kindred, 
and is most likely the main reason why PMS2-negative tumours escaped detection to date.  
The mechanisms underlying the limited penetrance of PMS2 germline mutations are under 
investigation.  
HNPCC is inherited in an autosomal dominant way, but MMR deficiency arises only 
when also the wild-type MMR allele is mutated or lost.  Thus, the disease is recessive at the 
somatic level.  Indeed, the tumour cells do not express the MMR protein, whereas cells in the 
normal tissue, which is almost always present in the same histological section (normal 
colonic crypt epithelium, germinal centers of lymphocytic folliculi, and dividing stromal 
cells), express the protein because they retain heterozygosity.   When do the cells of the 
colonic epithelium acquire the second hit and thus become fully MMR deficient ?   The 
carcinogenic process in MMR(-) HNPCC seems to follow the adenoma-carcinoma 
histological pathway, i.e., cancer arises in precancerous adenomatous polyps, which represent 
also the most frequent precancerous lesions leading to sporadic colorectal cancers and the 
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characteristic lesions in FAP.  These lesions are believed to arise from the normal colorectal 
epithelial crypts, because of a dysregulation of the Wnt signalling pathway (see below), but 
the temporal relationship between alterations in this or other signalling pathways and the 
onset of MMR deficiency in adenomas remains obscure.  It has been reported that MSI and 
lack of immunostaining for MMR proteins might not be a very early event, being detectable 
more often in adenomas of large size and tubulo-villous architecture with high degree of 
dysplasia 40 41.   In HNPCC, adenomas also develop at a younger age (early forties) than in 
the control population, and it is commonly believed that HNPCC adenomas transform into 
cancer very frequently and in a short period of time.  Indeed, the acquisition of the MMR 
deficiency and consequently of the mutator phenotype and MSI, should markedly accelerate 
the transformation process.  In spite of a germline mutation in a MMR gene present in all the 
epithelial cells of the colonic mucosa, it is still surprising and unexplained why the number of 
adenomatous polyps in HNPCC patients is not as high as in FAP.  Actually, the index 
adenoma in HNPCC cases is often isolated or almost never accompanied by more than five 
other adenomas. 
 In conclusion, MMR(-) colorectal cancers in HNPCC arise from isolated, early-onset 
adenomas along a fast transformation process driven by a high rate of mutations in the DNA, 
often in tumour suppressor genes 42 43.  This pathway is probably dominant to another frequent 
pathway in carcinogensis, that of chromosomal instability, since MMR-deficient tumours 
show only a limited number of chromosomal gains and losses and are often near-diploid.   
Fortunately, later on in carcinogenesis, their aggressiveness and invasiveness is restrained by 
a conspicuous anti-tumour immune response, whose molecular components have only 
recently started to be investigated 44, and which is believed to be triggered by the presentation 
of novel antigens produced by highly mutable, MMR(-) tumour cells.  Unfortunately, the 
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defect in MMR makes these tumours more tolerant to some drugs, in particular alkylating 
agents 45, and probably less responsive to the standard treatment with 5FU 46 47.  Due to the 
peculiar histological and molecular characteristics of MMR(-) tumours, more studies and 
clinical trials should aim to identify drugs that specifically kill this type of neoplastic cells. 
 
Serrated adenomatous polyposis as a model of the serrated pathway of transformation. 
A large number of familial colon cancer aggregations are not linked to germ-line 
alterations in MMR genes.  The intense study being dedicated to these kindreds has produced 
(among other things) compelling evidence for the existence of a familial CRC syndrome that 
is distinct from HNPCC and does not appear to evolve through the traditional adenoma-
carcinoma sequence.  The pathway involved in the development of these is known as the 
serrated pathway of colorectal carcinogenesis, which is thought to be responsible for 
approximately 20% of the sporadic cancers affecting this organ 48 49. 
The precursor lesions in the serrated pathway are characterized histologically by a 
saw-toothed pattern of glandular architecture (FIGURE 3)50.  Formerly referred to as 
hyperplastic polyps (a term that has gradually been abandoned over the past decade), these 
lesions are now known as serrated polyps.  For many years, they were considered innocuous 
with a negligible risk for progression to cancer.  It is becoming increasingly clear, however, 
that this morphologically and molecularly  heterogeneous set of lesions includes certain 
subtypes that are indeed likely to undergo malignant transformation 48 51 52.  A recently 
proposed classification scheme 53  divides serrated polyps into two broad categories.  Those 
with “normal proliferation” (in which the proliferative compartment is confined to the lower 
portion of the crypts) generally develop as protruding lesions located in the distal colon and 
rectum – features traditionally attributed to the so-called hyperplastic polyp.  Those with 
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“abnormal proliferation” (reflected by an upward shift of the proliferative compartment) 54 55 
can be further divided into two subgroups (FIGURE 3A and B): traditional serrated 
adenomas (TSA), which are quite rare (accounting for ~1% of all serrated polyps) and 
generally present as sessile or pedunculated polyps, and sessile serrated adenomas (SSA), 
which are much more common.  SSAs are sessile or non-polypoid lesions (i.e., usually 
slightly elevated) 56.  They are distinguished from TSAs (and from classical adenomas) by the 
absence of cytological dysplasia.  Nevertheless, an increasingly compelling body of evidence 
suggests that SSAs (especially those arising in the proximal colon) are precursors to 
adenocarcinomas with serrated features 57. 
Recent studies have also demonstrated molecular differences between classic 
adenomas and serrated polyps.  For instance, the latter are often characterized by DNA 
methylation of the promoter regions of multiple gene 48 51 58 (and references herein).  This 
phenomenon, which is known as the CpG-island methylator phenotype (CIMP), is found in 
approximately 20% of all sporadic colorectal cancers.  These cancers are encountered mainly 
in the proximal colon, and this pattern is consistent with previous reports of the increased risk 
for malignant transformation associated with serrated lesions in the left colon 59.  CpG-island 
methylation can result in the epigenetic silencing of various genes, including those with 
tumour suppressor function, and it is thus a potential driver of carcinogenesis.  In roughly half 
of all CIMP-positive cancers, the promoter of the MMR gene MLH1 is hypermethylated and 
this gene is not expressed (This mechanism accounts for those MLH1-deficient cancers 
mentioned in the previous section, which represent 10% of all sporadic CRCs.).  
Hypermethylation of MLH1 is considered by many to be a relatively late event associated 
with the transition to malignancy 58 60  . 
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Sporadic CIMP-positive cancers are also frequently characterized by somatic 
mutations of the BRAF gene, which encodes a serine/threonine kinase 48 61-63.  The BRAF 
mutation most frequently identified in sporadic serrated tumours 64 involves a glutamate-for-
valine substitution (V600E) in the regulatory domain of the gene, which results in a 
constitutively activated kinase with increased (~ 500-fold) activity 65.  Like RAS mutation 
(which is encountered more frequently in the adenoma-carcinoma pathway), BRAF V600E 
causes aberrant, growth factor-independent signaling through the RAS/RAF/MEK/ERK 
signalling pathway, which is crucial for the response of cells to growth signals. 
However, BRAFV600E is also a frequent finding in tumours from patients with 
familial colon cancer, particularly those that are CIMP(+) and MLH1-deficient.  In fact, some 
investigators have suggested that screening for BRAFV600E should be used to differentiate 
these tumours from HNPCCs caused by a germ-line mutation of an MMR gene 66 67.  Young 
et al. 68 recently analyzed 11 non-FAP, non-HNPCC CRC families characterized by 
interindividual (and sometimes intraindividual) variability in the MSI-status of colorectal 
tumours (MSI-H, MSI-L, or MSS), that they called MSI-V (variable) kindreds.  Seventy 
percent of the CRCs tested for BRAF mutation were positive (vs. 15.2% of an unselected CRC 
reference series and 0% of the reference HNPCCs), including all of those that were MSI-H, 
half of those that were MSI-L, and 67% of the MSS cancers.  All six of the tumours classified 
as MSI-H were cancers that presented immunohistochemical negativity for MLH1 protein 
expression and hypermethylation of MINT31, a marker of the CIMP.  Compared with their 
sporadic counterparts, the CIMP-positive CRCs in these MSI-V families had clearly earlier 
onsets (by about 10 years) although they occurred approximately two decades later than 
HNPCCs 68. 
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In the MSI-V kindreds, BRAF mutations were also found in 63% of the precancerous 
lesions of different histologic subtype.  Unlike the CRCs in this study, the polyps were all 
normal in immunohistochemical studies of the mismatch repair proteins.  This finding is 
consistent with the view that MLH1 silencing is a relatively late event associated with the 
transition to malignancy 58 60 (although it has also been detected in some early precancerous 
lesions 69). 
The picture that emerges from these findings is that of a familial condition 
characterized by somatic methylation of the MLH1 promoter caused by an unidentified 
genetic predisposition to CIMP.  The possibility that CRC-related hypermethylation of gene 
promoters is genetically determined has also emerged from previous studies, which revealed 
associations between CIMP and family histories of colon cancer 70 71 (although in one case 
this association was not statistically significant 72). 
BRAFV600E and CIMP are also associated with the apparently rare condition known 
as hyperplastic polyposis 68 71 73-79, which is diagnosed when the patient presents 80: i) at least 
five histologically diagnosed, hyperplastic polyps proximal to the sigmoid colon, including 
two with diameters exceeding 10 mm;  ii) any number of hyperplastic polyps proximal to the 
sigmoid colon and first-degree kinship with a patient already diagnosed with hyperplastic 
polyposis;  or iii) over 30 hyperplastic polyps distributed throughout the colon.  Hyperplastic 
polyposis is known to carry an increased risk for malignant transformation, although the 
magnitude of the risk varies to some extent from family to family 81-83.  Colorectal cancers 
complicating hyperplastic polyposis have been associated with a predilection for the proximal 
colon and onset age that is roughly 10 years earlier than that of sporadic CRCs but two 
decades later than that of HNPCC – both of which were also documented in the familial 
CIMP-positive, MLH1-deficient CRCs examined by Young et al. 68.  In patients with this 
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condition, the normal mucosa has a significantly higher frequency of methylated alleles than 
that of individuals with sporadic serrated lesions 84 85, which is also consistent with the 
possibility of genetically determined CIMP.  Indeed, it seems likely that hyperplastic 
polyposis arises as a result of an inherited predisposition.  However, fewer than 150 cases 
have been reported to date, and only a small percentage of these are characterized by familial 
aggregation.  Those that are seem to have dominant inheritance patterns 77 81 83 85 86. 
One of the peculiarities of hyperplastic polyposis is that it is manifested by a variety of 
polyp types, including hyperplastic polyps, larger SSA, and even classical adenomas.  
Torlakovic and Snover 59 suggest that this condition includes two different phenotypes, which 
must be distinguished from each other.  They reserve the term “hyperplastic polyposis” for 
cases characterized by multiple, small, pancolonic hyperplastic polyps.  The second 
phenotype, which is manifested by smaller numbers of relatively large, proximal hyperplastic 
polyps with features of SSA, should in their opinion be referred to as “serrated adenomatous 
polyposis”.  Their review of the literature indicates that this phenotype accounts for a large 
portion of the cases reported as hyperplastic polyposis. 
Serrated adenomatous polyposis is likely to be diagnosed with increasing frequency 
thanks to the introduction of innovative colonoscopy technologies and greater awareness of 
these lesions among pathologists.  If its inherited nature is confirmed, it might someday 
provide a model for the identification of the initial molecular alterations that trigger the 
serrated pathway of colorectal carcinogenesis. 
 
FAP and APC 
FAP is an inheritable colon cancer predisposition syndrome that is transmitted in an 
autosomal dominant way, although almost 30% of the patients represent new cases in the 
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family (i.e., de novo mutations).  FAP is characterized by the presence of hundreds (classical 
FAP) to thousands (severe FAP) colorectal adenomatous polyps developing during the first, 
second, and third decades of life.  In a milder form, called attenuated FAP (AFAP), patients 
show a later disease onset and develop less than 100 colorectal polyps 87.  Because around 5% 
of the polyps transform to cancer, the probability of colorectal cancer at the age of 40-50 
years is 100% in these patients.  In addition to colorectal adenomas, FAP and AFAP patients 
show extracolonic manifestations such as congenital hypertrophy of the retinal pigment 
epithelium (CHRPE), desmoid tumours of the abdomen, upper gastrointestinal adenomas and 
carcinomas, and, less frequently, osteomas, dental abnormalities, lipomas, and epidermoid 
cysts.  Malignant tumours of the brain, thyroid and hepatobiliary tract have also been 
associated with FAP.  
Germline mutations in the APC gene have been directly linked to FAP and AFAP 88-
90.  To date, more than 1000 mutations throughout the APC gene have been compiled in 
databases 91 (and http://www.hgmd.cf.ac.uk/ac/index.php).  However, mutations in the APC gene have not 
been identified with the current methods in 30-50% of FAP and AFAP 92 93.  In a portion of 
these cases, bi-allelic germline mutations have instead been detected in the base excision 
repair gene MYH.  This group is represented by recessively-inherited FAP or AFAP, in which 
the development of adenomatous polyposis is believed to occur through somatic mutations in 
the APC gene because of defective processing of DNA oxidative damage by the base 
excision repair system 94-98.  
APC mutations have been detected also in most of the sporadic adenomatous polyps 
(that is, somatic mutations).  Since these mutations have been found in the early stages of 
adenoma formation, the effects of the malfunction or inactivation of APC on the Wnt 
signalling (FIGURE 4A) are believed to be, similarly to FAP, an early event in sporadic 
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colorectal cancers arising from adenomas.  The canonical Wnt signalling cascade plays a 
crucial role in driving the division of epithelial cells within the lower third of the intestinal 
crypt, which represents one of the simplest self-renewing biological entities in humans.  In 
this proliferative crypt compartment, secreted proteins of the Wnt family bind to serpentine 
receptors of the frizzled family (FZD) and to low-density lipid receptors (LRP) on the crypt 
epithelial cells (FIGURE 4A).  The signal transduction pathway activated by this binding 
(formation of disheveled –DVL-/FZD complexes, phosphorylation of LRP by CK1γ, and 
relocation of Axin to the membrane) inhibits the formation of a cytoplasmic protein complex, 
which includes, among others, APC, glycogen synthase kinase-3β (GSK-3β), axin, and 
casein kinase 1α (CK1α).  This complex catalyzes the phosphorylation of β-catenin, 
targeting the protein for ubiquitin-mediated destruction.  In its absence, β-catenin 
accumulates in the cytoplasm and enters the nucleus, where it associates with DNA-binding 
proteins of the T-cell factor (TCF)/lymphoid enhancer factor (LEF1) family.  The formation 
of a β-catenin/TCF/LEF1 complex converts the latter polypeptides from transcription 
repressors into transcription activators, which activate the expression of genes encoding the 
transcription factors MYC, c-Jun, and PEA3, the cell cycle kinase activator cyclin D1 and the 
matrix metalloproteinase MMP-7.   Some of these genes are essential for the maintenance and 
proliferation of stem and cycling cells in the lower third of the colorectal crypts.  In contrast, 
cells in the upper two-thirds of the crypts are not stimulated by Wnt signalling proteins.  
Here, the key player in the Wnt pathway, β-catenin, is recruited to the destruction complex 
and degraded.  In this manner, cells of the upper crypts are allowed to differentiate as they 
migrate upward toward the intestinal lumen, where they undergo a form of apoptosis known 
as anoikis.   
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In sporadic and FAP adenomas, the inappropriate signalling reflects abnormal 
stabilization of β-catenin as a result of APC mutations.  APC encodes a 2843 amino acids 
protein containing several functional domains (briefly described in the legend to FIGURE 
4B).   Interestingly, nonsense germline APC mutations are predicted to give rise to N-
terminal APC fragments with diverse number and type of domains (for instance,  the number 
of the 20-aa repeat domains for β-catenin binding and degradation, or the number of axin-
binding domains SAMP that persist in a truncated APC polypeptide)  that may lead to 
different degree of Wnt signalling dysregulation and/or may have various deleterious effects 
on cell-cell adhesion, cell migration, cell division and chromosomal stability 99.  This 
phenomenon is believed to be associated with different levels of severity of the disease (the 
so-called genotype-phenotype association).  The frequency of mutations between codons 
1250 and 1464 (FIGURE 4B) is significantly higher than in the rest of the gene (mutation 
cluster region) 92 100.  Two clear mutational hotspots have been identified at codons 1309 and 
1061, which account for approximately 17% and 11% of all germline APC mutations, 
respectively 91 (although it should be considered that the general use of mutational analyses 
restricted to the mutation cluster region might mischaracterize the mutational spectrum).  
Mutations in the cluster region are generally found in patients with profuse or severe FAP, 
which is characterized by the presence of thousands of polyps at very early age (first and 
second decades) and an average onset of colorectal cancer at 30-35 years 101 102.  However, 
mutations in the cluster region were also found in a patient without a profuse polyposis 103.  
Furthermore, large genomic deletions leading to absence of truncated APC were detected in 
10-15% of mutation-negative cases carrying profuse or classical FAP. 104 105.  Individuals 
with profuse FAP usually present extracolonic manifestations.  Patients with classical or 
intermediate FAP develop hundreds of adenomas during their second and third decades of 
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life 101 106.  The average onset of cancer in untreated patients is 42 years 101.  CHRPE is the 
most common extracolonic manifestation of the intermediate polyposis, although desmoid 
tumours also appear in some patients 101.  It has been shown that codons 1249 and 1250 
might form the boundary between the profuse and intermediate phenotypes 101 107 108 
(FIGURE 4B).  Most of the APC germline mutations were located between codons 157 and 
1595, not including the mutation cluster region 1250-1464 100 101 103 108-110.   Finally, AFAP 
patients develop less than 100 adenomas, and the onset of cancer is delayed compared with 
the more severe FAP syndromes 111.  Extracolonic manifestations seem to be rare, but 
desmoid tumours and upper gastrointestinal tumours are frequently reported in AFAP 
patients.  The causative germline mutations of AFAP were mostly found in the 5’ or 3’ ends 
of the APC gene, as well as in the border between exons 4 and 5 and within exon 9 gene, a 
region that undergoes physiological alternative splicing93 100 103 107 108 112-120.  Among the 
extracolonic manifestations, CHRPE has often been linked to mutations between codons 311 
and 1465 103 107-109 113 121 122,  desmoid tumours to mutations in the 3’ end of APC, particularly 
beyond codon 1400 123-125,  and upper gastrointestinal tumours to mutations in the 3’ end 108 
121 123, exon 4 114 and between codons 564 and 1465 107 108. 
However, many studies have provided inconsistencies and contradictions of the 
genotype-phenotype correlation in FAP 103 118 119 126 127.  For instance, similar phenotypes 
have been described for germline mutations in very different sites of APC, and phenotype 
variability has been reported between families carrying the same mutation, or even within a 
family.  In addition, the stability of truncated APC proteins have been investigated in clinical 
samples only in few studies, and in some, the truncated polypeptide was not detected 116 119 
128 129.  Thus, although most of the germline APC mutations can be identified with in vitro 
transcription/translation assays (a reliable mutation detection method in the genetic diagnosis 
 23 
of FAP), and the biological role of truncated APC has been investigated in cell lines 130-133 
and mouse models 134 135, the in vivo situation (i.e. in human colorectal lesions) might be 
different.  The severity of the disease might also be dictated, at the somatic level, by the type 
of the second mutation occurring in the wild type APC allele, and even by a third hit in the 
mutated allele that may further diminish or abolish the partial function of the truncated APC 
protein encoded by the germline mutation 136-139.  However, during adenoma progression, the 
Wnt signalling dysregulation might be also modulated or reinforced by alterations in other 
components of this signalling pathway, such as the epigenetic silencing of the negative 
regulator of Wnt SFRP1 (secreted frizzled-related protein 1) 140.  Finally, alterations in as yet 
unknown modifier genes might contribute to the phenotype heterogeneity.  In conclusion, 
although genotype-phenotype correlation can be used to focus the initial mutation detection 
effort on a restricted region of the long APC gene, its use as guidance for the clinical 
surveillance of FAP patients should be discouraged. 
 
Hamartomatous polyposis syndromes 
 Although they account for less than 1% of all colorectal cancers, the hamartomatous 
polyposis syndromes represent an interesting example of the importance of integrating 
clinical and molecular knowledge for a better disease definition, classification and treatment.  
In these rare syndromes, colorectal hamartomas are one of a large list of clinical features in 
different organs, and colorectal cancer is not the only neoplasia to which individuals with 
these syndromes are predisposed (see ref. 141 for a more detailed description of clinical 
phenotypes).   Reports of previously-unreported clinical findings and scrupulous diagnostic 
re-evaluations of known series of cases and/or families affected by these syndromes lead to 
frequent revisions of the list of common manifestations that should be used as diagnostic 
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criteria.  As for FAP, the number of first cases in families (probable de novo mutations) is 
rather high (30-50%), and consequently a family history of colorectal cancer is often absent.  
However, in all the described kindred, inheritance appears to be autosomal dominant.  
Germline mutations in a number of genes have been found associated with a portion of cases 
in every syndrome, but other genes, still to be identified, are believed to be altered in the 
remainder of the cases.  The hamartomatous nature of the polyps (disproportionate growth 
and distribution of cellular lineages that are normal constituents of gastrointestinal mucosa 
and submucosa) may be explained by the fact that the mutated genes encode proteins 
involved in signalling pathways regulating the stromal/epithelial homeostasis, i.e., the cross-
talk between epithelium and the extracellular matrix, fibroblasts, inflammatory cells and 
blood vasculature. 
Hamartomatous polyposis syndromes fall into three categories: 1) Juvenile polyposis, 
characterized by the presence of multiple juvenile polyps (hamartomas with abundant lamina 
propria that lacks smooth muscle and may contain cystically dilated glands lined by normal-
appearing epithelium) in the colorectum and other gastrointestinal tracts, and predisposition 
to colorectal, gastric, duodenal and pancreatic cancers (atypical juvenile colonic polyps have 
been also reported in kindred with hereditary mixed polyposis syndrome, along with 
hyperplastic polyps, serrated and classical adenomas, and colon carcinomas – details on this 
rare syndrome in 142 –).  Juvenile polyposis can be associated with hereditary hemorrhagic 
telangiectasia;  2) Peutz-Jeghers syndrome, with hamartomatous polyps (hamartomas with 
bands of smooth muscle in the lamina propria, similar to those occurring in the colon of 
patients with tuberous sclerosis) occurring most frequently in the small intestine, 
characteristic mucocutanous pigmentation (most commonly around the mouth) and high risk 
for breast, colorectal, pancreatic, gastric, ovarian and other cancers;  3) Cowden’s disease, in 
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which the gastrointestinal hamartomas (often juvenile-like polyps that contain some neural 
elements with no increased risk of cancer) are not the defining feature as in the previous two 
syndromes, but in which the affected individuals display distinctive mucocutaneous 
manifestations (the trichilemmomas are patognomonic), benign and malignant breast and 
thyroid tumours, endometrial and renal cell carcinomas, and central nervous system features 
such as macrocephaly and adult-onset Lhermitte-Duclos disease, which is characterized by 
enlarged cerebellar folia containing abnormal ganglion cells.   Macrocephaly and 
gastrointestinal hamartomas similar to those found in Cowden’s disease are also 
manifestations of the developmental disorder Bannayan-Riley-Rulvalcaba syndrome.   
Colorectal hamartomas in juvenile polyposis and Peutz-Jeghers syndrome are 
considered neoplastic, and transformation is thought to initiate in the stroma, although 
adenomatous changes of the epithelium also occur during carcinogenesis.  Multiple 
adenomas, which have been detected concurrently with hamartomas in these conditions, 
might represent the precancerous lesions in some cases.  The genetic evidence accumulated 
to date indicates that in juvenile polyposis,  the primary alteration might deregulate the 
stroma/epithelium interaction.  Indeed, germline mutations in three components (SMAD4, 
BMPR1A and ENG) of the TGFβ and BMP signalling pathways have been detected in ~50% 
of juvenile polyposis 143 144.  These two cross-talking signalling pathways are considered 
important regulators of the interaction between stromal and epithelial cells 145,  however, 
whether the germline alteration in these genes is followed by their somatic inactivation (i.e., 
second hit in the wild-type allele) in the stromal or the epithelial cells (or both) of the juvenile 
polyps 146 147 is subject to discussion. 
Most of the Peutz-Jegers syndrome cases carry a germline alteration in the STK11 
gene (also called LKB1) 148-151, which encodes a nuclear and cytoplasmic serine/threonine 
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kinase.  STK11 is a tumour suppressor with growth-inhibitory effects mediated through 
induction of the cell-cycle regulators p21 and p27 expression 152 153 and negative regulation of 
the TSC2/mTOR signalling 154 155.  As shown in FIGURE 5, STK11 is activated in situations 
of energy deprivation, i.e., in conditions that are adverse to cell proliferation such as in the 
absence of nutrients or growth factors.  Activated STK11 phosphorylates and activates 
AMPK (AMP-activated protein kinase), another serine/threonine kinase, which in turn 
phosphorylates many substrates involved in energy conservation pathways.  One of these 
substrates is tuberin (TSC2), which, when phosphorylated and activated by AMPK, binds 
hamartin (TSC1).  Activated TSC1/2 inhibits mTOR (target of rapamycin), a critical 
regulator of protein translation.  Indeed, protein synthesis is one of the major energy-
consuming processes.  Thus, inactivating mutations or loss of STK11, as found in Peutz-
Jeghers cases, lead to decreased activation of AMPK, downregulation of TSC1/2 function, 
activation of mTOR and increased translation of proteins that might fuel tumour progression.   
Independently of this pathway, STK11 inactivation might also favour tumour formation by 
deregulation of cell polarity 156.  Mutations in either the TSC1 or TSC2 tumour suppressor 
genes also result in a complex hamartomatous syndrome, tuberous sclerosis, with 
hamartomas in several organs, but only rarely in the colon.  It is has been hypothesized that 
activation of mTOR may initiate hamartomatous tumours through the up-regulation of 
translation factors (such as eIF4E) and the hypoxia-inducible transcription factor (HIF), 
which in turn increases the expression of growth factors such as TGFα, PDGFβ and VEGF.  
For Peutz-Jeghers hamartomas, as for juvenile polyps, the sequence of somatic carcinogenic 
events in heterozygous STK11 cells (in particular whether STK11 haploinsufficiency is 
sufficient or LOH is necessary for transformation), and the cell lineages of the 
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gastrointestinal mucosa that are primarily involved in transformation, remain to be fully 
elucidated 157-160. 
Interestingly, another molecule, the lipid phosphatase PTEN (phosphatase with tensin 
homology), whose gene is mutated in the germline of individuals with a variety of clinical 
syndromes, including Cowden’s disease (in ~80% of cases) and Bannayan-Riley-Rulvalcaba 
syndrome (in ~50% of cases), also impinges on the TSC2/mTOR signalling (FIGURE 5).  
PTEN negatively regulates PI3K (phosphatidylinositol 3-kinase), which is normally activated 
in response to growth factors.  PI3K activates protein kinase B (PKB, also known as AKT), 
which in turn phosphorylates and inactivates TSC2, leading to increased mTOR activity.  
Thus, the loss of PTEN function derepresses the mTOR pathway and thus favours cell 
transformation.  It will be important to understand why mTOR signalling is associated with 
malignant transformation in the breast, the thyroid gland and the endometrium, but not of 
gastrointestinal hamartomas of patients with Cowden’s disease.   
Clinical manifestations in the hamartomatous syndromes are complex and clinicians 
are often unable to assign them to one or the other syndrome.  Although in some cases this is 
the result of poor diagnostics, most of the cases will be clarified by a better understanding of 
the functional consequences of genetic alterations.  For instance, very early onset juvenile 
polyposes have been reported to be associated with a deletion of a region of 10q 
encompassing both PTEN and BMPR1A 144 161 162, a situation in which both the mTOR and 
the TGFβ signalling are abnormal.  Different mutations could also affect the cellular 
localization of these proteins and mediate different phenotypes.  For example, although 
PTEN acts as a plasma-membrane lipid phosphatase, it is also found in the nucleus.  The 
Cowden’s disease associated K289E PTEN mutant was recently found to be defective in 
nuclear import, yet enzymatically functional, ascribing thus a tumour-suppressive function of 
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PTEN to its function(s) in the nucleus 163.  Cytoplasmic localization of STK11 is favoured by 
its interaction with LIP (LKB-interacting protein), and this could favour the formation of 
STK11-LIP1-SMAD4 ternary complex linking STK11 to the TGFβ pathway 164.   Even more 
intriguingly, STK11 also interacts with and phosphorylates PTEN, and also this interaction 
leads to cytoplasmic relocalization of STK11 165.  The dissection of the extensive cross-talk 
among pathways involved in different hamartomatoses will eventually help us understand the 
phenotype and predict the outcome of these diseases. 
In conclusion, the diagnosis and classification of hamartomatous syndromes appear 
much more difficult than those of HNPCC and FAP, due to the complex and variable 
phenotypes and to the absence of reliable diagnostic tests.  These tests will become available 
when the steps of the carcinogenic process at the somatic level are elucidated.  Tests aimed at 
the identification of abnormalities in the mTOR, TGFβ and BMP pathways in clinical 
samples should also be developed.  It is probable that alterations in other genes involved in 
these pathways might explain the cases where PTEN, STK11, SMAD4 and BMPR1A are 
found normal. 
 
Inflammatory factors in familial and sporadic colorectal neoplastic lesions. 
The involvement of inflammation in the development of colorectal cancer is 
documented by the high incidence of this cancer in patients with long-term ulcerative colitis.  
However, that inflammation may play a role in the formation of a much larger proportion of 
colorectal neoplasias was first suggested by epidemiological studies showing that long-term 
users of aspirin or other NSAID have a reduced risk of developing adenomas and carcinomas 
166 167.  Furthermore, the NSAID Sulindac was found to reduce the number and size of 
adenomas in FAP patients 168 169.  Sulindac showed only an anti-tumour promotion effect 
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since it was not effective to prevent the onset of adenomas in APC-mutation carriers who had 
not yet developed polyps 170.  In addition, the adenomas relapsed after the Sulindac treatment 
was stopped.  A worldwide chemopreventive trial with aspirin (CAPP2 study) has been 
initiated also in HNPCC mutation carriers, and the results are expected in 2007.  Evidence for 
an anti tumour initiation effect of NSAIDs came when these drugs (mainly aspirin and COX-
2 inhibitors) were used to verify the possibility of reducing the interval between 
colonoscopies in subjects with a previously-excised, sporadic adenoma 171 (and references herein).  
In these trials, long-term treatment reduced the risk of metachronous adenomas, but the 
relatively short period of treatment (less than 10 years) was not sufficient to provide evidence 
of a reduced risk of colorectal cancer.  Unfortunately, treatment with the COX-2 inhibitor 
Celecoxib has been recently found associated with an increased risk of cardiovascular events 
171 172.  These two latter observations, together with the obvious benefit of colonoscopy in 
preventing colon cancer through polypectomy, have recently reduced the enthusiasm in the 
field of chemoprevention of sporadic adenomas by NSAID, but the use of these substances in 
inherited polyposis may still be appropriate to reduce the risk of colonic and extra-colonic 
malignancies.  Neverthless, the considerable amount of information gathered from basic and 
clinical research during the last 15 years clearly indicates that alterations in inflammatory 
genes and pathways are important mediators of adenoma formation and progression 167 173.    
More attention should be focused on the complexity of alterations in factors involved 
in inflammation in colorectal neoplasms of different type and stage.  The finding of an 
increased expression of only one such factors might not be sufficient to embark on 
chemopreventive trials.  For instance, an increase of COX-2 expression has been detected not 
only in adenomatous polyps (more frequently in those of larger size) 174-177, but also in Peutz-
Jeghers polyps 178, familial juvenile polyps 179, serrated adenomas 180 and mixed lesions 181, 
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and Celecoxib has even been used in a small number of Peutz-Jeghers patients 182.  In such 
histologically different lesions, it is possible that the increased expression of COX-2 is 
limited to a particular cell type or subtype, or that it is associated with different patterns of 
expression of other inflammatory factors.  Inflammatory genes and pathways should also be 
investigated in non-colonic lesions of polyposis syndromes, since their location in organs less 
accessible than colon make them more difficult to detect and remove in early phase of 
development and for which a chemopreventive approach might be more justified.  
Genomic, transcriptomic and proteomic studies have opened new avenues to 
investigate the complexity of this phenomenon.  As an example of this complexity, we 
describe here results of a recent study in which we have studied the transcriptome of sporadic 
adenomatous polyps (≥1cm) compared with that of normal colonic mucosa and colorectal 
cancers [this latter group included both MMR(+) and MMR(-) tumours].  Although we have 
not used tissue microdissection to isolate RNA from different cell types (in our experience, 
this approach reduces RNA quality), our sampling procedure allowed us to enrich for 
epithelial cell RNA.  When we focused on the expression levels of genes included in the  
“prostaglandin” category by Gene Ontology 183, sporadic adenomas could be easily 
distinguished from normal mucosa and from colon cancers (FIGURE 6) (similar results were 
obtained using a larger series of genes classified in the Gene Ontology category 
“inflammatory response” – data not shown).  These data indicate that arachidonic acid 
metabolism might be considerably remodelled in colorectal tumours and that the remodelling 
is different in adenomas and carcinomas.  For a few genes, mainly those involved in the 
metabolism of prostaglandin E2 (PGE2), which has been associated with tumour progression 
in the colon 173 167, we show in FIGURE 6 the average values of expression in a series of 
colorectal tissues. Interestingly, PTGS2 (COX-2) mRNA was not significantly upregulated in 
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the adenomas compared with the normal mucosa, but the gene was more than 10 times more 
expressed in adenocarcinomas, suggesting that upregulation of PTGS2 is not an early event in 
colorectal transformation.  Thus, while the beneficial effects of COX-2 inhibitors in the 
treatment of fully-developed adenomas in FAP patients might be explained by our finding, it 
is difficult to understand the mechanism by which these drugs may prevent or delay the 
appearance of sporadic adenomas.  A second gene encoding the PGE2 synthesizing enzyme 
PTGES, was also significantly upregulated in carcinomas, whereas HPGD, which encodes 
the key enzyme of the PGE2 (and other PGs) biological inactivation, was downregulated to 
the same extent in both adenomas and carcinomas, confirming previous observations 184 185.  
The expression levels of IL1B, which plays a role in the regulation of HPGD and PTGS2 186, 
and of the four PGE2 receptors 187 in colorectal tissues are also reported in FIGURE 6 .  
Although these gene expression data need to be validated by the analysis of the 
corresponding proteins in colorectal tissues, they suggest that alternative approaches, such as 
inhibition of the PGE2 synthesis acting downstream of PTGS2 (on PTGES 188) or restoration 
of an efficient degradation of PGE2, should be considered to overcome some of the side 
effects of COX-2 inhibitors. 
 Global molecular screening analyses should be extended to non-adenomatous 
colorectal precancerous lesions, inherited or sporadic, and to extracolonic tumours of 
different familial polyposis.  The level and cellular localization of proteins whose genes have 
been found differentially expressed in these lesions will have to be analyzed with procedures 
that preserve tissue architecture.  The ultimate goal is to identify agents able to modulate 
molecular pathways, such as inflammation, Wnt, TGFβ, or TSC/mTOR signalling, in a 




Molecular genetics has made tremendous advances during the past decade.  This 
progress was driven on the one hand by technological developments that accompanied the 
human genome sequencing project and on the other by an increased understanding of the 
molecular pathways that control the rate of proliferation of cells of different tissues.  The 
latter discoveries were often made in model organisms ranging from yeast through nematodes 
to fruit flies, and their validity was tested in transgenic mice, which have become an 
indispensable tool of cancer research.  However, it would be wrong to ignore the painstaking 
efforts of numerous groups that searched for chromosomal aberrations in human cancer cells 
and that succeeded in identifying the loci, which were later shown to harbour key oncogenes 
and tumour suppressor genes that have since become household names. 
 In the specific case of colorectal cancer, the characterization of the Wnt signalling 
pathway helped us understand at the molecular level how the proliferation of colonic 
epithelial cells is controlled and why a perturbation of this machinery results in the 
appearance of polyps in both sporadic and familial colorectal cancer.  A better understanding 
of the biochemistry of DNA metabolism has also been of key importance.  Thus, intimate 
knowledge of mismatch repair helped explain the differences in penetrance of mutations in 
different MMR genes and understanding of the base excision repair of oxidative damage was 
of key importance in the identification of a link between somatic G to T transversion 
mutations in the APC gene of patients with multiple colonic adenomas and germline 
mutations in MYH.  The number of similar examples is getting larger, such that most familial 
cancers have in the past decade been linked to at least one genetic locus. 
 With this invaluable genetic information in hand, we have to ask ourselves how to use 
it most effectively.  At this time, it is inconceivable that an inherited mutation could be 
 33 
corrected, such that the cancer predisposition might be eliminated.  What remains are three 
avenues:  diagnosis, prevention and personalized therapy.  Identification of at-risk individuals 
by molecular genetic screening has gained broad acceptance, in spite of the ethical and 
psychological issues that such diagnosis carries with it.  This is particularly true for HNPCC, 
where the benefits are clear: on the one hand, mutation carriers can be enrolled in endoscopic 
surveillance programs that are extremely effective in preventing cancer onset by removing 
colonic polyps during their benign stage.  On the other hand, unaffected family members are 
relieved of the threat of cancer hanging over their heads like the sword of Damocles. 
 In other cancer predisposition syndromes, such as breast cancer associated with 
mutations in the BRCA1 and BRCA2 genes, cancer onset cannot be prevented, but frequent 
surveillance ensure that the tumours are detected at a very early stage, which significantly 
increases the chances of complete remission. 
 Cancer prevention has met with little success to date.  The use of NSAIDs in the 
prevention of colorectal cancer has suffered some serious setbacks, but this should not mean 
that attempts at curbing the growth of polyps should cease.  It may, however, be necessary to 
identify better intervention targets based on our latest knowledge of the mechanisms 
controlling epithelial cell growth.  Pathways leading to mutation should also be targeted, 
Thus, given that APC somatic mutations in homozygous MYH mutation carriers are linked to 
oxidative damage, it would be interesting to test the effects of antioxidants on polyp 
incidence. 
      In cases where cancer onset could not be prevented, we need to develop new 
therapeutic criteria that are tailor-made to the affected person.  We need to gather as much 
information as possible about the genetic background of the patient and of the tumour prior to 
initiating treatment.  In many cases, the side effects of chemo- and/or radiotherapy outweigh 
 34 
their benefits, and it is imperative that we learn to predict these scenarios in the future.  If a 
clinical study reveals that a particular therapeutic regimen had 80% responders, this should 
not be taken as a justification to treat 100% of the patients with that regimen.  Rather, it 
should bring up the question why 20% failed to respond and, having identified the reason, 
avoid treating them. 
 When cancer statistics of the past 30 years are examined, it transpires that we have 
made very little progress in treating advanced disease.  The successes lie in early diagnosis 
and thus in earlier intervention, as well as in advances in radio-oncology and tumour surgery. 
It is imperative that advances made in cancer genetics and in our understanding of the 
molecular mechanisms of cancer make their way into the clinic.  Familial cancer 
predisposition syndromes represent a patient pool, where a substantial wealth of knowledge is 
already available.  What is needed is for basic researchers and clinicians to join forces and 
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Figure 1. Mechanism with which microsatellite instability occurs in the DNA of 
mismatch repair deficient cells.  The DNA polymerase δ holonzyme can slip during 
replication of the DNA primer strand (white) on a template (black) containing a 
mononucleotide (i.e., a poly(A)n) or dinucleotide (i.e., poly(CA)n) microsatellite repeat.  
Insertion/deletion loops (IDLs) will form and if not repaired by the MMR, extrahelical 
 47 
nucleotides in the primer strand give rise to insertions, while extrahelical nucleotides in the 
template strand lead to deletions in the progeny DNA. 
 
Figure 2.  Mismatch repair at the replication fork.  This model is based on biochemical 
evidence from in vitro experiments using recombinant human proteins and DNA substrates 
carrying a base/base mismatch or IDLs.  Details on the steps of the MMR reaction depicted in 
this figure are provided in the text. 
 
Figure 3.  Colorectal lesions with serrated (i.e., saw-tooth contour) morphology.  In both 
panels, the serrated shape of the epithelium is evident in crypts cut longitudinally.  (A)  A 
traditional serrated adenoma (TSA) showing cytoplasmic eosinophilia (not appreciable in 
this black & white picture), and nuclear crowding and stratification extending up to the 
surface of the epithelium. This cytological abnormality is equivalent to mild dysplasia in a 
classical adenoma. (B)  A sessile serrated adenoma (SSA) with atypical crypt architecture 
including exaggerated serration, crypt branching and horizontally spreading crypts.  
Noteworthy, the architectural dysplasia of the serrated crypts, which is believed to emanate 
from abnormal proliferation and/or decreased apoptosis, is not associated with cytologic 
dysplasia.  Pictures kindly provided by Jeremy R. Jass (McGill University, Montreal)  
 
Figure 4. The Wnt signalling and the APC protein.  A) the Wnt signalling pathway is 
represented in its inactive (left) or active (right) state.  This latter can be achieved in several 
ways, for instance by production of Wnt ligands by epithelial or non-epithelial cells at the 
bottom of normal colorectal crypts, or by mutations in the APC gene (details are reported in 
the text).  B) In this panel, the protein APC domains are shown in the top bar representing the 
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primary structure of the protein, whereas the associations between the site of germline APC 
mutations and the FAP phenotype are graphically represented by the rest of bars of different 
length.  Truncated proteins start at the N-terminal part of APC and terminates at the site of 
the mutation or beyond it, retaining thus only a limited number of functional domains.  The 
Armadillo repeats domain functions as a protein-protein intraction site (between APC and a 
variety of proteins), whereas binding of β-catenin to APC occurs through three 15-aa repeats 
and seven 20-aa repeats, the latter being also important for β-catenin degradation.  The three 
SAMP repeats mediate binding to Axin.  The C-terminal region of APC binds to several 
different proteins, such as EB1 and HDLG, for normal cell division and chromosome 
segregation to occur. (Nuclear export sequences and nuclear localization signal domains of 
APC are not shown).  SAMP repeats: Serine Alanine Methionine Proline repeats;  EB1: End 
binding protein 1; HDLG: human disc large homolog; CHRPE: Congenital hypertrophy of 
the retinal pigment epithelium.  
 
Figure 5.  The mTOR signalling.  Model describing the upstream regulation of this 
signalling cascade by tumours suppressors (STK11, PTEN, and TSC1/TSC2) mutated in 
hamartoma syndromes.  Details on this pathway are provided in the text. 
 
Figure 6.  Expression profile of genes encoding proteins involved in the prostaglandin 
pathway.  A) Hierarchical clustering analysis of microarray data obtained with an 
Affymetrix gene expression platform: The 89 tissue samples represented on the x-axis 
include 32 adenomas, each with matched samples of normal mucosa, and 25 colon 
adenocarcinomas from a different group of patients.  Each probe (135 genes, whose 
expression levels changed significantly in adenomas and/or carcinomas compared with 
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normal mucosa with a minimal fold difference of 1.9) plotted on the y-axis is grayscale-coded 
to indicate the gene’s level of expression relative to its median expression level across the 
entire tissue-sample set (white: low; black: high).  Based on the expression of these set of 
genes, the three groups of samples were perfectly segragated (also most of the MMR(+) 
colorectal cancers clustered differently from most of those MMR(-)).  B) The expression 
levels (normalized intensity on y-axes; average with confidence intervals) of genes involved 
in the PGE2 pathway are shown in the three group of samples (white columns: normal colonic 
mucosa; light gray columns: colorectal adenomas; dark gray columns: colon 
adenocarcinomas).  (*): changes statistically significant when compared with the basal levels 
of expression in the normal mucosa.  PTGS2: prostaglandin-endoperoxide synthase 2; 
PTGES: prostaglandin E synthase; HPGD: hydroxyprostaglandin dehydrogenase 15-(NAD); 
IL1B: interleukin 1, beta;  PTGER3: prostaglandin E receptor 3 (subtype EP3) ;  PTGER4: 
prostaglandin E receptor 4 (subtype EP4). (The expression of the PTGER1 and 2 was similar 
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Introduction 
Colorectal tumorigenesis is one of the best known processes of cellular 
transformation in humans.  Its characterization has moved ahead by leaps and bounds 
during the last three decades thanks to major advances in the fields of endoscopy, 
histology and molecular pathology.  And as often happens when a human disease is 
subjected to in-depth  investigation, what originally appeared to be a single entity 
turns out to include several distinct clinical, histologic, and molecular phenotypes.  
Among other things, tumor phenotypes can tell us a great deal about the route taken 
by the tumor cells on their journey toward malignancy.  Not surprisingly, some 
tumors develop along pathways that are “heavily trafficked” (and for this reason, 
relatively well known); others follow the “roads less traveled.”  But if obstacles arise 
along the way, tumor cells are adept at exploiting alternative routes that permit them 
to continue their journey toward cancer, and these deviations can give rise to mixed 
phenotypes.  These phenotypes are nonetheless consistent with the concept of 
carcinogenesis as a nonrandom – and therefore, predictable --process.  Each pathway, 
each crossroads is the result of a specific set of genetic or epigenetic alterations.  
Many are already well defined, others are only partially characterized, and some are 
still in the realm of hypothesis.  Thus far, we have fairly reliable maps of at least two 
of the major pathways to colorectal cancer, but with increasingly sophisticated 
molecular analysis of preinvasive lesions, there is little doubt that we will eventually 
identify variants of these pathways and uncover others whose existence was not even 
suspected.   
In this chapter, we have attempted to provide an overview of the enormous 
amount of work and progress that has characterized this field over the past 30 years or 
so – a challenging task that has involved a number of difficult choices.  Some aspects 
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undeniably deserved much more attention than they have received, and important 
references have regrettably been omitted.  We have kept our focus on the basic 
pathogenesis of preinvasive lesions of the colorectum; as for their clinical 
management, there are several excellent articles that can and should be consulted [1-
10]. 
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On the way to cancer 
Preinvasive lesions of the human colorectum are small areas of tissue that alter 
the surface contour of the gut mucosa.  They are conventionally referred to as 
“polyps,” which indicates growth protruding into the intestinal lumen, and this is 
indeed a fair description of most premalignant colorectal lesions.  But we now know 
that there are also others, which are only slightly raised above the mucosal surface, or 
flat, or even depressed.  Standard colonoscopy is performed to identify and resect 
these benign lesions in the belief that some of them will progress to cancer.  Figure 1 
illustrates the conventional pathway by which this progression is thought to occur. 
The first step is the development of early morphologic changes in discrete clusters of 
epithelial crypts.  The benign polypoid lesion in panel C is believed to represent an 
intermediate stage between these aberrant crypt foci (ACFs) and invasive 
adenocarcinoma.  The transformation process summarized in the figure has never 
been directly documented ― when a preinvasive neoplasm is found at endoscopy, it 
has to be removed, so its natural history can never be monitored ― but it is consistent 
with the findings of innumerable endoscopic and histologic studies performed over 
the last three decades. 
In mucosal biopsies stained with methylene blue, ACFs appear darker than the 
normal mucosa surrounding them [11].  In situ, these minute lesions are invisible 
during standard colonoscopy, but they are easily identified when magnifying 
endoscopes are used with dyes (e.g., indigo carmine or methylene blue) that enhance 
mucosal detail, a process known as high-magnification-chromoscopic-colonoscopy 
or, more simply, magnifying chromoendoscopy [12].  The aberrant crypts are usually 
larger than normal and have thicker epithelial linings and dilated or slit-like openings 
that are raised slightly above the adjacent mucosa.   
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ACFs are classified histologically as dysplastic and nondysplastic.  Apart from 
their size, nondysplastic crypts are not remarkably abnormal, and their proliferative 
compartments are confined to the lower portion of the glands, as they should be.  
However, they often display signs of hyperplasia and infolding of the epithelium into 
the crypt lumen, a phenomenon referred to as serration, which is discussed in greater 
detail below.  Dysplastic crypts, in contrast, present signs of cellular atypia (mucin 
depletion, nuclear enlargement, stratification, and loss of polarity) and upward 
expansion of the proliferative compartment toward the mouth of the crypts.   
Around 60% of all healthy adults have a few ACFs in their colons, but these 
lesions are rarely dysplastic.  ACFs are encountered much more frequently in colons 
harboring adenomatous polyps or adenocarcinomas (80%-100% of all cases), and 
20%-50% of these show signs of dysplasia [13].  Dysplastic ACFs are also frequently 
detected in the colons of patients with familial adenomatous polyposis (FAP) [14], a 
high-penetrance genetic condition that causes a clear predisposition to colorectal 
cancer.  And in ulcerative colitis (a chronic inflammatory disease that also increases 
the risk for colorectal cancer), the number of ACFs increases when the colon also 
presents signs of epithelial dysplasia or cancer [15].  The view of ACFs as probable 
precursors of preinvasive colorectal neoplasms is supported by findings of identical 
molecular changes in both types of lesions.  Indeed, although they are more common 
features of premalignant neoplasms, mutations involving the KRAS or BRAF 
oncogene or the adenomatous polyposis coli (APC) tumor-suppressor gene, nuclear 
accumulation of β-catenin, aberrant DNA methylation, and low-level genomic 
instability have also been reported in some ACFs. 
It is widely acknowledged that, while a few ACFs will progress to the 
preinvasive and, later, invasive stages (adenocarcinomas), others will not, and some 
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might actually regress spontaneously [16].  These lesions are so small and so 
numerous that it is virtually impossible to eliminate them by endoscopic resection 
(which is no problem with larger preinvasive lesions), but they do seem to respond to 
chemoprevention [13].  The weight that should be assigned to ACFs ― their 
presence, number, and type ― in planning surveillance colonoscopy is currently 
unclear, but the increasing use of magnifying chromoendoscopy is expected to 
provide important information on this question. 
Preinvasive neoplasms ― the next stage ― are also a frequent finding.  They 
are identified in roughly one third of all asymptomatic adults undergoing standard 
colonoscopy, but, like ACFs, some may regress on their own, and only a fraction will 
be transformed into cancers.  The progression process generally involves increases in 
size and in the degree of cellular atypia.  Lesions over 1 cm in diameter with high-
grade dysplasia (referred to as advanced adenomas) are the ones farthest along on the 
road toward malignancy.  (The term adenoma is used hereafter to refer to neoplasms -
- regardless of their macroscopic appearance -- that display epithelial dysplasia.)   
Several lines of evidence indicate that some of these preinvasive lesions will 
indeed give rise to colorectal cancers.  For one thing, the frequency of these benign 
neoplasms and that of colorectal cancers both increase with age, but the 
age/prevalence curve for the former is shifted to the left by ~10 years.  The regional 
distribution of cancers within the colon also parallels that of large adenomas.  In 
addition, the expected incidence of colorectal cancer is substantially reduced by 
colonoscopy with polypectomy (even though 10-20% of all premalignant lesions, 
mainly those with diameters <5 mm, are likely to be missed on standard endoscopy) 
[17].  And finally, there is the impressive frequency at which invasive 
adenocarcinomas are detected within an advanced adenoma, especially those 
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displaying villous growth patterns and particularly severe dysplasia.  About half of all 
adenocarcinomas are elevated above the surrounding mucosa, and in the other half 
growth occurs at or below the surface of the normal tissue, so it seems that both 
polypoid and nonpolypoid benign lesions give rise to cancer. 
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Breaking convention: The contributions of modern endoscopy and histology 
For decades, all preinvasive colorectal lesions were referred to as polyps.  Pre-
neoplastic growth that did not protrude into the gut lumen was first detected in the 
eighties by Japanese endoscopists [18].  Once these nonprojecting lesions were 
recognized, they were reported with increasing frequency in other countries as well, 
where they represented 10-40% of all the preinvasive neoplasms encountered during 
screening colonoscopy [19].   
Since then, attempts have been made to reclassify preinvasive lesions of the 
digestive tract.  These efforts have been more or less successful, but older terms are 
still encountered, and they can be a source of considerable confusion.  When possible, 
we will give preference in this chapter to the newer, more precise terminology, which 
refers to all protruding lesions as polypoid and sub-classifies them as pedunculated 
(attached with a pedicle or stalk) or sessile (attached by a broad base).  At the other 
end of the spectrum are the nonpolypoid lesions.  They are still widely referred to as 
“flat” although most are actually slightly elevated (< 2.5 mm above the surface of the 
gut mucosa); those that  are completely flat or slightly depressed are rare, but even 
when they are small, they are generally farther along on the road to cancer (Figure 2) 
[20].  O’Brien et al. highlighted the impact of the new terminology in their recent 
reassessment of 1505 superficial neoplasms classified as polyps in the United States’ 
National Polyp Study.  Around 30% ― specifically, two-thirds of those originally 
considered sessile polyps  ― met the new criteria for nonpolypoid neoplasms [21].   
These lesions had all been detected in the 1980s with standard colonoscopy.  
In a more recent study based on high-magnification chromoendoscopy, 38% of the 
adenomatous lesions were nonpolypoid [22].  This approach also allows accurate in 
vivo classification of lesions based on surface morphology.  The shape of the colon 
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crypt lumen in particular (the so-called pit pattern) has proved to be a very reliable 
predictor of a lesion’s histologic features [23].  These newer techniques are becoming 
increasingly popular, and their use will undoubtedly improve the accuracy of 
endoscopic diagnoses.  Nevertheless, high-quality standard colonoscopy ― that is, 
complete examination of a clean colon, all the way to the cecum, with slow, careful 
withdrawal and re-examination of potential blind spots ― is still widely regarded as a 
reliable tool for detecting preinvasive lesions and preventing colorectal cancer. 
The more accurate endoscopic classification of preinvasive colorectal lesions 
led to some important observations.  While true polypoid lesions were more 
frequently detected in the left colon (from the splenic flexure to rectum), nonpolypoid 
neoplasms were more common in the right colon (from the cecum to the splenic 
flexure).  Even more important was the discovery that, while most of the latter lesions 
had classic adenomatous features, others presented a peculiar histologic pattern 
characterized by infolding of the glandular epithelium.  As noted earlier, this 
phenomenon is referred to as serration, because it produces a saw-toothed (or 
serrated) pattern in longitudinally sectioned crypts [24] (Figure 2E-F).  On cross-
section, the serrated crypt has a star-shaped appearance, and this feature can also be 
discerned in vivo by careful examination of crypt mouths with magnification 
chromoendoscopy.   
Serrated crypt architecture proved to be typical of lesions that were then (and 
sometimes still are) being referred to as hyperplastic polyps.  They had long been 
considered innocuous with a negligible risk for progression to cancer, mainly because, 
in spite of their architectural abnormality, they showed no clear signs of epithelial 
dysplasia.  The term hyperplastic polyp is gradually being abandoned in favor of 
nondysplastic serrated polyp (although in both cases, the term “polyp” is a misnomer 
 11 
since many of these lesions are nonpolypoid).  It is also becoming increasingly clear 
that this category includes morphologically and molecularly distinct subsets with 
different propensities for malignant transformation.   
Three major histologic subtypes have been identified thus far (see [25] for 
details).  Goblet-cell serrated polyps (GCSPs) have the fewest architectural 
anomalies, and it is generally agreed that they are unlikely to progress to cancer. 
These lesions are found primarily in the left colon, and most are small rectal lesions. 
They contain enlarged, nonbranching crypts displaying little or no epithelial 
infolding.  Their main abnormality consists in an increased goblet cell / columnar cell 
ratio that affects the entire length of the gland.  Microvesicular serrated polyps 
(MVSPs) are more common than GCSPs.  They are found throughout the colon, 
although their frequency is also highest in the left colon and rectum.  The crypts are 
elongated and funnel-shaped, but the proliferative compartment is normally confined 
to the bottom of the gland.  The upper crypts contain numerous microvacuolated 
columnar cells.  The upper 2/3 of the crypt (and less commonly the crypt base as well) 
typically presents epithelial serration.  The third subset comprises lesions that are still 
widely referred to as sessile serrated adenomas (SSAs).  The term is imprecise: first, 
because the group includes both sessile polyps and nonpolypoid lesions, and second, 
because the dysplasia that is the hallmark of an adenoma is absent in these lesions. 
SSAs are generally found in the right colon.  They are characterized by L-shaped or 
inverted-T shaped crypts lined with infolded epithelium from base to mouth.  The 
proliferative compartment is sometimes expanded, but as noted, there is no real 
cytologic dysplasia.   
Histologic and molecular findings (detailed in the next section) suggest that 
SSAs evolve from MVSPs and that some do eventually become dysplastic.   But at 
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this point, they are usually referred to as serrated adenomas (SAs).  The histologic 
definition of this term is still a matter of debate among pathologists so their diagnosis 
displays substantial interobserver variation.  Because cellular dysplasia is an essential 
feature of SAs, some are likely to be classified as conventional adenomas.  Mixed 
lesions containing serrated areas interspersed with areas displaying conventional 
adenomatous changes can also be found [26].   
In a recent study [27], 65% of the premalignant lesions resected during 
standard colonoscopy were conventional adenomas.  The other 35% displayed 
serrated architecture and were generally classified as “hyperplastic polyps.”  Most of 
the latter were MVSPs or GCSPs (30%), a few were SSAs (~4%), and less than 2% 
were dysplastic.  Similar figures (~60% conventional adenomas, ~40% serrated 
lesions) emerged from another study based on magnifying chromoendoscopy [28]. 
Nine percent of all lesions removed in this study were SSAs, and 2.4% were 
dysplastic (SAs).  The coexistence of adenomatous and serrated lesions in the same 
patient is a common finding. 
Therefore, alongside the conventional adenoma-carcinoma pathway illustrated 
in Figure 1, there seems to be a second, less-frequented route, the serrated pathway, 
which also leads to the development of colorectal adenocarcinoma (Figure 3). There 
is evidence of its existence at both ends of the transformation process.  Serrated / 
stellate crypt morphology has, in fact, been described in some nondysplastic (or 
hyperplastic) ACFs [29], and ~10% of all colorectal cancers have predominantly 
serrated histologic patterns (the serrated adenocarcinomas) [30] or contain peripheral 
remnants of serrated adenoma [31].  The mixed (serrated and conventionally 
adenomatous) histology observed in some preinvasive lesions suggests that the two 
pathways have somehow intersected or merged during tumorigenesis. 
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In summary, 2 out of 3 preinvasive colorectal lesions discovered at endoscopy 
are classic adenomas with tubular and/or villous architecture and some degree of 
dysplasia (Figures 1 and 2E).  The third will present a serrated histological pattern, in 
rare cases combined with dysplastic changes (Figure 2F).  The classic adenomas are 
usually pedunculated (or less frequently, sessile) polyps, but around 1/3 are 
nonpolypoid [22,27,28] (Figure 2A-D).  Among serrated lesions, polypoid and 
nonpolypoid growth patterns are more or less equally represented.  Small serrated 
polyps (<5 mm in diameter) with microvesicular or goblet-cell features are likely to 
be encountered in the left colon and rectum.  Larger MVSPs (which are usually 
sessile polyps or nonpolypoid lesions) and SSAs are more frequently found in the 
right colon.  As for the dysplastic serrated lesions (SA), over two thirds are polypoid, 
and most are located in the left colon [32].  However, there is compelling molecular 
evidence (see next section) that their less common, right-colon counterparts are far 
more important: these proximal SAs seem to be the ones that evolve along the 
serrated pathway, presumably giving rise to ~ 20% of adenocarcinomas found in the 
colorectum. 
Advances in the fields of endoscopy and pathology have provided us with a 
more accurate classification of preinvasive lesions that better reflects their relevance 
in colorectal tumorigenesis.  In the next section, we will review the results of studies 
aimed at defining the molecular features of these lesions. 
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Convention-breaking findings from molecular biology 
The availability of tissue samples of preinvasive lesions removed during 
endoscopy or surgery fuelled attempts to identify the crucial molecular events that 
allow these lesions to form and progress toward cancer.  In general, increases in 
lesion size ― from tiny ACFs to advanced adenomas over 1 cm in diameter ― are 
paralleled by increasingly bizarre architectural and cytologic atypia, and the larger 
lesions (polypoid or nonpolypoid) are the ones most likely to become malignant.  
Analyzing lesions of different sizes thus reveals distinct stages or steps in the 
transformation process.  And when molecular changes are discovered in malignant 
tumors (adenocarcinomas), we can backtrack along the various steps of the pathway 
to find out when (and perhaps why) the alteration appeared.  Some abnormalities can 
even be traced back to the normal mucosa, where they reflect a genetically- and/or 
environmentally-determined field defect. 
Interestingly, molecular alterations considered highly relevant to the 
transformation process in the colon are often found in some but not all premalignant 
lesions, and when they are present, their prevalence frequently correlates poorly with 
the size or severity of lesions.  Some well known examples are oncogene mutations 
(KRAS and BRAF) and more extensive genetic or epigenetic alterations, such as 
microsatellite instability or the methylator phenotype (see below).  The fact that some 
of these changes appear to be mutually exclusive suggests that pre-cancerous cells can 
be transformed into invasive cancer cells by different sequences of mutations. 
Nevertheless, there does seem to be a common denominator in the onset and 
progression of most, if not all, pre-cancerous lesions of the colorectum: aberrant 
activation of the Wnt signaling cascade.  Canonical Wnt signaling is a crucial driver 
of epithelial-cell division within the lower third of the intestinal crypt, which 
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represents one of the simplest self-renewing biological entities in mammals [33]. In 
this proliferative compartment of the gland, secreted Wnt proteins interact with 
serpentine receptors of the frizzled family and low-density lipid receptors 5 or 6 
expressed by the dividing epithelial cells.  Signal transduction activated by this 
binding inhibits the formation of a cytoplasmic complex whose core components 
include APC (a multidomain protein encoded by the adenomatous polyposis coli 
gene), glycogen synthase kinase-3ß, the scaffolding protein axin, and casein kinase 1.  
This so-called destruction complex catalyzes the phosphorylation of ß-catenin, 
thereby targeting it for ubiquitin-mediated degradation.  In its absence, ß-catenin 
accumulates in the cytoplasm and eventually translocates into nucleus, where it 
encounters DNA-binding proteins of the T-cell factor (TCF)/lymphoid enhancer 
factor (LEF) family.  ß-catenin binding converts the TCF and LEF1 proteins from 
transcription repressors to transcription activators.  Among their targets are genes 
whose products play fundamental roles in maintaining stem- and cycling-cell 
populations at the bases of colon crypts (other transcription factors like CMYC, the 
cell cycle kinase activator cyclin D, and matrix metalloproteinase 7, to name a few).  
Cells in the upper two-thirds of the crypt are not stimulated by Wnt signaling proteins, 
so the ß-catenin in these cells is recruited to the destruction complex and promptly 
degraded.  This leaves the upper-crypt cells free to differentiate as they migrate 
upward toward the intestinal lumen.  
Constitutive Wnt signaling leads to an expansion of the proliferative 
compartment of the crypt, destroying the equilibrium between proliferation and 
differentiation, and this loss generally coincides with the development of 
precancerous lesions.  In virtually all colorectal tumors (preinvasive and invasive), 
this inappropriate signaling reflects abnormal stabilization of ß-catenin, and in 60%-
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80%, the cause is homozygous mutation of the well-known tumor suppressor gene 
APC [34-37] (Figure 4), which presumably occurs in the progenitor stem cells at the 
crypt base [38,39].  APC mutation is therefore a frequent event in the initial stages of 
colon tumorigenesis, but it is not the only cause of the altered stability and 
distribution of ß-catenin that characterize colorectal tumors.  Wnt signaling can also 
be constitutively activated by somatic changes affecting other crucial pathway 
components.  They can be genetic (e.g., mutations involving the gene that encodes ß-
catenin, which generally result in substitution of serine or threonine residues whose 
phosphorylation allows the protein to be degraded by the destruction complex [40-
42]) or epigenetic (transcriptional silencing of the SFRP1 gene [43], which encodes a 
receptor that normally inhibits Wnt signaling).   
APC and ß-catenin mutations are mutually exclusive in colorectal neoplasms, 
but other genetic and epigenetic changes in Wnt-pathway components are often found 
together in the same tumor.  Many human tumors develop and evolve as a result of 
the deregulation of multiple signaling pathways, and this is undoubtedly true of 
colorectal tumors as well, but colorectal tumorigenesis also seems to be characterized 
by the selection of repeated alterations (or “hits”) involving the Wnt pathway.  These 
observations suggest that Wnt signalling dysregulation itself may be modulated 
during transformation to meet the specific needs of the tumor at various points in its 
journey.  
Changes of this type can naturally have an impact on the tumor phenotype.  
For example, biallelic mutation of tumor suppressor genes is generally envisioned as 
causing loss of protein function, but in the case of APC, the mutant gene products are 
usually stable, truncated proteins that may well retain some ability to interact with ß-
catenin, for example [44]).  The mutant alleles (i.e., the first and second hits) seem to 
 17 
be co-selected to achieve a level of aberrant Wnt signaling that is “optimal” for tumor 
cell proliferation and DNA replication.  During tumor progression, however, one of 
the two APC alleles may develop a second mutation – a “third hit” that readjusts the 
level or characteristics of the dysregulated signaling to meet the tumor’s current needs 
[45].   
The quality of the dysregulated signaling also changes when one pathway 
component instead of another is altered.  For instance, compared with tumors bearing 
ß-catenin mutations, those with abnormal APC function are thought to be more prone 
to DNA ploidy changes, because APC is also involved in mitotic spindle formation 
and chromosome segregation, processes that are essential for the maintenance of 
chromosomal stability [46].  Low-level chromosomal instability has in fact been 
detected in adenomatous polyps (mainly gains of chromosome 7 and 20, as well as 
deletions in multiple regions) and in dysplastic ACFs of patients with APC mutations 
[47,48], although no genomic imbalances were found when a small series of 
adenomas with biallelic APC mutations were recently subjected to comparative 
genomic hybridization analysis [49] 
The RAS/RAF/MEK/ERK (or MAPK/ERK) cascade is another signaling 
pathway that is frequently dysregulated in colorectal carcinogenesis, and it, too, 
transforms extracellular signals into transcriptional regulation.  The MAPK/ERK 
cascade is a classical “survival” pathway, in that it promotes cell proliferation and 
prevents apoptosis.  Two of its gene components,  KRAS and BRAF, are known 
oncogenes that often present gain-of-function mutations in preinvasive colorectal 
lesions.  The hyperactive mutant kinases they encode (KRASG12D and BRAFV600E, for 
example) maintain a state of chronically activated “survival signaling” in 
premalignant cells.  
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The level of this aberrant MAPK/ERK activity has yet to be well defined, but 
the balance between cellular proliferation and apoptosis undoubtedly differs from that 
observed in the normal mucosa.  Loss of this normal homeostatic equilibrium seems 
to be associated with a substantial increase in DNA replication stress.  Unlike the 
proliferating cells of normal colorectal crypts, premalignant epithelial cells with 
oncogene-activated survival signaling display classic examples of cellular responses 
to DNA damage, including phosphorylation of checkpoint kinase CHK2 and the 
histone protein H2AX, or signs of telomere attrition [50,51].  These events halt the 
cells at a specific stage of the cell cycle so that the DNA damage can be repaired.  
This checkpoint repair system is probably one of several mechanisms that put a brake 
on the progression of tumorigenesis and allow lesions to remain in the preinvasive 
stage for years (Figure 4). 
BRAF and KRAS oncogene mutations are early mutually exclusive events that 
can already be detected in ACFs [29].  The former is more frequent in serrated ACFs, 
and the latter is more common in ACFs that lack serration.  Interestingly enough, this 
difference is maintained as transformation progresses.  In fact, BRAF mutations are 
found in over two thirds of all MVSPs, SSAs, and dysplastic SAs, and they are also 
present in ~15% of all adenocarcinomas, mainly those right-colon cancers that 
develop along the serrated pathway.  KRAS mutations are detected in 30-40% of 
conventional adenomas and in ~1/3 of all adenocarcinomas [31,52] (Figure 4).   
Therefore, although KRAS is located immediately upstream to BRAF in the 
MAPK/ERK signaling pathway and each intermediate is frequently mutated in 
preinvasive colorectal lesions, the phenotypic consequences of these mutations are 
quite different.  (We saw the same thing above, when we looked at mutations of APC 
and β-catenin in the Wnt pathway.)  The distinctive effects of mutations involving 
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two components of a given pathway, even those that are adjacent to one another in the 
signaling cascade, are not surprising, because each component is transduced 
differently downstream and each interacts in its own way with factors of other 
signaling pathways (e.g., cross-talk  between components of the MAPK/ERK and 
PTEN/PI3K/AKT/mTOR pathways [53]). 
While activating mutation of KRAS or BRAF seems to be an early event in the 
process of colorectal transformation, 50-60% of all colorectal adenocarcinomas show 
no sign of either mutation (Figure 4).  If, as it seems, oncogene activation of survival 
signaling allows preinvasive lesions to avoid cell death for many years, it seems 
reasonable to expect that benign lesions without KRAS or BRAF mutation would have 
mutations/alterations involving other oncogenes.  To date, however, none have been 
identified. 
The end of this more or less lengthy preinvasive stage and the onset of true 
malignancy is believed to be caused by the addition of one or more new genetic or 
epigenetic alterations.  The “brake-releasing” events are nonrandom, but they may 
differ, depending on the nature of the preinvasive neoplasm.  Some lesions are set in 
motion by mutation of the tumor-suppressor gene TP53, which is often altered in 
advanced colorectal tumors; in others, the crucial event affects another survival 
signaling pathway (e.g., mutation of PIK3CA or PTEN in the  
PTEN/PI3K/AKT/mTOR pathway [54]) or another Wnt signaling protein; and in 
others, the brake-releasing hit targets a gene needed for genomic stability (the DNA 
mismatch repair gene, MLH1, for example).  The type of event(s) necessary to 
provoke the transition to invasiveness seems to be dictated at least in part by the 
original genetic features of the premalignant lesion. (Somatic MLH1 silencing, for 
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instance, seems to be the most common trigger for progression of BRAF-mutated 
serrated lesions.)   
Analysis of a dozen or more different genetic and epigenetic alterations in a 
substantial number of colorectal neoplasms has revealed at least 2 clearly discernable 
paths toward the invasive stage (Figure 4).  Each includes a number of molecular 
crossroads, however, and the tumor-in-motion can thus be deviated toward a different 
pathway by biological obstacles encountered during progression (most of which have 
yet to be characterized).  Route changes of this type can result in mixed phenotypes 
[55-58].   
The serrated pathway shown in Figure 4 generates colorectal neoplasms that 
are phenotypically distinct from those that develop through the conventional, APC-
driven, adenoma-carcinoma sequence.  BRAF-mutated, serrated lesions give rise to 
sporadic MLH1-deficient cancers of the right colon, which are more frequent in 
women and occur later than other sporadic colorectal cancers (peak prevalence 
between the ages of 70 and 80 years).  A frequent feature of these neoplasms is the 
CpG island methylator phenotype (CIMP), which is characterized by nonrandom 
transcriptional silencing of several cancer-relevant gene promoters, like those of p16 
and MLH1 [31,59-66].  Relatively rare in conventional adenomas, the CIMP is found 
in 70%-80% of all dysplastic serrated lesions of the right colon, and it is closely 
associated with BRAF mutations.  The basis of this association is unknown, and it is 
also unclear why CIMP-positive tumors prefer the right colon of women.  The latter 
aspect presumably highlights roles played by hormonal and environmental factors 
(including cigarette smoking [67] and hypoxia [68,69]).  
High-throughput sequencing technology and system biology studies (based on 
genomics, transcriptomics, and proteomics, and other more specific –omics) will 
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certainly improve mutation detection, providing us with a more precise picture of the 
colorectal oncogenetic tree [70,71] than the one represented in Figure 4.  These 
advances will bring us several steps closer to the goal of type-specific treatment for 
colorectal cancers.  The different phenotypes might also have specific mechanisms for 
developing resistance to treatment regimens, so detailed knowledge of a given 
phenotype might also facilitate the early detection and prompt treatment of tumors 
that are no longer responding to treatment. 
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Fast-track transformation models: Inherited syndromes and inflammatory 
bowel disease 
The adenomatous and serrated pathways of colorectal transformation can be 
discerned within three inherited syndromes that are major risk factors for the 
development of colon cancer.  Because the susceptibility to cancer is inherited, 
tumorigenesis generally begins earlier and proceeds more rapidly than it does in 
sporadic disease, and mutation carriers frequently develop adenocarcinomas between 
the third and fifth decades of life. 
Familial adenomatous polyposis – Less than 1% of all colorectal cancers are related 
to familial adenomatous polyposis (FAP), but this syndrome provides us with an 
invaluable “fast-forward” view of mutant APC-driven transformation through the 
adenomatous pathway.  Individuals with FAP are born with a heterozygous germ-line 
mutation in APC, and by adolescence or early adulthood, their colons are filled with 
hundreds or thousands of classical adenomatous polyps.  They also develop 
extracolonic disease, such as congenital hypertrophy of the retinal pigment 
epithelium, desmoid tumors of the abdomen, upper gastrointestinal adenomas and 
carcinomas, and, less frequently, osteomas, dental abnormalities, lipomas, and 
epidermoid cysts.  Malignant tumors of the brain, thyroid, and hepatobiliary tract have 
also been associated with FAP. 
FAP is transmitted in an autosomal dominant fashion, although ~30% of all 
patients represent new cases in the family (i.e., de novo mutations).  There is also a 
milder variant, attenuated FAP, characterized by later disease onset and a smaller 
number of colorectal polyps (conventionally, fewer than 100) [72].  But since 
approximately 5% of all adenomas eventually become cancers, the probability of 
colorectal cancer by the age of 40-50 years is 100% even in these patients.  FAP 
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adenomas do not seem to be more prone to transformation than their sporadic 
counterparts.  The accelerated tumorigenesis associated with this syndrome appears to 
be related primarily to the prodigious numbers of polyps that form and the early age at 
which they appear.  
APC encodes a 2843-amino-acid protein with several functional domains, 
including several that bind with β-catenin and others that interacts with axin.  As 
mentioned in the previous section, nonsense germ-line APC mutations usually 
generate partially functional N-terminal APC fragments lacking one or more of these 
domains.  Variability in the domain make-up of these truncated proteins is reflected 
by different degrees of Wnt signaling dysregulation, which produce different effects 
on cell-cell adhesion, cell migration, cell division, and chromosomal stability [73].  
This is the basis for the genotype-phenotype association model of FAP (reviewed in 
[74]), which holds that the severity of the disease ― in terms of number and onset of 
colorectal adenomas and extracolonic manifestations ― depends on the location of 
the germ-line mutation within the APC gene.   
The model has some obvious shortcomings.  For one thing, past analyses have 
been largely restricted to the mutation cluster region of APC, and this may have 
provided a skewed picture of the mutational spectrum in this gene.  Furthermore, the 
transformation process within single lesions can also be influenced by the 
characteristics of second and (in some cases) third hits involving APC at the somatic 
level (as discussed in the previous section).   Numerous studies have revealed 
inconsistencies and contradictions in the genotype-phenotype association model, the 
most striking of which is the fact that, in 30%-50% of patients with FAP or attenuated 
FAP phenotypes, current testing methods reveal no APC mutations at all!  In some of 
these cases, bi-allelic germ-line mutations involving the base excision repair gene 
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MYH have been detected.  They represent a recessively inherited variant of FAP (or 
attenuated FAP), in which the development of adenomatous polyposis is believed to 
be triggered by somatic APC mutations resulting from defective processing of 
oxidative DNA damage by the base excision repair system [75-77]. 
Lynch syndrome – This is the most common colorectal cancer predisposition 
syndrome of known etiology and the cause of ~3% of all adenocarcinomas of the 
colon.  Like FAP, Lynch syndrome is a model of accelerated transformation along the 
conventional adenomatous pathway, but the driving force here is completely different.  
Lynch syndrome patients generally harbor a heterozygous germ-line mutation 
involving one of four genes that are essential for DNA mismatch repair (MMR): 
MSH2, MSH6, MLH1, and PMS2.  As a result, base/base mismatches and strand 
misalignments generated during DNA replication by polymerase δ or ε go unrepaired, 
and the rate of mutations rises markedly (reviewed in [78]).  This defect results in 
what is known as a mutator phenotype characterized by the accumulation of large 
numbers of mutations in the genome. 
MMR is normally initiated when a mispair or misalignment is bound by the 
mismatch recognition complex, MSH2/MSH6.  The heterodimer then undergoes an 
ATP-driven conformational change, which allows it to interact with another MMR 
protein heterodimer, MLH1/PMS2.  This interaction activates the endonucleolytic 
function of PMS2, which nicks the newly synthesized DNA strand on the 3′ and 5′ 
sides of the mismatch.  Exonuclease 1 then degrades the mispair-containing segment, 
beginning at the 5′ nick, and the resulting gap is then filled in with the correct 
sequence by replicating DNA polymerase δ or ε.   
 Genes whose germ-line mutations cause inherited forms of cancer are often 
found to be somatically altered in certain sporadic tumors, and the MMR genes are no 
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exception [79].  This is especially true of MLH1.  Loss of MLH1 expression is found 
in approximately 10% of all colorectal carcinomas, and the vast majority are unrelated 
to Lynch syndrome.  Sporadic, MLH1-defective tumors are in fact the most common 
MMR-defective colorectal cancers.  These are the cancers discussed in the previous 
section, the ones that are almost always found in the right colon.  They arise through 
the serrated pathway and are often characterized by BRAF mutations and CIMP-
positivity, which leads to somatic silencing of MLH1 via bi-allelic methylation of its 
promoter. 
In contrast, the inherited MMR-defective colorectal cancers associated with 
Lynch syndrome develop along the conventional adenomatous pathway.  The first hit 
-- heterozygous germ-line mutation of one of the MMR genes – predisposes the 
carrier to MMR deficiency, but the system remains proficient until some somatic 
event leads to the mutation or loss of the wild-type allele of this gene.  So, the disease 
is inherited as an autosomal dominant predisposition, but it is recessive at the somatic 
level.  Consequently, the affected MMR protein is fully expressed in normal tissue, 
where heterozygosity has been maintained, but absent in tumor cells, where the wild-
type allele has been lost.   
When does this second hit occur in the epithelial cells of the colon? 
Heterozygosity is generally believed to be lost fairly early in the pre-cancerous 
adenomatous polyp stage [80].  Failure of the MMR system gives rise to a mutator 
phenotype and microsatellite instability, which should markedly accelerate the 
adenoma’s transformation, and Lynch syndrome adenomas do indeed progress to 
adenocarcinoma more rapidly (within 2-5 years) and at a higher frequency than their 
sporadic counterparts.  As noted above, adenoma formation itself seems to be 
triggered by dysregulation of Wnt signaling, which is a very early event in colorectal 
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tumorigenesis (Figure 4).  In fact, although the temporal relationships between the 
various events are still fairly obscure, aberrant Wnt signaling almost certainly 
precedes the loss of the wild type MMR allele.  The adenomatous polyps associated 
with Lynch syndrome are by no means as numerous as those seen in FAP.  In most 
cases, the patient presents with a single adenoma, and there are rarely more than five 
or six.  It seems then that these early dysplastic lesions somehow favor the loss of 
MMR in heterozygous cells. 
In summary, the MMR-defective colorectal cancers associated with the Lynch 
syndrome arise from isolated adenomatous lesions, which undergo “fast-track” 
transformation driven by high-rate mutation that often targets tumor suppressor genes 
[81,82].  This mechanism probably predominates over chromosomal instability 
(another frequent driver of carcinogenesis), since MMR-deficient tumors have few 
chromosomal gains and losses and are often near-diploid (Figue 4).  Later on, their 
aggressiveness and invasiveness are fortunately curbed by a strong antitumor immune 
response.  The molecular components of this response are now under investigation 
[70], but the trigger seems to consist in the presentation of novel antigens produced by 
highly mutable, MMR-defective tumor cells.  
Hyperplastic polyposis – The paradigm of “fast-track transformation” along the 
serrated pathway is the syndrome known as hyperplastic polyposis (HP), a rare (and 
underdiagnosed) condition that is often associated with BRAFV600E and the CIMP.  HP 
is diagnosed when there are [83]: i) at least five histologically diagnosed hyperplastic 
polyps proximal to the sigmoid colon, including two with diameters exceeding 10 
mm;  ii) any number of hyperplastic polyps proximal to the sigmoid colon plus first-
degree kinship with a patient known to have HP;  or iii) over 30 hyperplastic polyps 
distributed throughout the colon.  HP presents with a variety of preinvasive lesions, 
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which include not only hyperplastic polyps but also larger SSAs and even classical 
adenomas.  The syndrome is now known to confer an increased risk for malignant 
transformation, although the reported magnitude of this risk varies to some extent 
from study to study [84-86].  HP-related colorectal cancers show a predilection for the 
proximal colon, and their onset occurs roughly 10 years earlier than that of sporadic 
colorectal cancers and about two decades later than those related to the Lynch 
syndrome.   
Fewer than 150 cases of HP have been reported to date, and the picture that is 
emerging is that of a heterogeneous entity.  Some authors have suggested [87] that 
there are actually two different phenotypes.  They advocate reserving the term 
“hyperplastic polyposis” for cases characterized by multiple, small, pancolonic 
hyperplastic polyps and using “serrated adenomatous polyposis” when there are 
smaller numbers of relatively large, proximal, hyperplastic polyps with features of 
SSA.  Familial aggregation has been documented in relatively few cases.  When 
present, it seems to reflect dominant transmission of an unidentified genetic 
predisposition to CIMP, which frequently leads to somatic methylation of the MLH1 
promoter [88,89].  Compared with patients harboring sporadic serrated lesions, those 
with HP have a significantly higher frequency of methylated alleles in the normal 
colon mucosa [90,91], and this finding is also consistent with the possibility of 
genetically determined CIMP.   
Inflammatory bowel disease - Third on the list of conditions conferring high risk for 
colorectal cancer – after the Lynch syndrome and FAP – is inflammatory bowel 
disease (IBD).  Ulcerative colitis and Crohn’s disease are chronic disorders with an 
onset peak between the second and fourth decades of life.  They are caused by the 
combined effects of genetic, immune, and environmental factors – most of which are 
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still poorly characterized.  Strong evidence supports the view that both involve a 
dysregulated immune response to commensal bacteria in genetically susceptible 
individuals [92,93].  The risk for IBD has been linked to variations in numerous genes 
[94].  
Both ulcerative colitis and Crohn’s disease confer an increased risk for 
colorectal cancer, but this risk varies with disease duration, the extent of colonic 
involvement, age at diagnosis, the severity of inflammation, family history of colon 
cancer, and the presence or absence of primary sclerosing cholangitis.  The 
cumulative risk in patients with ulcerative colitis was recently estimated to be 8% at 
20 years and 18% at 30 years; similar figures have been reported for Crohn’s disease 
[95,96].  Most of what we know about colitis-associated carcinogenesis comes from 
studies of ulcerative colitis, so the rest of this section will focus mainly on this IBD. 
The mechanism that links chronic inflammation to carcinogenesis has never 
been precisely defined.  However, persistent inflammation is believed to trigger and 
sustain oxidative stress that increases proliferation and eventually leads to dysplasia 
[97].  Two important features of colitis-associated dysplasia are macroscopic 
heterogeneity and multifocality [98].  Elevated lesions (sometimes referred to as  
DALM [dysplasia-associated lesion or mass]) range from circumscribed, 
pedunculated or sessile polyps that resemble noncolitic adenomas to nonadenoma-like 
lesions that are irregular, broad-based, or poorly circumscribed.  These latter lesions 
often contain ulcerated or hemorrhagic foci, and the flat mucosa surrounding them is 
also frequently dysplastic.  They have often been referred to as “invisible dysplasia,” 
because they are usually undetectable with standard colonoscopy.  The only way to 
demonstrate their existence was to collect large numbers of biopsies from randomly 
selected sites throughout the colon, and this approach is still used today. However, 
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thanks to the introduction of magnifying chromoendoscopy, these flat lesions can be 
identified and biopsied, and this advance has greatly facilitated the demonstration of 
IBD-related dysplasia [99].   
The finding of flat or elevated areas of high-grade dysplasia in a patient with 
ulcerative colitis is an indication for proctocolectomy because these lesions are likely 
to be multifocal, and their presence is associated with a high risk (~50%) for 
concurrent or imminent colorectal cancer [100].  Prophylactic surgery for low-grade 
dysplasia is more controversial [101], in part because there is no real consensus on the 
criteria for a pathologic diagnosis of this type.  Endoscopic detection of preinvasive 
lesions and histologic assessment of dysplasia are problematic in settings of chronic 
inflammation, but thus far colorectal carcinogenesis in ulcerative colitis also seems to 
involve the development of dysplastic ACFs followed by low-grade and then high-
grade dysplastic lesions that are eventually transformed into cancers.  The 
identification of molecular markers of these stages will undoubtedly improve the 
quality of the clinical choices during the follow up of these patients.  
Numerous studies have analyzed the molecular profiles of colitis-associated 
preinvasive lesions and the nonlesional inflamed mucosa.  The typical approach 
involves the search for molecular abnormalities found in noncolitic carcinogenesis  -- 
the chromosomal and microsatellite instability, epigenetic alterations, and oncogene 
and tumor-suppressor-gene mutations mentioned in the previous sections.  As 
expected, most have also been detectable in colitis-associated mucosal lesions, but in 
many cases it is still unclear how their frequency and timing differ from those 
observed in the absence of chronic inflammation.   
The discrepancies that have arisen were to be expected for several reasons.  
The availability of tissue samples of colitis-associated lesions is limited, and the linear 
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correlation between lesion size and disease severity observed in noncolitic 
tumorigenesis tends to break down in IBD, where small lesions are often advanced 
and molecular changes can also be found in the inflamed, nonneoplastic mucosa.  The 
molecular analyses were also marred by selection biases related to the difficulties 
mentioned above in the endoscopic detection and histologic classification of colitis-
associated lesions, as well as other methodologic flaws that had hampered the 
molecular investigation of noncolitic lesions (analysis restricted to the most 
frequently mutated regions of genes, the use of different -- sometimes incomplete – 
marker panels for the detection of specific phenotypes, suboptimal diagnostic 
reliability of most of the methods used).   
Nevertheless, certain differences with respect to noncolitic carcinogenesis 
have emerged from these studies.  KRAS and APC mutations, for example, are rare in 
IBD-related carcinogenesis, whereas TP53 mutations are frequently encountered in 
the early stages and are sometimes found even in nondysplastic mucosa [15,102-104].  
DNA methylation [105] and microsatellite instability [106] seem to play less 
important roles, but chromosomal instability is very common and appears to be an 
early event that probably stems from TP53 mutations and inflammation-triggered 
DNA damage [107].  Genome-wide screening with comparative genomic 
hybridization has revealed several recurrent genomic imbalances.  Losses of 
chromosome 5q and 18q, for example, were found in nondysplastic colitis tissue 
[108] (Figure 5), but their frequency was higher in dysplastic colitis tissue and higher 
still in colitis-associated colorectal cancer.  Progression was also associated with the 
accumulation of other genomic imbalances typical of colorectal cancer such as -4, +7, 
+8q, +13q, +20q and +X.  Changes detected in premalignant colitis tissue were 
encountered more often in colitis-associated colorectal cancers than in their sporadic 
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counterparts (for example: -5q: 53% vs. 10%; -18q: 76% vs. 49%; Figure 5) (data 
through www.progenetix.net; [109]).  The presence of specific genomic changes in 
colon tissues from patients with ulcerative colitis is evidence of preinvasive clonal 
expansion, and it might someday serve as an additional marker for disease monitoring 
in these patients. 
In conclusion, magnifying chromoendoscopy and the analysis of TP53 
mutations and chromosomal abnormalities in endoscopic biopsies are important tools 
that can substantially improve early diagnosis of colorectal cancer in patients with 
ulcerative colitis.  The challenge is to implement these adjunctive diagnostic 
modalities in the surveillance of all patients with long-standing ulcerative in a way 
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Legends to Figures 
 
Figure 1:  A simplified 4-stage model of the transformation of normal colorectal 
mucosa into adenocarcinoma.  The figure shows the histologic features of the four 
stages of the adenoma-carcinoma pathway to colorectal cancer: A: normal mucosa; B: 
aberrant crypt focus (ACF); C: tubulo-villous adenoma with epithelial dysplasia; and 
D: invasive adenocarcinoma.  The dysplastic ACF shown in panel B came from the 
colon of a patient with colon cancer (H&E staining, 25x magnification).  The 
photomicrogram shows approximately 12 of the 50 or so aberrant crypts included in 
the ACF, which is slightly raised above (≈ 500 µm) the surface of the gut mucosa.  
Compared with the surrounding normal crypts (right, upper corner), the aberrant 
crypts are larger and longer with initial signs of branching and infolding of the 
epithelium.  The epithelial lining presents low-grade dysplasia (mild mucin depletion, 
hyperchromatic nuclei, initial signs of nuclear enlargement, occasional areas of 
stratification).  In the lower left corner, the crypt lumens are enlarged – a frequent 
finding at the borders of ACFs.  C: the adenomatous polypoid lesion shows a 
prevalent tubular growth pattern with some villous projections.  The degree of 
dysplasia varies from low-grade (left half of the lesion) to high-grade (right half, 
superficial).  In the lower left corner is present a portion of normal mucosa of the 
stalk.  D (adenocarcinoma):  irregular branching of glands showing atypical 
epithelium.  They are surrounded by stroma composed of dense fibrous tissue 
comprising spindle cells in a collagenuos and inflammatory background 
(desmoplastic reaction).  (Magnification: Normal mucosa, 10 X;  ACF, 10X;  
Adenoma, 2X;  Adenocarcinoma, 10X) 
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Figure 2:  Polypoid and nonpolypoid preinvasive lesions of the colorectum.  A 
and B, Types of tumor growth associated with the development of colorectal 
neoplasia (Paris classification, ref. [20]).  Polypoid (A) lesions can be pedunculated 
(Type Ip) or sessile (Type Is); most nonpolypoid (B) lesions are slightly elevated 
(Type IIa), but some are completely flat (Type IIb) or depressed (Type IIc).  Mixed 
growth patterns can also be found.  The endoscopic appearances of polypoid 
(pedunculated) and nonpolypoid (slightly elevated) lesions are shown in panel C and 
D, respectively.  Histological examination shows conventional adenomatous features 
(tubular proliferation with low-grade epithelial dysplasia) in a pedunculated polyp (E; 
magnification, 10X) and the serrated pattern (irregular shape of the crypts with 
serration of glandular lumens) in a nonpolypoid lesion (F; magnification, 10X).  (See 
text for description of the histotypes.)  Either of these histological patterns can be 
found in polypoid and nonpolypoid lesions. 
 
Figure 3:  The best characterized pathways to colorectal adenocarcinoma.  The 
conventional adenomatous pathway is the most common route to adenocarcinoma. 
The cancers that arise through this pathway can be located anywhere in the 
colorectum, but they are more frequent in the left colon and rectum.  Progressively 
severe cellular and architectural dysplasia (shaded region) is the hallmark of this 
pathway. It can already be found in the earliest-stage lesions, such as ACFs.  The 
putative stations in the “less traveled” serrated pathway are shown on the right.  
Architectural abnormalities are an early feature of this pathway, whereas cellular 
dysplasia appears late (details in the text).  Among the lesions that develop through 
this pathway, those most likely to develop into cancer are located in the right colon. 
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Figure 4:  Molecular pathways and crossroads in colorectal transformation.  The 
conventional adenomatous pathway and the serrated pathway are currently the best 
characterized stepwise models of colorectal carcinogenesis.  In both, dysregulation of 
Wnt signaling (β-catenin stabilization and nuclear translocation) is an early event.  It 
can be caused by different (epi)mutations. (In the conventional adenomatous pathway, 
the most frequent cause is APC mutation).  Other early events have also been 
documented, including mutations affecting components of the MAPK/ERK cascades 
(i.e., KRAS or BRAF mutations, which are mutually exclusive) and chromosomal 
changes, like CIN  (lower-level compared to that seen in advanced adenocarcinomas) 
or CIMP.  And there are undoubtedly others that have yet to be discovered.  They 
account for roughly half of all adenocarcinomas, i.e., those with no evidence of the 
early alterations listed above (far right column – light blue segment).  Mutations 
involving “survival signaling” cascades (e.g., MAPK/ERK) alter the normal 
homeostatic equilibrium between proliferation, checkpoint repair of DNA damage, 
and apoptosis, allowing preinvasive lesions to survive for years.  Additional mutations 
are necessary to allow the tumor to move on into the advanced stage, where 
malignancy is imminent.  The nature of these “brake-releasing” events differs, 
depending on which pathway the tumor is moving along.  Crossroad warning sign: 
Examples from the literature [26,55-58,64] of “molecular deviation” from the original 
pathway, a phenomenon that can occur at almost any stage of carcinogenesis.  
Accelerators: Colon cancer predisposition syndromes - each represents high-speed 
transformation along one of the pathways shown in this figure: the adenomatous 
pathway in Lynch syndrome and familial adenomatous polyposis; the serrated 
pathway in hyperplastic polyposis.  
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The information reported in this figure is based on rates of detection of a dozen or so 
genetic and epigenetic alterations in preinvasive colorectal lesions and their 
persistence in advanced adenocarcinomas.  The relative frequency of a given 
alteration or combination of alterations can vary considerably from study to study 
owing to differences in inclusion criteria (i.e., types of lesion studied), in the number 
and type of molecular changes investigated, and in the method(s) employed to detect 
these changes.  Abbreviations: CIN (chromosomal instability); CIMP (CpG island 
methylator phenotype); MIN: microsatellite instability. 
 
Figure 5.  Chromosomal instability in preinvasive and invasive colorectal lesions 
from patients with and without ulcerative colitis.  Histograms show the frequency 
of genomic imbalances in selected colorectal tissue samples (gains appear in green 
above the baseline; losses appear below in red).  In ulcerative colitis (upper panel), 
chromosomal aberrations leading to clonal imbalances can already be observed in 
nondysplastic tissues.  Examples are the recurring deletions involving the long arms 
of chromosomes 5 and 18, which increase in frequency as malignancy progresses.  
Interestingly, both aberrations are earlier and more frequent events in tumorigenesis 
associated with ulcerative colitis than in sporadic adenomatous tumorigenesis (two 
lower panels) or FAP-related tumorigenesis, where 5q deletions are rarely detected 
(data not shown).  During progression, colitis-associated lesions accumulate most of 
the other genomic imbalances observed in sporadic tumors, namely gains of 
chromosomes 7, 8q, 13q, 20 and X, as well as deletions of chromosomes 4 and 8p.  
The data was extracted from the Progenetix database (www.progenetix.net; [109]). 





